



US012391993B2

(12) **United States Patent**
Hahn et al.

(10) **Patent No.:** US 12,391,993 B2
(45) **Date of Patent:** *Aug. 19, 2025

(54) **METHODS, TREATMENT, AND COMPOSITIONS FOR CHARACTERIZING THYROID NODULE**

(71) Applicant: **City of Hope**, Duarte, CA (US)

(72) Inventors: **Maria A. Hahn**, Duarte, CA (US); **John H. Yim**, San Marino, CA (US); **Yuman Fong**, Duarte, CA (US); **Arthur X. Li**, Covina, CA (US); **Xiwei Wu**, Diamond Bar, CA (US)

(73) Assignee: **CITY OF HOPE**, Duarte, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 37 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **17/813,904**

(22) Filed: **Jul. 20, 2022**

(65) **Prior Publication Data**

US 2023/0227913 A1 Jul. 20, 2023

Related U.S. Application Data

(63) Continuation of application No. 15/217,645, filed on Jul. 22, 2016, now Pat. No. 11,505,829.

(60) Provisional application No. 62/196,678, filed on Jul. 24, 2015.

(51) **Int. Cl.**
C12Q 1/6886 (2018.01)

(52) **U.S. Cl.**
CPC **C12Q 1/6886** (2013.01); **C12Q 2600/118** (2013.01); **C12Q 2600/154** (2013.01)

(58) **Field of Classification Search**
CPC C12Q 1/6886; C12Q 2600/118; C12Q 2600/154

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2017/0022570 A1 1/2017 Hahn et al.

OTHER PUBLICATIONS

Cottrell, S.E. (Jul. 2004). "Molecular diagnostic applications of DNA methylation technology," *Clin Biochem* 37(7):595-604.

Dean, D.S. et al. (2008) "Epidemiology of thyroid nodules," *Best Pract Res Clin Endocrinol Metab* 22(6):901-911.

Ellis, R.J. et al. (Feb. 2014, e-published Dec. 11, 2013). "Genome-wide methylation patterns in papillary thyroid cancer are distinct based on histological subtype and tumor genotype," *J Clin Endocrinol Metab* 99(2):E329-E337.

Gu, H. et al. (Feb. 2010, e-published Jan. 10, 2010). "Genome-scale DNA methylation mapping of clinical samples at single-nucleotide resolution," *Nature Methods* 7(2):133-136.

Hansen, K.D. et al. (Jun. 26, 2011). "Increased methylation variation in epigenetic domains across cancer types," *Nature Genetics* 43(8):768-775.

Ionnidis, J.P.A. (Aug. 2005). "Why most published research findings are false," *PLoS Med* 2(8):e124.

UCSC Genome Brower on Human Feb. 2009 (GRCh37/hg19) Assembly, 3 pages.

Kent, W.J. et al. (2002) "The human genome browser at UCSC," *Genome Res* 12(6):996-1006.

Kroese, M. et al. (Nov.-Dec. 2004). "Genetic tests and their evaluation: can we answer the key questions?" *Genetics in Medicine* 6(6):475-480.

Primary Examiner — Sarae L Bausch



(74) **Attorney, Agent, or Firm** — Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

(57) **ABSTRACT**

The current disclosure provides, inter alia, method of determining benign nodules from thyroid cancer in a subject that is found to have a thyroid nodule, method of treating thyroid cancer in a subject detected to have thyroid cancer by the method of the current disclosure, compositions for determining benign nodules from thyroid cancer in a subject, and kits including reagents and composition for determining benign nodules from thyroid cancer in a subject.

20 Claims, 7 Drawing Sheets

Specification includes a Sequence Listing.

FIG. 1A**FIG. 1B**




FIG. 2B




FIG. 3A




FIG. 3B




FIG. 3C




FIG. 4






FIG. 5

FIG. 6

1

**METHODS, TREATMENT, AND
COMPOSITIONS FOR CHARACTERIZING
THYROID NODULE**

**CROSS-REFERENCE TO RELATED
APPLICATIONS**

This application is a continuation of U.S. patent application Ser. No. 15/217,645, filed Jul. 22, 2016, now U.S. Pat. No. 11,505,829, issued on Nov. 22, 2022, which claims the benefit of priority under 35 U.S.C. § 119 (e) to U.S. Provisional Application No. 62/196,678, filed Jul. 24, 2015, the content of which are incorporated herein by reference in their entireties.

**INCORPORATION-BY-REFERENCE OF
SEQUENCE LISTING**

The content of the XML file named “048440-573C01US_Sequence_Listing.xml”, which was created on Dec. 2, 2022, and is 22,950 kilobytes in size, is hereby incorporated by reference in its entirety.

BACKGROUND OF THE DISCLOSURE

Palpable thyroid nodules are typically detected in 2-6% of the population, and this increases to 19-35% with ultrasound detection (Dean D S and Gharib H. Best Pract Res Clin Endocrinol Metab 2008; 22:901-11). Approximately 5-15% of thyroid nodules are found to be thyroid cancer, making the existence of a nodule clinically relevant. Fine needle aspiration (FNA) with cytology is currently the standard diagnostic procedure used to evaluate thyroid nodules. However, in as many as 30% of cases, the cytological diagnosis is indeterminate because of cytological features that overlap between benign and malignant nodules. For most indeterminate cases half or the entire thyroid is resected, yet as many as 80% of these cases are found to be benign.

Most thyroid nodules do not cause symptoms. Often, thyroid nodules are discovered incidentally during a routine physical examination or on imaging tests like CT scans or neck ultrasound done for completely unrelated reasons. Occasionally, patients themselves find thyroid nodules by noticing a lump in their neck while looking in a mirror, buttoning their collar, or fastening a necklace. Abnormal thyroid function tests may occasionally be the reason a thyroid nodule is found. Thyroid nodules may produce excess amounts of thyroid hormone causing hyperthyroidism. However, most thyroid nodules, including those that cancerous, are actually non-functioning, meaning current diagnostic test readouts such as the level of Thyroid-Stimulating Hormone (TSH) are normal. Rarely, patients with thyroid nodules may complain of pain in the neck, jaw, or ear. If a nodule is large enough to compress the windpipe or esophagus, it may cause difficulty with breathing, swallowing, or cause a “tickle in the throat”. Even less commonly, hoarseness can be caused if the nodule invades the nerve that controls the vocal cords but this is usually related to thyroid cancer.

Molecular testing is a potential alternative to cytopathological examination. However, FNA molecular testing based on DNA mutations frequently fails. There are two major reasons for this failure: (i) not all papillary thyroid carcinoma (PTC) specimens are characterized by a common set of cancer associated mutations, and (ii) cancer associated mutations like KRAS are frequently found in benign thyroid nodule (BTN) specimens. At the same time commercial

2

diagnostic tests for FNA based on transcriptional activity and currently implemented in clinical practice is complicated due to RNA instability and associated with only an approximately 50% positive predictive value. Thus, there is an urgent need for highly sensitive, low cost biomarker panels that can accurately diagnose thyroid nodules from FNA biopsies.

BRIEF SUMMARY OF THE DISCLOSURE

The present subject matter provides, inter alia, a method of determining benign nodules from thyroid cancer in a subject that is found to have a thyroid nodule, a method of treating thyroid cancer in a subject detected to have thyroid cancer, compositions for determining benign nodules from thyroid cancer in a subject, and kits including reagents and compositions for determining benign nodules from thyroid cancer in a subject.

In embodiments, aspects of the present subject matter provide a method of detecting methylation or unmethylation of a thyroid nodule DNA of a subject, the method including: (i) isolating DNA from a thyroid nodule of the subject thereby forming isolated thyroid nodule DNA, (ii) contacting the isolated thyroid nodule DNA with a bisulfite salt (such as sodium bisulfite) thereby forming a reacted thyroid nodule DNA, (iii) detecting the presence or absence of uracil in the reacted thyroid nodule DNA at a methylation site set forth in Table 1, thereby detecting methylation or unmethylation of the thyroid nodule DNA of the subject.

Also provided is a method of determining a thyroid cancer or risk of developing thyroid cancer in a subject in need thereof. The method includes isolating DNA from a thyroid nodule of the subject thereby forming isolated thyroid nodule DNA. The isolated thyroid nodule DNA is contacted with sodium bisulfite thereby forming a reacted thyroid nodule DNA. The presence or absence of uracil is detected in the reacted thyroid nodule DNA at a methylation site set forth in Table 1 thereby determining thyroid cancer in the subject.

In embodiments, provided herein is a method of treating thyroid cancer in a subject by administering to the subject an active agent for treating thyroid cancer. The method includes identifying the subject for treatment by a method including isolating DNA from a thyroid nodule of the subject thereby forming isolated thyroid nodule DNA. The isolated thyroid nodule DNA is contacted with sodium bisulfite thereby forming a reacted thyroid nodule DNA. The presence or absence of uracil in the reacted thyroid nodule DNA is detected at a methylation site set forth in Table 1 thereby determining thyroid cancer in the subject.

Also included herein is a deoxyribonucleic acid 5 to 100, 5 to 200, 5 to 300, or at least about 5, 50, 100, 150, 200, 250, 300, or more nucleotides in length including a uracil-containing sequence identical to at least a 5 contiguous nucleotides within a sequence including SEQ ID NO: 1 to SEQ ID NO:550.

In embodiments, provided herein is an oligonucleotide 5 to 100, 5 to 200, 5 to 300, or at least about 5, 50, 100, 150, 200, 250, 300, or more nucleotides in length including identical or complementary to at least 5, 10, 20, 25, 50, 100, 150, 200, 250, or 300 contiguous nucleotides within a sequence including SEQ ID NO:1 to SEQ ID NO:550.

Aspects of the present subject matter also include a deoxyribonucleic acid including SEQ ID NO: 551 to SEQ ID NO: 782, in which the nucleic acid is hybridized to a complementary DNA sequence having uridine or cytosine.

Also provided is a kit including a plurality (e.g., at least about 10, 20, 40, 50, 100, 150, 200, 225, or 232) nucleic acids each independently comprising SEQ ID NO: 551 to SEQ ID NO: 782, in which the nucleic acids do not simultaneously include the same sequence of SEQ ID NO: 551 to SEQ ID NO: 782.

Aspects of the present subject matter also provide a system for detecting methylation or unmethylation of a thyroid nodule deoxyribonucleic acid (DNA) of a subject. The system can include at least one processor; and at least one memory including program code which when executed by the at least one memory provides operations. The operations can include: isolating DNA from a thyroid nodule of the subject thereby forming isolated thyroid nodule DNA; contacting the isolated thyroid nodule DNA with bisulfite salt thereby forming a reacted thyroid nodule DNA; detecting a presence or absence of uracil in the reacted thyroid nodule DNA at a plurality of methylation sites set forth in Table 1, thereby detecting methylation or unmethylation of the thyroid nodule DNA of the subject; and generating a diagnosis for the subject based at least in part on the presence or absence of uracil in the reacted thyroid nodule DNA at the plurality of methylation sites set forth in Table 1; and providing, via a user interface, the diagnosis for the subject.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A-1B show a drawing defining a threshold for thyroid adenoma specific signature for individual cytosine regions. FIG. 1A: Adenoma specific hypomethylation signature. FIG. 1B: Adenoma specific hypermethylation signature.

FIGS. 2A and 2B show 364 cytosines associated with BTN or PTC specific DNA methylation changes. Legend (FIG. 2A): Cancer specific signature (gray); benign specific signature (black). FIG. 2B: 364 CpG sites associated with benign- and thyroid cancer-specific DNA methylation changes. Each row represents a single cytosine. Each column represents tissue specimen. Dark gray, light gray and black indicate high, low and medium levels of DNA methylation, respectively. Abbreviation “A” is for thyroid benign nodule and “T” is for thyroid cancer.

FIGS. 3A-3C depict exemplary thyroid cancer diagnostics based on DNA methylation signatures. FIG. 3A: Thyroid cancer diagnostics based on benign DNA methylation signature, cancer DNA methylation signature and cancer risk scores. FIG. 3B: DNA methylation signatures for malignant and benign thyroid nodules according to leave one-out-cross-validation technique. Specimens with indeterminate epigenetic signature are underlined. Abbreviation “A” is for thyroid benign nodule and “T” is for thyroid cancer. FIG. 3C: Algorithm for the diagnosis prediction based on BTN, PTC and cancer risk scores.

FIG. 4 depicts a block diagram illustrating an exemplary thyroid cancer diagnostics system.

FIG. 5 depicts a flowchart illustrating an exemplary process for diagnosing thyroid cancer.

FIG. 6 depicts a flowchart illustrating an exemplary process for diagnosing thyroid cancer.

DETAILED DESCRIPTION OF THE DISCLOSURE

Provided herein are, inter alia, compositions, methods, kits, and systems for detecting unmethylated DNA. In

embodiments, compositions, methods, kits, and systems for detecting unmethylated DNA from thyroid nodule are included herein.

The following definitions are included for the purpose of understanding the present subject matter and for constructing the appended patent claims. Abbreviations used herein have their conventional meaning within the chemical and biological arts.

10

Definitions

The term “thyroid nodule” is used according to its plain ordinary meaning and refers to an abnormal growth of thyroid cells. The abnormal growth may form, for example, a mass or lump within or on the thyroid gland. The mass or lump may be fluid-filled or solid. The thyroid nodules may be benign (noncancerous) or cancerous.

Thyroid fine needle aspiration biopsy (FNA or FNAB): For a fine needle biopsy, a needle is used to withdraw cells from a thyroid nodule. In embodiments, several samples are taken from different parts of the nodule, e.g., to increase the chance of finding cancerous cells if they are present. In embodiments, a sample is taken from one part of the nodule. In embodiments, examination of the cells under a microscope is not necessary. In non-limiting examples, the needle used for FNA is a 20-35 gauge needle (such as a 23, 24 or 25 gauge needle).

The term “disease” refers to any deviation from the normal health of a mammal and includes a state when disease symptoms are present, as well as conditions in which a deviation (e.g., infection, gene mutation, genetic defect, etc.) has occurred, but symptoms are not yet manifested. According to the present disclosure, the methods disclosed herein are suitable for use in a patient that is a member of the Vertebrate class, Mammalia, including, without limitation, primates, livestock and domestic pets (e.g., a companion animal). Typically, a patient will be a human patient. As used herein, a “symptom” of a disease includes and clinical or laboratory manifestation associated with the disease, and is not limited to what a subject can feel or observe.

The terms “subject,” “patient,” “individual,” and the like as used herein are not intended to be limiting and can be generally interchanged. That is, an individual described as a “patient” does not necessarily have a given disease, but may be merely seeking medical advice.

The term “subject” as used herein includes all members of the animal kingdom that may suffer from the indicated disorder. In some aspects, the subject is a mammal, and in some aspects, the subject is a human.

It must be noted that as used herein and in the appended embodiments, the singular forms “a,” “an,” and “the” include the plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to “a disease,” “a disease state”, “a nucleic acid” or “a CpG site” is a reference to one or more such embodiments, and includes equivalents thereof known to those skilled in the art and so forth.

Throughout the description and claims of this specification the word “comprise” and other forms of the word, such as “comprising” and “comprises,” means including but not limited to, and is not intended to exclude, for example, other components.

A “control” sample or value refers to a sample that serves as a reference, usually a known reference, for comparison to a test sample. For example, a test sample can be taken from a patient suspected or at risk of having thyroid cancer and compared to samples from a known thyroid cancer patient,

or a known normal (non-disease) individual. A control can also represent an average value gathered from a population of similar individuals, e.g., thyroid cancer patients or healthy individuals with a similar medical background, same age, weight, etc. A control value can also be obtained from the same individual, e.g., from an earlier-obtained sample, prior to disease, or prior to treatment. One of skill will recognize that controls can be designed for assessment of any number of parameters.

One of skill in the art will understand which controls are valuable in a given situation and be able to analyze data based on comparisons to control values. Controls are also valuable for determining the significance of data. For example, if values for a given parameter are widely variant in controls, variation in test samples will not be considered as significant.

The term "diagnosis" refers to a relative probability that a disease is present in the subject. Similarly, the term "prognosis" refers to a relative probability that a certain future outcome may occur in the subject. For example, in the context of the present disclosure, prognosis can refer to the likelihood that an individual will develop a disease, or the likely severity of the disease (e.g., severity of symptoms, rate of functional decline, survival, etc.). The terms are not intended to be absolute, as will be appreciated by any one of skill in the field of medical diagnostics.

"Nucleic acid" or "oligonucleotide" or "polynucleotide" or grammatical equivalents used herein means at least two nucleotides covalently linked together. Oligonucleotides are typically from about 5, 6, 7, 8, 9, 10, 12, 15, 25, 30, 40, 50 or more nucleotides in length, up to about 100 nucleotides in length. Nucleic acids, including ribonucleic acids (RNA) and deoxyribonucleic acids (DNA), and polynucleotides are polymers of any length, including longer lengths, e.g., 200, 300, 500, 1000, 2000, 3000, 5000, 7000, 10,000, etc. A nucleic acid of the present invention will generally contain phosphodiester bonds, although in some cases, nucleic acid analogs are included that may have alternate backbones, comprising, e.g., phosphoramidate, phosphorothioate, phosphorodithioate, or O-methylphosphorimidite linkages (see Eckstein, *Oligonucleotides and Analogues: A Practical Approach*, Oxford University Press); and peptide nucleic acid backbones and linkages. Other analog nucleic acids include those with positive backbones; non-ionic backbones, and non-ribose backbones, including those described in U.S. Pat. Nos. 5,235,033 and 5,034,506, and Chapters 6 and 7, ASC Symposium Series 580, *Carbohydrate Modifications in Antisense Research*, Sanghui & Cook, eds. Nucleic acids containing one or more carbocyclic sugars are also included within one definition of nucleic acids. Modifications of the ribose-phosphate backbone may be done for a variety of reasons, e.g., to increase the stability and half-life of such molecules in physiological environments or as probes on a biochip. Mixtures of naturally occurring nucleic acids and analogs can be made; alternatively, mixtures of different nucleic acid analogs, and mixtures of naturally occurring nucleic acids and analogs may be made.

The term "bp" and the like refer, in the usual and customary sense, to the indicated number of base pairs.

The terms "identical" or percent "identity," in the context of two or more nucleic acids (e.g., genomic sequences or subsequences or coding sequences) or polypeptide sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same (i.e., 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more identity

over a specified region), when compared and aligned for maximum correspondence over a comparison window, or designated region as measured using one of the following sequence comparison algorithms or by manual alignment and visual inspection. Such sequences are then said to be "substantially identical." This definition also refers to the compliment of a test sequence. Optionally, the identity exists over a region that is at least about 10 to about 100, about 20 to about 75, about 30 to about 50 amino acids or nucleotides in length.

An example of algorithms suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al., *Nuc. Acids Res.* 25:3389-3402 (1977) and Altschul et al., *J. Mol. Biol.* 215:403-410 (1990), respectively. As will be appreciated by one of skill in the art, the software for performing BLAST analyses is publicly available through the website of the National Center for Biotechnology Information.

A "label" or a "detectable moiety" is a composition detectable by spectroscopic, photochemical, biochemical, immunochemical, chemical, or other physical means. For example, useful labels include ³²P, fluorescent dyes, electron-dense reagents, enzymes (e.g., as commonly used in an ELISA), biotin, digoxigenin, or haptens and proteins or other entities which can be made detectable, e.g., by incorporating a radiolabel into a peptide or antibody specifically reactive with a target peptide. Any method known in the art for conjugating an antibody to the label may be employed, e.g., using methods described in Hermanson, *Bioconjugate Techniques* 1996, Academic Press, Inc., San Diego.

The term "associated" or "associated with" in the context of a substance (e.g., level of uracil or methylation level in a thyroid nodule) does not necessarily mean that the disease is caused by (in whole or in part), or a symptom of the disease is caused by (in whole or in part) the substance or substance activity or function (i.e., level of uracil in the regions of chromosomes assayed).

The term "unmethylated DNA" or "demethylated DNA" means DNA that lacks a methyl group conjugated to cytosine in a segment of the DNA. DNA methylation typically occurs in a CpG dinucleotide context. DNA methylation at 5' position of cytosine may have the specific effect on gene expression *in vivo*. DNA methylation may also form the basis of epigenetic structure, which typically enables a single cell to grow into multiple organs or perform multiple functions.

The CpG sites or CG sites are regions of DNA where a cytosine nucleotide occurs next to a guanine nucleotide in the linear sequence of bases along its length. "CpG" is shorthand for "-C-phosphate-G-", that is, cytosine and guanine separated by only one phosphate; phosphate links any two nucleosides together in DNA. The "CpG" notation is used to distinguish this linear sequence from the CG base-pairing of cytosine and guanine. The CpG notation can also be interpreted as the cytosine being 5' prime to the guanine base.

In embodiments, methylation is detected based on a chemical reaction of sodium bisulfite with DNA that converts unmethylated cytosines of CpG dinucleotides to uracil or UpG. However, methylated cytosine is not converted in this process, the methods described herein allow determination of methylation status as methylated or unmethylated. Evaluation of Thyroid Fine Needle Biopsies by Visual Examination

Cells in a thyroid vine needle biopsy sample may be examined under a microscope by, e.g., a pathologist. The

report of a thyroid fine needle biopsy followed by examination under a microscope will usually indicate one of the following findings:

1. The nodule is benign (noncancerous). This result is obtained in up to 80% of biopsies. The risk of overlooking a cancer when the biopsy is benign is generally less than 3 in 100 tests or 3%. This is even lower when the biopsy is reviewed by an experienced pathologist at a major medical center. Generally, benign thyroid nodules do not need to be removed unless they are causing symptoms like choking or difficulty swallowing. Follow up ultrasound exams are important. Occasionally, another biopsy may be required in the future, especially if the nodule grows over time.

2. The nodule is malignant (cancerous) or suspicious for malignancy. A malignant result is obtained in about 5% of biopsies and is most often due to papillary cancer, which is the most common type of thyroid cancer. A malignant diagnosis has a >99% risk of cancer in the nodule. A suspicious biopsy has a 50-75% risk of cancer in the nodule. These diagnoses require surgical removal of the thyroid after consultation with the endocrinologist and surgeon.

3. The nodule is indeterminate. This is actually a group of several diagnoses that may occur in up to 30% of cases. An indeterminate finding means that even though an adequate number of cells was removed during the fine needle biopsy, examination with a microscope cannot reliably classify the result as benign or cancer. The biopsy may be indeterminate because the nodule is described as a Follicular Lesion. These nodules are cancerous 20-30% of the time. However, under the current state of the art, the diagnosis can only be made by surgery. Because the odds that the nodule is not a cancer are much better by surgery (70-80%), only the side of the thyroid with the nodule is usually removed. If a cancer is found, the remaining thyroid gland is usually removed as well. If the surgery confirms that no cancer is present, no additional surgery to "complete" the thyroidectomy is necessary.

The biopsy may also be indeterminate because the cells from the nodule have features that cannot be placed in one of the other diagnostic categories. This diagnosis is called atypia, or a follicular lesion of undetermined significance. Diagnoses in this category will contain cancer rarely, so repeat evaluation with FNA or surgical biopsy to remove half of the thyroid containing the nodule is usually recommended.

4. The biopsy may also be non-diagnostic or inadequate. This result indicates that not enough cells were obtained to make a diagnosis but is a common result if the nodule is a cyst. These nodules may require reevaluation with second fine needle biopsy, or may need to be removed surgically depending on the clinical judgment of the doctor.

Methods, compositions, kits, and systems provided herein provide significant advantages over the visual examination of biopsies.

Method of Detection Methylation Status of a Thyroid Nodule DNA

In an aspect, provided herein is a method of detecting methylation or unmethylation of a thyroid nodule DNA of a subject. The method includes: (i) isolating a thyroid nodule DNA molecule from a thyroid nodule of the subject thereby forming an isolated thyroid nodule DNA molecule, (ii) contacting the isolated thyroid nodule DNA molecule with a bisulfite salt (such as sodium bisulfite) thereby forming a reacted thyroid nodule DNA molecule, (iii) detecting the presence or absence of uracil in the reacted thyroid nodule DNA molecule at a methylation site set forth in Table 1, thereby detecting methylation or unmethylation of the thy-

roid nodule DNA molecule of the subject. In embodiments, contacting the isolated thyroid nodule DNA with a bisulfite salt comprises adding a solution comprising the bisulfite salt to a solution comprising the isolated single stranded DNA.

5 In an aspect, provided herein is a method of detecting methylation or unmethylation of a thyroid nodule DNA molecule of a subject comprising (i) isolating a plurality of thyroid nodule DNA molecules from the thyroid nodule of the subject thereby forming a plurality of isolated thyroid nodule DNA molecules, (ii) contacting the plurality of isolated thyroid nodule DNA molecules with the bisulfite salt thereby forming a plurality of reacted thyroid nodule DNA molecules, (iii) detecting the level of reacted thyroid nodule DNA molecules in the plurality of reacted thyroid nodule DNA molecules having a uracil at a methylation site set forth in Table 1, thereby detecting the level of methylation or unmethylation in the plurality of thyroid nodule DNA molecules of the subject.

10 In an aspect, provided herein is a method of detecting methylation or unmethylation of a thyroid nodule DNA molecule of a subject comprising (i) isolating a plurality of thyroid nodule DNA molecules from the thyroid nodule of the subject thereby forming a plurality of isolated thyroid nodule DNA molecules, (ii) contacting the plurality of isolated thyroid nodule DNA molecules with the bisulfite salt thereby forming a plurality of reacted thyroid nodule DNA molecules, (iii) detecting the presence or absence of uracil in a reacted thyroid nodule DNA molecule at a methylation site set forth in Table 1, thereby detecting methylation or unmethylation of the thyroid nodule DNA molecule of the subject.

15 In an aspect, provided herein is a method of detecting methylation or unmethylation of a thyroid nodule DNA of a subject. The method includes: (i) isolating a thyroid nodule DNA molecule from a thyroid nodule of the subject thereby forming an isolated thyroid nodule DNA molecule, (ii) contacting the isolated thyroid nodule DNA molecule with a bisulfite salt (such as sodium bisulfite) thereby forming a reacted thyroid nodule DNA molecule, (iii) amplifying the reacted thyroid nodule DNA molecule thereby forming a reacted thyroid nodule DNA amplicon molecule, (iv) detecting the presence or absence of thymidine in a reacted thyroid nodule DNA amplicon molecule at a methylation site set forth in Table 1, thereby detecting methylation or unmethylation of the thyroid nodule DNA molecule of the subject. In embodiments, contacting the isolated thyroid nodule DNA with a bisulfite salt comprises adding a solution comprising the bisulfite salt to a solution comprising the isolated single stranded DNA.

20 In an aspect, provided herein is a method of detecting methylation or unmethylation of a thyroid nodule DNA molecule of a subject comprising (i) isolating a plurality of thyroid nodule DNA molecules from the thyroid nodule of the subject thereby forming a plurality of isolated thyroid nodule DNA molecules, (ii) contacting the plurality of isolated thyroid nodule DNA molecules with the bisulfite salt thereby forming a plurality of reacted thyroid nodule DNA molecules, (iii) amplifying the plurality of reacted thyroid nodule DNA molecules thereby forming a plurality of reacted thyroid nodule DNA amplicon molecules, (iv) detecting one or more thyroid nodule DNA amplicon molecules within the plurality of reacted thyroid nodule DNA amplicon molecules having a thymidine at a methylation site set forth in Table 1, thereby detecting methylation or unmethylation of the thyroid nodule DNA molecule of the subject.

In embodiments, detecting one or more thyroid nodule DNA amplicon molecules comprises detecting the level of one or more one or more thyroid nodule DNA amplicon molecules. In embodiments, detecting one or more thyroid nodule DNA amplicon molecules comprises detecting the level of reacted thyroid nodule DNA amplicon molecules in the plurality of reacted thyroid nodule DNA amplicon molecules having a thymidine at a methylation site set forth in Table 1, thereby detecting the level of methylation or unmethylation in the plurality of thyroid nodule DNA molecules of the subject.

In embodiments, detecting a level includes determining the number (e.g. quantitating) or molecules having, e.g., a thymidine or a uracil. In embodiments, detecting a level includes detecting the portion or proportion of a population or plurality of molecules having, e.g., a thymidine or a uracil.

In embodiments, the isolated thyroid nodule DNA sample is treated with a bisulfite reagent, e.g., a bisulfite salt (i.e., a process called DNA bisulfite conversion). Non-limiting examples of bisulfite salts include sodium bisulfite, potassium bisulfite, ammonium bisulfite, magnesium bisulfite, sodium metabisulfite, potassium metabisulfite, ammonium metabisulfite and magnesium metabisulfite. Bisulfite salts such as sodium bisulfite or ammonium bisulfite can convert cytosine to uracil and leave 5-methylcytosine (5-mC) the same. Thus after bisulfite treatment methylated cytosine in the DNA remains the same and unmodified cytosines will be changed to uracil. The bisulfite treatment can be performed by using the methods disclosed herein or in the art, and/or with commercial kits such as the Bisulflash DNA Modification Kit (Epigentek) and Imprint DNA Modification Kit (Sigma). For achieving the optimal bisulfite conversion, the bisulfite reaction should be carried out in an appropriate concentration of bisulfite reagents, appropriate temperature and appropriate reaction time period. A reagent such as potassium chloride that reduces thermophilic DNA degradation could also be used in bisulfite treatment so that the DNA bisulfite process can be much shorter without interrupting a completed conversion of unmethylated cytosine to uracil and without a significant thermodegradation of DNA resulted from depurination. In embodiments, a commercially available bisulfite treatment kit is used. A non-limiting example of such a kit is EZ DNA Methylation-Gold™ Kit (Zymo Research, Irvine, CA, USA).

In embodiments, once DNA bisulfite conversion is complete, DNA is captured, desulphonated and washed. In embodiments, the bisulfite-treated DNA can be captured by, e.g., a solid matrix selected from silica salt, silica dioxide, silica polymers, magnetic beads, glass fiber, celite diatoms and nitrocellulose in the presence of high concentrations of chaotropic or non-chaotropic salts. In embodiments, the bisulfite-treated DNA is further desulphonated with an alkalinized solution, preferably sodium hydroxide at concentrations from 10 mM to 300 mM. In embodiments, the DNA is then eluted and collected into a capped microcentrifuge tube. Non-limiting examples of elution solutions include DEPC-treated water and TE buffer (10 mM Tris-HCL, pH 8.0, and 1 mM EDTA).

In embodiments, the reacted thyroid nodule DNA resulting from bisulfite treatment is amplified. In embodiments, detecting the presence or absence of uracil in reacted thyroid nodule DNA molecule at a methylation site comprises amplifying the reacted thyroid nodule DNA molecule thereby forming a reacted thyroid nodule DNA amplicon molecule, and detecting the presence or absence of thymidine in a reacted thyroid nodule DNA amplicon molecule at

the methylation site. In embodiments, a polymerase chain reaction (PCR) method is used for amplifying the reacted thyroid nodule DNA. PCR methods are known to those of ordinary skill in the art. In general, the PCR reactions can be set up by adding sample, dNTPs, and appropriate polymerase such as Taq polymerase, primers, and a buffer.

In embodiments, the method of detecting methylation or unmethylation of a thyroid nodule DNA of a subject, includes detecting methylation or unmethylation at a plurality of methylation sites set forth in Table 1. In embodiments, the plurality of methylation sites comprises at least about 2, 3, 4, 5, 10, 25, 50, 75, 80, 85, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, or 550, or 5-550 methylation sites. In embodiments, the plurality of methylation sites comprises less than about 550, 500, 450, 400, 350, 300, 250, 200, 150, 100, 90, 85, 80, 75, 50, 25, or 10 methylation sites. In embodiments, the plurality of methylation sites is about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 50, 75, 80, 85, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, or 550, or 5-550 methylation sites. In embodiments, the plurality of methylation sites includes two or more methylation sites set forth in Table 1 and no other methylation sites.

In embodiments, the method includes detecting methylation or unmethylation of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 25, 50, 100, 200, 300, 400, or 500 of the following sites: Chromosome 1 (Chr1) position 2996653, Chr1 position 11979164, Chr1 position 12655938, Chr1 position 16450525, Chr1 position 16450542, Chr1 position 16450545, Chr1 position 16469987, Chr1 position 17494491, Chr1 position 25473203, Chr1 position 27640460, Chr1 position 29565080, Chr1 position 38493013, Chr1 position 38493030, Chr1 position 38493074, Chr1 position 46713777, Chr1 position 46914121, Chr1 position 46955744, Chr1 position 55008344, Chr1 position 109816092, Chr1 position 109816111, Chr1 position 110074669, Chr1 position 110074681, Chr1 position 110074685, Chr1 position 150949856, Chr1 position 150949857, Chr1 position 153540282, Chr1 position 155162704, Chr1 position 155162714, Chr1 position 156676611, Chr1 position 157611881, Chr1 position 182205324, Chr1 position 204118999, Chr1 position 206741875, Chr1 position 206741989, Chr1 position 212587673, Chr1 position 212841198, Chr1 position 223403952, Chr1 position 233430972, Chr1 position 234342767, Chromosome 2 (Chr2) position 3454277, Chr2 position 8793724, Chr2 position 20412441, Chr2 position 42329402, Chr2 position 42329494, Chr2 position 55289272, Chr2 position 65064865, Chr2 position 70823641, Chr2 position 73143689, Chr2 position 74454110, Chr2 position 122014529, Chr2 position 128158884, Chr2 position 128158910, Chr2 position 203114171, Chr2 position 218221671, Chr2 position 219745335, Chr2 position 238341465, Chr2 position 238341542, Chr2 position 238341546, Chr2 position 238774763, Chromosome 3 (Chr3) position 13323642, Chr3 position 14180153, Chr3 position 45209073, Chr3 position 45209207, Chr3 position 52525100, Chr3 position 62589658, Chr3 position 65388317, Chr3 position 65388388, Chr3 position 73599302, Chr3 position 195636893, Chr3 position 197093846, Chromosome 4 (Chr4) position 3743223, Chr4 position 5755716, Chr4 position 5755717, Chr4 position 5755728, Chr4 position 5755729, Chr4 position 5755734, Chr4 position 8372861, Chr4 position 57548289, Chromosome 5 (Chr5) position 1118280, Chr5 position 34564389, Chr5 position 73871907, Chr5 position 78013596, Chr5 position 78013643, Chr5 position 137802650, Chr5 position

US 12,391,993 B2

11

139051189, Chr5 position 167838221, Chr5 position 177541401, Chr5 position 180018672, Chr5 position 180101026, Chromosome 6 (Chr6) position 3394325, Chr6 position 3887581, Chr6 position 7236568, Chr6 position 7728692, Chr6 position 34203617, Chr6 position 37751320, Chr6 position 41410682, Chr6 position 41438516, Chr6 position 41438575, Chr6 position 43464150, Chr6 position 158734279, Chromosome 7 (Chr7) position 989235, Chr7 position 2673543, Chr7 position 73508602, Chr7 position 105079565, Chr7 position 105079631, Chr7 position 151425103, Chr7 position 151425104, Chromosome 8 (Chr8) position 11764017, Chr8 position 21647308, Chr8 position 22548399, Chr8 position 22548483, Chr8 position 133570537, Chr8 position 141320393, Chr8 position 141320410, Chromosome 9 (Chr9) position 6566568, Chr9 position 16197862, Chr9 position 34591313, Chr9 position 98225096, Chr9 position 126126741, Chr9 position 132083428, Chr9 position 136077410, Chr9 position 139655018, Chr9 position 140205985, Chr9 position 140205985, Chr9 position 140205997, Chromosome 10 (Chr10) position 3929071, Chr10 position 30047012, Chr10 position 79702989, Chr10 position 87984905, Chr10 position 94838789, Chr10 position 102131187, Chr10 position 104196489, Chr10 position 11766879, Chr10 position 112258886, Chr10 position 112258984, Chr10 position 112259015, Chr10 position 116391763, Chr10 position 120011530, Chr10 position 126172714, Chr10 position 126172747, Chromosome 11 (Chr11) position 556355, Chr11 position 821282, Chr11 position 12188937, Chr11 position 12188948, Chr11 position 12188995, Chr11 position 36057726, Chr11 position 48070143, Chr11 position 48070163, Chr11 position 48070166, Chr11 position 48070174, Chr11 position 65158294, Chr11 position 65158342, Chr11 position 65297089, Chr11 position 66104481, Chr11 position 66104485, Chr11 position 66104578, Chr11 position 68608767, Chr11 position 70236292, Chr11 position 70236320, Chr11 position 70236331, Chr11 position 115530032, Chr11 position 117950310, Chr11 position 117950329, Chr11 position 117950361, Chr11 position 117950362, Chr11 position 119293593, Chromosome 12 (Chr12) position 679803, Chr12 position 26039132, Chr12 position 31004558, Chr12 position 45610695, Chr12 position 45610701, Chr12 position 45610702, Chr12 position 45610706, Chr12 position 50286016, Chr12 position 52243258, Chr12 position 52243286, Chr12 position 54145732, Chr12 position 54145741, Chr12 position 54145825, Chr12 position 56115043, Chr12 position 66262229, Chr12 position 66262230, Chr12 position 66262233, Chr12 position 66262234, Chr12 position 77266621, Chr12 position 117580102, Chr12 position 123435962, Chr12 position 123436011, Chr12 position 123436065, Chr12 position 123540893, Chromosome 13 (Chr13) position 20735797, Chr13 position 23500419, Chr13 position 46771519, Chr13 position 46771520, Chr13 position 53313426, Chr13 position 113807393, Chromosome 14 (Chr14) position 38599118, Chr14 position 69170010, Chr14 position 75701632, Chr14 position 75701643, Chr14 position 90850454, Chr14 position 97524282, Chr14 position 103541602, Chr14 position 103768055, Chr14 position 104209000, Chr14 position 104209068, Chr14 position 104354645, Chr14 position 104360487, Chromosome 15 (Chr15) position 41068807, Chr15 position 61152225, Chr15 position 61152253, Chr15 position 61152313, Chr15 position 65186440, Chr15 position 68851629, Chr15 position 70667596, Chr15 position 70767206, Chr15 position 75251486, Chr15 position 77984014, Chr15 position

12

77989064, Chr15 position 83952081, Chr15 position 85402496, Chr15 position 85402497, Chr15 position 99417337, Chromosome 16 (Chr16) position 1231873, Chr16 position 1458639, Chr16 position 3023231, Chr16 position 23135832, Chr16 position 29616265, Chr16 position 31009547, Chr16 position 31009548, Chr16 position 31009590, Chr16 position 57793674, Chr16 position 57793715, Chr16 position 57793727, Chr16 position 70771056, Chr16 position 70771079, Chr16 position 70771141, Chr16 position 77332010, Chr16 position 78540378, Chr16 position 79333435, Chr16 position 84262419, Chr16 position 88701114, Chr16 position 89988308, Chr16 position 89988644, Chromosome 17 (Chr17) position 1509928, Chr17 position 1509945, Chr17 position 1509952, Chr17 position 1509953, Chr17 position 7644013, Chr17 position 16323460, Chr17 position 16323473, Chr17 position 16924561, Chr17 position 16924562, Chr17 position 16924594, Chr17 position 17717918, Chr17 position 17718591, Chr17 position 18139506, Chr17 position 35278031, Chr17 position 39677570, Chr17 position 40826257, Chr17 position 43037426, Chr17 position 43200096, Chr17 position 43200239, Chr17 position 43510142, Chr17 position 47987828, Chr17 position 48178379, Chr17 position 48596391, Chr17 position 48764165, Chr17 position 55701962, Chr17 position 73584599, Chr17 position 73993165, Chr17 position 75827716, Chr17 position 76882243, Chr17 position 78765910, Chr17 position 79544478, Chr17 position 80696474, Chromosome 18 (Chr18) position 19751759, Chr18 position 21440760, Chr18 position 45555437, Chr18 position 45555438, Chr18 position 46547891, Chr18 position 55888885, Chr18 position 56452096, Chr18 position 56452476, Chr18 position 56887181, Chr18 position 76002973, Chr18 position 77331090, Chromosome 19 (Chr19) position 677895, Chr19 position 884044, Chr19 position 884059, Chr19 position 884105, Chr19 position 884115, Chr19 position 1136511, Chr19 position 1177605, Chr19 position 1177612, Chr19 position 1177640, Chr19 position 1860601, Chr19 position 1860607, Chr19 position 2503954, Chr19 position 3434917, Chr19 position 3434921, Chr19 position 3434930, Chr19 position 3434939, Chr19 position 3434952, Chr19 position 3434954, Chr19 position 3434962, Chr19 position 3434964, Chr19 position 3434979, Chr19 position 3434985, Chr19 position 4052713, Chr19 position 4052714, Chr19 position 4052749, Chr19 position 4374591, Chr19 position 5013982, Chr19 position 5048836, Chr19 position 5048867, Chr19 position 5048877, Chr19 position 8367279, Chr19 position 8428573, Chr19 position 10254577, Chr19 position 10254578, Chr19 position 10463956, Chr19 position 10464137, Chr19 position 13203671, Chr19 position 13266925, Chr19 position 13266934, Chr19 position 13266970, Chr19 position 13842142, Chr19 position 14248494, Chr19 position 15375465, Chr19 position 17218912, Chr19 position 17346702, Chr19 position 17346702, Chr19 position 18157161, Chr19 position 18157221, Chr19 position 18157258, Chr19 position 18415877, Chr19 position 18415890, Chr19 position 30606642, Chr19 position 35531842, Chr19 position 44303112, Chr19 position 47173037, Chr19 position 47316268, Chr19 position 47778278, Chr19 position 47778298, Chromosome 20 (Chr20) position 34206950, Chr20 position 3671969, Chr20 position 48993661, Chr20 position 58406398, Chr20 position 61976049, Chr20 position 61976073, Chr20 position 62588571, Chr20 position 62588579, Chromosome 22 (Chr22) position 19738127, Chr22 position 35965176, Chr22 position 36549809, Chr22

position 36973375, Chr22 position 37447953, Chr22 position 37914998, Chr22 position 38307317, Chr22 position 39662794, and Chr22 position 45622980.

In embodiments, the method includes detecting methylation or unmethylation of at least 1 of the following sites: Chr1 position 2996653, Chr1 position 11979164, Chr1 position 12655938, Chr1 position 16450525, Chr1 position 16450542, Chr1 position 16450545, Chr1 position 16469987, Chr1 position 17494491, Chr1 position 25473203, Chr1 position 27640460, Chr1 position 29565080, Chr1 position 38493013, Chr1 position 38493030, Chr1 position 38493074, Chr1 position 46713777, Chr1 position 46914121, Chr1 position 46955744, Chr1 position 55008344, Chr1 position 109816092, Chr1 position 109816111, Chr1 position 110074669, Chr1 position 110074681, Chr1 position 110074685, Chr1 position 150949856, Chr1 position 150949857, Chr1 position 153540282, Chr1 position 155162704, Chr1 position 155162714, Chr1 position 156676611, Chr1 position 157611881, Chr1 position 182205324, Chr1 position 204118999, Chr1 position 206741875, Chr1 position 206741989, Chr1 position 212587673, Chr1 position 212841198, Chr1 position 223403952, Chr1 position 233430972, Chr1 position 234342767, Chr2 position 3454277, Chr2 position 8793724, Chr2 position 20412441, Chr2 position 42329402, Chr2 position 42329494, Chr2 position 55289272, Chr2 position 65064865, Chr2 position 70823641, Chr2 position 73143689, Chr2 position 74454110, Chr2 position 122014529, Chr2 position 128158884, Chr2 position 128158910, Chr2 position 203114171, Chr2 position 218221671, Chr2 position 219745335, Chr2 position 238341465, Chr2 position 238341542, Chr2 position 238341546, Chr2 position 238774763, Chr3 position 13323642, Chr3 position 14180153, Chr3 position 45209073, Chr3 position 45209207, Chr3 position 52525100, Chr3 position 62589658, Chr3 position 65388317, Chr3 position 65388388, Chr3 position 73599302, Chr3 position 195636893, Chr3 position 197093846, Chr4 position 3743223, Chr4 position 5755716, Chr4 position 5755717, Chr4 position 5755728, Chr4 position 5755729, Chr4 position 5755734, Chr4 position 8372861, Chr4 position 57548289, Chr5 position 1118280, Chr5 position 34564389, Chr5 position 73871907, Chr5 position 78013596, Chr5 position 78013643, Chr5 position 137802650, Chr5 position 139051189, Chr5 position 167838221, Chr5 position 177541401, Chr5 position 180018672, Chr5 position 180101026, Chr6 position 3394325, Chr6 position 3887581, Chr6 position 7236568, Chr6 position 7728692, Chr6 position 34203617, Chr6 position 37751320, Chr6 position 41410682, Chr6 position 41438516, Chr6 position 41438575, Chr6 position 43464150, Chr6 position 158734279, Chr7 position 989235, Chr7 position 2673543, Chr7 position 73508602, Chr7 position 105079565, Chr7 position 105079631, Chr7 position 151425103, Chr7 position 151425104, Chr8 position 11764017, Chr8 position 21647308, Chr8 position 22548399, Chr8 position 22548483, Chr8 position 133570537, Chr8 position 141320393, Chr8 position 141320410, Chr9 position 6566568, Chr9 position 16197862, Chr9 position 34591313, Chr9 position 98225096, Chr9 position 126126741, Chr9 position 132083428, Chr9 position 136077410, Chr9 position 139655018, Chr9 position 140205985, Chr9 position 140205985, Chr9 position 3929071, Chr10 position 30047012, Chr10 position 79702989, Chr10 position 87984905, Chr10 position

94838789, Chr10 position 102131187, Chr10 position 104196489, Chr10 position 111766879, Chr10 position 112258886, Chr10 position 112258984, Chr10 position 112259015, Chr10 position 116391763, Chr10 position 120011530, Chr10 position 126172714, Chr10 position 126172747, Chr11 position 556355, Chr11 position 821282, Chr11 position 12188937, Chr11 position 12188948, Chr11 position 12188995, Chr11 position 36057726, Chr11 position 48070143, Chr11 position 48070163, Chr11 position 10 48070166, Chr11 position 48070174, Chr11 position 65158294, Chr11 position 65158342, Chr11 position 65297089, Chr11 position 66104481, Chr11 position 66104485, Chr11 position 66104578, Chr11 position 68608767, Chr11 position 70236292, Chr11 position 70236320, Chr11 position 70236331, Chr11 position 15 115530032, Chr11 position 117950310, Chr11 position 117950329, Chr11 position 117950361, Chr11 position 117950362, Chr11 position 119293593, Chr12 position 679803, Chr12 position 26039132, Chr12 position 20 31004558, Chr12 position 45610695, Chr12 position 45610701, Chr12 position 45610702, Chr12 position 45610706, Chr12 position 50286016, Chr12 position 52243258, Chr12 position 52243286, Chr12 position 54145732, Chr12 position 54145741, Chr12 position 54145825, Chr12 position 56115043, Chr12 position 66262229, Chr12 position 66262230, Chr12 position 66262233, Chr12 position 66262234, Chr12 position 77266621, Chr12 position 117580102, Chr12 position 123435962, Chr12 position 123436011, Chr12 position 30 123436065, Chr12 position 123540893, Chr13 position 20735797, Chr13 position 23500419, Chr13 position 46771519, Chr13 position 46771520, Chr13 position 53313426, Chr13 position 113807393, Chr14 position 38599118, Chr14 position 69170010, Chr14 position 35 75701632, Chr14 position 75701643, Chr14 position 90850454, Chr14 position 97524282, Chr14 position 103541602, Chr14 position 103768055, Chr14 position 104209000, Chr14 position 104209068, Chr14 position 104354645, Chr14 position 104360487, Chr15 position 40 41068807, Chr15 position 61152225, Chr15 position 61152253, Chr15 position 61152313, Chr15 position 65186440, Chr15 position 68851629, Chr15 position 70667596, Chr15 position 70767206, Chr15 position 75251486, Chr15 position 77984014, Chr15 position 45 77989064, Chr15 position 83952081, Chr15 position 85402496, Chr15 position 85402497, Chr15 position 99417337, Chr16 position 1231873, Chr16 position 1458639, Chr16 position 3023231, Chr16 position 23135832, Chr16 position 29616265, Chr16 position 50 31009547, Chr16 position 31009548, Chr16 position 31009590, Chr16 position 57793674, Chr16 position 57793715, Chr16 position 57793727, Chr16 position 70771056, Chr16 position 70771079, Chr16 position 70771141, Chr16 position 77332010, Chr16 position 78540378, Chr16 position 79333435, Chr16 position 84262419, Chr16 position 88701114, Chr16 position 89988308, Chr16 position 89988644, Chr17 position 1509928, Chr17 position 1509945, Chr17 position 1509952, Chr17 position 1509953, Chr17 position 7644013, Chr17 position 60 16323460, Chr17 position 16323473, Chr17 position 16924561, Chr17 position 16924562, Chr17 position 16924594, Chr17 position 17717918, Chr17 position 17718591, Chr17 position 18139506, Chr17 position 35278031, Chr17 position 39677570, Chr17 position 40826257, Chr17 position 43037426, Chr17 position 43200096, Chr17 position 43200239, Chr17 position 43510142, Chr17 position 47987828, Chr17 position

48178379, Chr17 position 48596391, Chr17 position 48596391, Chr17 position 55701962, Chr17 position 55701962, Chr17 position 73993165, Chr17 position 73993165, Chr17 position 76882243, Chr17 position 76882243, Chr17 position 79544478, Chr17 position 79544478, Chr17 position 19751759, Chr18 position 19751759, Chr18 position 45555437, Chr18 position 45555437, Chr18 position 46547891, Chr18 position 46547891, Chr18 position 56452096, Chr18 position 56452096, Chr18 position 56887181, Chr18 position 56887181, Chr18 position 77331090, Chr19 position 77331090, Chr19 position 884044, Chr19 position 884044, Chr19 position 884059, Chr19 position 884059, Chr19 position 884105, Chr19 position 884105, Chr19 position 1136511, Chr19 position 1136511, Chr19 position 1177605, Chr19 position 1177605, Chr19 position 1177612, Chr19 position 1177612, Chr19 position 1177640, Chr19 position 1177640, Chr19 position 1860601, Chr19 position 1860601, Chr19 position 1860607, Chr19 position 1860607, Chr19 position 2503954, Chr19 position 2503954, Chr19 position 3434917, Chr19 position 3434917, Chr19 position 3434921, Chr19 position 3434921, Chr19 position 3434930, Chr19 position 3434930, Chr19 position 3434939, Chr19 position 3434939, Chr19 position 3434952, Chr19 position 3434952, Chr19 position 3434954, Chr19 position 3434954, Chr19 position 3434962, Chr19 position 3434962, Chr19 position 3434964, Chr19 position 3434964, Chr19 position 3434979, Chr19 position 3434979, Chr19 position 3434985, Chr19 position 3434985, Chr19 position 4052713, Chr19 position 4052713, Chr19 position 4052714, Chr19 position 4052714, Chr19 position 4052749, Chr19 position 4052749, Chr19 position 4374591, Chr19 position 5013982, Chr19 position 5013982, Chr19 position 5048836, Chr19 position 5048836, Chr19 position 5048867, Chr19 position 5048867, Chr19 position 8367279, Chr19 position 8367279, Chr19 position 8428573, Chr19 position 8428573, Chr19 position 10254577, Chr19 position 10254577, Chr19 position 10254578, Chr19 position 10254578, Chr19 position 104643956, Chr19 position 104643956, Chr19 position 10464137, Chr19 position 10464137, Chr19 position 13203671, Chr19 position 13203671, Chr19 position 13266925, Chr19 position 13266925, Chr19 position 13266934, Chr19 position 13266934, Chr19 position 13266970, Chr19 position 13266970, Chr19 position 13842142, Chr19 position 13842142, Chr19 position 14248494, Chr19 position 14248494, Chr19 position 15375465, Chr19 position 15375465, Chr19 position 17218912, Chr19 position 17218912, Chr19 position 17346702, Chr19 position 17346702, Chr19 position 17346702, Chr19 position 18157161, Chr19 position 18157161, Chr19 position 18157221, Chr19 position 18157221, Chr19 position 18157258, Chr19 position 18157258, Chr19 position 18415877, Chr19 position 18415877, Chr19 position 18415890, Chr19 position 18415890, Chr19 position 30606642, Chr19 position 30606642, Chr19 position 35531842, Chr19 position 35531842, Chr19 position 44303112, Chr19 position 44303112, Chr19 position 47173037, Chr19 position 47173037, Chr19 position 47316268, Chr19 position 47316268, Chr19 position 47778278, Chr19 position 47778278, Chr19 position 47778298, Chr20 position 47778298, Chr20 position 34206950, Chr20 position 34206950, Chr20 position 36771969, Chr20 position 36771969, Chr20 position 48993661, Chr20 position 48993661, Chr20 position 58406398, Chr20 position 58406398, Chr20 position 61976049, Chr20 position 61976049, Chr20 position 61976073, Chr20 position 61976073, Chr20 position 62588571, Chr20 position 62588571, Chr20 position 62588579, Chr22 position 62588579, Chr22 position 19738127, Chr22 position 19738127, Chr22 position 35965176, Chr22 position 35965176, Chr22 position 36549809, Chr22 position 36549809, Chr22 position 36973375, Chr22 position 36973375, Chr22 position 37447953, Chr22 position 37447953, Chr22 position 37914998, Chr22 position 37914998, Chr22 position 38307317, Chr22 position 38307317, Chr22 position 39662794, and Chr22 position 45622980.

In embodiments, the method includes detecting methylation or unmethylation of at least 2 of the following sites: Chr1 position 2996653, Chr1 position 11979164, Chr1 position 12655938, Chr1 position 16450525, Chr1 position 16450542, Chr1 position 16450542, Chr1 position 16450545, Chr1 position 16469987, Chr1 position 16469987, Chr1 position 17494491, Chr1 position 17494491, Chr1 position 25473203, Chr1 position 25473203, Chr1 position 27640460, Chr1 position 27640460, Chr1 position 29565080, Chr1 position 29565080, Chr1 position 38493013, Chr1 position 38493013, Chr1 position 38493030, Chr1 position 38493030, Chr1 position 38493074, Chr1 position 38493074, Chr1 position 46713777, Chr1 position 46713777, Chr1 position 46914121, Chr1 position 46914121, Chr1 position 46955744, Chr1 position 46955744, Chr1 position 55008344, Chr1 position 55008344, Chr1 position 109816092, Chr1 position 109816092, Chr1 position 109816111, Chr1 position 109816111, Chr1 position 110074669, Chr1 position 110074669, Chr1 position 110074685, Chr1 position 110074685, Chr1 position 150949856, Chr1 position 150949856, Chr1 position 153540282, Chr1 position 153540282, Chr1 position 155162704, Chr1 position 155162704, Chr1 position 155162714, Chr1 position 155162714, Chr1 position 156676611, Chr1 position 156676611, Chr1 position 157611881, Chr1 position 157611881, Chr1 position 182205324, Chr1 position 182205324, Chr1 position 204118999, Chr1 position 204118999, Chr1 position 206741989, Chr1 position 206741989, Chr1 position 212841198, Chr1 position 212841198, Chr1 position 223403952, Chr1 position 223403952, Chr1 position

234342767, Chr2 position 3454277, Chr2 position 8793724, Chr2 position 20412441, Chr2 position 42329402, Chr2 position 42329494, Chr2 position 55289272, Chr2 position 65064865, Chr2 position 65064865, Chr2 position 70823641, Chr2 position 73143689, Chr2 position 73143689, Chr2 position 122014529, Chr2 position 122014529, Chr2 position 128158910, Chr2 position 128158910, Chr2 position 203114171, Chr2 position 218221671, Chr2 position 218221671, Chr2 position 219745335, Chr2 position 238341465, Chr2 position 238341465, Chr2 position 238341546, Chr2 position 238341546, Chr2 position 238774763, Chr3 position 13323642, Chr3 position 13323642, Chr3 position 45209073, Chr3 position 45209073, Chr3 position 52525100, Chr3 position 52525100, Chr3 position 65388317, Chr3 position 65388317, Chr3 position 73599302, Chr3 position 73599302, Chr3 position 197093846, Chr4 position 3743223, Chr4 position 5755716, Chr4 position 5755717, Chr4 position 5755728, Chr4 position 5755729, Chr4 position 5755734, Chr4 position 8372861, Chr4 position 8372861, Chr5 position 34564389, Chr5 position 34564389, Chr5 position 73871907, Chr5 position 78013596, Chr5 position 78013643, Chr5 position 137802650, Chr5 position 137802650, Chr5 position 139051189, Chr5 position 167838221, Chr5 position 167838221, Chr5 position 177541401, Chr5 position 180018672, Chr5 position 180018672, Chr6 position 3394325, Chr6 position 3394325, Chr6 position 3887581, Chr6 position 3887581, Chr6 position 7236568, Chr6 position 7236568, Chr6 position 7728692, Chr6 position 7728692, Chr6 position 34203617, Chr6 position 34203617, Chr6 position 37751320, Chr6 position 37751320, Chr6 position 41410682, Chr6 position 41410682, Chr6 position 41438516, Chr6 position 41438516, Chr6 position 41438575, Chr6 position 41438575, Chr6 position 43464150, Chr6 position 43464150, Chr6 position 158734279, Chr7 position 989235, Chr7 position 2673543, Chr7 position 2673543, Chr7 position 73508602, Chr7 position 73508602, Chr7 position 105079565, Chr7 position 105079565, Chr7 position 105079631, Chr7 position 105079631, Chr7 position 151425103, Chr7 position 151425103, Chr8 position 11764017, Chr8 position 11764017, Chr8 position 21647308, Chr8 position 21647308, Chr8 position 22548399, Chr8 position 22548399, Chr8 position 133570537, Chr8 position 133570537, Chr8 position 141320410, Chr9 position 141320410, Chr9 position 141320410, Chr9 position 141320410, Chr9 position 16197862, Chr9 position 16197862, Chr9 position 34591313, Chr9 position 34591313, Chr9 position 98225096, Chr9 position 98225096, Chr9 position 126126741, Chr9 position 126126741, Chr9 position 132083428, Chr9 position 132083428, Chr9 position 136077410, Chr9 position 136077410, Chr9 position 139655018, Chr9 position 139655018, Chr9 position 140205985, Chr9 position 140205985, Chr9 position 140205985, Chr9 position 140205985, Chr9 position 140205997, Chr10 position 140205997, Chr10 position 3929071, Chr10 position 3929071, Chr10 position 30047012, Chr10 position 30047012, Chr10 position 79702989, Chr10 position 79702989, Chr10 position 87984905, Chr10 position 87984905, Chr10 position 94838789, Chr10 position 94838789, Chr10 position 102131187, Chr10 position 102131187, Chr10 position 104196489, Chr10 position 104196489, Chr10 position 111766879, Chr10 position 111766879, Chr10 position 112258886, Chr10 position 112258886, Chr10 position 112258886, Chr10 position 112258886, Chr10 position 112259015, Chr10 position 112259015, Chr10 position 116391763, Chr10 position 116391763, Chr10 position 120011530, Chr10 position 120011530, Chr10 position 126172714, Chr10 position 126172714, Chr10 position 126172747, Chr11 position 5563555, Chr11 position 5563555, Chr11 position 821282, Chr11 position 821282, Chr11 position 12188937, Chr11 position 12188937, Chr11 position 12188948, Chr11 position 12188948, Chr11 position 12188995, Chr11 position 12188995, Chr11 position 36057726, Chr11 position 48070143, Chr11 position 48070143, Chr11 position 48070163, Chr11 position 48070163, Chr11 position 48070166, Chr11 position 48070166, Chr11 position 48070174, Chr11 position 48070174, Chr11 position 65158294, Chr11 position 65158294, Chr11 position 65158342, Chr11 position 65158342, Chr11 position 65297089, Chr11 position 65297089, Chr11 position 66104481, Chr11 position 66104481, Chr11 position 66104485, Chr11 position 66104485, Chr11 position 66104578, Chr11 position 66104578, Chr11 position 68608767, Chr11 position 68608767, Chr11 position 70236320, Chr11 position 70236320, Chr11 position 70236331, Chr11 position 70236331, Chr11 position 115530032, Chr11 position 115530032, Chr11 position 117950310, Chr11 position 117950310, Chr11 position 117950329, Chr11 position 117950329, Chr11 position 117950361, Chr11 position 117950361, Chr11 position 117950362, Chr11 position 117950362, Chr12 position 119293593, Chr12 position 119293593, Chr12 position 679803, Chr12 position 679803, Chr12 position 26039132, Chr12 position 26039132, Chr12 position 31004558, Chr12 position 31004558, Chr12 position 45610695, Chr12 position 45610695, Chr12 position 45610701, Chr12 position 45610701, Chr12 position 45610702, Chr12 position 45610702, Chr12 position 50286016, Chr12 position 50286016, Chr12 position 52243258, Chr12 position 52243258, Chr12 position 52243286, Chr12 position 52243286, Chr12 position 54145732, Chr12 position 54145732, Chr12 position 54145741, Chr12 position 54145741, Chr12 position

54145825, Chr12 position 56115043, Chr12 position 66262229, Chr12 position 66262230, Chr12 position 66262233, Chr12 position 66262234, Chr12 position 77266621, Chr12 position 117580102, Chr12 position 123435962, Chr12 position 123436011, Chr12 position 123436065, Chr12 position 123540893, Chr13 position 20735797, Chr13 position 23500419, Chr13 position 46771519, Chr13 position 46771520, Chr13 position 53313426, Chr13 position 113807393, Chr14 position 38599118, Chr14 position 69170010, Chr14 position 75701632, Chr14 position 75701643, Chr14 position 90850454, Chr14 position 97524282, Chr14 position 103541602, Chr14 position 103768055, Chr14 position 104209000, Chr14 position 104209068, Chr14 position 104354645, Chr14 position 104360487, Chr15 position 41068807, Chr15 position 61152225, Chr15 position 61152253, Chr15 position 61152313, Chr15 position 65186440, Chr15 position 68851629, Chr15 position 70667596, Chr15 position 70767206, Chr15 position 75251486, Chr15 position 77984014, Chr15 position 77989064, Chr15 position 83952081, Chr15 position 85402496, Chr15 position 85402497, Chr15 position 99417337, Chr16 position 1231873, Chr16 position 1458639, Chr16 position 3023231, Chr16 position 23135832, Chr16 position 29616265, Chr16 position 31009547, Chr16 position 31009548, Chr16 position 31009590, Chr16 position 57793674, Chr16 position 57793715, Chr16 position 57793727, Chr16 position 70771056, Chr16 position 70771079, Chr16 position 70771141, Chr16 position 77332010, Chr16 position 78540378, Chr16 position 79333435, Chr16 position 84262419, Chr16 position 88701114, Chr16 position 89988308, Chr16 position 89988644, Chr17 position 1509928, Chr17 position 1509945, Chr17 position 1509952, Chr17 position 1509953, Chr17 position 7644013, Chr17 position 16323460, Chr17 position 16323473, Chr17 position 16924561, Chr17 position 16924562, Chr17 position 16924594, Chr17 position 17717918, Chr17 position 17718591, Chr17 position 18139506, Chr17 position 35278031, Chr17 position 39677570, Chr17 position 40826257, Chr17 position 43037426, Chr17 position 43200096, Chr17 position 43200239, Chr17 position 43510142, Chr17 position 47987828, Chr17 position 48178379, Chr17 position 48596391, Chr17 position 48764165, Chr17 position 55701962, Chr17 position 73584599, Chr17 position 73993165, Chr17 position 75827716, Chr17 position 76882243, Chr17 position 78765910, Chr17 position 79544478, Chr17 position 80696474, Chr18 position 19751759, Chr18 position 21440760, Chr18 position 45555437, Chr18 position 45555438, Chr18 position 46547891, Chr18 position 55888885, Chr18 position 56452096, Chr18 position 56452476, Chr18 position 56887181, Chr18 position 76002973, Chr18 position 77331090, Chr19 position 677895, Chr19 position 884044, Chr19 position 884059, Chr19 position 884105, Chr19 position 884115, Chr19 position 1136511, Chr19 position 1177605, Chr19 position 1177612, Chr19 position 1177640, Chr19 position 1860601, Chr19 position 1860607, Chr19 position 2503954, Chr19 position 3434917, Chr19 position 3434921, Chr19 position 3434930, Chr19 position 3434939, Chr19 position 3434952, Chr19 position 3434954, Chr19 position 3434962, Chr19 position 3434964, Chr19 position 3434979, Chr19 position 3434985, Chr19 position 4052713, Chr19 position 4052714, Chr19 position 4052749, Chr19 position 4374591, Chr19 position 5013982, Chr19 position 5048836, Chr19 position 5048867, Chr19 position 5048877, Chr19 position 8367279,

Chr19 position 8428573, Chr19 position 10254577, Chr19 position 10254578, Chr19 position 10463956, Chr19 position 10464137, Chr19 position 13203671, Chr19 position 13266925, Chr19 position 13266934, Chr19 position 5 13266970, Chr19 position 13842142, Chr19 position 14248494, Chr19 position 15375465, Chr19 position 17218912, Chr19 position 17346702, Chr19 position 17346702, Chr19 position 18157161, Chr19 position 18157221, Chr19 position 18157258, Chr19 position 10 18415877, Chr19 position 18415890, Chr19 position 30606642, Chr19 position 35531842, Chr19 position 44303112, Chr19 position 47173037, Chr19 position 47316268, Chr19 position 47778278, Chr19 position 47778298, Chr20 position 34206950, Chr20 position 15 36771969, Chr20 position 48993661, Chr20 position 58406398, Chr20 position 61976049, Chr20 position 61976073, Chr20 position 62588571, Chr20 position 62588579, Chr22 position 19738127, Chr22 position 35965176, Chr22 position 36549809, Chr22 position 20 36973375, Chr22 position 37447953, Chr22 position 37914998, Chr22 position 38307317, Chr22 position 39662794, and Chr22 position 45622980.

In embodiments, the method includes detecting methylation or unmethylation of at least 3 of the following sites:

25 Chr1 position 2996653, Chr1 position 11979164, Chr1 position 12655938, Chr1 position 16450525, Chr1 position 16450542, Chr1 position 16450545, Chr1 position 16469987, Chr1 position 17494491, Chr1 position 25 25473203, Chr1 position 27640460, Chr1 position 29565080, Chr1 position 38493013, Chr1 position 38493030, Chr1 position 38493074, Chr1 position 46713777, Chr1 position 46914121, Chr1 position 46955744, Chr1 position 55008344, Chr1 position 109816092, Chr1 position 109816111, Chr1 position 35 110074669, Chr1 position 110074681, Chr1 position 110074685, Chr1 position 150949856, Chr1 position 150949857, Chr1 position 153540282, Chr1 position 155162704, Chr1 position 155162714, Chr1 position 156676611, Chr1 position 157611881, Chr1 position 40 182205324, Chr1 position 204118999, Chr1 position 206741875, Chr1 position 206741989, Chr1 position 212587673, Chr1 position 212841198, Chr1 position 223403952, Chr1 position 233430972, Chr1 position 234342767, Chr2 position 3454277, Chr2 position 8793724, 45 Chr2 position 20412441, Chr2 position 42329402, Chr2 position 42329494, Chr2 position 55289272, Chr2 position 65064865, Chr2 position 70823641, Chr2 position 73143689, Chr2 position 74454110, Chr2 position 122014529, Chr2 position 128158884, Chr2 position 50 128158910, Chr2 position 203114171, Chr2 position 218221671, Chr2 position 219745335, Chr2 position 238341465, Chr2 position 238341542, Chr2 position 238341546, Chr2 position 238774763, Chr3 position 13323642, Chr3 position 14180153, Chr3 position 45209073, Chr3 position 45209207, Chr3 position 52525100, Chr3 position 62589658, Chr3 position 65388317, Chr3 position 65388388, Chr3 position 73599302, Chr3 position 195636893, Chr3 position 197093846, Chr4 position 3743223, Chr4 position 5755716, 60 Chr4 position 5755717, Chr4 position 5755728, Chr4 position 5755729, Chr4 position 5755734, Chr4 position 8372861, Chr4 position 57548289, Chr5 position 1118280, Chr5 position 34564389, Chr5 position 73871907, Chr5 position 78013596, Chr5 position 78013643, Chr5 position 137802650, Chr5 position 139051189, Chr5 position 167838221, Chr5 position 177541401, Chr5 position 180018672, Chr6 position

3394325, Chr6 position 3887581, Chr6 position 7236568, Chr6 position 7728692, Chr6 position 34203617, Chr6 position 37751320, Chr6 position 41410682, Chr6 position 41438516, Chr6 position 41438575, Chr6 position 43464150, Chr6 position 158734279, Chr7 position 989235, Chr7 position 2673543, Chr7 position 73508602, Chr7 position 105079565, Chr7 position 105079631, Chr7 position 151425103, Chr7 position 151425104, Chr8 position 11764017, Chr8 position 21647308, Chr8 position 22548399, Chr8 position 22548483, Chr8 position 133570537, Chr8 position 141320393, Chr8 position 141320410, Chr9 position 6566568, Chr9 position 16197862, Chr9 position 34591313, Chr9 position 98225096, Chr9 position 126126741, Chr9 position 132083428, Chr9 position 136077410, Chr9 position 139655018, Chr9 position 140205985, Chr9 position 140205985, Chr9 position 140205997, Chr10 position 3929071, Chr10 position 30047012, Chr10 position 79702989, Chr10 position 87984905, Chr10 position 94838789, Chr10 position 102131187, Chr10 position 104196489, Chr10 position 111766879, Chr10 position 112258886, Chr10 position 112258984, Chr10 position 112259015, Chr10 position 116391763, Chr10 position 120011530, Chr10 position 126172714, Chr10 position 126172747, Chr11 position 556355, Chr11 position 821282, Chr11 position 12188937, Chr11 position 12188948, Chr11 position 12188995, Chr11 position 36057726, Chr11 position 48070143, Chr11 position 48070163, Chr11 position 48070166, Chr11 position 48070174, Chr11 position 65158294, Chr11 position 65158342, Chr11 position 65297089, Chr11 position 66104481, Chr11 position 66104485, Chr11 position 66104578, Chr11 position 68608767, Chr11 position 70236292, Chr11 position 70236320, Chr11 position 70236331, Chr11 position 115530032, Chr11 position 117950310, Chr11 position 117950329, Chr11 position 117950361, Chr11 position 117950362, Chr11 position 119293593, Chr12 position 679803, Chr12 position 26039132, Chr12 position 31004558, Chr12 position 45610695, Chr12 position 45610701, Chr12 position 45610702, Chr12 position 45610706, Chr12 position 50286016, Chr12 position 52243258, Chr12 position 52243286, Chr12 position 54145732, Chr12 position 54145741, Chr12 position 54145825, Chr12 position 56115043, Chr12 position 66262229, Chr12 position 66262230, Chr12 position 66262233, Chr12 position 66262234, Chr12 position 77266621, Chr12 position 117580102, Chr12 position 123435962, Chr12 position 123436011, Chr12 position 123436065, Chr12 position 123540893, Chr13 position 20735797, Chr13 position 23500419, Chr13 position 46771519, Chr13 position 46771520, Chr13 position 53313426, Chr13 position 113807393, Chr14 position 38599118, Chr14 position 69170010, Chr14 position 75701632, Chr14 position 75701643, Chr14 position 90850454, Chr14 position 97524282, Chr14 position 103541602, Chr14 position 103768055, Chr14 position 104209000, Chr14 position 104209068, Chr14 position 104354645, Chr14 position 104360487, Chr15 position 41068807, Chr15 position 61152225, Chr15 position 61152253, Chr15 position 61152313, Chr15 position 65186440, Chr15 position 68851629, Chr15 position 70667596, Chr15 position 70767206, Chr15 position 75251486, Chr15 position 77984014, Chr15 position 77989064, Chr15 position 83952081, Chr15 position 85402496, Chr15 position 85402497, Chr15 position 99417337, Chr16 position 1231873, Chr16 position 1458639, Chr16 position 3023231, Chr16 position 23135832, Chr16 position 31009547, Chr16 position 31009590, Chr16 position 57793715, Chr16 position 57793727, Chr16 position 5 70771056, Chr16 position 70771141, Chr16 position 78540378, Chr16 position 84262419, Chr16 position 89988308, Chr16 position 10 1509928, Chr17 position 1509945, Chr17 position 1509953, Chr17 position 7644013, Chr17 position 16323460, Chr17 position 16323473, Chr17 position 16924561, Chr17 position 16924562, Chr17 position 16924594, Chr17 position 17718591, Chr17 position 35278031, Chr17 position 40826257, Chr17 position 43200096, Chr17 position 43510142, Chr17 position 20 48178379, Chr17 position 48764165, Chr17 position 73584599, Chr17 position 75827716, Chr17 position 78765910, Chr17 position 80696474, Chr18 position 21440760, Chr18 position 45555438, Chr18 position 55888885, Chr18 position 30 56452476, Chr18 position 76002973, Chr18 position 677895, Chr19 position 884044, Chr19 position 884059, Chr19 position 884105, Chr19 position 884115, Chr19 position 1136511, Chr19 position 1177605, Chr19 position 1177612, Chr19 position 1177640, Chr19 position 1860601, 35 Chr19 position 1860607, Chr19 position 2503954, Chr19 position 3434917, Chr19 position 3434921, Chr19 position 3434930, Chr19 position 3434939, Chr19 position 3434952, Chr19 position 3434954, Chr19 position 3434962, Chr19 position 3434964, Chr19 position 3434979, Chr19 position 40 3434985, Chr19 position 4052713, Chr19 position 4052714, Chr19 position 4052749, Chr19 position 4374591, Chr19 position 5013982, Chr19 position 5048836, Chr19 position 5048867, Chr19 position 5048877, Chr19 position 8367279, Chr19 position 8428573, Chr19 position 10254577, Chr19 position 45 10254578, Chr19 position 10464137, Chr19 position 13203671, Chr19 position 13266925, Chr19 position 13266934, Chr19 position 13266970, Chr19 position 13842142, Chr19 position 14248494, Chr19 position 15375465, Chr19 position 17218912, Chr19 position 17346702, Chr19 position 17346702, Chr19 position 1815721, Chr19 position 18157221, Chr19 position 18415877, Chr19 position 30 30606642, Chr19 position 44303112, Chr19 position 47316268, Chr19 position 47778298, Chr20 position 36771969, Chr20 position 58406398, Chr20 position 60 61976073, Chr20 position 62588579, Chr22 position 35965176, Chr22 position 36973375, Chr22 position 37914998, Chr22 position 65 39662794, and Chr22 position 45622980.

In embodiments, the method includes detecting methylation or unmethylation of at least 4 of the following sites:

Chr1 position 2996653, Chr1 position 11979164, Chr1 position 12655938, Chr1 position 16450525, Chr1 position 16450542, Chr1 position 16450545, Chr1 position 16469987, Chr1 position 17494491, Chr1 position 25473203, Chr1 position 27640460, Chr1 position 29565080, Chr1 position 38493013, Chr1 position 38493030, Chr1 position 38493074, Chr1 position 46713777, Chr1 position 46914121, Chr1 position 46955744, Chr1 position 55008344, Chr1 position 109816092, Chr1 position 109816111, Chr1 position 110074669, Chr1 position 110074685, Chr1 position 150949856, Chr1 position 150949857, Chr1 position 153540282, Chr1 position 155162704, Chr1 position 155162714, Chr1 position 156676611, Chr1 position 157611881, Chr1 position 182205324, Chr1 position 204118999, Chr1 position 206741875, Chr1 position 206741989, Chr1 position 212587673, Chr1 position 212841198, Chr1 position 223403952, Chr1 position 233430972, Chr1 position 234342767, Chr2 position 3454277, Chr2 position 8793724, Chr2 position 20412441, Chr2 position 42329402, Chr2 position 42329494, Chr2 position 55289272, Chr2 position 65064865, Chr2 position 70823641, Chr2 position 73143689, Chr2 position 74454110, Chr2 position 122014529, Chr2 position 128158884, Chr2 position 128158910, Chr2 position 203114171, Chr2 position 218221671, Chr2 position 219745335, Chr2 position 238341465, Chr2 position 238341542, Chr2 position 238341546, Chr2 position 238774763, Chr3 position 13323642, Chr3 position 14180153, Chr3 position 45209073, Chr3 position 45209207, Chr3 position 52525100, Chr3 position 62589658, Chr3 position 65388317, Chr3 position 65388388, Chr3 position 73599302, Chr3 position 195636893, Chr3 position 197093846, Chr4 position 3743223, Chr4 position 5755716, Chr4 position 5755717, Chr4 position 5755728, Chr4 position 5755729, Chr4 position 5755734, Chr4 position 8372861, Chr4 position 57548289, Chr5 position 1118280, Chr5 position 34564389, Chr5 position 73871907, Chr5 position 78013596, Chr5 position 78013643, Chr5 position 137802650, Chr5 position 139051189, Chr5 position 167838221, Chr5 position 177541401, Chr5 position 180018672, Chr5 position 180101026, Chr6 position 3394325, Chr6 position 3887581, Chr6 position 7236568, Chr6 position 7728692, Chr6 position 34203617, Chr6 position 37751320, Chr6 position 41410682, Chr6 position 41438516, Chr6 position 41438575, Chr6 position 43464150, Chr6 position 158734279, Chr7 position 989235, Chr7 position 2673543, Chr7 position 73508602, Chr7 position 105079565, Chr7 position 105079631, Chr7 position 151425103, Chr7 position 151425104, Chr8 position 11764017, Chr8 position 21647308, Chr8 position 22548399, Chr8 position 22548483, Chr8 position 133570537, Chr8 position 141320393, Chr8 position 141320410, Chr9 position 6566568, Chr9 position 16197862, Chr9 position 34591313, Chr9 position 98225096, Chr9 position 126126741, Chr9 position 132083428, Chr9 position 136077410, Chr9 position 139655018, Chr9 position 140205985, Chr9 position 140205985, Chr9 position 140205997, Chr10 position 3929071, Chr10 position 30047012, Chr10 position 79702989, Chr10 position 87984905, Chr10 position 94838789, Chr10 position 102131187, Chr10 position 104196489, Chr10 position 111766879, Chr10 position 112258886, Chr10 position 112258984, Chr10 position 112259015, Chr10 position 116391763, Chr10 position 120011530, Chr10 position 126172714, Chr10 position

126172747, Chr11 position 556355, Chr11 position 821282, Chr11 position 12188937, Chr11 position 12188948, Chr11 position 12188995, Chr11 position 36057726, Chr11 position 48070143, Chr11 position 48070163, Chr11 position 5 48070166, Chr11 position 48070174, Chr11 position 65158294, Chr11 position 65158342, Chr11 position 65297089, Chr11 position 66104481, Chr11 position 66104578, Chr11 position 68608767, Chr11 position 70236292, Chr11 position 10 70236320, Chr11 position 70236331, Chr11 position 115530032, Chr11 position 117950310, Chr11 position 117950329, Chr11 position 117950361, Chr11 position 117950362, Chr11 position 119293593, Chr12 position 15 679803, Chr12 position 26039132, Chr12 position 31004558, Chr12 position 45610695, Chr12 position 45610701, Chr12 position 45610702, Chr12 position 45610706, Chr12 position 50286016, Chr12 position 52243258, Chr12 position 52243286, Chr12 position 54145732, Chr12 position 54145741, Chr12 position 20 54145825, Chr12 position 56115043, Chr12 position 66262229, Chr12 position 66262230, Chr12 position 66262233, Chr12 position 66262234, Chr12 position 77266621, Chr12 position 117580102, Chr12 position 123435962, Chr12 position 123436011, Chr12 position 25 123436065, Chr12 position 123540893, Chr13 position 20735797, Chr13 position 23500419, Chr13 position 46771519, Chr13 position 46771520, Chr13 position 53313426, Chr13 position 113807393, Chr14 position 38599118, Chr14 position 69170010, Chr14 position 30 75701632, Chr14 position 75701643, Chr14 position 90850454, Chr14 position 97524282, Chr14 position 103541602, Chr14 position 103768055, Chr14 position 104209000, Chr14 position 104209068, Chr14 position 104354645, Chr14 position 104360487, Chr15 position 40 41068807, Chr15 position 61152225, Chr15 position 61152253, Chr15 position 65186440, Chr15 position 68851629, Chr15 position 70667596, Chr15 position 70767206, Chr15 position 75251486, Chr15 position 77984014, Chr15 position 77989064, Chr15 position 83952081, Chr15 position 85402496, Chr15 position 85402497, Chr15 position 99417337, Chr16 position 1231873, Chr16 position 1458639, Chr16 position 3023231, Chr16 position 23135832, Chr16 position 29616265, Chr16 position 45 31009547, Chr16 position 31009548, Chr16 position 31009590, Chr16 position 57793674, Chr16 position 57793715, Chr16 position 57793727, Chr16 position 70771056, Chr16 position 70771079, Chr16 position 70771141, Chr16 position 77332010, Chr16 position 78540378, Chr16 position 79333435, Chr16 position 84262419, Chr16 position 88701114, Chr16 position 89988308, Chr16 position 89988644, Chr17 position 1509928, Chr17 position 1509945, Chr17 position 1509952, Chr17 position 1509953, Chr17 position 7644013, Chr17 50 55 16323460, Chr17 position 16323473, Chr17 position 16924561, Chr17 position 16924562, Chr17 position 16924594, Chr17 position 17717918, Chr17 position 17718591, Chr17 position 18139506, Chr17 position 35278031, Chr17 position 39677570, Chr17 position 40826257, Chr17 position 43037426, Chr17 position 43200096, Chr17 position 43200239, Chr17 position 43510142, Chr17 position 47987828, Chr17 position 48178379, Chr17 position 48596391, Chr17 position 48764165, Chr17 position 55701962, Chr17 position 65 73584599, Chr17 position 73993165, Chr17 position 75827716, Chr17 position 76882243, Chr17 position 78765910, Chr17 position 79544478, Chr17 position

US 12,391,993 B2

23

80696474, Chr18 position 19751759, Chr18 position 21440760, Chr18 position 45555437, Chr18 position 45555438, Chr18 position 46547891, Chr18 position 55888885, Chr18 position 56452096, Chr18 position 56452476, Chr18 position 56887181, Chr18 position 76002973, Chr18 position 77331090, Chr19 position 677895, Chr19 position 884044, Chr19 position 884059, Chr19 position 884105, Chr19 position 884115, Chr19 position 1136511, Chr19 position 1177605, Chr19 position 1177612, Chr19 position 1177640, Chr19 position 1860601, Chr19 position 1860607, Chr19 position 2503954, Chr19 position 3434917, Chr19 position 3434921, Chr19 position 3434930, Chr19 position 3434939, Chr19 position 3434952, Chr19 position 3434954, Chr19 position 3434962, Chr19 position 3434964, Chr19 position 3434979, Chr19 position 3434985, Chr19 position 4052713, Chr19 position 4052714, Chr19 position 4052749, Chr19 position 4374591, Chr19 position 5013982, Chr19 position 5048836, Chr19 position 5048867, Chr19 position 5048877, Chr19 position 8367279, Chr19 position 8428573, Chr19 position 10254577, Chr19 position 10254578, Chr19 position 10463956, Chr19 position 10464137, Chr19 position 13203671, Chr19 position 13266925, Chr19 position 13266934, Chr19 position 13266970, Chr19 position 13842142, Chr19 position 14248494, Chr19 position 15375465, Chr19 position 17218912, Chr19 position 17346702, Chr19 position 17346702, Chr19 position 18157161, Chr19 position 18157221, Chr19 position 18157258, Chr19 position 18415877, Chr19 position 18415890, Chr19 position 30606642, Chr19 position 35531842, Chr19 position 44303112, Chr19 position 47173037, Chr19 position 47316268, Chr19 position 47778278, Chr19 position 47778298, Chr20 position 34206950, Chr20 position 36771969, Chr20 position 48993661, Chr20 position 58406398, Chr20 position 61976049, Chr20 position 61976073, Chr20 position 62588571, Chr20 position 62588579, Chr22 position 19738127, Chr22 position 35965176, Chr22 position 36549809, Chr22 position 36973375, Chr22 position 37447953, Chr22 position 37914998, Chr22 position 38307317, Chr22 position 39662794, and Chr22 position 45622980.

In embodiments, the method includes detecting methylation or unmethylation of at least 5 of the following sites: Chr1 position 2996653, Chr1 position 11979164, Chr1 position 12655938, Chr1 position 16450525, Chr1 position 16450542, Chr1 position 16450545, Chr1 position 16469987, Chr1 position 17494491, Chr1 position 25473203, Chr1 position 27640460, Chr1 position 29565080, Chr1 position 38493013, Chr1 position 38493030, Chr1 position 38493074, Chr1 position 46713777, Chr1 position 46914121, Chr1 position 46955744, Chr1 position 55008344, Chr1 position 109816092, Chr1 position 109816111, Chr1 position 110074669, Chr1 position 110074681, Chr1 position 110074685, Chr1 position 150949856, Chr1 position 150949857, Chr1 position 153540282, Chr1 position 155162704, Chr1 position 155162714, Chr1 position 156676611, Chr1 position 157611881, Chr1 position 182205324, Chr1 position 204118999, Chr1 position 206741875, Chr1 position 206741989, Chr1 position 212587673, Chr1 position 212841198, Chr1 position 223403952, Chr1 position 233430972, Chr1 position 234342767, Chr2 position 3454277, Chr2 position 8793724, Chr2 position 20412441, Chr2 position 42329402, Chr2 position 42329494, Chr2 position 55289272, Chr2 position 65064865, Chr2 position 70823641, Chr2 position 73143689, Chr2 position 74454110, Chr2 position

24

122014529, Chr2 position 128158910, Chr2 position 218221671, Chr2 position 238341465, Chr2 position 238341542, Chr2 position 5 238341546, Chr2 position 238774763, Chr3 position 13323642, Chr3 position 14180153, Chr3 position 45209073, Chr3 position 45209207, Chr3 position 52525100, Chr3 position 62589658, Chr3 position 65388317, Chr3 position 65388388, Chr3 position 10 73599302, Chr3 position 195636893, Chr3 position 197093846, Chr4 position 3743223, Chr4 position 5755716, Chr4 position 5755717, Chr4 position 5755728, Chr4 position 5755729, Chr4 position 5755734, Chr4 position 8372861, Chr4 position 57548289, Chr5 position 1118280, Chr5 position 34564389, Chr5 position 73871907, Chr5 position 78013596, Chr5 position 78013643, Chr5 position 137802650, Chr5 position 139051189, Chr5 position 167838221, Chr5 position 177541401, Chr5 position 180018672, Chr5 position 180101026, Chr6 position 15 20 3394325, Chr6 position 3887581, Chr6 position 7236568, Chr6 position 7728692, Chr6 position 34203617, Chr6 position 37751320, Chr6 position 41410682, Chr6 position 41438516, Chr6 position 41438575, Chr6 position 43464150, Chr6 position 158734279, Chr7 position 989235, Chr7 position 2673543, Chr7 position 73508602, Chr7 position 105079565, Chr7 position 105079631, Chr7 position 151425103, Chr7 position 151425104, Chr8 position 11764017, Chr8 position 21647308, Chr8 position 22548399, Chr8 position 22548483, Chr8 position 30 35 133570537, Chr8 position 141320393, Chr8 position 141320410, Chr9 position 6566568, Chr9 position 16197862, Chr9 position 34591313, Chr9 position 98225096, Chr9 position 126126741, Chr9 position 132083428, Chr9 position 136077410, Chr9 position 139655018, Chr9 position 140205985, Chr9 position 140205985, Chr9 position 140205997, Chr10 position 3929071, Chr10 position 30047012, Chr10 position 79702989, Chr10 position 87984905, Chr10 position 94838789, Chr10 position 102131187, Chr10 position 40 45 104196489, Chr10 position 111766879, Chr10 position 112258886, Chr10 position 112258984, Chr10 position 112259015, Chr10 position 116391763, Chr10 position 120011530, Chr10 position 126172714, Chr10 position 126172747, Chr11 position 556355, Chr11 position 821282, Chr11 position 12188937, Chr11 position 12188948, Chr11 position 12188995, Chr11 position 36057726, Chr11 position 48070143, Chr11 position 48070163, Chr11 position 48070166, Chr11 position 48070174, Chr11 position 65158294, Chr11 position 65158342, Chr11 position 50 55 65297089, Chr11 position 66104481, Chr11 position 66104485, Chr11 position 66104578, Chr11 position 68608767, Chr11 position 70236292, Chr11 position 70236320, Chr11 position 70236331, Chr11 position 115530032, Chr11 position 117950310, Chr11 position 117950329, Chr11 position 117950361, Chr11 position 117950362, Chr11 position 119293593, Chr12 position 679803, Chr12 position 26039132, Chr12 position 31004558, Chr12 position 45610695, Chr12 position 45610701, Chr12 position 45610702, Chr12 position 45610706, Chr12 position 50286016, Chr12 position 52243258, Chr12 position 52243286, Chr12 position 54145732, Chr12 position 54145741, Chr12 position 54145825, Chr12 position 56115043, Chr12 position 66262229, Chr12 position 66262230, Chr12 position 66262233, Chr12 position 66262234, Chr12 position 77266621, Chr12 position 117580102, Chr12 position 123435962, Chr12 position 123436011, Chr12 position

123436065, Chr12 position 123540893, Chr13 position 20735797, Chr13 position 23500419, Chr13 position 46771519, Chr13 position 46771520, Chr13 position 53313426, Chr13 position 113807393, Chr14 position 38599118, Chr14 position 69170010, Chr14 position 75701632, Chr14 position 75701643, Chr14 position 90850454, Chr14 position 97524282, Chr14 position 103541602, Chr14 position 103768055, Chr14 position 104209000, Chr14 position 104209068, Chr14 position 104354645, Chr14 position 104360487, Chr15 position 41068807, Chr15 position 61152225, Chr15 position 61152253, Chr15 position 61152313, Chr15 position 65186440, Chr15 position 68851629, Chr15 position 70667596, Chr15 position 70767206, Chr15 position 75251486, Chr15 position 77984014, Chr15 position 77989064, Chr15 position 83952081, Chr15 position 85402496, Chr15 position 85402497, Chr15 position 99417337, Chr16 position 1231873, Chr16 position 1458639, Chr16 position 3023231, Chr16 position 23135832, Chr16 position 29616265, Chr16 position 31009547, Chr16 position 31009548, Chr16 position 31009590, Chr16 position 57793674, Chr16 position 57793715, Chr16 position 57793727, Chr16 position 70771056, Chr16 position 70771079, Chr16 position 70771141, Chr16 position 77332010, Chr16 position 78540378, Chr16 position 79333435, Chr16 position 84262419, Chr16 position 88701114, Chr16 position 89988308, Chr16 position 89988644, Chr17 position 1509928, Chr17 position 1509945, Chr17 position 1509952, Chr17 position 1509953, Chr17 position 7644013, Chr17 position 16323460, Chr17 position 16323473, Chr17 position 16924561, Chr17 position 16924562, Chr17 position 16924594, Chr17 position 17717918, Chr17 position 17718591, Chr17 position 18139506, Chr17 position 35278031, Chr17 position 39677570, Chr17 position 40826257, Chr17 position 43037426, Chr17 position 43200096, Chr17 position 43200239, Chr17 position 43510142, Chr17 position 47987828, Chr17 position 48178379, Chr17 position 48596391, Chr17 position 48764165, Chr17 position 55701962, Chr17 position 73584599, Chr17 position 73993165, Chr17 position 75827716, Chr17 position 76882243, Chr17 position 78765910, Chr17 position 79544478, Chr17 position 80696474, Chr18 position 19751759, Chr18 position 21440760, Chr18 position 45555437, Chr18 position 45555438, Chr18 position 46547891, Chr18 position 55888885, Chr18 position 56452096, Chr18 position 56452476, Chr18 position 56887181, Chr18 position 76002973, Chr18 position 77331090, Chr19 position 677895, Chr19 position 884044, Chr19 position 884059, Chr19 position 884105, Chr19 position 884115, Chr19 position 1136511, Chr19 position 1177605, Chr19 position 1177612, Chr19 position 1177640, Chr19 position 1860601, Chr19 position 1860607, Chr19 position 2503954, Chr19 position 3434917, Chr19 position 3434921, Chr19 position 3434930, Chr19 position 3434939, Chr19 position 3434952, Chr19 position 3434954, Chr19 position 3434962, Chr19 position 3434964, Chr19 position 3434979, Chr19 position 3434985, Chr19 position 4052713, Chr19 position 4052714, Chr19 position 4052749, Chr19 position 4374591, Chr19 position 5013982, Chr19 position 5048836, Chr19 position 5048867, Chr19 position 5048877, Chr19 position 8367279, Chr19 position 8428573, Chr19 position 10254577, Chr19 position 10254578, Chr19 position 10463956, Chr19 position 10464137, Chr19 position 13203671, Chr19 position 13266925, Chr19 position 13266934, Chr19 position 13266970, Chr19 position 13842142, Chr19 position

14248494, Chr19 position 15375465, Chr19 position 17218912, Chr19 position 17346702, Chr19 position 17346702, Chr19 position 18157161, Chr19 position 18157221, Chr19 position 18157258, Chr19 position 18415877, Chr19 position 18415890, Chr19 position 30606642, Chr19 position 35531842, Chr19 position 44303112, Chr19 position 47173037, Chr19 position 47316268, Chr19 position 47778278, Chr19 position 47778298, Chr20 position 34206950, Chr20 position 36771969, Chr20 position 48993661, Chr20 position 58406398, Chr20 position 61976049, Chr20 position 61976073, Chr20 position 62588571, Chr20 position 62588579, Chr22 position 19738127, Chr22 position 35965176, Chr22 position 36549809, Chr22 position 36973375, Chr22 position 37447953, Chr22 position 37914998, Chr22 position 38307317, Chr22 position 39662794, and Chr22 position 45622980.

In embodiments, the method includes detecting methylation or unmethylation of at least 6 of the following sites: 20 Chr1 position 2996653, Chr1 position 11979164, Chr1 position 12655938, Chr1 position 16450525, Chr1 position 16450542, Chr1 position 16450545, Chr1 position 16469987, Chr1 position 17494491, Chr1 position 25473203, Chr1 position 27640460, Chr1 position 29565080, Chr1 position 38493013, Chr1 position 38493030, Chr1 position 38493074, Chr1 position 46713777, Chr1 position 46914121, Chr1 position 46955744, Chr1 position 55008344, Chr1 position 109816092, Chr1 position 109816111, Chr1 position 30 110074669, Chr1 position 110074681, Chr1 position 110074685, Chr1 position 150949856, Chr1 position 150949857, Chr1 position 153540282, Chr1 position 155162704, Chr1 position 155162714, Chr1 position 156676611, Chr1 position 157611881, Chr1 position 182205324, Chr1 position 204118999, Chr1 position 206741875, Chr1 position 206741989, Chr1 position 212587673, Chr1 position 212841198, Chr1 position 223403952, Chr1 position 233430972, Chr1 position 234342767, Chr2 position 3454277, Chr2 position 8793724, 40 Chr2 position 20412441, Chr2 position 42329402, Chr2 position 42329494, Chr2 position 55289272, Chr2 position 65064865, Chr2 position 70823641, Chr2 position 73143689, Chr2 position 74454110, Chr2 position 122014529, Chr2 position 128158884, Chr2 position 128158910, Chr2 position 203114171, Chr2 position 218221671, Chr2 position 219745335, Chr2 position 238341465, Chr2 position 238341542, Chr2 position 238341546, Chr2 position 238774763, Chr3 position 13323642, Chr3 position 14180153, Chr3 position 45 45209073, Chr3 position 45209207, Chr3 position 52525100, Chr3 position 62589658, Chr3 position 65388317, Chr3 position 65388388, Chr3 position 73599302, Chr3 position 195636893, Chr3 position 197093846, Chr4 position 3743223, Chr4 position 5755716, 55 Chr4 position 5755717, Chr4 position 5755728, Chr4 position 5755729, Chr4 position 5755734, Chr4 position 8372861, Chr4 position 57548289, Chr5 position 1118280, Chr5 position 34564389, Chr5 position 73871907, Chr5 position 78013596, Chr5 position 78013643, Chr5 position 137802650, Chr5 position 139051189, Chr5 position 167838221, Chr5 position 177541401, Chr5 position 180018672, Chr5 position 180101026, Chr6 position 3394325, Chr6 position 3887581, Chr6 position 7236568, Chr6 position 7728692, Chr6 position 34203617, Chr6 position 37751320, Chr6 position 41410682, Chr6 position 41438516, Chr6 position 41438575, Chr6 position 43464150, Chr6 position 158734279, Chr7 position 989235,

US 12,391,993 B2

27

Chr7 position 2673543, Chr7 position 73508602, Chr7 position 105079565, Chr7 position 105079631, Chr7 position 151425103, Chr7 position 151425104, Chr8 position 11764017, Chr8 position 21647308, Chr8 position 22548399, Chr8 position 22548483, Chr8 position 133570537, Chr8 position 141320393, Chr8 position 141320410, Chr9 position 6566568, Chr9 position 16197862, Chr9 position 34591313, Chr9 position 98225096, Chr9 position 126126741, Chr9 position 132083428, Chr9 position 136077410, Chr9 position 139655018, Chr9 position 140205985, Chr9 position 140205985, Chr9 position 140205997, Chr10 position 3929071, Chr10 position 30047012, Chr10 position 79702989, Chr10 position 87984905, Chr10 position 94838789, Chr10 position 102131187, Chr10 position 104196489, Chr10 position 111766879, Chr10 position 112258886, Chr10 position 112258984, Chr10 position 112259015, Chr10 position 116391763, Chr10 position 120011530, Chr10 position 126172714, Chr10 position 126172747, Chr11 position 556355, Chr11 position 821282, Chr11 position 12188937, Chr11 position 12188948, Chr11 position 12188995, Chr11 position 36057726, Chr11 position 48070143, Chr11 position 48070163, Chr11 position 48070166, Chr11 position 48070174, Chr11 position 65158294, Chr11 position 65158342, Chr11 position 65297089, Chr11 position 66104481, Chr11 position 66104485, Chr11 position 66104578, Chr11 position 68608767, Chr11 position 70236292, Chr11 position 70236320, Chr11 position 70236331, Chr11 position 115530032, Chr11 position 117950310, Chr11 position 117950329, Chr11 position 117950361, Chr11 position 117950362, Chr11 position 119293593, Chr12 position 679803, Chr12 position 26039132, Chr12 position 31004558, Chr12 position 45610695, Chr12 position 45610701, Chr12 position 45610702, Chr12 position 45610706, Chr12 position 50286016, Chr12 position 52243258, Chr12 position 52243286, Chr12 position 54145732, Chr12 position 54145741, Chr12 position 54145825, Chr12 position 56115043, Chr12 position 66262229, Chr12 position 66262230, Chr12 position 66262233, Chr12 position 66262234, Chr12 position 77266621, Chr12 position 117580102, Chr12 position 123435962, Chr12 position 123436011, Chr12 position 123436065, Chr12 position 123540893, Chr13 position 20735797, Chr13 position 23500419, Chr13 position 46771519, Chr13 position 46771520, Chr13 position 53313426, Chr13 position 113807393, Chr14 position 38599118, Chr14 position 69170010, Chr14 position 75701632, Chr14 position 75701643, Chr14 position 90850454, Chr14 position 97524282, Chr14 position 103541602, Chr14 position 103768055, Chr14 position 104209000, Chr14 position 104209068, Chr14 position 104354645, Chr14 position 104360487, Chr15 position 41068807, Chr15 position 61152225, Chr15 position 61152253, Chr15 position 61152313, Chr15 position 65186440, Chr15 position 68851629, Chr15 position 70667596, Chr15 position 70767206, Chr15 position 75251486, Chr15 position 77984014, Chr15 position 77989064, Chr15 position 83952081, Chr15 position 85402496, Chr15 position 85402497, Chr15 position 99417337, Chr16 position 1231873, Chr16 position 1458639, Chr16 position 3023231, Chr16 position 23135832, Chr16 position 29616265, Chr16 position 31009547, Chr16 position 31009548, Chr16 position 31009590, Chr16 position 57793674, Chr16 position 57793715, Chr16 position 57793727, Chr16 position 70771056, Chr16 position 70771079, Chr16 position

28

70771141, Chr16 position 77332010, Chr16 position 78540378, Chr16 position 79333435, Chr16 position 84262419, Chr16 position 88701114, Chr16 position 89988308, Chr16 position 89988644, Chr17 position 5 1509928, Chr17 position 1509945, Chr17 position 1509952, Chr17 position 1509953, Chr17 position 7644013, Chr17 position 16323460, Chr17 position 16323473, Chr17 position 16924561, Chr17 position 16924562, Chr17 position 16924594, Chr17 position 17717918, Chr17 position 10 17718591, Chr17 position 18139506, Chr17 position 35278031, Chr17 position 39677570, Chr17 position 40826257, Chr17 position 43037426, Chr17 position 43200096, Chr17 position 43200239, Chr17 position 43510142, Chr17 position 47987828, Chr17 position 15 48178379, Chr17 position 48596391, Chr17 position 48764165, Chr17 position 55701962, Chr17 position 73584599, Chr17 position 73993165, Chr17 position 75827716, Chr17 position 76882243, Chr17 position 78765910, Chr17 position 79544478, Chr17 position 20 80696474, Chr18 position 19751759, Chr18 position 21440760, Chr18 position 45555437, Chr18 position 45555438, Chr18 position 46547891, Chr18 position 55888885, Chr18 position 56452096, Chr18 position 56452476, Chr18 position 56887181, Chr18 position 25 76002973, Chr18 position 77331090, Chr19 position 677895, Chr19 position 884044, Chr19 position 884059, Chr19 position 884105, Chr19 position 884115, Chr19 position 1136511, Chr19 position 1177605, Chr19 position 1177612, Chr19 position 1177640, Chr19 position 1860601, 30 Chr19 position 1860607, Chr19 position 2503954, Chr19 position 3434917, Chr19 position 3434921, Chr19 position 3434930, Chr19 position 3434939, Chr19 position 3434952, Chr19 position 3434954, Chr19 position 3434962, Chr19 position 3434964, Chr19 position 3434979, Chr19 position 3434985, Chr19 position 4052713, Chr19 position 4052714, Chr19 position 4052749, Chr19 position 4374591, Chr19 position 5013982, Chr19 position 5048836, Chr19 position 5048867, Chr19 position 5048877, Chr19 position 8367279, Chr19 position 8428573, Chr19 position 10254577, Chr19 position 40 10254578, Chr19 position 10463956, Chr19 position 10464137, Chr19 position 13203671, Chr19 position 13266925, Chr19 position 13266934, Chr19 position 13266970, Chr19 position 13842142, Chr19 position 14248494, Chr19 position 15375465, Chr19 position 17218912, Chr19 position 17346702, Chr19 position 17346702, Chr19 position 18157161, Chr19 position 18157221, Chr19 position 18157258, Chr19 position 18415877, Chr19 position 18415890, Chr19 position 30 30606642, Chr19 position 35531842, Chr19 position 44303112, Chr19 position 47173037, Chr19 position 47316268, Chr19 position 47778278, Chr19 position 47778298, Chr20 position 34206950, Chr20 position 36771969, Chr20 position 48993661, Chr20 position 58406398, Chr20 position 61976049, Chr20 position 55 61976073, Chr20 position 62588571, Chr20 position 62588579, Chr22 position 19738127, Chr22 position 35965176, Chr22 position 36549809, Chr22 position 36973375, Chr22 position 37447953, Chr22 position 37914998, Chr22 position 38307317, Chr22 position 60 39662794, and Chr22 position 45622980.

In embodiments, the method includes detecting methylation or unmethylation of at least 7 of the following sites: Chr1 position 2996653, Chr1 position 11979164, Chr1 position 12655938, Chr1 position 16450525, Chr1 position 16450542, Chr1 position 16450545, Chr1 position 16469987, Chr1 position 17494491, Chr1 position 25473203, Chr1 position 27640460, Chr1 position

US 12,391,993 B2

29

29565080, Chr1 position 38493013, Chr1 position 65158294, Chr11 position 65158342, Chr11 position
 38493030, Chr1 position 38493074, Chr1 position 65297089, Chr11 position 66104481, Chr11 position
 46713777, Chr1 position 46914121, Chr1 position 66104485, Chr11 position 66104578, Chr11 position
 46955744, Chr1 position 55008344, Chr1 position 68608767, Chr11 position 70236292, Chr11 position
 109816092, Chr1 position 109816111, Chr1 position 5 70236320, Chr11 position 70236331, Chr11 position
 110074669, Chr1 position 110074681, Chr1 position 115530032, Chr11 position 117950310, Chr11 position
 110074685, Chr1 position 150949856, Chr1 position 117950329, Chr11 position 117950361, Chr11 position
 150949857, Chr1 position 153540282, Chr1 position 117950362, Chr11 position 119293593, Chr12 position
 155162704, Chr1 position 155162714, Chr1 position 679803, Chr12 position 26039132, Chr12 position
 156676611, Chr1 position 157611881, Chr1 position 10 31004558, Chr12 position 45610695, Chr12 position
 182205324, Chr1 position 204118999, Chr1 position 45610701, Chr12 position 45610702, Chr12 position
 206741875, Chr1 position 206741989, Chr1 position 45610706, Chr12 position 50286016, Chr12 position
 212587673, Chr1 position 212841198, Chr1 position 52243258, Chr12 position 52243286, Chr12 position
 223403952, Chr1 position 233430972, Chr1 position 54145732, Chr12 position 54145741, Chr12 position
 234342767, Chr2 position 3454277, Chr2 position 15 54145825, Chr12 position 56115043, Chr12 position
 Chr2 position 20412441, Chr2 position 42329402, Chr2 position 66262229, Chr12 position 66262230, Chr12 position
 position 42329494, Chr2 position 55289272, Chr2 position 66262233, Chr12 position 66262234, Chr12 position
 65064865, Chr2 position 70823641, Chr2 position 77266621, Chr12 position 117580102, Chr12 position
 73143689, Chr2 position 74454110, Chr2 position 123435962, Chr12 position 123436011, Chr12 position
 122014529, Chr2 position 128158884, Chr2 position 20 123436065, Chr12 position 123540893, Chr13 position
 128158910, Chr2 position 203114171, Chr2 position 20735797, Chr13 position 23500419, Chr13 position
 218221671, Chr2 position 219745335, Chr2 position 46771519, Chr13 position 46771520, Chr13 position
 238341465, Chr2 position 238341542, Chr2 position 53313426, Chr13 position 113807393, Chr14 position
 238341546, Chr2 position 238774763, Chr3 position 38599118, Chr14 position 69170010, Chr14 position
 13323642, Chr3 position 14180153, Chr3 position 25 75701632, Chr14 position 75701643, Chr14 position
 45209073, Chr3 position 45209207, Chr3 position 90850454, Chr14 position 97524282, Chr14 position
 52525100, Chr3 position 62589658, Chr3 position 103541602, Chr14 position 103768055, Chr14 position
 65388317, Chr3 position 65388388, Chr3 position 104209000, Chr14 position 104209068, Chr14 position
 73599302, Chr3 position 195636893, Chr3 position 104354645, Chr14 position 104360487, Chr15 position
 197093846, Chr4 position 3743223, Chr4 position 30 5755716, 41068807, Chr15 position 61152225, Chr15 position
 Chr4 position 5755717, Chr4 position 5755728, Chr4 position 61152253, Chr15 position 61152313, Chr15 position
 5755729, Chr4 position 5755734, Chr4 position 65186440, Chr15 position 68851629, Chr15 position
 8372861, Chr4 position 57548289, Chr5 position 1118280, 70667596, Chr15 position 70767206, Chr15 position
 Chr5 position 34564389, Chr5 position 73871907, Chr5 75251486, Chr15 position 77984014, Chr15 position
 position 78013596, Chr5 position 78013643, Chr5 position 35 77989064, Chr15 position 83952081, Chr15 position
 137802650, Chr5 position 139051189, Chr5 position 85402496, Chr15 position 85402497, Chr15 position
 167838221, Chr5 position 177541401, Chr5 position 99417337, Chr16 position 1231873, Chr16 position
 180018672, Chr5 position 180101026, Chr6 position 1458639, Chr16 position 3023231, Chr16 position
 3394325, Chr6 position 3887581, Chr6 position 7236568, 23135832, Chr16 position 29616265, Chr16 position
 Chr6 position 7728692, Chr6 position 34203617, Chr6 position 40 31009547, Chr16 position 31009548, Chr16 position
 position 37751320, Chr6 position 41410682, Chr6 position 31009590, Chr16 position 57793674, Chr16 position
 41438516, Chr6 position 41438575, Chr6 position 57793715, Chr16 position 57793727, Chr16 position
 43464150, Chr6 position 158734279, Chr7 position 989235, 70771056, Chr16 position 70771079, Chr16 position
 Chr7 position 2673543, Chr7 position 73508602, Chr7 70771141, Chr16 position 77332010, Chr16 position
 position 105079565, Chr7 position 105079631, Chr7 position 45 78540378, Chr16 position 79333435, Chr16 position
 151425103, Chr7 position 151425104, Chr8 position 84262419, Chr16 position 88701114, Chr16 position
 11764017, Chr8 position 21647308, Chr8 position 89988308, Chr16 position 89988644, Chr17 position
 22548399, Chr8 position 22548483, Chr8 position 1509928, Chr17 position 1509945, Chr17 position 1509952,
 133570537, Chr8 position 141320393, Chr8 position Chr17 position 1509953, Chr17 position 7644013, Chr17
 141320410, Chr9 position 6566568, Chr9 position 50 16323460, Chr17 position 16323473, Chr17 position
 16197862, Chr9 position 34591313, Chr9 position 16924594, Chr17 position 16924561, Chr17 position
 98225096, Chr9 position 126126741, Chr9 position 16924594, Chr17 position 17717918, Chr17 position
 132083428, Chr9 position 136077410, Chr9 position 17718591, Chr17 position 18139506, Chr17 position
 139655018, Chr9 position 140205985, Chr9 position 35278031, Chr17 position 39677570, Chr17 position
 140205985, Chr9 position 140205997, Chr10 position 55 40826257, Chr17 position 43037426, Chr17 position
 3929071, Chr10 position 30047012, Chr10 position 43200096, Chr17 position 43200239, Chr17 position
 79702989, Chr10 position 87984905, Chr10 position 43510142, Chr17 position 47987828, Chr17 position
 94838789, Chr10 position 102131187, Chr10 position 48178379, Chr17 position 48596391, Chr17 position
 104196489, Chr10 position 111766879, Chr10 position 48764165, Chr17 position 55701962, Chr17 position
 112258886, Chr10 position 112258984, Chr10 position 60 73584599, Chr17 position 73993165, Chr17 position
 112259015, Chr10 position 116391763, Chr10 position 75827716, Chr17 position 76882243, Chr17 position
 120011530, Chr10 position 126172714, Chr10 position 78765910, Chr17 position 79544478, Chr17 position
 126172747, Chr11 position 556355, Chr11 position 80696474, Chr18 position 19751759, Chr18 position
 Chr11 position 12188937, Chr11 position 12188948, Chr11 21440760, Chr18 position 45555437, Chr18 position
 position 12188995, Chr11 position 36057726, Chr11 position 45555438, Chr18 position 46547891, Chr18 position
 48070143, Chr11 position 48070163, Chr11 position 55888885, Chr18 position 56452096, Chr18 position
 48070166, Chr11 position 48070174, Chr11 position 56452476, Chr18 position 56887181, Chr18 position

30

76002973, Chr18 position 77331090, Chr19 position 677895, Chr19 position 884044, Chr19 position 884059, Chr19 position 884105, Chr19 position 884115, Chr19 position 1136511, Chr19 position 1177605, Chr19 position 1177612, Chr19 position 1177640, Chr19 position 1860601, Chr19 position 1860607, Chr19 position 2503954, Chr19 position 3434917, Chr19 position 3434921, Chr19 position 3434930, Chr19 position 3434939, Chr19 position 3434952, Chr19 position 3434954, Chr19 position 3434962, Chr19 position 3434964, Chr19 position 3434979, Chr19 position 3434985, Chr19 position 4052713, Chr19 position 4052714, Chr19 position 4052749, Chr19 position 4374591, Chr19 position 5013982, Chr19 position 5048836, Chr19 position 5048867, Chr19 position 5048877, Chr19 position 8367279, Chr19 position 8428573, Chr19 position 10254577, Chr19 position 10254578, Chr19 position 10463956, Chr19 position 10464137, Chr19 position 13203671, Chr19 position 13266925, Chr19 position 13266934, Chr19 position 13266970, Chr19 position 13842142, Chr19 position 14248494, Chr19 position 15375465, Chr19 position 17218912, Chr19 position 17346702, Chr19 position 17346702, Chr19 position 18157161, Chr19 position 18157221, Chr19 position 18157258, Chr19 position 18415877, Chr19 position 18415890, Chr19 position 30606642, Chr19 position 35531842, Chr19 position 44303112, Chr19 position 47173037, Chr19 position 47316268, Chr19 position 47778278, Chr19 position 47778298, Chr20 position 34206950, Chr20 position 36771969, Chr20 position 48993661, Chr20 position 58406398, Chr20 position 61976049, Chr20 position 61976073, Chr20 position 62588571, Chr20 position 62588579, Chr22 position 19738127, Chr22 position 35965176, Chr22 position 36549809, Chr22 position 36973375, Chr22 position 37447953, Chr22 position 37914998, Chr22 position 38307317, Chr22 position 39662794, and Chr22 position 45622980.

In embodiments, the method includes detecting methylation or unmethylation of at least 8 of the following sites: Chr1 position 2996653, Chr1 position 11979164, Chr1 position 12655938, Chr1 position 16450525, Chr1 position 16450542, Chr1 position 16450545, Chr1 position 16469987, Chr1 position 17494491, Chr1 position 25473203, Chr1 position 27640460, Chr1 position 29565080, Chr1 position 38493013, Chr1 position 38493030, Chr1 position 38493074, Chr1 position 46713777, Chr1 position 46914121, Chr1 position 46955744, Chr1 position 55008344, Chr1 position 109816092, Chr1 position 109816111, Chr1 position 110074669, Chr1 position 110074681, Chr1 position 110074685, Chr1 position 150949856, Chr1 position 150949857, Chr1 position 153540282, Chr1 position 155162704, Chr1 position 155162714, Chr1 position 156676611, Chr1 position 157611881, Chr1 position 182205324, Chr1 position 204118999, Chr1 position 206741875, Chr1 position 206741989, Chr1 position 212587673, Chr1 position 212841198, Chr1 position 223403952, Chr1 position 233430972, Chr1 position 234342767, Chr2 position 3454277, Chr2 position 8793724, Chr2 position 20412441, Chr2 position 42329402, Chr2 position 42329494, Chr2 position 55289272, Chr2 position 65064865, Chr2 position 70823641, Chr2 position 73143689, Chr2 position 74454110, Chr2 position 122014529, Chr2 position 128158884, Chr2 position 128158910, Chr2 position 203114171, Chr2 position 218221671, Chr2 position 219745335, Chr2 position 238341465, Chr2 position 238341542, Chr2 position 238341546, Chr2 position 238774763, Chr3 position

13323642, Chr3 position 14180153, Chr3 position 45209073, Chr3 position 45209207, Chr3 position 52525100, Chr3 position 62589658, Chr3 position 65388317, Chr3 position 65388388, Chr3 position 73599302, Chr3 position 195636893, Chr3 position 197093846, Chr4 position 3743223, Chr4 position 5755716, Chr4 position 5755717, Chr4 position 5755728, Chr4 position 5755729, Chr4 position 5755734, Chr4 position 8372861, Chr4 position 57548289, Chr5 position 1118280, Chr5 position 34564389, Chr5 position 73871907, Chr5 position 78013596, Chr5 position 78013643, Chr5 position 137802650, Chr5 position 139051189, Chr5 position 167838221, Chr5 position 177541401, Chr5 position 180018672, Chr5 position 180101026, Chr6 position 3394325, Chr6 position 3887581, Chr6 position 7236568, Chr6 position 7728692, Chr6 position 34203617, Chr6 position 37751320, Chr6 position 41410682, Chr6 position 41438516, Chr6 position 41438575, Chr6 position 43464150, Chr6 position 158734279, Chr7 position 989235, Chr7 position 2673543, Chr7 position 73508602, Chr7 position 105079565, Chr7 position 105079631, Chr7 position 151425103, Chr7 position 151425104, Chr8 position 11764017, Chr8 position 21647308, Chr8 position 22548399, Chr8 position 22548483, Chr8 position 133570537, Chr8 position 141320393, Chr8 position 141320410, Chr9 position 6566568, Chr9 position 16197862, Chr9 position 34591313, Chr9 position 98225096, Chr9 position 126126741, Chr9 position 132083428, Chr9 position 136077410, Chr9 position 139655018, Chr9 position 140205985, Chr9 position 140205985, Chr9 position 140205997, Chr10 position 3929071, Chr10 position 30047012, Chr10 position 79702989, Chr10 position 87984905, Chr10 position 94838789, Chr10 position 102131187, Chr10 position 104196489, Chr10 position 111766879, Chr10 position 112258886, Chr10 position 112258984, Chr10 position 112259015, Chr10 position 116391763, Chr10 position 120011530, Chr10 position 126172714, Chr10 position 126172747, Chr11 position 556355, Chr11 position 821282, Chr11 position 12188937, Chr11 position 12188948, Chr11 position 12188995, Chr11 position 36057726, Chr11 position 48070143, Chr11 position 48070163, Chr11 position 48070166, Chr11 position 48070174, Chr11 position 65158294, Chr11 position 65158342, Chr11 position 65297089, Chr11 position 66104481, Chr11 position 66104485, Chr11 position 66104578, Chr11 position 68608767, Chr11 position 70236292, Chr11 position 70236320, Chr11 position 70236331, Chr11 position 115530032, Chr11 position 117950310, Chr11 position 117950329, Chr11 position 117950361, Chr11 position 117950362, Chr11 position 119293593, Chr12 position 679803, Chr12 position 26039132, Chr12 position 31004558, Chr12 position 45610695, Chr12 position 45610701, Chr12 position 45610702, Chr12 position 45610706, Chr12 position 50286016, Chr12 position 52243258, Chr12 position 52243286, Chr12 position 54145732, Chr12 position 54145741, Chr12 position 54145825, Chr12 position 56115043, Chr12 position 66262229, Chr12 position 66262230, Chr12 position 66262233, Chr12 position 66262234, Chr12 position 77266621, Chr12 position 117580102, Chr12 position 123435962, Chr12 position 123436011, Chr12 position 123436065, Chr12 position 123540893, Chr13 position 20735797, Chr13 position 23500419, Chr13 position 46771519, Chr13 position 46771520, Chr13 position 53313426, Chr13 position 113807393, Chr14 position 38599118, Chr14 position 69170010, Chr14 position

75701632, Chr14 position 90850454, Chr14 position 103541602, Chr14 position 104209000, Chr14 position 104354645, Chr14 position 41068807, Chr15 position 61152253, Chr15 position 65186440, Chr15 position 70667596, Chr15 position 75251486, Chr15 position 77989064, Chr15 position 85402496, Chr15 position 99417337, Chr16 position 1458639, Chr16 position 23135832, Chr16 position 31009547, Chr16 position 31009590, Chr16 position 57793715, Chr16 position 70771056, Chr16 position 70771141, Chr16 position 78540378, Chr16 position 84262419, Chr16 position 89988308, Chr16 position 1509928, Chr17 position 1509953, Chr17 position 16323460, Chr17 position 16924561, Chr17 position 16924594, Chr17 position 177118591, Chr17 position 35278031, Chr17 position 40826257, Chr17 position 43200096, Chr17 position 43510142, Chr17 position 48178379, Chr17 position 48764165, Chr17 position 73584599, Chr17 position 75827716, Chr17 position 78765910, Chr17 position 80696474, Chr18 position 21440760, Chr18 position 45555438, Chr18 position 55888885, Chr18 position 56452476, Chr18 position 76002973, Chr18 position 677895, Chr19 position 884044, Chr19 position 884105, Chr19 position 884115, Chr19 position 1136511, Chr19 position 1177605, Chr19 position 1177612, Chr19 position 1177640, Chr19 position 1860601, Chr19 position 1860607, Chr19 position 2503954, Chr19 position 3434917, Chr19 position 3434921, Chr19 position 3434930, Chr19 position 3434939, Chr19 position 3434952, Chr19 position 3434954, Chr19 position 3434962, Chr19 position 3434964, Chr19 position 3434979, Chr19 position 3434985, Chr19 position 4052713, Chr19 position 4052714, Chr19 position 4052749, Chr19 position 4374591, Chr19 position 5013982, Chr19 position 5048836, Chr19 position 5048867, Chr19 position 5048877, Chr19 position 8367279, Chr19 position 8428573, Chr19 position 10254577, Chr19 position 10254578, Chr19 position 10463956, Chr19 position 10464137, Chr19 position 13203671, Chr19 position 13266934, Chr19 position 13842142, Chr19 position 15375465, Chr19 position 17346702, Chr19 position 18157161, Chr19 position 18157258, Chr19 position 18415890, Chr19 position 30606642, Chr19 position 44303112, Chr19 position 47316268, Chr19 position 47778298, Chr20 position 5 36771969, Chr20 position 58406398, Chr20 position 61976073, Chr20 position 62588571, Chr22 position 35965176, Chr22 position 36973375, Chr22 position 37914998, Chr22 position 39662794, and Chr22 position 35531842, Chr19 position 47173037, Chr19 position 47778278, Chr19 position 34206950, Chr20 position 48993661, Chr20 position 61976049, Chr20 position 62588571, Chr20 position 19738127, Chr22 position 36549809, Chr22 position 37447953, Chr22 position 38307317, Chr22 position 39662794, and Chr22 position 45622980.	In embodiments, the method includes detecting methylation or unmethylation of at least 9 of the following sites: 15 Chr1 position 2996653, Chr1 position 11979164, Chr1 position 12655938, Chr1 position 16450525, Chr1 position 16450542, Chr1 position 16450545, Chr1 position 16469987, Chr1 position 17494491, Chr1 position 25473203, Chr1 position 27640460, Chr1 position 29565080, Chr1 position 38493013, Chr1 position 38493030, Chr1 position 38493074, Chr1 position 46713777, Chr1 position 46914121, Chr1 position 46955744, Chr1 position 55008344, Chr1 position 109816092, Chr1 position 109816111, Chr1 position 110074669, Chr1 position 110074681, Chr1 position 110074685, Chr1 position 150949856, Chr1 position 150949857, Chr1 position 153540282, Chr1 position 155162704, Chr1 position 155162714, Chr1 position 156676611, Chr1 position 157611881, Chr1 position 30 182205324, Chr1 position 204118999, Chr1 position 206741875, Chr1 position 206741989, Chr1 position 212587673, Chr1 position 212841198, Chr1 position 223403952, Chr1 position 233430972, Chr1 position 234342767, Chr2 position 3454277, Chr2 position 8793724, 35 Chr2 position 20412441, Chr2 position 42329402, Chr2 position 42329494, Chr2 position 55289272, Chr2 position 65064865, Chr2 position 70823641, Chr2 position 73143689, Chr2 position 74454110, Chr2 position 122014529, Chr2 position 128158884, Chr2 position 40 128158910, Chr2 position 203114171, Chr2 position 218221671, Chr2 position 219745335, Chr2 position 238341465, Chr2 position 238341542, Chr2 position 238341546, Chr2 position 238774763, Chr3 position 13323642, Chr3 position 14180153, Chr3 position 45209073, Chr3 position 45209207, Chr3 position 52525100, Chr3 position 62589658, Chr3 position 65388317, Chr3 position 65388388, Chr3 position 73599302, Chr3 position 195636893, Chr3 position 197093846, Chr4 position 3743223, Chr4 position 5755716, 50 Chr4 position 5755717, Chr4 position 5755728, Chr4 position 5755729, Chr4 position 5755734, Chr4 position 8372861, Chr4 position 57548289, Chr5 position 1118280, Chr5 position 34564389, Chr5 position 73871907, Chr5 position 78013596, Chr5 position 78013643, Chr5 position 137802650, Chr5 position 139051189, Chr5 position 167838221, Chr5 position 177541401, Chr5 position 180018672, Chr5 position 180101026, Chr6 position 3394325, Chr6 position 3887581, Chr6 position 7236568, Chr6 position 7728692, Chr6 position 34203617, Chr6 position 37751320, Chr6 position 41410682, Chr6 position 41438516, Chr6 position 41438575, Chr6 position 43464150, Chr6 position 158734279, Chr7 position 989235, Chr7 position 2673543, Chr7 position 73508602, Chr7 position 105079565, Chr7 position 105079631, Chr7 position 151425103, Chr7 position 151425104, Chr8 position 11764017, Chr8 position 21647308, Chr8 position 22548399, Chr8 position 22548483, Chr8 position
--	---

133570537, Chr8 position 141320393, Chr8 position 141320410, Chr9 position 6566568, Chr9 position 16197862, Chr9 position 34591313, Chr9 position 98225096, Chr9 position 126126741, Chr9 position 132083428, Chr9 position 136077410, Chr9 position 139655018, Chr9 position 140205985, Chr9 position 140205985, Chr9 position 140205997, Chr10 position 3929071, Chr10 position 30047012, Chr10 position 79702989, Chr10 position 87984905, Chr10 position 94838789, Chr10 position 102131187, Chr10 position 104196489, Chr10 position 111766879, Chr10 position 112258886, Chr10 position 112258984, Chr10 position 112259015, Chr10 position 116391763, Chr10 position 120011530, Chr10 position 126172714, Chr10 position 126172747, Chr11 position 556355, Chr11 position 821282, Chr11 position 12188937, Chr11 position 12188948, Chr11 position 12188995, Chr11 position 36057726, Chr11 position 48070143, Chr11 position 48070163, Chr11 position 48070166, Chr11 position 48070174, Chr11 position 65158294, Chr11 position 65158342, Chr11 position 65297089, Chr11 position 66104481, Chr11 position 66104485, Chr11 position 66104578, Chr11 position 68608767, Chr11 position 70236292, Chr11 position 70236320, Chr11 position 70236331, Chr11 position 115530032, Chr11 position 117950310, Chr11 position 117950329, Chr11 position 117950361, Chr11 position 117950362, Chr11 position 119293593, Chr12 position 679803, Chr12 position 26039132, Chr12 position 31004558, Chr12 position 45610695, Chr12 position 45610701, Chr12 position 45610702, Chr12 position 45610706, Chr12 position 50286016, Chr12 position 52243258, Chr12 position 52243286, Chr12 position 54145732, Chr12 position 54145741, Chr12 position 54145825, Chr12 position 56115043, Chr12 position 66262229, Chr12 position 66262230, Chr12 position 66262233, Chr12 position 66262234, Chr12 position 77266621, Chr12 position 117580102, Chr12 position 123435962, Chr12 position 123436011, Chr12 position 123436065, Chr12 position 123540893, Chr13 position 20735797, Chr13 position 23500419, Chr13 position 46771519, Chr13 position 46771520, Chr13 position 53313426, Chr13 position 113807393, Chr14 position 38599118, Chr14 position 69170010, Chr14 position 75701632, Chr14 position 75701643, Chr14 position 90850454, Chr14 position 97524282, Chr14 position 103541602, Chr14 position 103768055, Chr14 position 104209000, Chr14 position 104209068, Chr14 position 104354645, Chr14 position 104360487, Chr15 position 41068807, Chr15 position 61152225, Chr15 position 61152253, Chr15 position 61152313, Chr15 position 65186440, Chr15 position 68851629, Chr15 position 70667596, Chr15 position 70767206, Chr15 position 75251486, Chr15 position 77984014, Chr15 position 77989064, Chr15 position 83952081, Chr15 position 85402496, Chr15 position 85402497, Chr15 position 99417337, Chr16 position 1231873, Chr16 position 1458639, Chr16 position 3023231, Chr16 position 23135832, Chr16 position 29616265, Chr16 position 31009547, Chr16 position 31009548, Chr16 position 31009590, Chr16 position 57793674, Chr16 position 57793715, Chr16 position 57793727, Chr16 position 70771056, Chr16 position 70771079, Chr16 position 70771141, Chr16 position 77332010, Chr16 position 78540378, Chr16 position 79333435, Chr16 position 84262419, Chr16 position 88701114, Chr16 position 89988308, Chr16 position 89988644, Chr17 position 1509928, Chr17 position 1509945, Chr17 position 1509952,

Chr17 position 1509953, Chr17 position 7644013, Chr17 position 16323460, Chr17 position 16323473, Chr17 position 16924561, Chr17 position 16924562, Chr17 position 16924594, Chr17 position 17717918, Chr17 position 17718591, Chr17 position 18139506, Chr17 position 35278031, Chr17 position 39677570, Chr17 position 40826257, Chr17 position 43037426, Chr17 position 43200239, Chr17 position 43510142, Chr17 position 47987828, Chr17 position 48178379, Chr17 position 48596391, Chr17 position 48764165, Chr17 position 55701962, Chr17 position 73584599, Chr17 position 73993165, Chr17 position 75827716, Chr17 position 76882243, Chr17 position 78765910, Chr17 position 79544478, Chr17 position 80696474, Chr18 position 19751759, Chr18 position 21440760, Chr18 position 45555437, Chr18 position 45555438, Chr18 position 46547891, Chr18 position 55888885, Chr18 position 56452096, Chr18 position 56452476, Chr18 position 56887181, Chr18 position 76002973, Chr18 position 77331090, Chr19 position 677895, Chr19 position 8840444, Chr19 position 884059, Chr19 position 884105, Chr19 position 884115, Chr19 position 1136511, Chr19 position 1177605, Chr19 position 1177612, Chr19 position 1177640, Chr19 position 1860601, Chr19 position 1860607, Chr19 position 2503954, Chr19 position 3434917, Chr19 position 3434921, Chr19 position 3434930, Chr19 position 3434939, Chr19 position 3434952, Chr19 position 3434954, Chr19 position 3434962, Chr19 position 3434964, Chr19 position 3434979, Chr19 position 3434985, Chr19 position 4052713, Chr19 position 4052714, Chr19 position 4052749, Chr19 position 4374591, Chr19 position 5013982, Chr19 position 5048836, Chr19 position 5048867, Chr19 position 5048877, Chr19 position 8367279, Chr19 position 8428573, Chr19 position 10254577, Chr19 position 10254578, Chr19 position 10463956, Chr19 position 10464137, Chr19 position 13203671, Chr19 position 13266925, Chr19 position 13266934, Chr19 position 13266970, Chr19 position 13842142, Chr19 position 14248494, Chr19 position 15375465, Chr19 position 17218912, Chr19 position 17346702, Chr19 position 17346702, Chr19 position 18157161, Chr19 position 18157221, Chr19 position 18157258, Chr19 position 18415877, Chr19 position 18415890, Chr19 position 30606642, Chr19 position 35531842, Chr19 position 44303112, Chr19 position 47173037, Chr19 position 47316268, Chr19 position 47778278, Chr19 position 47778298, Chr20 position 34206950, Chr20 position 36771969, Chr20 position 48993661, Chr20 position 58406398, Chr20 position 61976049, Chr20 position 61976073, Chr20 position 62588571, Chr20 position 62588579, Chr22 position 19738127, Chr22 position 35965176, Chr22 position 36549809, Chr22 position 36973375, Chr22 position 37447953, Chr22 position 37914998, Chr22 position 38307317, Chr22 position 39662794, and Chr22 position 45622980.

In embodiments, the method includes detecting methylation or unmethylation of at least 10 of the following sites: Chr1 position 2996653, Chr1 position 11979164, Chr1 position 12655938, Chr1 position 16450525, Chr1 position 16450542, Chr1 position 16450545, Chr1 position 16469987, Chr1 position 17494491, Chr1 position 25473203, Chr1 position 27640460, Chr1 position 29565080, Chr1 position 38493013, Chr1 position 38493030, Chr1 position 38493074, Chr1 position 46713777, Chr1 position 46914121, Chr1 position 46955744, Chr1 position 55008344, Chr1 position 109816092, Chr1 position 109816111, Chr1 position

US 12,391,993 B2

37

110074669, Chr1 position 110074681, Chr1 position 110074685, Chr1 position 150949856, Chr1 position 150949857, Chr1 position 153540282, Chr1 position 155162704, Chr1 position 155162714, Chr1 position 156676611, Chr1 position 157611881, Chr1 position 182205324, Chr1 position 204118999, Chr1 position 206741987, Chr1 position 206741989, Chr1 position 212587673, Chr1 position 212841198, Chr1 position 223403952, Chr1 position 233430972, Chr1 position 234342767, Chr2 position 3454277, Chr2 position 8793724, Chr2 position 20412441, Chr2 position 42329402, Chr2 position 42329494, Chr2 position 55289272, Chr2 position 65064865, Chr2 position 70823641, Chr2 position 73143689, Chr2 position 74454110, Chr2 position 122014529, Chr2 position 128158884, Chr2 position 128158910, Chr2 position 203114171, Chr2 position 218221671, Chr2 position 219745335, Chr2 position 238341465, Chr2 position 238341542, Chr2 position 238341546, Chr2 position 238774763, Chr3 position 13323642, Chr3 position 14180153, Chr3 position 45209073, Chr3 position 45209207, Chr3 position 52525100, Chr3 position 62589658, Chr3 position 65388317, Chr3 position 65388388, Chr3 position 73599302, Chr3 position 195636893, Chr3 position 197093846, Chr4 position 3743223, Chr4 position 5755716, Chr4 position 5755717, Chr4 position 5755728, Chr4 position 5755729, Chr4 position 5755734, Chr4 position 8372861, Chr4 position 57548289, Chr5 position 1118280, Chr5 position 34564389, Chr5 position 73871907, Chr5 position 78013596, Chr5 position 78013643, Chr5 position 137802650, Chr5 position 139051189, Chr5 position 167838221, Chr5 position 177541401, Chr5 position 180018672, Chr5 position 180101026, Chr6 position 3394325, Chr6 position 3887581, Chr6 position 7236568, Chr6 position 7728692, Chr6 position 34203617, Chr6 position 37751320, Chr6 position 41410682, Chr6 position 41438516, Chr6 position 41438575, Chr6 position 43464150, Chr6 position 158734279, Chr7 position 989235, Chr7 position 2673543, Chr7 position 73508602, Chr7 position 105079565, Chr7 position 105079631, Chr7 position 151425103, Chr7 position 151425104, Chr8 position 11764017, Chr8 position 21647308, Chr8 position 22548399, Chr8 position 22548483, Chr8 position 133570537, Chr8 position 141320393, Chr8 position 141320410, Chr9 position 6566568, Chr9 position 16197862, Chr9 position 34591313, Chr9 position 98225096, Chr9 position 126126741, Chr9 position 132083428, Chr9 position 136077410, Chr9 position 139655018, Chr9 position 140205985, Chr9 position 140205985, Chr9 position 140205997, Chr10 position 3929071, Chr10 position 30047012, Chr10 position 79702989, Chr10 position 87984905, Chr10 position 94838789, Chr10 position 102131187, Chr10 position 104196489, Chr10 position 111766879, Chr10 position 112258886, Chr10 position 112258984, Chr10 position 112259015, Chr10 position 116391763, Chr10 position 120011530, Chr10 position 126172714, Chr10 position 126172747, Chr11 position 556355, Chr11 position 821282, Chr11 position 12188937, Chr11 position 12188948, Chr11 position 12188995, Chr11 position 36057726, Chr11 position 48070143, Chr11 position 48070163, Chr11 position 48070166, Chr11 position 48070174, Chr11 position 65158294, Chr11 position 65158342, Chr11 position 65297089, Chr11 position 66104481, Chr11 position 66104485, Chr11 position 66104578, Chr11 position 68608767, Chr11 position 70236292, Chr11 position 70236320, Chr11 position

38

115530032, Chr11 position 117950310, Chr11 position 117950329, Chr11 position 117950361, Chr11 position 117950362, Chr11 position 119293593, Chr12 position 679803, Chr12 position 26039132, Chr12 position 5 31004558, Chr12 position 45610695, Chr12 position 45610701, Chr12 position 45610702, Chr12 position 45610706, Chr12 position 50286016, Chr12 position 52243286, Chr12 position 54145732, Chr12 position 54145741, Chr12 position 10 54145825, Chr12 position 56115043, Chr12 position 66262229, Chr12 position 66262230, Chr12 position 66262233, Chr12 position 66262234, Chr12 position 77266621, Chr12 position 117580102, Chr12 position 123435962, Chr12 position 123436011, Chr12 position 123436065, Chr12 position 123540893, Chr13 position 20 20735797, Chr13 position 23500419, Chr13 position 46771519, Chr13 position 46771520, Chr13 position 53313426, Chr13 position 113807393, Chr14 position 38599118, Chr14 position 69170010, Chr14 position 75701632, Chr14 position 75701643, Chr14 position 90850454, Chr14 position 97524282, Chr14 position 103541602, Chr14 position 103768055, Chr14 position 104209000, Chr14 position 104209068, Chr14 position 104354645, Chr14 position 104360487, Chr15 position 25 41068807, Chr15 position 61152225, Chr15 position 61152313, Chr15 position 65186440, Chr15 position 68851629, Chr15 position 70667596, Chr15 position 70767206, Chr15 position 75251486, Chr15 position 77984014, Chr15 position 77989064, Chr15 position 83952081, Chr15 position 85402496, Chr15 position 85402497, Chr15 position 99417337, Chr16 position 1231873, Chr16 position 1458639, Chr16 position 30 3023231, Chr16 position 23135832, Chr16 position 29616265, Chr16 position 31009547, Chr16 position 31009548, Chr16 position 31009590, Chr16 position 57793674, Chr16 position 57793715, Chr16 position 57793727, Chr16 position 70771056, Chr16 position 70771079, Chr16 position 70771141, Chr16 position 77332010, Chr16 position 78540378, Chr16 position 79333435, Chr16 position 84262419, Chr16 position 88701114, Chr16 position 89988308, Chr16 position 89988644, Chr17 position 1509928, Chr17 position 1509945, Chr17 position 1509952, Chr17 position 1509953, Chr17 position 7644013, Chr17 position 45 16323460, Chr17 position 16323473, Chr17 position 16924561, Chr17 position 16924562, Chr17 position 16924594, Chr17 position 17717918, Chr17 position 17718591, Chr17 position 18139506, Chr17 position 35278031, Chr17 position 39677570, Chr17 position 40826257, Chr17 position 43037426, Chr17 position 43200096, Chr17 position 43200239, Chr17 position 43510142, Chr17 position 47987828, Chr17 position 48178379, Chr17 position 48596391, Chr17 position 48764165, Chr17 position 55701962, Chr17 position 55 73584599, Chr17 position 73993165, Chr17 position 75827716, Chr17 position 76882243, Chr17 position 78765910, Chr17 position 79544478, Chr17 position 80696474, Chr18 position 19751759, Chr18 position 21440760, Chr18 position 45555437, Chr18 position 60 45555438, Chr18 position 46547891, Chr18 position 55888885, Chr18 position 56452096, Chr18 position 56452476, Chr18 position 56887181, Chr18 position 76002973, Chr18 position 77331090, Chr19 position 677895, Chr19 position 884044, Chr19 position 884059, Chr19 position 884105, Chr19 position 884115, Chr19 position 1136511, Chr19 position 1177605, Chr19 position 1177612, Chr19 position 1177640, Chr19 position 1860601,

Chr19 position 1860607, Chr19 position 2503954, Chr19 position 3434917, Chr19 position 3434921, Chr19 position 3434930, Chr19 position 3434939, Chr19 position 3434952, Chr19 position 3434954, Chr19 position 3434962, Chr19 position 3434964, Chr19 position 3434979, Chr19 position 3434985, Chr19 position 4052713, Chr19 position 4052714, Chr19 position 4052749, Chr19 position 4374591, Chr19 position 5013982, Chr19 position 5048836, Chr19 position 5048867, Chr19 position 5048877, Chr19 position 8367279, Chr19 position 8428573, Chr19 position 10254577, Chr19 position 10254578, Chr19 position 10463956, Chr19 position 10464137, Chr19 position 13203671, Chr19 position 13266925, Chr19 position 13266934, Chr19 position 13266970, Chr19 position 13842142, Chr19 position 14248494, Chr19 position 15375465, Chr19 position 17218912, Chr19 position 17346702, Chr19 position 17346702, Chr19 position 18157161, Chr19 position 18157221, Chr19 position 18157258, Chr19 position 18415877, Chr19 position 18415890, Chr19 position 30606642, Chr19 position 35531842, Chr19 position 44303112, Chr19 position 47173037, Chr19 position 47316268, Chr19 position 47778278, Chr19 position 47778298, Chr20 position 34206950, Chr20 position 36771969, Chr20 position 48993661, Chr20 position 58406398, Chr20 position 61976049, Chr20 position 61976073, Chr20 position 62588571, Chr20 position 62588579, Chr22 position 19738127, Chr22 position 35965176, Chr22 position 36549809, Chr22 position 36973375, Chr22 position 37447953, Chr22 position 37914998, Chr22 position 38307317, Chr22 position 39662794, and Chr22 position 45622980.

In embodiments, the method includes detecting methylation or unmethylation of at least 50 of the following sites: Chr1 position 2996653, Chr1 position 11979164, Chr1 position 12655938, Chr1 position 16450525, Chr1 position 16450542, Chr1 position 16450545, Chr1 position 16469987, Chr1 position 17494491, Chr1 position 25473203, Chr1 position 27640460, Chr1 position 29565080, Chr1 position 38493013, Chr1 position 38493030, Chr1 position 38493074, Chr1 position 46713777, Chr1 position 46914121, Chr1 position 46955744, Chr1 position 55008344, Chr1 position 109816092, Chr1 position 109816111, Chr1 position 110074669, Chr1 position 110074681, Chr1 position 110074685, Chr1 position 150949856, Chr1 position 150949857, Chr1 position 153540282, Chr1 position 155162704, Chr1 position 155162714, Chr1 position 156676611, Chr1 position 157611881, Chr1 position 182205324, Chr1 position 204118999, Chr1 position 206741875, Chr1 position 206741989, Chr1 position 212587673, Chr1 position 212841198, Chr1 position 223403952, Chr1 position 233430972, Chr1 position 234342767, Chr2 position 3454277, Chr2 position 8793724, Chr2 position 20412441, Chr2 position 42329402, Chr2 position 42329494, Chr2 position 55289272, Chr2 position 65064865, Chr2 position 70823641, Chr2 position 73143689, Chr2 position 74454110, Chr2 position 122014529, Chr2 position 128158884, Chr2 position 128158910, Chr2 position 203114171, Chr2 position 218221671, Chr2 position 219745335, Chr2 position 238341465, Chr2 position 238341542, Chr2 position 238341546, Chr2 position 238774763, Chr3 position 13323642, Chr3 position 14180153, Chr3 position 45209073, Chr3 position 45209207, Chr3 position 52525100, Chr3 position 62589658, Chr3 position 65388317, Chr3 position 65388388, Chr3 position 73599302, Chr3 position 195636893, Chr3 position

197093846, Chr4 position 3743223, Chr4 position 5755716, Chr4 position 5755717, Chr4 position 5755728, Chr4 position 5755729, Chr4 position 5755734, Chr4 position 8372861, Chr4 position 57548289, Chr5 position 1118280, Chr5 position 34564389, Chr5 position 73871907, Chr5 position 78013596, Chr5 position 78013643, Chr5 position 137802650, Chr5 position 139051189, Chr5 position 167838221, Chr5 position 177541401, Chr5 position 180018672, Chr5 position 180101026, Chr6 position 3394325, Chr6 position 3887581, Chr6 position 7236568, Chr6 position 7728692, Chr6 position 34203617, Chr6 position 37751320, Chr6 position 41410682, Chr6 position 41438516, Chr6 position 41438575, Chr6 position 43464150, Chr6 position 158734279, Chr7 position 989235, Chr7 position 2673543, Chr7 position 73508602, Chr7 position 105079565, Chr7 position 105079631, Chr7 position 151425103, Chr7 position 151425104, Chr8 position 11764017, Chr8 position 21647308, Chr8 position 22548399, Chr8 position 22548483, Chr8 position 133570537, Chr8 position 141320393, Chr8 position 141320410, Chr9 position 6566568, Chr9 position 16197862, Chr9 position 34591313, Chr9 position 98225096, Chr9 position 126126741, Chr9 position 132083428, Chr9 position 136077410, Chr9 position 139655018, Chr9 position 140205985, Chr9 position 140205985, Chr9 position 140205997, Chr10 position 3929071, Chr10 position 30047012, Chr10 position 79702989, Chr10 position 87984905, Chr10 position 94838789, Chr10 position 102131187, Chr10 position 104196489, Chr10 position 111766879, Chr10 position 112258886, Chr10 position 112258984, Chr10 position 112259015, Chr10 position 116391763, Chr10 position 120011530, Chr10 position 126172714, Chr10 position 126172747, Chr11 position 556355, Chr11 position 821282, Chr11 position 12188937, Chr11 position 12188948, Chr11 position 12188995, Chr11 position 36057726, Chr11 position 48070143, Chr11 position 48070163, Chr11 position 48070166, Chr11 position 48070174, Chr11 position 65158294, Chr11 position 65158342, Chr11 position 65297089, Chr11 position 66104481, Chr11 position 66104485, Chr11 position 66104578, Chr11 position 68608767, Chr11 position 70236292, Chr11 position 70236320, Chr11 position 70236331, Chr11 position 115530032, Chr11 position 117950310, Chr11 position 117950329, Chr11 position 117950361, Chr11 position 117950362, Chr11 position 119293593, Chr12 position 679803, Chr12 position 26039132, Chr12 position 31004558, Chr12 position 45610695, Chr12 position 45610701, Chr12 position 45610702, Chr12 position 45610706, Chr12 position 50286016, Chr12 position 52243258, Chr12 position 52243286, Chr12 position 54145732, Chr12 position 54145741, Chr12 position 54145825, Chr12 position 56115043, Chr12 position 66262229, Chr12 position 66262233, Chr12 position 66262234, Chr12 position 77266621, Chr12 position 117580102, Chr12 position 123435962, Chr12 position 123436011, Chr12 position 123436065, Chr12 position 123540893, Chr13 position 20735797, Chr13 position 23500419, Chr13 position 46771519, Chr13 position 46771520, Chr13 position 53313426, Chr13 position 113807393, Chr14 position 38599118, Chr14 position 69170010, Chr14 position 75701632, Chr14 position 75701643, Chr14 position 90850454, Chr14 position 97524282, Chr14 position 103541602, Chr14 position 103768055, Chr14 position 104209000, Chr14 position 104209068, Chr14 position 104354645, Chr14 position 104360487, Chr15 position

US 12,391,993 B2

41

41068807, Chr15 position 61152225, Chr15 position 61152313, Chr15 position 61152253, Chr15 position 61152313, Chr15 position 65186440, Chr15 position 68851629, Chr15 position 68851629, Chr15 position 70667596, Chr15 position 70767206, Chr15 position 70767206, Chr15 position 75251486, Chr15 position 77984014, Chr15 position 77984014, Chr15 position 77989064, Chr15 position 83952081, Chr15 position 83952081, Chr15 position 85402496, Chr15 position 85402497, Chr15 position 85402497, Chr15 position 99417337, Chr16 position 1231873, Chr16 position 1231873, Chr16 position 14586393, Chr16 position 3023231, Chr16 position 3023231, Chr16 position 23135832, Chr16 position 29616265, Chr16 position 29616265, Chr16 position 31009547, Chr16 position 31009548, Chr16 position 31009548, Chr16 position 31009590, Chr16 position 57793674, Chr16 position 57793674, Chr16 position 57793715, Chr16 position 57793727, Chr16 position 57793727, Chr16 position 70771056, Chr16 position 70771079, Chr16 position 70771079, Chr16 position 70771141, Chr16 position 77332010, Chr16 position 77332010, Chr16 position 78540378, Chr16 position 79333435, Chr16 position 79333435, Chr16 position 84262419, Chr16 position 88701114, Chr16 position 88701114, Chr16 position 89988308, Chr16 position 89988644, Chr17 position 89988644, Chr17 position 1509928, Chr17 position 1509945, Chr17 position 1509952, Chr17 position 1509953, Chr17 position 7644013, Chr17 position 16323460, Chr17 position 16323473, Chr17 position 16924561, Chr17 position 16924562, Chr17 position 16924594, Chr17 position 17717918, Chr17 position 17717918, Chr17 position 17718591, Chr17 position 18139506, Chr17 position 18139506, Chr17 position 35278031, Chr17 position 39677570, Chr17 position 39677570, Chr17 position 40826257, Chr17 position 43037426, Chr17 position 43037426, Chr17 position 43200096, Chr17 position 43200239, Chr17 position 43200239, Chr17 position 43510142, Chr17 position 47987828, Chr17 position 47987828, Chr17 position 48178379, Chr17 position 48596391, Chr17 position 48596391, Chr17 position 48764165, Chr17 position 55701962, Chr17 position 55701962, Chr17 position 73584599, Chr17 position 73993165, Chr17 position 73993165, Chr17 position 75827716, Chr17 position 76882243, Chr17 position 76882243, Chr17 position 78765910, Chr17 position 79544478, Chr17 position 79544478, Chr17 position 80696474, Chr18 position 19751759, Chr18 position 19751759, Chr18 position 21440760, Chr18 position 45555437, Chr18 position 45555437, Chr18 position 45555438, Chr18 position 46547891, Chr18 position 46547891, Chr18 position 55888885, Chr18 position 56452096, Chr18 position 56452096, Chr18 position 56452476, Chr18 position 56887181, Chr18 position 56887181, Chr18 position 76002973, Chr18 position 77331090, Chr19 position 77331090, Chr19 position 677895, Chr19 position 884044, Chr19 position 884059, Chr19 position 884105, Chr19 position 884115, Chr19 position 1136511, Chr19 position 1177605, Chr19 position 1177612, Chr19 position 1177640, Chr19 position 1860601, Chr19 position 1860607, Chr19 position 2503954, Chr19 position 3434917, Chr19 position 3434921, Chr19 position 3434930, Chr19 position 3434939, Chr19 position 3434952, Chr19 position 3434954, Chr19 position 3434962, Chr19 position 3434964, Chr19 position 3434979, Chr19 position 3434985, Chr19 position 4052713, Chr19 position 4052714, Chr19 position 4052749, Chr19 position 4374591, Chr19 position 5013982, Chr19 position 5048836, Chr19 position 5048867, Chr19 position 5048877, Chr19 position 8367279, Chr19 position 8428573, Chr19 position 10254577, Chr19 position 10254578, Chr19 position 10463956, Chr19 position 10464137, Chr19 position 13203671, Chr19 position 13266925, Chr19 position 13266934, Chr19 position 13266970, Chr19 position 13842142, Chr19 position 14248494, Chr19 position 15375465, Chr19 position 17218912, Chr19 position 17346702, Chr19 position 17346702, Chr19 position 18157221, Chr19 position 18157258, Chr19 position 18415877, Chr19 position 18415890, Chr19 position 30606642, Chr19 position 35531842, Chr19 position 44303112, Chr19 position 47173037, Chr19 position 47316268, Chr19 position 47778278, Chr19 position 47778298, Chr20 position 34206950, Chr20 position 36771969, Chr20 position 48993661, Chr20 position

42

58406398, Chr20 position 61976049, Chr20 position 61976073, Chr20 position 62588571, Chr20 position 62588579, Chr22 position 19738127, Chr22 position 35965176, Chr22 position 36549809, Chr22 position 36973375, Chr22 position 37447953, Chr22 position 37914998, Chr22 position 38307317, Chr22 position 39662794, and Chr22 position 45622980. In embodiments, the method includes detecting methylation or unmethylation of at least 100 of the following sites: 10 Chr1 position 2996653, Chr1 position 11979164, Chr1 position 12655938, Chr1 position 16450525, Chr1 position 16450542, Chr1 position 16450545, Chr1 position 16469987, Chr1 position 17494491, Chr1 position 25473203, Chr1 position 27640460, Chr1 position 29565080, Chr1 position 38493013, Chr1 position 38493030, Chr1 position 38493074, Chr1 position 46713777, Chr1 position 46914121, Chr1 position 46955744, Chr1 position 55008344, Chr1 position 109816092, Chr1 position 109816111, Chr1 position 110074669, Chr1 position 110074681, Chr1 position 110074685, Chr1 position 150949856, Chr1 position 150949857, Chr1 position 153540282, Chr1 position 155162704, Chr1 position 155162714, Chr1 position 156676611, Chr1 position 157611881, Chr1 position 182205324, Chr1 position 204118999, Chr1 position 206741875, Chr1 position 206741989, Chr1 position 212587673, Chr1 position 212841198, Chr1 position 223403952, Chr1 position 233430972, Chr1 position 234342767, Chr2 position 3454277, Chr2 position 8793724, 20 Chr2 position 20412441, Chr2 position 42329402, Chr2 position 42329494, Chr2 position 55289272, Chr2 position 65064865, Chr2 position 70823641, Chr2 position 73143689, Chr2 position 74454110, Chr2 position 122014529, Chr2 position 128158884, Chr2 position 128158910, Chr2 position 203114171, Chr2 position 218221671, Chr2 position 219745335, Chr2 position 238341465, Chr2 position 238341542, Chr2 position 238341546, Chr2 position 238774763, Chr3 position 13323642, Chr3 position 14180153, Chr3 position 45209073, Chr3 position 45209207, Chr3 position 52525100, Chr3 position 62589658, Chr3 position 65388317, Chr3 position 65388388, Chr3 position 73599302, Chr3 position 195636893, Chr3 position 197093846, Chr4 position 3743223, Chr4 position 5755716, 30 Chr4 position 5755717, Chr4 position 5755728, Chr4 position 5755729, Chr4 position 5755734, Chr4 position 8372861, Chr4 position 57548289, Chr5 position 1118280, Chr5 position 34564389, Chr5 position 73871907, Chr5 position 78013596, Chr5 position 78013643, Chr5 position 137802650, Chr5 position 139051189, Chr5 position 167838221, Chr5 position 177541401, Chr5 position 180018672, Chr5 position 180101026, Chr6 position 3394325, Chr6 position 3887581, Chr6 position 7236568, Chr6 position 7728692, Chr6 position 34203617, Chr6 position 37751320, Chr6 position 41410682, Chr6 position 41438516, Chr6 position 41438575, Chr6 position 43464150, Chr6 position 158734279, Chr7 position 989235, Chr7 position 2673543, Chr7 position 73508602, Chr7 position 105079565, Chr7 position 105079631, Chr7 position 151425103, Chr7 position 151425104, Chr8 position 11764017, Chr8 position 21647308, Chr8 position 22548399, Chr8 position 22548483, Chr8 position 133570537, Chr8 position 141320393, Chr8 position 141320410, Chr9 position 6566568, Chr9 position 16197862, Chr9 position 34591313, Chr9 position 98225096, Chr9 position 126126741, Chr9 position 132083428, Chr9 position 136077410, Chr9 position

139655018, Chr9 position 140205985, Chr9 position 140205985, Chr9 position 140205985, Chr9 position 3929071, Chr10 position 30047012, Chr10 position 79702989, Chr10 position 87984905, Chr10 position 94838789, Chr10 position 102131187, Chr10 position 104196489, Chr10 position 111766879, Chr10 position 112258886, Chr10 position 112258984, Chr10 position 112259015, Chr10 position 116391763, Chr10 position 120011530, Chr10 position 126172714, Chr10 position 126172747, Chr11 position 556355, Chr11 position 821282, Chr11 position 12188937, Chr11 position 12188948, Chr11 position 12188995, Chr11 position 36057726, Chr11 position 48070143, Chr11 position 48070163, Chr11 position 48070166, Chr11 position 48070174, Chr11 position 65158294, Chr11 position 65158342, Chr11 position 65297089, Chr11 position 66104481, Chr11 position 66104485, Chr11 position 66104578, Chr11 position 68608767, Chr11 position 70236292, Chr11 position 70236320, Chr11 position 115530032, Chr11 position 117950310, Chr11 position 117950329, Chr11 position 117950361, Chr11 position 117950362, Chr11 position 119293593, Chr12 position 679803, Chr12 position 26039132, Chr12 position 31004558, Chr12 position 45610695, Chr12 position 45610701, Chr12 position 45610702, Chr12 position 45610706, Chr12 position 50286016, Chr12 position 52243258, Chr12 position 52243286, Chr12 position 54145732, Chr12 position 54145741, Chr12 position 54145825, Chr12 position 56115043, Chr12 position 66262229, Chr12 position 66262234, Chr12 position 77266621, Chr12 position 117580102, Chr12 position 123435962, Chr12 position 123436011, Chr12 position 123436065, Chr12 position 123540893, Chr13 position 20735797, Chr13 position 23500419, Chr13 position 46771519, Chr13 position 46771520, Chr13 position 53313426, Chr13 position 113807393, Chr14 position 38599118, Chr14 position 69170010, Chr14 position 75701632, Chr14 position 75701643, Chr14 position 90850454, Chr14 position 97524282, Chr14 position 103541602, Chr14 position 103768055, Chr14 position 104209000, Chr14 position 104209068, Chr14 position 104354645, Chr14 position 104360487, Chr15 position 41068807, Chr15 position 61152225, Chr15 position 61152253, Chr15 position 65186440, Chr15 position 68851629, Chr15 position 70667596, Chr15 position 70767206, Chr15 position 75251486, Chr15 position 77984014, Chr15 position 77989064, Chr15 position 83952081, Chr15 position 85402496, Chr15 position 85402497, Chr15 position 99417337, Chr16 position 1231873, Chr16 position 1458639, Chr16 position 23135832, Chr16 position 3023231, Chr16 position 31009547, Chr16 position 31009548, Chr16 position 31009590, Chr16 position 57793674, Chr16 position 57793715, Chr16 position 70771056, Chr16 position 70771079, Chr16 position 70771141, Chr16 position 77332010, Chr16 position 78540378, Chr16 position 84262419, Chr16 position 88701114, Chr16 position 89988308, Chr16 position 89988644, Chr17 position 1509928, Chr17 position 1509945, Chr17 position 1509952, Chr17 position 1509953, Chr17 position 7644013, Chr17 position 16323460, Chr17 position 16323473, Chr17 position 16924561, Chr17 position 16924562, Chr17 position 16924594, Chr17 position 17717918, Chr17 position 17718591, Chr17 position 5 48178379, Chr17 position 48764165, Chr17 position 73584599, Chr17 position 75827716, Chr17 position 78765910, Chr17 position 80696474, Chr18 position 21440760, Chr18 position 45555438, Chr18 position 55888885, Chr18 position 56452476, Chr18 position 76002973, Chr18 position 677895, Chr19 position 884044, Chr19 position 884059, Chr19 position 884105, Chr19 position 884115, Chr19 position 1136511, Chr19 position 1177605, Chr19 position 1177612, Chr19 position 1177640, Chr19 position 1860601, Chr19 position 1860607, Chr19 position 2503954, Chr19 position 3434917, Chr19 position 3434921, Chr19 position 3434930, Chr19 position 3434939, Chr19 position 3434952, Chr19 position 3434954, Chr19 position 3434962, Chr19 position 3434964, Chr19 position 3434979, Chr19 position 3434985, Chr19 position 4052713, Chr19 position 4052714, Chr19 position 4052749, Chr19 position 4374591, Chr19 position 5013982, Chr19 position 5048836, Chr19 position 5048867, Chr19 position 5048877, Chr19 position 8367279, Chr19 position 8428573, Chr19 position 10254577, Chr19 position 30 10254578, Chr19 position 10463956, Chr19 position 10464137, Chr19 position 13203671, Chr19 position 13266925, Chr19 position 13266934, Chr19 position 13266970, Chr19 position 13842142, Chr19 position 14248494, Chr19 position 15375465, Chr19 position 17218912, Chr19 position 17346702, Chr19 position 17346702, Chr19 position 18157221, Chr19 position 18157258, Chr19 position 18415877, Chr19 position 18415890, Chr19 position 30606642, Chr19 position 35531842, Chr19 position 40 44303112, Chr19 position 47173037, Chr19 position 47316268, Chr19 position 47778278, Chr19 position 47778298, Chr20 position 34206950, Chr20 position 36771969, Chr20 position 48993661, Chr20 position 58406398, Chr20 position 61976049, Chr20 position 61976073, Chr20 position 62588571, Chr20 position 62588579, Chr22 position 19738127, Chr22 position 35965176, Chr22 position 36973375, Chr22 position 37447953, Chr22 position 37914998, Chr22 position 38307317, Chr22 position 39662794, and Chr22 position 45622980.
--

182205324, Chr1 position 204118999, Chr1 position 206741875, Chr1 position 206741989, Chr1 position 212587673, Chr1 position 212841198, Chr1 position 223403952, Chr1 position 233430972, Chr1 position 234342767, Chr2 position 3454277, Chr2 position 8793724, Chr2 position 20412441, Chr2 position 42329402, Chr2 position 42329494, Chr2 position 55289272, Chr2 position 65064865, Chr2 position 70823641, Chr2 position 73143689, Chr2 position 74454110, Chr2 position 122014529, Chr2 position 128158884, Chr2 position 128158910, Chr2 position 203114171, Chr2 position 218221671, Chr2 position 219745335, Chr2 position 238341465, Chr2 position 238341542, Chr2 position 238341546, Chr2 position 238774763, Chr3 position 13323642, Chr3 position 14180153, Chr3 position 45209073, Chr3 position 45209207, Chr3 position 52525100, Chr3 position 62589658, Chr3 position 65388317, Chr3 position 65388388, Chr3 position 73599302, Chr3 position 195636893, Chr3 position 197093846, Chr4 position 3743223, Chr4 position 5755716, Chr4 position 5755717, Chr4 position 5755728, Chr4 position 5755729, Chr4 position 5755734, Chr4 position 8372861, Chr4 position 57548289, Chr5 position 1118280, Chr5 position 34564389, Chr5 position 73871907, Chr5 position 78013596, Chr5 position 78013643, Chr5 position 137802650, Chr5 position 139051189, Chr5 position 167838221, Chr5 position 177541401, Chr5 position 180018672, Chr5 position 180101026, Chr6 position 3394325, Chr6 position 3887581, Chr6 position 7236568, Chr6 position 7728692, Chr6 position 34203617, Chr6 position 37751320, Chr6 position 41410682, Chr6 position 41438516, Chr6 position 41438575, Chr6 position 43464150, Chr6 position 158734279, Chr7 position 989235, Chr7 position 2673543, Chr7 position 73508602, Chr7 position 105079565, Chr7 position 105079631, Chr7 position 151425103, Chr7 position 151425104, Chr8 position 11764017, Chr8 position 21647308, Chr8 position 22548399, Chr8 position 22548483, Chr8 position 133570537, Chr8 position 141320393, Chr8 position 141320410, Chr9 position 6566568, Chr9 position 16197862, Chr9 position 34591313, Chr9 position 98225096, Chr9 position 126126741, Chr9 position 132083428, Chr9 position 136077410, Chr9 position 139655018, Chr9 position 140205985, Chr9 position 140205985, Chr9 position 140205997, Chr10 position 3929071, Chr10 position 30047012, Chr10 position 79702989, Chr10 position 87984905, Chr10 position 94838789, Chr10 position 102131187, Chr10 position 104196489, Chr10 position 111766879, Chr10 position 112258886, Chr10 position 112258984, Chr10 position 112259015, Chr10 position 116391763, Chr10 position 120011530, Chr10 position 126172714, Chr10 position 126172747, Chr11 position 556355, Chr11 position 821282, Chr11 position 12188937, Chr11 position 12188948, Chr11 position 12188995, Chr11 position 36057726, Chr11 position 48070143, Chr11 position 48070163, Chr11 position 48070166, Chr11 position 48070174, Chr11 position 65158294, Chr11 position 65158342, Chr11 position 65297089, Chr11 position 66104481, Chr11 position 66104485, Chr11 position 66104578, Chr11 position 68608767, Chr11 position 70236292, Chr11 position 70236320, Chr11 position 70236331, Chr11 position 115530032, Chr11 position 117950310, Chr11 position 117950329, Chr11 position 117950361, Chr11 position 117950362, Chr11 position 119293593, Chr12 position 679803, Chr12 position 26039132, Chr12 position 31004558, Chr12 position 45610695, Chr12 position

45610701, Chr12 position 45610702, Chr12 position 45610706, Chr12 position 50286016, Chr12 position 52243258, Chr12 position 52243286, Chr12 position 54145732, Chr12 position 54145741, Chr12 position 54145825, Chr12 position 56115043, Chr12 position 66262229, Chr12 position 66262230, Chr12 position 66262234, Chr12 position 77266621, Chr12 position 117580102, Chr12 position 123435962, Chr12 position 123436011, Chr12 position 123436065, Chr12 position 123540893, Chr13 position 20735797, Chr13 position 23500419, Chr13 position 46771519, Chr13 position 46771520, Chr13 position 53313426, Chr13 position 113807393, Chr14 position 38599118, Chr14 position 69170010, Chr14 position 75701632, Chr14 position 75701643, Chr14 position 90850454, Chr14 position 97524282, Chr14 position 103541602, Chr14 position 103768055, Chr14 position 104209000, Chr14 position 104209068, Chr14 position 104354645, Chr14 position 104360487, Chr15 position 41068807, Chr15 position 61152225, Chr15 position 61152253, Chr15 position 61152313, Chr15 position 65186440, Chr15 position 68851629, Chr15 position 70667596, Chr15 position 70767206, Chr15 position 75251486, Chr15 position 77984014, Chr15 position 77989064, Chr15 position 83952081, Chr15 position 85402496, Chr15 position 85402497, Chr15 position 99417337, Chr16 position 1231873, Chr16 position 1458639, Chr16 position 3023231, Chr16 position 23135832, Chr16 position 29616265, Chr16 position 31009547, Chr16 position 31009548, Chr16 position 31009590, Chr16 position 57793674, Chr16 position 57793715, Chr16 position 57793727, Chr16 position 70771056, Chr16 position 70771079, Chr16 position 70771141, Chr16 position 77332010, Chr16 position 78540378, Chr16 position 79333435, Chr16 position 84262419, Chr16 position 88701114, Chr16 position 89988308, Chr16 position 89988644, Chr17 position 1509928, Chr17 position 1509945, Chr17 position 1509952, Chr17 position 1509953, Chr17 position 7644013, Chr17 position 16323460, Chr17 position 16323473, Chr17 position 16924561, Chr17 position 16924562, Chr17 position 16924594, Chr17 position 17717918, Chr17 position 17718591, Chr17 position 18139506, Chr17 position 35278031, Chr17 position 39677570, Chr17 position 40826257, Chr17 position 43037426, Chr17 position 43200096, Chr17 position 43200239, Chr17 position 43510142, Chr17 position 47987828, Chr17 position 48178379, Chr17 position 48596391, Chr17 position 48764165, Chr17 position 55701962, Chr17 position 573584599, Chr17 position 73993165, Chr17 position 75827716, Chr17 position 76882243, Chr17 position 78765910, Chr17 position 79544478, Chr17 position 80696474, Chr18 position 19751759, Chr18 position 21440760, Chr18 position 45555437, Chr18 position 45555438, Chr18 position 46547891, Chr18 position 55888885, Chr18 position 56452096, Chr18 position 56452476, Chr18 position 56887181, Chr18 position 76002973, Chr18 position 77331090, Chr19 position 677895, Chr19 position 884044, Chr19 position 884059, Chr19 position 884105, Chr19 position 884115, Chr19 position 1136511, Chr19 position 1177605, Chr19 position 1177612, Chr19 position 1177640, Chr19 position 1860601, Chr19 position 1860607, Chr19 position 2503954, Chr19 position 3434917, Chr19 position 3434921, Chr19 position 3434930, Chr19 position 3434939, Chr19 position 3434952, Chr19 position 3434954, Chr19 position 3434962, Chr19 position 3434964, Chr19 position 3434979, Chr19 position

3434985, Chr19 position 4052713, Chr19 position 4052714, Chr19 position 4052749, Chr19 position 4374591, Chr19 position 5013982, Chr19 position 5048836, Chr19 position 5048867, Chr19 position 5048877, Chr19 position 8367279, Chr19 position 8428573, Chr19 position 10254577, Chr19 position 10254578, Chr19 position 10463956, Chr19 position 10464137, Chr19 position 13203671, Chr19 position 13266925, Chr19 position 13266934, Chr19 position 13266970, Chr19 position 13842142, Chr19 position 14248494, Chr19 position 15375465, Chr19 position 17218912, Chr19 position 17346702, Chr19 position 17346702, Chr19 position 18157161, Chr19 position 18157221, Chr19 position 18157258, Chr19 position 18415877, Chr19 position 18415890, Chr19 position 30606642, Chr19 position 35531842, Chr19 position 44303112, Chr19 position 47173037, Chr19 position 47316268, Chr19 position 47778278, Chr19 position 47778298, Chr20 position 34206950, Chr20 position 36771969, Chr20 position 48993661, Chr20 position 58406398, Chr20 position 61976049, Chr20 position 61976073, Chr20 position 62588571, Chr20 position 62588579, Chr22 position 19738127, Chr22 position 35965176, Chr22 position 36549809, Chr22 position 36973375, Chr22 position 37447953, Chr22 position 37914998, Chr22 position 38307317, Chr22 position 39662794, and Chr22 position 45622980.

In embodiments, the method includes detecting methylation or unmethylation of at least 300 of the following sites: Chr1 position 2996653, Chr1 position 11979164, Chr1 position 12655938, Chr1 position 16450525, Chr1 position 16450542, Chr1 position 16450545, Chr1 position 16469987, Chr1 position 17494491, Chr1 position 25473203, Chr1 position 27640460, Chr1 position 29565080, Chr1 position 38493013, Chr1 position 38493030, Chr1 position 38493074, Chr1 position 46713777, Chr1 position 46914121, Chr1 position 46955744, Chr1 position 55008344, Chr1 position 109816092, Chr1 position 109816111, Chr1 position 110074669, Chr1 position 110074681, Chr1 position 110074685, Chr1 position 150949856, Chr1 position 150949857, Chr1 position 153540282, Chr1 position 155162704, Chr1 position 155162714, Chr1 position 156676611, Chr1 position 157611881, Chr1 position 182205324, Chr1 position 204118999, Chr1 position 206741875, Chr1 position 206741989, Chr1 position 212587673, Chr1 position 212841198, Chr1 position 223403952, Chr1 position 233430972, Chr1 position 234342767, Chr2 position 3454277, Chr2 position 8793724, Chr2 position 20412441, Chr2 position 42329402, Chr2 position 42329494, Chr2 position 55289272, Chr2 position 65064865, Chr2 position 70823641, Chr2 position 73143689, Chr2 position 74454110, Chr2 position 122014529, Chr2 position 128158884, Chr2 position 128158910, Chr2 position 203114171, Chr2 position 218221671, Chr2 position 219745335, Chr2 position 238341465, Chr2 position 238341542, Chr2 position 238341546, Chr2 position 238774763, Chr3 position 13323642, Chr3 position 14180153, Chr3 position 45209073, Chr3 position 45209207, Chr3 position 52525100, Chr3 position 62589658, Chr3 position 65388317, Chr3 position 65388388, Chr3 position 73599302, Chr3 position 195636893, Chr3 position 197093846, Chr4 position 3743223, Chr4 position 5755716, Chr4 position 5755717, Chr4 position 5755728, Chr4 position 5755729, Chr4 position 5755734, Chr4 position 8372861, Chr4 position 57548289, Chr5 position 1118280, Chr5 position 34564389, Chr5 position 73871907, Chr5

position 78013596, Chr5 position 78013643, Chr5 position 137802650, Chr5 position 139051189, Chr5 position 167838221, Chr5 position 177541401, Chr5 position 180018672, Chr5 position 180101026, Chr6 position 3394325, Chr6 position 3887581, Chr6 position 7236568, Chr6 position 7728692, Chr6 position 34203617, Chr6 position 37751320, Chr6 position 41410682, Chr6 position 41438516, Chr6 position 41438575, Chr6 position 43464150, Chr6 position 158734279, Chr7 position 989235, Chr7 position 2673543, Chr7 position 73508602, Chr7 position 105079565, Chr7 position 105079631, Chr7 position 151425103, Chr7 position 151425104, Chr8 position 11764017, Chr8 position 21647308, Chr8 position 22548399, Chr8 position 22548483, Chr8 position 133570537, Chr8 position 141320393, Chr8 position 141320410, Chr9 position 6566568, Chr9 position 16197862, Chr9 position 34591313, Chr9 position 98225096, Chr9 position 126126741, Chr9 position 132083428, Chr9 position 136077410, Chr9 position 139655018, Chr9 position 140205985, Chr9 position 140205985, Chr9 position 140205997, Chr10 position 3929071, Chr10 position 30047012, Chr10 position 79702989, Chr10 position 87984905, Chr10 position 94838789, Chr10 position 102131187, Chr10 position 25 104196489, Chr10 position 111766879, Chr10 position 112258886, Chr10 position 112258984, Chr10 position 112259015, Chr10 position 116391763, Chr10 position 120011530, Chr10 position 126172714, Chr10 position 126172747, Chr11 position 556355, Chr11 position 821282, Chr11 position 12188937, Chr11 position 12188948, Chr11 position 12188995, Chr11 position 36057726, Chr11 position 48070143, Chr11 position 48070163, Chr11 position 48070166, Chr11 position 48070174, Chr11 position 65158294, Chr11 position 65158342, Chr11 position 65297089, Chr11 position 66104481, Chr11 position 66104485, Chr11 position 66104578, Chr11 position 68608767, Chr11 position 70236292, Chr11 position 70236320, Chr11 position 70236331, Chr11 position 115530032, Chr11 position 117950310, Chr11 position 40 117950329, Chr11 position 117950361, Chr11 position 117950362, Chr11 position 119293593, Chr12 position 679803, Chr12 position 26039132, Chr12 position 31004558, Chr12 position 45610695, Chr12 position 45610701, Chr12 position 45610702, Chr12 position 45610706, Chr12 position 50286016, Chr12 position 52243258, Chr12 position 52243286, Chr12 position 54145732, Chr12 position 54145741, Chr12 position 54145825, Chr12 position 56115043, Chr12 position 66262229, Chr12 position 66262230, Chr12 position 66262233, Chr12 position 66262234, Chr12 position 77266621, Chr12 position 117580102, Chr12 position 123435962, Chr12 position 123436011, Chr12 position 123436065, Chr12 position 123540893, Chr13 position 20735797, Chr13 position 23500419, Chr13 position 55 46771519, Chr13 position 46771520, Chr13 position 53313426, Chr13 position 113807393, Chr14 position 38599118, Chr14 position 69170010, Chr14 position 75701632, Chr14 position 75701643, Chr14 position 90850454, Chr14 position 97524282, Chr14 position 103541602, Chr14 position 103768055, Chr14 position 104209000, Chr14 position 104209068, Chr14 position 104354645, Chr14 position 104360487, Chr15 position 41068807, Chr15 position 61152225, Chr15 position 61152253, Chr15 position 61152313, Chr15 position 65 65186440, Chr15 position 68851629, Chr15 position 70667596, Chr15 position 70767206, Chr15 position 75251486, Chr15 position 77984014, Chr15 position

77989064, Chr15 position 83952081, Chr15 position 85402496, Chr15 position 85402497, Chr15 position 99417337, Chr16 position 1231873, Chr16 position 1458639, Chr16 position 3023231, Chr16 position 23135832, Chr16 position 29616265, Chr16 position 31009547, Chr16 position 31009548, Chr16 position 31009590, Chr16 position 57793674, Chr16 position 57793715, Chr16 position 57793727, Chr16 position 70771056, Chr16 position 70771079, Chr16 position 70771141, Chr16 position 77332010, Chr16 position 78540378, Chr16 position 79333435, Chr16 position 84262419, Chr16 position 88701114, Chr16 position 89988308, Chr16 position 89988644, Chr17 position 1509928, Chr17 position 1509945, Chr17 position 1509952, Chr17 position 1509953, Chr17 position 7644013, Chr17 position 16323460, Chr17 position 16323473, Chr17 position 16924561, Chr17 position 16924562, Chr17 position 16924594, Chr17 position 17717918, Chr17 position 17718591, Chr17 position 18139506, Chr17 position 35278031, Chr17 position 39677570, Chr17 position 40826257, Chr17 position 43037426, Chr17 position 43200096, Chr17 position 43200239, Chr17 position 43510142, Chr17 position 47987828, Chr17 position 48178379, Chr17 position 48596391, Chr17 position 48764165, Chr17 position 55701962, Chr17 position 73584599, Chr17 position 73993165, Chr17 position 75827716, Chr17 position 76882243, Chr17 position 78765910, Chr17 position 79544478, Chr17 position 80696474, Chr18 position 19751759, Chr18 position 21440760, Chr18 position 45555437, Chr18 position 45555438, Chr18 position 46547891, Chr18 position 55888885, Chr18 position 56452096, Chr18 position 56452476, Chr18 position 56887181, Chr18 position 76002973, Chr18 position 77331090, Chr19 position 677895, Chr19 position 884044, Chr19 position 884059, Chr19 position 884105, Chr19 position 884115, Chr19 position 1136511, Chr19 position 1177605, Chr19 position 1177612, Chr19 position 1177640, Chr19 position 1860601, Chr19 position 1860607, Chr19 position 2503954, Chr19 position 3434917, Chr19 position 3434921, Chr19 position 3434930, Chr19 position 3434939, Chr19 position 3434952, Chr19 position 3434954, Chr19 position 3434962, Chr19 position 3434964, Chr19 position 3434979, Chr19 position 3434985, Chr19 position 4052713, Chr19 position 4052714, Chr19 position 4052749, Chr19 position 4374591, Chr19 position 5013982, Chr19 position 5048836, Chr19 position 5048867, Chr19 position 5048877, Chr19 position 8367279, Chr19 position 8428573, Chr19 position 10254577, Chr19 position 10254578, Chr19 position 10463956, Chr19 position 10464137, Chr19 position 13203671, Chr19 position 13266925, Chr19 position 13266934, Chr19 position 13266970, Chr19 position 13842142, Chr19 position 14248494, Chr19 position 15375465, Chr19 position 17218912, Chr19 position 17346702, Chr19 position 17346702, Chr19 position 18157161, Chr19 position 18157221, Chr19 position 18157258, Chr19 position 18415877, Chr19 position 18415890, Chr19 position 30606642, Chr19 position 35531842, Chr19 position 44303112, Chr19 position 47173037, Chr19 position 47316268, Chr19 position 47778278, Chr19 position 47778298, Chr20 position 34206950, Chr20 position 36771969, Chr20 position 48993661, Chr20 position 58406398, Chr20 position 61976049, Chr20 position 61976073, Chr20 position 62588571, Chr20 position 62588579, Chr22 position 19738127, Chr22 position 35965176, Chr22 position 36549809, Chr22 position 36973375, Chr22 position 37447953, Chr22 position

37914998, Chr22 position 38307317, Chr22 position 39662794, and Chr22 position 45622980. In embodiments, the method includes detecting methylation or unmethylation of at least 400 of the following sites: 5 Chr1 position 2996653, Chr1 position 11979164, Chr1 position 12655938, Chr1 position 16450525, Chr1 position 16450542, Chr1 position 16450545, Chr1 position 16469987, Chr1 position 17494491, Chr1 position 25473203, Chr1 position 27640460, Chr1 position 29565080, Chr1 position 38493013, Chr1 position 38493030, Chr1 position 38493074, Chr1 position 46713777, Chr1 position 46914121, Chr1 position 46955744, Chr1 position 55008344, Chr1 position 109816092, Chr1 position 109816111, Chr1 position 110074669, Chr1 position 110074681, Chr1 position 110074685, Chr1 position 150949856, Chr1 position 150949857, Chr1 position 153540282, Chr1 position 155162704, Chr1 position 155162714, Chr1 position 156676611, Chr1 position 157611881, Chr1 position 182205324, Chr1 position 204118999, Chr1 position 206741875, Chr1 position 206741989, Chr1 position 212587673, Chr1 position 212841198, Chr1 position 223403952, Chr1 position 233430972, Chr1 position 234342767, Chr2 position 3454277, Chr2 position 8793724, 15 Chr2 position 20412441, Chr2 position 42329402, Chr2 position 42329494, Chr2 position 55289272, Chr2 position 65064865, Chr2 position 70823641, Chr2 position 73143689, Chr2 position 74454110, Chr2 position 122014529, Chr2 position 128158884, Chr2 position 128158910, Chr2 position 203114171, Chr2 position 218221671, Chr2 position 219745335, Chr2 position 238341465, Chr2 position 238341542, Chr2 position 238341546, Chr2 position 238774763, Chr3 position 13323642, Chr3 position 14180153, Chr3 position 45209073, Chr3 position 45209207, Chr3 position 52525100, Chr3 position 62589658, Chr3 position 65388317, Chr3 position 65388388, Chr3 position 73599302, Chr3 position 195636893, Chr3 position 197093846, Chr4 position 3743223, Chr4 position 5755716, 20 Chr4 position 5755717, Chr4 position 5755728, Chr4 position 5755729, Chr4 position 5755734, Chr4 position 8372861, Chr4 position 57548289, Chr5 position 1118280, Chr5 position 34564389, Chr5 position 73871907, Chr5 position 78013596, Chr5 position 78013643, Chr5 position 137802650, Chr5 position 139051189, Chr5 position 167838221, Chr5 position 177541401, Chr5 position 180018672, Chr5 position 180101026, Chr6 position 3394325, Chr6 position 3887581, Chr6 position 7236568, Chr6 position 7728692, Chr6 position 34203617, Chr6 position 37751320, Chr6 position 41410682, Chr6 position 41438516, Chr6 position 41438575, Chr6 position 43464150, Chr6 position 158734279, Chr7 position 989235, Chr7 position 2673543, Chr7 position 73508602, Chr7 position 105079565, Chr7 position 105079631, Chr7 position 151425103, Chr7 position 151425104, Chr8 position 11764017, Chr8 position 21647308, Chr8 position 22548399, Chr8 position 22548483, Chr8 position 133570537, Chr8 position 141320393, Chr8 position 141320410, Chr9 position 6566568, Chr9 position 16197862, Chr9 position 34591313, Chr9 position 98225096, Chr9 position 126126741, Chr9 position 132083428, Chr9 position 136077410, Chr9 position 139655018, Chr9 position 140205985, Chr9 position 140205985, Chr9 position 140205997, Chr10 position 3929071, Chr10 position 30047012, Chr10 position 79702989, Chr10 position 87984905, Chr10 position 94838789, Chr10 position 102131187, Chr10 position

104196489, Chr10 position 111766879, Chr10 position 112258886, Chr10 position 112258984, Chr10 position 112259015, Chr10 position 116391763, Chr10 position 120011530, Chr10 position 126172714, Chr10 position 126172747, Chr11 position 556355, Chr11 position 821282, Chr11 position 12188937, Chr11 position 12188948, Chr11 position 12188995, Chr11 position 36057726, Chr11 position 48070143, Chr11 position 48070163, Chr11 position 48070166, Chr11 position 48070174, Chr11 position 65158294, Chr11 position 65158342, Chr11 position 65297089, Chr11 position 66104481, Chr11 position 66104485, Chr11 position 66104578, Chr11 position 68608767, Chr11 position 70236292, Chr11 position 70236320, Chr11 position 70236331, Chr11 position 115530032, Chr11 position 117950310, Chr11 position 117950329, Chr11 position 117950361, Chr11 position 117950362, Chr11 position 119293593, Chr12 position 679803, Chr12 position 26039132, Chr12 position 31004558, Chr12 position 45610695, Chr12 position 45610701, Chr12 position 45610702, Chr12 position 45610706, Chr12 position 50286016, Chr12 position 52243258, Chr12 position 52243286, Chr12 position 54145732, Chr12 position 54145741, Chr12 position 54145825, Chr12 position 56115043, Chr12 position 66262229, Chr12 position 66262230, Chr12 position 66262233, Chr12 position 66262234, Chr12 position 77266621, Chr12 position 117580102, Chr12 position 123435962, Chr12 position 123436011, Chr12 position 123436065, Chr12 position 123540893, Chr13 position 20735797, Chr13 position 23500419, Chr13 position 46771519, Chr13 position 46771520, Chr13 position 53313426, Chr13 position 113807393, Chr14 position 38599118, Chr14 position 69170010, Chr14 position 75701632, Chr14 position 75701643, Chr14 position 90850454, Chr14 position 97524282, Chr14 position 103541602, Chr14 position 103768055, Chr14 position 104209000, Chr14 position 104209068, Chr14 position 104354645, Chr14 position 104360487, Chr15 position 41068807, Chr15 position 61152225, Chr15 position 61152253, Chr15 position 61152313, Chr15 position 65186440, Chr15 position 68851629, Chr15 position 70667596, Chr15 position 70767206, Chr15 position 75251486, Chr15 position 77984014, Chr15 position 77989064, Chr15 position 83952081, Chr15 position 85402496, Chr15 position 85402497, Chr15 position 99417337, Chr16 position 1231873, Chr16 position 1458639, Chr16 position 3023231, Chr16 position 23135832, Chr16 position 29616265, Chr16 position 31009547, Chr16 position 31009548, Chr16 position 31009590, Chr16 position 57793674, Chr16 position 57793715, Chr16 position 57793727, Chr16 position 70771056, Chr16 position 70771079, Chr16 position 70771141, Chr16 position 77332010, Chr16 position 78540378, Chr16 position 79333435, Chr16 position 84262419, Chr16 position 88701114, Chr16 position 89988308, Chr16 position 89988644, Chr17 position 1509928, Chr17 position 1509945, Chr17 position 1509952, Chr17 position 1509953, Chr17 position 7644013, Chr17 position 16323460, Chr17 position 16323473, Chr17 position 16924561, Chr17 position 16924562, Chr17 position 16924594, Chr17 position 17717918, Chr17 position 17718591, Chr17 position 18139506, Chr17 position 35278031, Chr17 position 39677570, Chr17 position 40826257, Chr17 position 43037426, Chr17 position 43200096, Chr17 position 43200239, Chr17 position 43510142, Chr17 position 47987828, Chr17 position 48178379, Chr17 position

48764165, Chr17 position 73584599, Chr17 position 75827716, Chr17 position 78765910, Chr17 position 80696474, Chr18 position 5 80696474, Chr18 position 19751759, Chr18 position 21440760, Chr18 position 45555437, Chr18 position 45555438, Chr18 position 46547891, Chr18 position 55888885, Chr18 position 56452096, Chr18 position 56452476, Chr18 position 56887181, Chr18 position 10 76002973, Chr18 position 77331090, Chr19 position 677895, Chr19 position 884044, Chr19 position 884059, Chr19 position 884105, Chr19 position 884115, Chr19 position 1136511, Chr19 position 1177605, Chr19 position 1177612, Chr19 position 1177640, Chr19 position 1860601, Chr19 position 1860607, Chr19 position 2503954, Chr19 position 3434917, Chr19 position 3434921, Chr19 position 3434930, Chr19 position 3434939, Chr19 position 3434952, Chr19 position 3434954, Chr19 position 3434962, Chr19 position 3434964, Chr19 position 3434979, Chr19 position 20 3434985, Chr19 position 4052713, Chr19 position 4052714, Chr19 position 4052749, Chr19 position 4374591, Chr19 position 5013982, Chr19 position 5048836, Chr19 position 5048867, Chr19 position 5048877, Chr19 position 8367279, Chr19 position 8428573, Chr19 position 10254577, Chr19 position 25 10254578, Chr19 position 10463956, Chr19 position 10464137, Chr19 position 13203671, Chr19 position 13266925, Chr19 position 13266934, Chr19 position 13266970, Chr19 position 13842142, Chr19 position 14248494, Chr19 position 15375465, Chr19 position 17218912, Chr19 position 17346702, Chr19 position 17346702, Chr19 position 18157161, Chr19 position 18157221, Chr19 position 18157258, Chr19 position 18415877, Chr19 position 18415890, Chr19 position 30 30606642, Chr19 position 35531842, Chr19 position 44303112, Chr19 position 47173037, Chr19 position 47316268, Chr19 position 47778278, Chr19 position 47778298, Chr20 position 34206950, Chr20 position 36771969, Chr20 position 48993661, Chr20 position 58406398, Chr20 position 61976049, Chr20 position 61976073, Chr20 position 62588571, Chr20 position 62588579, Chr22 position 19738127, Chr22 position 35965176, Chr22 position 36549809, Chr22 position 36973375, Chr22 position 37447953, Chr22 position 37914998, Chr22 position 38307317, Chr22 position 45 39662794, and Chr22 position 45622980.

In embodiments, the method includes detecting methylation or unmethylation of at least 500 of the following sites: Chr1 position 2996653, Chr1 position 11979164, Chr1 position 12655938, Chr1 position 16450525, Chr1 position 16450542, Chr1 position 16450545, Chr1 position 16469987, Chr1 position 17494491, Chr1 position 25473203, Chr1 position 27640460, Chr1 position 29565080, Chr1 position 38493013, Chr1 position 38493030, Chr1 position 38493074, Chr1 position 46713777, Chr1 position 46914121, Chr1 position 46955744, Chr1 position 55008344, Chr1 position 109816092, Chr1 position 109816111, Chr1 position 110074669, Chr1 position 110074681, Chr1 position 110074685, Chr1 position 150949856, Chr1 position 150949857, Chr1 position 153540282, Chr1 position 155162714, Chr1 position 156676611, Chr1 position 157611881, Chr1 position 182205324, Chr1 position 204118999, Chr1 position 206741875, Chr1 position 206741989, Chr1 position 212587673, Chr1 position 212841198, Chr1 position 223403952, Chr1 position 233430972, Chr1 position 234342767, Chr2 position 3454277, Chr2 position 8793724,

Chr2 position 20412441, Chr2 position 42329402, Chr2 position 42329494, Chr2 position 55289272, Chr2 position 65064865, Chr2 position 70823641, Chr2 position 73143689, Chr2 position 74454110, Chr2 position 122014529, Chr2 position 128158884, Chr2 position 128158910, Chr2 position 203114171, Chr2 position 218221671, Chr2 position 219745335, Chr2 position 238341465, Chr2 position 238341542, Chr2 position 238341546, Chr2 position 238774763, Chr3 position 13323642, Chr3 position 14180153, Chr3 position 45209073, Chr3 position 45209207, Chr3 position 52525100, Chr3 position 62589658, Chr3 position 65388317, Chr3 position 65388388, Chr3 position 73599302, Chr3 position 195636893, Chr3 position 197093846, Chr4 position 3743223, Chr4 position 5755716, Chr4 position 5755717, Chr4 position 5755728, Chr4 position 5755729, Chr4 position 5755734, Chr4 position 8372861, Chr4 position 57548289, Chr5 position 1118280, Chr5 position 34564389, Chr5 position 73871907, Chr5 position 78013596, Chr5 position 78013643, Chr5 position 137802650, Chr5 position 139051189, Chr5 position 167838221, Chr5 position 177541401, Chr5 position 180018672, Chr5 position 180101026, Chr6 position 3394325, Chr6 position 3887581, Chr6 position 7236568, Chr6 position 7728692, Chr6 position 34203617, Chr6 position 37751320, Chr6 position 41410682, Chr6 position 41438516, Chr6 position 41438575, Chr6 position 43464150, Chr6 position 158734279, Chr7 position 989235, Chr7 position 2673543, Chr7 position 73508602, Chr7 position 105079565, Chr7 position 105079631, Chr7 position 151425103, Chr7 position 151425104, Chr8 position 11764017, Chr8 position 21647308, Chr8 position 22548399, Chr8 position 22548483, Chr8 position 133570537, Chr8 position 141320393, Chr8 position 141320410, Chr9 position 6566568, Chr9 position 16197862, Chr9 position 34591313, Chr9 position 98225096, Chr9 position 126126741, Chr9 position 132083428, Chr9 position 136077410, Chr9 position 139655018, Chr9 position 140205985, Chr9 position 140205985, Chr9 position 140205997, Chr10 position 3929071, Chr10 position 30047012, Chr10 position 79702989, Chr10 position 87984905, Chr10 position 94838789, Chr10 position 102131187, Chr10 position 104196489, Chr10 position 111766879, Chr10 position 112258886, Chr10 position 112258984, Chr10 position 112259015, Chr10 position 116391763, Chr10 position 120011530, Chr10 position 126172714, Chr10 position 126172747, Chr11 position 556355, Chr11 position 821282, Chr11 position 12188937, Chr11 position 12188948, Chr11 position 12188995, Chr11 position 36057726, Chr11 position 48070143, Chr11 position 48070163, Chr11 position 48070166, Chr11 position 48070174, Chr11 position 65158294, Chr11 position 65158342, Chr11 position 65297089, Chr11 position 66104481, Chr11 position 66104485, Chr11 position 66104578, Chr11 position 68608767, Chr11 position 70236292, Chr11 position 70236320, Chr11 position 70236331, Chr11 position 115530032, Chr11 position 117950310, Chr11 position 117950329, Chr11 position 117950361, Chr11 position 117950362, Chr11 position 119293593, Chr12 position 679803, Chr12 position 26039132, Chr12 position 31004558, Chr12 position 45610695, Chr12 position 45610701, Chr12 position 45610702, Chr12 position 45610706, Chr12 position 50286016, Chr12 position 52243258, Chr12 position 52243286, Chr12 position 54145732, Chr12 position 54145741, Chr12 position 54145825, Chr12 position 56115043, Chr12 position

66262229, Chr12 position 66262230, Chr12 position 66262233, Chr12 position 66262234, Chr12 position 77266621, Chr12 position 117580102, Chr12 position 123435962, Chr12 position 123436011, Chr12 position 5 123436065, Chr12 position 123540893, Chr13 position 20735797, Chr13 position 23500419, Chr13 position 46771519, Chr13 position 46771520, Chr13 position 53313426, Chr13 position 113807393, Chr14 position 38599118, Chr14 position 69170010, Chr14 position 10 75701632, Chr14 position 75701643, Chr14 position 90850454, Chr14 position 97524282, Chr14 position 103541602, Chr14 position 103768055, Chr14 position 104209000, Chr14 position 104209068, Chr14 position 104354645, Chr14 position 104360487, Chr15 position 15 41068807, Chr15 position 61152225, Chr15 position 61152253, Chr15 position 61152313, Chr15 position 65186440, Chr15 position 68851629, Chr15 position 70667596, Chr15 position 70767206, Chr15 position 75251486, Chr15 position 77984014, Chr15 position 20 77989064, Chr15 position 83952081, Chr15 position 85402496, Chr15 position 85402497, Chr15 position 99417337, Chr16 position 1231873, Chr16 position 1458639, Chr16 position 3023231, Chr16 position 23135832, Chr16 position 29616265, Chr16 position 25 31009547, Chr16 position 31009548, Chr16 position 31009590, Chr16 position 57793674, Chr16 position 57793715, Chr16 position 57793727, Chr16 position 70771056, Chr16 position 70771079, Chr16 position 70771141, Chr16 position 77332010, Chr16 position 30 78540378, Chr16 position 79333435, Chr16 position 84262419, Chr16 position 88701114, Chr16 position 89988308, Chr16 position 89988644, Chr17 position 1509928, Chr17 position 1509945, Chr17 position 1509952, Chr17 position 1509953, Chr17 position 7644013, Chr17 position 35 16323460, Chr17 position 16323473, Chr17 position 16924561, Chr17 position 16924562, Chr17 position 16924594, Chr17 position 17717918, Chr17 position 17718591, Chr17 position 18139506, Chr17 position 35278031, Chr17 position 39677570, Chr17 position 40 40826257, Chr17 position 43037426, Chr17 position 43200096, Chr17 position 43200239, Chr17 position 43510142, Chr17 position 47987828, Chr17 position 48178379, Chr17 position 48596391, Chr17 position 48764165, Chr17 position 55701962, Chr17 position 45 73584599, Chr17 position 73993165, Chr17 position 75827716, Chr17 position 76882243, Chr17 position 78765910, Chr17 position 79544478, Chr17 position 80696474, Chr18 position 19751759, Chr18 position 21440760, Chr18 position 45555437, Chr18 position 45555438, Chr18 position 46547891, Chr18 position 55888885, Chr18 position 56452096, Chr18 position 56452476, Chr18 position 56887181, Chr18 position 76002973, Chr18 position 77331090, Chr19 position 677895, Chr19 position 884044, Chr19 position 884059, 55 884105, Chr19 position 884115, Chr19 position 1136511, Chr19 position 1177605, Chr19 position 1177612, Chr19 position 1177640, Chr19 position 1860601, Chr19 position 1860607, Chr19 position 2503954, Chr19 position 3434917, Chr19 position 3434921, Chr19 position 3434930, Chr19 position 3434939, Chr19 position 3434952, Chr19 position 3434954, Chr19 position 3434962, Chr19 position 3434964, Chr19 position 3434979, Chr19 position 3434985, Chr19 position 4052713, Chr19 position 4052714, Chr19 position 4052749, Chr19 position 4374591, Chr19 position 60 5013982, Chr19 position 5048836, Chr19 position 5048867, Chr19 position 5048877, Chr19 position 8367279, Chr19 position 8428573, Chr19 position 10254577, Chr19

position 10254578, Chr19 position 10463956, Chr19 position 10464137, Chr19 position 13203671, Chr19 position 13266925, Chr19 position 13266934, Chr19 position 13266970, Chr19 position 13842142, Chr19 position 14248494, Chr19 position 15375465, Chr19 position 17218912, Chr19 position 17346702, Chr19 position 17346702, Chr19 position 18157161, Chr19 position 18157221, Chr19 position 18157258, Chr19 position 18415877, Chr19 position 18415890, Chr19 position 30606642, Chr19 position 35531842, Chr19 position 44303112, Chr19 position 47173037, Chr19 position 47316268, Chr19 position 47778278, Chr19 position 47778298, Chr20 position 34206950, Chr20 position 36771969, Chr20 position 48993661, Chr20 position 58406398, Chr20 position 61976049, Chr20 position 61976073, Chr20 position 62588571, Chr20 position 62588579, Chr22 position 19738127, Chr22 position 35965176, Chr22 position 36549809, Chr22 position 36973375, Chr22 position 37447953, Chr22 position 37914998, Chr22 position 38307317, Chr22 position 39662794, and Chr22 position 45622980.

In embodiments, a method provided herein is practiced for a subject more than once over time. In embodiments, methylation or unmethylation of thyroid nodule DNA from a subject is assessed using a method provided herein at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more times. In embodiments, the method is repeated at least once every 4, 6, 8, 12 or 18 months, or at least once every 2, 3, 4, or 5 more years.

In embodiments, the method includes: (i) isolating DNA from multiple cells of a thyroid nodule of the subject thereby forming a plurality of isolated thyroid nodule DNA molecules, (ii) contacting the plurality of isolated thyroid nodule DNA molecules with a bisulfite salt thereby forming a plurality of reacted thyroid nodule DNA molecules, (iii) detecting the proportion of DNA molecules in the plurality of reacted thyroid nodule DNA molecules having a uracil at a methylation site set forth in Table 1, thereby detecting methylation or unmethylation of said thyroid nodule DNA of the subject.

The methylation of a CpG site of interest may vary between individual cells (and even between chromosome pairs of individual cells) in a biological sample. When DNA is obtained from a biological sample and treated with a bisulfite salt to convert unmethylated cytosines to uracils, the bisulfite-treated DNA will typically contain (i) a proportion of DNA molecules with a cytosine at the site of interest (indicating that the site was methylated); and (ii) a proportion of DNA molecules with a uracil at the site of interest (indicating that the site was unmethylated). Since a uracil at a site of interest in bisulfite-treated DNA indicates that the site was unmethylated in the untreated DNA, a thymidine at the corresponding site in an amplicon of the bisulfite-treated DNA (e.g., an amplicon obtained by PCR) also indicates that the site was unmethylated in the untreated DNA.

In embodiments, the level of methylation at a site of interest is the proportion of bisulfite-treated DNA molecules having a cytosine rather than a uracil at that site of interest. In embodiments, the level of methylation at a site of interest is the proportion of amplicons of bisulfite-treated DNA molecules having a cytosine rather than a thymidine at that site of interest.

In embodiments, the level of unmethylation at a site of interest is the proportion of bisulfite-treated DNA molecules having a uracil rather than a cytosine at that site of interest. In embodiments, the level of unmethylation at a site of interest is the proportion of amplicons of bisulfite-treated DNA molecules having a thymidine rather than a cytosine at

that site of interest. In Table 1, an indicated level of uracil is the proportion of bisulfite-treated DNA molecules having a uracil rather than a cytosine at the specified methylation site. The same levels listed in Table 1 also apply to the thymidine levels at a site of interest in an amplicon, i.e., the proportion of amplicons (derived from the PCR amplification of bisulfite-treated DNA molecules) having a thymidine rather than a cytosine at the specified methylation site.

The level of DNA methylation at a site of interest (e.g., a methylation site listed in Table 1) may be determined using sequencing technology. Sequencing technology can reveal nucleotide sequence variations in a plurality of DNA molecules at a single nucleotide base resolution. For example, the proportions of corresponding DNA molecules having a uracil, a thymidine, and/or a cytosine at a site may be determined. A non-limiting example of a sequencing-based method for determining the methylation level at a site of interest is described in Masser et al. (2015) Targeted DNA Methylation Analysis by Next-generation Sequencing, *J Vis Exp.* (96): 52488, the entire content of which is incorporated herein by reference.

The chromosomal positions listed in Tables 1-4 relate to the human genome that is publicly accessible in the University of California Santa Cruz (UCSC) genome browser database under accession number HG19, the entire content of which is incorporated herein by reference in its entirety. Non-limiting information regarding the UCSC Genome Browser is provided in Kent W J, Sugnet C W, Furey T S, Roskin K M, Pringle T H, Zahler A M, Haussler D. The human genome browser at UCSC. *Genome Res.* 2002 June; 12 (6): 996-1006, the entire content of which is incorporated herein by reference. Each methylation site of interest listed in Table 1 may be located in other human genomes (e.g., within the genome of a specific subject or group of subjects) by replacing every U and R in the corresponding sequence with a C and then searching for the location of the X within a reference genome by aligning the sequence against the reference genome. For example, the methylation site of interest "X" in SEQ ID NO: 1 may be located within a genome by replacing each U and R in SEQ ID NO: 1 with a C (to obtain the pre-bisulfite-modified sequence having an X at the site of interest) and then aligning the sequence against the genome using a BLAST algorithm. Also expressly provided, disclosed, and incorporated herein is the non-bisulfite-modified sequence corresponding to each of SEQ ID NOS: 1-550. The non-bisulfite-modified sequence corresponding to each of SEQ ID NOS: 1-550 is each respective sequence in which each U and R is replaced with a C, where X is the methylation site of interest. For example, the non-bisulfite-modified sequence corresponding to SEQ ID NO: 1 provided herein is a modified version of SEQ ID NO:1 in which each U and R in SEQ ID NO: 1 is replaced with a C, where X is the methylation site of interest; the non-bisulfite-modified sequence corresponding to SEQ ID NO:2 provided herein is a modified version of SEQ ID NO: 2 in which each U and R in SEQ ID NO:2 is replaced with a C, where X is the methylation site of interest; the non-bisulfite-modified sequence corresponding to SEQ ID NO:3 provided herein is a modified version of SEQ ID NO:3 in which each U and R in SEQ ID NO:3 is replaced with a C, where X is the methylation site of interest, and so on.

TABLE 1

Chromosome (chr)	Chr Position	Uracil level in reacted thyroid nodule DNA from cancer tissues is above indicated level*	Uracil level in reacted thyroid nodule DNA from benign tissues is above indicated level*	Uracil level in reacted thyroid nodule DNA from benign tissues is below indicated level*	SEQ ID NO: Forward Strand	SEQ ID NO: Reverse Strand
chr1	2996653	N/A	88.84	N/A	1	2
chr1	11979164	89.29	N/A	N/A	3	4
chr1	12655938	N/A	N/A	69.23	5	6
chr1	16450525	70.00	N/A	N/A	7	8
chr1	16450542	72.00	N/A	N/A	7	8
chr1	16450545	73.33	N/A	N/A	7	8
chr1	16469987	80.00	N/A	N/A	9	10
chr1	17494491	86.00	N/A	N/A	11	12
chr1	25473203	88.89	N/A	N/A	13	14
chr1	27640460	N/A	80.56	N/A	15	16
chr1	29565080	N/A	N/A	60.00	17	18
chr1	38493013	86.36	N/A	N/A	19	20
chr1	38493030	79.17	N/A	N/A	19	20
chr1	38493074	80.95	N/A	N/A	19	20
chr1	46713777	N/A	N/A	73.33	21	22
chr1	46914121	N/A	N/A	60.00	23	24
chr1	46955744	N/A	N/A	77.78	25	26
chr1	55008344	N/A	N/A	60.00	27	28
chr1	109816092	80.77	N/A	N/A	29	30
chr1	109816111	80.77	N/A	N/A	29	30
chr1	110074669	75.00	N/A	N/A	31	32
chr1	110074681	71.43	N/A	N/A	31	32
chr1	110074685	63.16	N/A	N/A	31	32
chr1	150949856	89.29	N/A	N/A	33	34
chr1	150949857	88.46	N/A	N/A	33	34
chr1	153540282	78.26	N/A	N/A	35	36
chr1	155162704	84.21	N/A	N/A	37	38
chr1	155162714	88.64	N/A	N/A	37	38
chr1	156676611	N/A	N/A	84.62	39	40
chr1	157611881	83.05	N/A	N/A	41	42
chr1	182205324	77.50	N/A	N/A	43	44
chr1	204118999	59.09	N/A	N/A	45	46
chr1	206741875	83.33	N/A	N/A	47	48
chr1	206741989	66.67	N/A	N/A	49	50
chr1	212587673	N/A	N/A	80.00	51	52
chr1	212841198	85.29	N/A	N/A	53	54
chr1	223403952	79.17	N/A	N/A	55	56
chr1	233430972	N/A	N/A	86.67	57	58
chr1	234342767	76.67	N/A	N/A	59	60
chr10	3929071	88.68	N/A	N/A	61	62
chr10	30047012	86.84	N/A	N/A	63	64
chr10	79702989	83.33	N/A	N/A	65	66
chr10	87984905	86.36	N/A	N/A	67	68
chr10	94838789	63.33	N/A	N/A	69	70
chr10	102131187	90.00	N/A	N/A	71	72
chr10	104196489	75.00	N/A	N/A	73	74
chr10	111766879	89.47	N/A	N/A	75	76
chr10	112258886	81.82	N/A	N/A	77	78
chr10	112258984	83.33	N/A	N/A	79	80
chr10	112259015	82.61	N/A	N/A	79	80
chr10	116391763	N/A	N/A	75.00	81	82
chr10	120011530	79.55	N/A	N/A	83	84
chr10	126172714	N/A	80.00	N/A	85	86
chr10	126172747	N/A	84.62	N/A	85	86
chr11	556355	N/A	N/A	75.00	87	88
chr11	821282	89.13	N/A	N/A	89	90
chr11	12188937	83.33	N/A	N/A	91	92
chr11	12188948	77.78	N/A	N/A	91	92
chr11	12188995	78.57	N/A	N/A	93	94
chr11	36057726	N/A	79.63	N/A	95	96
chr11	48070143	N/A	84.38	N/A	97	98
chr11	48070163	N/A	87.50	N/A	97	98
chr11	48070166	N/A	84.38	N/A	97	98
chr11	48070174	N/A	84.48	N/A	97	98
chr11	65158294	78.00	N/A	N/A	99	100
chr11	65158342	85.00	N/A	N/A	99	100
chr11	65297089	75.00	N/A	N/A	101	102

TABLE 1-continued

Chromosome (chr)	Chr Position	Uracil level in reacted thyroid nodule DNA from cancer tissues is above indicated level*	Uracil level in reacted thyroid nodule DNA from benign tissues is above indicated level*	Uracil level in reacted thyroid nodule DNA from benign tissues is below indicated level*	SEQ ID NO: Forward Strand	SEQ ID NO: Reverse Strand
chr11	66104481	81.58	N/A	N/A	103	104
chr11	66104485	83.33	N/A	N/A	103	104
chr11	66104578	81.82	N/A	N/A	105	106
chr11	68608767	N/A	N/A	73.33	107	108
chr11	70236292	89.29	N/A	N/A	109	110
chr11	70236320	85.71	N/A	N/A	109	110
chr11	70236331	70.83	N/A	N/A	109	110
chr11	115530032	N/A	N/A	79.49	111	112
chr11	117950310	79.55	N/A	N/A	113	114
chr11	117950329	79.55	N/A	N/A	113	114
chr11	117950361	80.00	N/A	N/A	115	116
chr11	117950362	81.82	N/A	N/A	115	116
chr11	119293593	N/A	N/A	60.00	117	118
chr12	679803	86.84	N/A	N/A	119	120
chr12	26039132	73.91	N/A	N/A	121	122
chr12	31004558	N/A	N/A	81.82	123	124
chr12	45610695	N/A	N/A	83.33	125	126
chr12	45610701	N/A	N/A	86.67	125	126
chr12	45610702	N/A	N/A	89.47	125	126
chr12	45610706	N/A	N/A	80.00	125	126
chr12	50286016	82.14	N/A	N/A	127	128
chr12	52243258	82.00	N/A	N/A	129	130
chr12	52243286	82.50	N/A	N/A	129	130
chr12	54145732	N/A	N/A	82.35	131	132
chr12	54145741	N/A	N/A	76.47	131	132
chr12	54145825	N/A	N/A	70.59	131	132
chr12	56115043	89.29	N/A	N/A	133	134
chr12	66262229	72.22	N/A	N/A	135	136
chr12	66262230	71.74	N/A	N/A	135	136
chr12	66262233	68.27	N/A	N/A	135	136
chr12	66262234	71.74	N/A	N/A	135	136
chr12	77266621	N/A	73.53	N/A	137	138
chr12	117580102	84.62	N/A	N/A	139	140
chr12	123435962	63.89	N/A	N/A	141	142
chr12	123436011	71.88	N/A	N/A	143	144
chr12	123436065	69.44	N/A	N/A	143	144
chr12	123540893	77.27	N/A	N/A	145	146
chr13	20735797	N/A	N/A	82.35	147	148
chr13	23500419	N/A	N/A	68.42	149	150
chr13	46771519	67.65	N/A	N/A	151	152
chr13	46771520	73.91	N/A	N/A	151	152
chr13	53313426	N/A	N/A	60.00	153	154
chr13	113807393	N/A	N/A	27.27	155	156
chr14	38599118	65.91	N/A	N/A	157	158
chr14	69170010	86.36	N/A	N/A	159	160
chr14	75701632	68.42	N/A	N/A	161	162
chr14	75701643	68.75	N/A	N/A	161	162
chr14	90850454	N/A	N/A	54.55	163	164
chr14	97524282	N/A	88.89	N/A	165	166
chr14	103541602	N/A	N/A	52.00	167	168
chr14	103768055	76.09	N/A	N/A	169	170
chr14	104209000	N/A	80.77	N/A	171	172
chr14	104209068	N/A	83.33	N/A	171	172
chr14	104354645	72.92	N/A	N/A	173	174
chr14	104360487	83.33	N/A	N/A	175	176
chr15	41068807	69.12	N/A	N/A	17	178
chr15	61152225	83.33	N/A	N/A	179	180
chr15	61152253	86.67	N/A	N/A	181	182
chr15	61152313	86.67	N/A	N/A	183	184
chr15	651864440	N/A	N/A	55.56	185	186
chr15	68851629	N/A	N/A	63.64	187	188
chr15	70667596	83.33	N/A	N/A	189	190
chr15	70767206	90.00	N/A	N/A	191	192
chr15	75251486	N/A	N/A	60.00	193	194
chr15	77984014	N/A	88.89	N/A	195	196
chr15	77989064	73.53	N/A	N/A	197	198
chr15	83952081	N/A	N/A	72.73	199	200

TABLE 1-continued

Chromosome (chr)	Chr Position	Uracil level in reacted thyroid nodule DNA from cancer tissues is above indicated level*	Uracil level in reacted thyroid nodule DNA from benign tissues is above indicated level*	Uracil level in reacted thyroid nodule DNA from benign tissues is below indicated level*	SEQ ID NO: Forward Strand	SEQ ID NO: Reverse Strand
chr15	85402496	82.10	N/A	N/A	201	202
chr15	85402497	79.49	N/A	N/A	201	202
chr15	99417337	88.89	N/A	N/A	203	204
chr16	1231873	86.36	N/A	N/A	205	206
chr16	1458639	N/A	N/A	75.00	207	208
chr16	3023231	N/A	84.00	N/A	209	210
chr16	23135832	87.50	N/A	N/A	211	212
chr16	29616265	85.71	N/A	N/A	213	214
chr16	31009547	84.00	N/A	N/A	215	216
chr16	31009548	85.00	N/A	N/A	215	216
chr16	31009590	85.00	N/A	N/A	215	216
chr16	57793674	80.95	N/A	N/A	217	218
chr16	57793715	85.71	N/A	N/A	217	218
chr16	57793727	80.95	N/A	N/A	217	218
chr16	70771056	68.75	N/A	N/A	219	220
chr16	70771079	63.33	N/A	N/A	219	220
chr16	70771141	65.79	N/A	N/A	219	220
chr16	77332010	72.58	N/A	N/A	221	222
chr16	78540378	75.76	N/A	N/A	223	224
chr16	79333435	N/A	89.61	N/A	225	226
chr16	84262419	87.23	N/A	N/A	227	228
chr16	88701114	N/A	N/A	66.67	229	230
chr16	89988308	N/A	N/A	83.33	231	232
chr16	89988644	N/A	N/A	47.37	233	234
chr17	1509928	N/A	88.46	N/A	235	236
chr17	1509945	N/A	88.46	N/A	235	236
chr17	1509952	N/A	83.93	N/A	235	236
chr17	1509953	N/A	85.00	N/A	235	236
chr17	7644013	N/A	85.42	N/A	237	238
chr17	16323460	85.00	N/A	N/A	239	240
chr17	16323473	84.21	N/A	N/A	239	240
chr17	16924561	80.36	N/A	N/A	241	242
chr17	16924562	75.71	N/A	N/A	241	242
chr17	16924594	75.71	N/A	N/A	241	242
chr17	17717918	72.73	N/A	N/A	243	244
chr17	17718591	84.38	N/A	N/A	245	246
chr17	18139506	82.81	N/A	N/A	247	248
chr17	35278031	N/A	N/A	28.42	249	250
chr17	39677570	71.88	N/A	N/A	251	252
chr17	40826257	N/A	N/A	23.81	253	254
chr17	43037426	N/A	N/A	33.33	255	256
chr17	43200096	77.78	N/A	N/A	257	258
chr17	43200239	85.00	N/A	N/A	259	260
chr17	43510142	N/A	N/A	81.82	261	262
chr17	47987828	N/A	N/A	69.23	263	264
chr17	48178379	83.33	N/A	N/A	265	266
chr17	48596391	N/A	88.64	N/A	267	268
chr17	48764165	88.89	N/A	N/A	269	270
chr17	55701962	68.75	N/A	N/A	271	272
chr17	73584599	N/A	N/A	60.00	273	274
chr17	73993165	90.00	N/A	N/A	275	276
chr17	75827716	78.57	N/A	N/A	277	278
chr17	76882243	61.54	N/A	N/A	279	280
chr17	78765910	88.71	N/A	N/A	281	282
chr17	79544478	83.15	N/A	N/A	283	284
chr17	80696474	60.00	N/A	N/A	285	286
chr18	19751759	N/A	N/A	33.33	287	288
chr18	21440760	67.86	N/A	N/A	289	290
chr18	45555437	66.18	N/A	N/A	291	292
chr18	45555438	73.68	N/A	N/A	291	292
chr18	46547891	76.09	N/A	N/A	293	294
chr18	55888885	75.47	N/A	N/A	295	296
chr18	56452096	90.00	N/A	N/A	297	298
chr18	56452476	81.82	N/A	N/A	299	300
chr18	56887181	N/A	N/A	60.00	301	302
chr18	76002973	81.58	N/A	N/A	303	304
chr18	77331090	81.03	N/A	N/A	305	306

TABLE 1-continued

Chromosome (chr)	Chr Position	Uracil level in reacted thyroid nodule DNA from cancer tissues is above indicated level*	Uracil level in reacted thyroid nodule DNA from benign tissues is above indicated level*	Uracil level in reacted thyroid nodule DNA from benign tissues is below indicated level*	SEQ ID NO: Forward Strand	SEQ ID NO: Reverse Strand
chr19	677895	85.29	N/A	N/A	307	308
chr19	884044	76.92	N/A	N/A	309	310
chr19	884059	76.92	N/A	N/A	309	310
chr19	884105	84.62	N/A	N/A	311	312
chr19	884115	84.62	N/A	N/A	311	312
chr19	1136511	86.96	N/A	N/A	313	314
chr19	1177605	73.68	N/A	N/A	315	316
chr19	1177612	72.73	N/A	N/A	315	316
chr19	1177640	81.82	N/A	N/A	315	316
chr19	1860601	88.46	N/A	N/A	317	318
chr19	1860607	82.81	N/A	N/A	317	318
chr19	2503954	90.00	N/A	N/A	319	320
chr19	3434917	N/A	N/A	40.00	321	322
chr19	3434921	N/A	N/A	42.86	321	322
chr19	3434930	N/A	N/A	57.14	321	322
chr19	3434939	N/A	N/A	71.43	321	322
chr19	3434952	N/A	N/A	71.43	321	322
chr19	3434954	N/A	N/A	60.00	321	322
chr19	3434962	N/A	N/A	71.43	321	322
chr19	3434964	N/A	N/A	71.43	321	322
chr19	3434979	N/A	N/A	66.67	321	322
chr19	3434985	N/A	N/A	55.56	321	322
chr19	4052713	85.56	N/A	N/A	323	324
chr19	4052714	85.14	N/A	N/A	323	324
chr19	4052749	84.62	N/A	N/A	323	324
chr19	4374591	82.14	N/A	N/A	325	326
chr19	5013982	N/A	83.33	N/A	327	328
chr19	5048836	77.27	N/A	N/A	329	330
chr19	5048867	70.59	N/A	N/A	329	330
chr19	5048877	73.53	N/A	N/A	329	330
chr19	8367279	75.00	N/A	N/A	331	332
chr19	8428573	N/A	N/A	75.00	333	334
chr19	10254577	76.25	N/A	N/A	335	336
chr19	10254578	79.17	N/A	N/A	335	336
chr19	10463956	N/A	86.73	N/A	337	338
chr19	10464137	N/A	89.29	N/A	339	340
chr19	13203671	75.86	N/A	N/A	341	342
chr19	13266925	N/A	N/A	66.67	343	344
chr19	13266934	N/A	N/A	66.67	343	344
chr19	13266970	N/A	N/A	63.64	343	344
chr19	13842142	N/A	N/A	76.47	345	346
chr19	14248494	N/A	N/A	73.91	347	348
chr19	15375465	72.22	N/A	N/A	349	350
chr19	17218912	81.25	N/A	N/A	351	352
chr19	17346702	N/A	N/A	85.71	353	354
chr19	17346702	N/A	N/A	78.95	353	354
chr19	18157161	88.24	N/A	N/A	355	356
chr19	18157221	86.76	N/A	N/A	357	358
chr19	18157258	65.22	N/A	N/A	359	360
chr19	18415877	N/A	N/A	47.83	361	362
chr19	18415890	N/A	N/A	47.83	361	362
chr19	30606642	80.56	N/A	N/A	363	364
chr19	35531842	N/A	N/A	83.33	365	366
chr19	44303112	N/A	N/A	77.78	367	368
chr19	47173037	N/A	88.64	N/A	369	370
chr19	47316268	76.67	N/A	N/A	371	372
chr19	47778278	N/A	N/A	66.67	373	374
chr19	47778298	N/A	N/A	83.33	373	374
chr2	3454277	N/A	84.78	N/A	375	376
chr2	8793724	N/A	78.57	N/A	377	378
chr2	20412441	85.71	N/A	N/A	379	380
chr2	42329402	N/A	N/A	78.95	381	382
chr2	42329494	N/A	N/A	60.00	381	382
chr2	55289272	N/A	75.00	N/A	383	384
chr2	65064865	64.71	N/A	N/A	385	386
chr2	70823641	79.03	N/A	N/A	387	388
chr2	73143689	N/A	N/A	77.78	389	390

TABLE 1-continued

Chromosome (chr)	Chr Position	Uracil level in reacted thyroid nodule DNA from cancer	Uracil level in reacted thyroid nodule DNA from benign	Uracil level in reacted thyroid nodule DNA from benign	tissues is above indicated level*	tissues is above indicated level*	tissues is below indicated level*	SEQ ID NO: Forward Strand	SEQ ID NO: Reverse Strand
chr2	74454110	70.00	N/A	N/A	391	392			
chr2	122014529	N/A	86.36	N/A	393	394			
chr2	128158884	85.00	N/A	N/A	395	396			
chr2	128158910	77.50	N/A	N/A	395	396			
chr2	203114171	79.63	N/A	N/A	397	398			
chr2	218221671	N/A	85.19	N/A	399	400			
chr2	219745335	N/A	N/A	81.82	401	402			
chr2	238341465	86.36	N/A	N/A	403	404			
chr2	238341542	90.00	N/A	N/A	405	406			
chr2	238341546	87.50	N/A	N/A	405	406			
chr2	238774763	67.57	N/A	N/A	407	408			
chr20	31126186	87.50	N/A	N/A	409	410			
chr20	31126189	84.21	N/A	N/A	409	410			
chr20	34206950	N/A	N/A	76.47	411	412			
chr20	36771969	79.31	N/A	N/A	413	414			
chr20	48993661	80.00	N/A	N/A	415	416			
chr20	58406398	89.66	N/A	N/A	417	418			
chr20	61976049	87.93	N/A	N/A	419	420			
chr20	61976073	89.66	N/A	N/A	419	420			
chr20	62588571	N/A	N/A	50.00	421	422			
chr20	62588579	N/A	N/A	38.46	421	422			
chr22	19738127	70.59	N/A	N/A	423	424			
chr22	35965176	76.32	N/A	N/A	425	426			
chr22	36549809	83.33	N/A	N/A	427	428			
chr22	36973375	80.43	N/A	N/A	429	430			
chr22	37447953	N/A	N/A	73.33	431	432			
chr22	37914998	N/A	N/A	69.23	433	434			
chr22	38307317	N/A	89.66	N/A	435	436			
chr22	39662794	84.62	N/A	N/A	437	438			
chr22	45622980	85.00	N/A	N/A	439	440			
chr3	13323642	N/A	N/A	72.73	441	442			
chr3	14180153	57.89	N/A	N/A	443	444			
chr3	45209073	N/A	N/A	60.00	445	446			
chr3	45209207	N/A	N/A	83.33	447	448			
chr3	52525100	79.41	N/A	N/A	449	450			
chr3	62589658	87.50	N/A	N/A	451	452			
chr3	65388317	71.43	N/A	N/A	453	454			
chr3	65388388	79.31	N/A	N/A	455	456			
chr3	73599302	85.11	N/A	N/A	457	458			
chr3	195636893	N/A	N/A	84.62	459	460			
chr3	197093846	80.00	N/A	N/A	461	462			
chr4	3743223	68.18	N/A	N/A	463	464			
chr4	5755716	85.48	N/A	N/A	465	466			
chr4	5755717	80.00	N/A	N/A	465	466			
chr4	5755728	82.26	N/A	N/A	465	466			
chr4	5755729	79.17	N/A	N/A	465	466			
chr4	5755734	79.17	N/A	N/A	465	466			
chr4	8372861	N/A	85.71	N/A	467	468			
chr4	57548289	80.23	N/A	N/A	469	470			
chr5	1118280	73.08	N/A	N/A	471	472			
chr5	34564389	89.29	N/A	N/A	473	474			
chr5	73871907	89.47	N/A	N/A	475	476			
chr5	78013596	70.00	N/A	N/A	477	478			
chr5	78013643	80.00	N/A	N/A	479	480			
chr5	137802650	72.73	N/A	N/A	481	482			
chr5	139051189	84.09	N/A	N/A	483	484			
chr5	167838221	68.18	N/A	N/A	485	486			
chr5	177541401	N/A	N/A	69.23	487	488			
chr5	180018672	N/A	N/A	72.73	489	490			
chr5	180101026	N/A	N/A	64.71	491	492			
chr6	3394325	N/A	87.84	N/A	493	494			
chr6	3887581	N/A	85.71	N/A	495	496			
chr6	7236568	84.43	N/A	N/A	497	498			
chr6	7728692	N/A	N/A	73.33	499	500			
chr6	34203617	N/A	N/A	45.45	501	502			
chr6	37751320	N/A	N/A	78.57	503	504			
chr6	41410682	N/A	N/A	77.78	505	506			

TABLE 1-continued

Chromosome (chr)	Chr Position	Uracil level in reacted thyroid nodule DNA from cancer tissues is above indicated level*	Uracil level in reacted thyroid nodule DNA from benign tissues is above indicated level*	Uracil level in reacted thyroid nodule DNA from benign tissues is below indicated level*	SEQ ID NO: Forward Strand	SEQ ID NO: Reverse Strand
chr6	41438516	N/A	N/A	39.13	507	508
chr6	41438575	89.66	N/A	N/A	507	508
chr6	43464150	75.76	N/A	N/A	509	510
chr6	158734279	N/A	86.84	N/A	511	512
chr7	989235	76.67	N/A	N/A	513	514
chr7	2673543	82.14	N/A	N/A	515	516
chr7	73508602	N/A	N/A	85.71	517	518
chr7	105079565	78.75	N/A	N/A	519	520
chr7	105079631	71.25	N/A	N/A	519	520
chr7	151425103	86.96	N/A	N/A	521	522
chr7	151425104	76.19	N/A	N/A	521	522
chr8	11764017	80.77	N/A	N/A	523	524
chr8	21647308	N/A	N/A	71.43	525	526
chr8	22548399	N/A	88.16	N/A	527	528
chr8	22548483	N/A	87.50	N/A	527	528
chr8	133570537	N/A	80.00	N/A	529	530
chr8	141320393	75.00	N/A	N/A	531	532
chr8	141320410	85.00	N/A	N/A	531	532
chr9	6566568	86.84	N/A	N/A	533	534
chr9	16197862	N/A	86.36	N/A	535	536
chr9	34591313	N/A	N/A	80.00	537	538
chr9	98225096	N/A	N/A	22.22	539	540
chr9	126126741	86.11	N/A	N/A	541	542
chr9	132083428	N/A	N/A	70.59	543	544
chr9	136077410	73.91	N/A	N/A	545	546
chr9	139655018	83.33	N/A	N/A	547	548
chr9	140205985	75.00	N/A	N/A	549	550
chr9	140205985	83.33	N/A	N/A	549	550
chr9	140205997	79.17	N/A	N/A	549	550

*Level values provided are the proportion (percentage) of reacted thyroid nodule DNA molecules having a uracil at the methylation site of interest. When amplicons generated from reacted thyroid nodule DNA molecules (e.g., by PCR) are used to assess the level of methylation, the values provided correspond to the proportion of amplicons having a thymidine at the nucleotide position that corresponds to the methylation site of interest.

In embodiments, the method of detecting methylation or unmethylation of a thyroid nodule DNA of a subject detects an alteration in methylation including increase or loss of uracil level at plurality of methylation sites. In embodiments, the method of detecting methylation or unmethylation of a thyroid nodule DNA of a subject detects an alteration in methylation including increase or loss of thymidine level at plurality of methylation sites. The indicated levels in Tables 1, 2, 3, and 4, are approximate indicated levels, and include values that are within about 15%, about 10%, or about 5% above and below the indicated levels.

In embodiments, the method detects the uracil level above about a threshold as set forth in Table 2 in subjects with a cancerous thyroid nodule. In embodiments, the method detects the thymidine level above about a threshold as set forth in Table 2 in subjects with a cancerous thyroid nodule.

TABLE 2

Methylation Threshold for Cancerous Thyroid Nodule		
Chromosome	Chromosomal Position	Uracil level in reacted thyroid nodule DNA from cancer tissues is about above indicated level*
chr1	11979164	89.29
chr1	16450525	70.00

TABLE 2-continued

Methylation Threshold for Cancerous Thyroid Nodule		
Chromosome	Chromosomal Position	Uracil level in reacted thyroid nodule DNA from cancer tissues is about above indicated level*
chr1	16450542	72.00
chr1	16450545	73.33
chr1	16469987	80.00
chr1	17494491	86.00
chr1	25473203	88.89
chr1	38493013	86.36
chr1	38493030	79.17
chr1	38493074	80.95
chr1	109816092	80.77
chr1	109816111	80.77
chr1	110074669	75.00
chr1	110074681	71.43
chr1	110074685	63.16
chr1	150949856	89.29
chr1	150949857	88.46
chr1	153540282	78.26
chr1	155162704	84.21
chr1	155162714	88.64
chr1	157611881	83.05
chr1	182205324	77.50
chr1	204118999	59.09

TABLE 2-continued

Methylation Threshold for Cancerous Thyroid Nodule		
Chromosome	Chromosomal Position	Uracil level in reacted thyroid nodule DNA from cancer tissues is about above indicated level*
chr1	206741875	83.33
chr1	206741989	66.67
chr1	212841198	85.29
chr1	223403952	79.17
chr1	234342767	76.67
chr10	3929071	88.68
chr10	30047012	86.84
chr10	79702989	83.33
chr10	87984905	86.36
chr10	94838789	63.33
chr10	102131187	90.00
chr10	104196489	75.00
chr10	111766879	89.47
chr10	112258886	81.82
chr10	112258984	83.33
chr10	112259015	82.61
chr10	120011530	79.55
chr11	821282	89.13
chr11	12188937	83.33
chr11	12188948	77.78
chr11	12188995	78.57
chr11	65158294	78.00
chr11	65158342	85.00
chr11	65297089	75.00
chr11	66104481	81.58
chr11	66104485	83.33
chr11	66104578	81.82
chr11	70236292	89.29
chr11	70236320	85.71
chr11	70236331	70.83
chr11	117950310	79.55
chr11	117950329	79.55
chr11	117950361	80.00
chr11	117950362	81.82
chr12	679803	86.84
chr12	26039132	73.91
chr12	50286016	82.14
chr12	52243258	82.00
chr12	52243286	82.50
chr12	56115043	89.29
chr12	66262229	72.22
chr12	66262230	71.74
chr12	66262233	68.27
chr12	66262234	71.74
chr12	117580102	84.62
chr12	123435962	63.89
chr12	123436011	71.88
chr12	123436065	69.44
chr12	123540893	77.27
chr13	46771519	67.65
chr13	46771520	73.91
chr14	38599118	65.91
chr14	69170010	86.36
chr14	75701632	68.42
chr14	75701643	68.75
chr14	103768055	76.09
chr14	104354645	72.92
chr14	104360487	83.33
chr15	41068807	69.12
chr15	61152225	83.33
chr15	61152253	86.67
chr15	61152313	86.67
chr15	70667596	83.33
chr15	70767206	90.00
chr15	77989064	73.53
chr15	85402496	82.10
chr15	85402497	79.49
chr15	99417337	88.89
chr16	1231873	86.36
chr16	23135832	87.50
chr16	29616265	85.71
chr16	31009547	84.00
chr16	31009548	85.00

TABLE 2-continued

Methylation Threshold for Cancerous Thyroid Nodule			
Chromosome	Chromosomal Position	Uracil level in reacted thyroid nodule DNA from cancer tissues is about above indicated level*	
5	chr16	31009590	85.00
10	chr16	57793674	80.95
10	chr16	57793715	85.71
10	chr16	57793727	80.95
10	chr16	70771056	68.75
10	chr16	70771079	63.33
10	chr16	70771141	65.79
10	chr16	77332010	72.58
10	chr16	78540378	75.76
15	chr16	84262419	87.23
15	chr17	16323460	85.00
15	chr17	16323473	84.21
15	chr17	16924561	80.36
15	chr17	16924562	75.71
15	chr17	16924594	75.71
20	chr17	17717918	72.73
20	chr17	17718591	84.38
20	chr17	18139506	82.81
20	chr17	39677570	71.88
20	chr17	43200096	77.78
20	chr17	43200239	85.00
25	chr17	48178379	83.33
25	chr17	48764165	88.89
25	chr17	55701962	68.75
25	chr17	73993165	90.00
25	chr17	75827716	78.57
25	chr17	76882243	61.54
30	chr17	78765910	88.71
30	chr17	79544478	83.15
30	chr17	80696474	60.00
30	chr18	21440760	67.86
30	chr18	45555437	66.18
30	chr18	45555438	73.68
35	chr18	46547891	76.09
35	chr18	55888885	75.47
35	chr18	56452096	90.00
35	chr18	56452476	81.82
35	chr18	76002973	81.58
35	chr18	77331090	81.03
35	chr19	677895	85.29
40	chr19	884044	76.92
40	chr19	884059	76.92
40	chr19	884105	84.62
40	chr19	884115	84.62
40	chr19	1136511	86.96
40	chr19	1177605	73.68
45	chr19	1177612	72.73
45	chr19	1177640	81.82
45	chr19	1860601	88.46
45	chr19	1860607	82.81
45	chr19	2503954	90.00
45	chr19	4052713	85.56
50	chr19	4052714	85.14
50	chr19	4052749	84.62
50	chr19	4374591	82.14
50	chr19	5048836	77.27
50	chr19	5048867	70.59
50	chr19	5048877	73.53
55	chr19	8367279	75.00
55	chr19	10254577	76.25
55	chr19	10254578	79.17
55	chr19	13203671	75.86
55	chr19	15375465	72.22
55	chr19	17218912	81.25
55	chr19	18157161	88.24
60	chr19	18157221	86.76
60	chr19	18157258	65.22
60	chr19	30606642	80.56
60	chr19	47316268	76.67
60	chr2	20412441	85.71
60	chr2	65064865	64.71
65	chr2	70823641	79.03
65	chr2	74454110	70.00

TABLE 2-continued

Chromosome	Chromosomal Position	Uracil level in reacted thyroid nodule DNA from cancer tissues is about above indicated level*
chr2	128158884	85.00
chr2	128158910	77.50
chr2	203114171	79.63
chr2	238341465	86.36
chr2	238341542	90.00
chr2	238341546	87.50
chr2	238774763	67.57
chr20	31126186	87.50
chr20	31126189	84.21
chr20	36771969	79.31
chr20	48993661	80.00
chr20	58406398	89.66
chr20	61976049	87.93
chr20	61976073	89.66
chr22	19738127	70.59
chr22	35965176	76.32
chr22	36549809	83.33
chr22	36973375	80.43
chr22	39662794	84.62
chr22	45622980	85.00
chr3	14180153	57.89
chr3	52525100	79.41
chr3	62589658	87.50
chr3	65388317	71.43
chr3	65388388	79.31
chr3	73599302	85.11
chr3	197093846	80.00
chr4	3743223	68.18
chr4	5755716	85.48
chr4	5755717	80.00
chr4	5755728	82.26
chr4	5755729	79.17
chr4	5755734	79.17
chr4	57548289	80.23
chr5	1118280	73.08
chr5	34564389	89.29
chr5	73871907	89.47
chr5	78013596	70.00
chr5	78013643	80.00
chr5	137802650	72.73
chr5	139051189	84.09
chr5	167838221	68.18
chr6	7236568	84.43
chr6	41438575	89.66
chr6	43464150	75.76
chr7	989235	76.67
chr7	2673543	82.14
chr7	105079565	78.75
chr7	105079631	71.25
chr7	151425103	86.96
chr7	151425104	76.19
chr8	11764017	80.77
chr8	141320393	75.00
chr8	141320410	85.00
chr9	6566568	86.84
chr9	126126741	86.11
chr9	136077410	73.91
chr9	139655018	83.33
chr9	140205985	75.00
chr9	140205989	83.33
chr9	140205997	79.17

*Level values provided are the proportion (percentage) of reacted thyroid nodule DNA molecules having a uracil at the methylation site of interest. When amplicons generated from reacted thyroid nodule DNA molecules (e.g., by PCR) are used to assess the level of methylation, the values provided correspond to the proportion of amplicons having a thymidine at the nucleotide position that corresponds to the methylation site of interest.

In embodiments, the uracil level is above a threshold as set forth in Table 3 in subjects with benign thyroid nodules. In embodiments, the thymidine level is above a threshold as set forth in Table 3 in subjects with benign thyroid nodules.

TABLE 3

Chromosome	Chromosomal Position	Uracil level in reacted thyroid nodule DNA from benign tissues is about above indicated level*
5		
10	chr1	2996653
10	chr1	27640460
10	chr10	126172714
10	chr10	126172747
10	chr11	36057726
10	chr11	48070143
10	chr11	48070163
10	chr11	48070166
10	chr11	48070174
10	chr12	77266621
10	chr14	97524282
10	chr14	104209000
10	chr14	104209068
15	chr15	77984014
15	chr16	3023231
15	chr16	79333435
15	chr17	1509928
15	chr17	1509945
15	chr17	1509952
15	chr17	1509953
15	chr17	7644013
15	chr17	48596391
15	chr19	5013982
15	chr19	10463956
15	chr19	10464137
15	chr19	47173037
20	chr2	3454277
20	chr2	8793724
20	chr2	55289272
20	chr2	122014529
20	chr2	218221671
20	chr22	38307317
20	chr4	8372861
20	chr6	3394325
20	chr6	3887581
20	chr6	1.59E+08
20	chr8	22548399
20	chr8	22548483
20	chr9	1.34E+08
20	chr9	16197862

*Level values provided are the proportion (percentage) of reacted thyroid nodule DNA molecules having a uracil at the methylation site of interest. When amplicons generated from reacted thyroid nodule DNA molecules (e.g., by PCR) are used to assess the level of methylation, the values provided correspond to the proportion of amplicons having a thymidine at the nucleotide position that corresponds to the methylation site of interest.

In embodiments, the uracil level is below a threshold as set forth in Table 4 in subjects with benign thyroid nodule. In embodiments, the thymidine level is below a threshold as set forth in Table 4 in subjects with benign thyroid nodule.

TABLE 4

Chromosome	Chromosomal Position	Uracil level in reacted thyroid nodule DNA from benign tissues is about below indicated level*
55		
60	chr1	12655938
60	chr1	29565080
60	chr1	46713777
60	chr1	46914121
60	chr1	46955744
60	chr1	55008344
60	chr1	156676611
60	chr1	212587673
60	chr1	233430972
60	chr10	116391763

*Level values provided are the proportion (percentage) of reacted thyroid nodule DNA molecules having a uracil at the methylation site of interest. When amplicons generated from reacted thyroid nodule DNA molecules (e.g., by PCR) are used to assess the level of methylation, the values provided correspond to the proportion of amplicons having a thymidine at the nucleotide position that corresponds to the methylation site of interest.

TABLE 4-continued

Methylation Threshold for Benign Thyroid Nodule		
Chromosome	Chromosomal Position	Uracil level in reacted thyroid nodule DNA from benign tissues is about below indicated level*
chr11	556355	75.00
chr11	68608767	73.33
chr11	115530032	79.49
chr11	119293593	60.00
chr12	31004558	81.82
chr12	45610695	83.33
chr12	45610701	86.67
chr12	45610702	89.47
chr12	45610706	80.00
chr12	54145732	82.35
chr12	54145741	76.47
chr12	54145825	70.59
chr13	20735797	82.35
chr13	23500419	68.42
chr13	53313426	60.00
chr13	113807393	27.27
chr14	90850454	54.55
chr14	103541602	52.00
chr15	65186440	55.56
chr15	68851629	63.64
chr15	75251486	60.00
chr15	83952081	72.73
chr16	1458639	75.00
chr16	88701114	66.67
chr16	89988308	83.33
chr16	89988644	47.37
chr17	35278031	28.42
chr17	40826257	23.81
chr17	43037426	33.33
chr17	43510142	81.82
chr17	47987828	69.23
chr17	73584599	60.00
chr18	19751759	33.33
chr18	56887181	60.00
chr19	3434917	40.00
chr19	3434921	42.86
chr19	3434930	57.14
chr19	3434939	71.43
chr19	3434952	71.43
chr19	3434954	60.00
chr19	3434962	71.43
chr19	3434964	71.43
chr19	3434979	66.67
chr19	3434985	55.56
chr19	8428573	75.00
chr19	13266925	66.67
chr19	13266934	66.67
chr19	13266970	63.64
chr19	13842142	76.47
chr19	14248494	73.91
chr19	17346702	85.71
chr19	17346735	78.95
chr19	18415877	47.83
chr19	18415890	47.83
chr19	35531842	83.33
chr19	44303112	77.78
chr19	47778278	66.67
chr19	47778298	83.33
chr2	42329402	78.95
chr2	42329494	60.00
chr2	73143689	77.78
chr2	219745335	81.82
chr20	34206950	76.47
chr20	62588571	50.00
chr20	62588579	38.46
chr22	37447953	73.33
chr22	37914998	69.23
chr3	13323642	72.73
chr3	45209073	60.00
chr3	45209207	83.33
chr3	195636893	84.62
chr5	177541401	69.23
chr5	180018672	72.73

TABLE 4-continued

Methylation Threshold for Benign Thyroid Nodule		
Chromosome	Chromosomal Position	Uracil level in reacted thyroid nodule DNA from benign tissues is about below indicated level*
5	180101026	64.71
chr6	7728692	73.33
10	34203617	45.45
chr6	37751320	78.57
chr6	41410682	77.78
chr6	41438516	39.13
chr7	73508602	85.71
chr8	21647308	71.43
chr9	34591313	80.00
15	98225096	22.22
chr9	132083428	70.59

*Level values provided are the proportion (percentage) of reacted thyroid nodule DNA molecules having a uracil at the methylation site of interest. When amplicons generated from reacted thyroid nodule DNA molecules (e.g., by PCR) are used to assess the level of methylation, the values provided correspond to the proportion of amplicons having a thymidine at the nucleotide position that corresponds to the methylation site of interest.

In embodiments, the method of detecting methylation or unmethylation of a thyroid nodule DNA is of a candidate thyroid cancer patient. In embodiments, the subject is suspected of having thyroid cancer. In embodiments, the subject has thyroid cancer.

In embodiments, the method of detecting methylation or unmethylation of a thyroid nodule DNA is based on the level of uracil as set forth Table 2, in which the uracil level above the threshold identifies the thyroid nodule as a cancerous thyroid nodule. In embodiments, the method of detecting methylation or unmethylation of a thyroid nodule DNA is based on a level of thymidine indicated in Table 2, in which the thymidine level above the threshold identifies the thyroid nodule as a cancerous thyroid nodule. In embodiments, the level is the proportion of molecules (e.g., in a plurality of reacted thyroid nodule DNA molecules or a plurality of reacted thyroid nodule DNA amplicons) having a uracil or thymidine as determined by a quantitation method. Non-limiting examples of quantitation methods include sequencing and microarray methods.

In embodiments, the method of detecting methylation or unmethylation of a thyroid nodule DNA is based on the level of uracil as set forth Table 3, in which the uracil level above the threshold identifies the thyroid nodule as a benign thyroid nodule. In embodiments, the method of detecting methylation or unmethylation of a thyroid nodule DNA is based on a level of thymidine indicated in Table 3, in which the thymidine level above the threshold identifies the thyroid nodule as a benign thyroid nodule. In embodiments, the level is the proportion of molecules (e.g., in a plurality of reacted thyroid nodule DNA molecules or a plurality of reacted thyroid nodule DNA amplicons) having a uracil or thymidine as determined by a quantitation method.

In embodiments, the method of detecting methylation or unmethylation of a thyroid nodule DNA is based on the level of uracil as set forth Table 4, in which the uracil level below the threshold identifies the thyroid nodule as a benign thyroid nodule. In embodiments, the method of detecting methylation or unmethylation of a thyroid nodule DNA is based on a level of thymidine indicated in Table 4, in which the thymidine level below the threshold identifies the thyroid nodule as a benign thyroid nodule. In embodiments, the level is the proportion of molecules (e.g., in a plurality of reacted thyroid nodule DNA molecules or a plurality of reacted thyroid nodule DNA amplicons) having a uracil or thymidine as determined by a quantitation method.

In embodiments, the thyroid nodule is a specimen obtained by biopsy or by surgical resection of a subject.

In embodiments, the subject has undergone thyroid surgery, radiation therapy, radioactive iodine therapy, chemotherapy, thyroid hormone therapy, and administration of an active agent before the subject undergoes the method of detecting methylation or unmethylation of a thyroid nodule DNA.

In embodiments, the method includes a determination of prognosis for local recurrence in thyroid cancer. In embodiments, the method includes determination of prognosis of distant recurrence of thyroid cancer.

In embodiments, the method of detecting DNA methylation level in DNA of thyroid nodule may lead to changes in therapeutic regimen for treating the subject. In embodiments a subject identified as having thyroid cancer may be treated with tyrosine kinase inhibitors.

In embodiments, the active agent administered to a subject before or after detecting the level of methylation or unmethylation is: Cabozantinib-S-Malate, Caprelsa® (Vandetanib), Cometriq® (Cabozantinib-S-Malate), Doxorubicin Hydrochloride, Lenvatinib Mesylate, Lenvima® (Lenvatinib Mesylate), Nexavar® (Sorafenib Tosylate), Sorafenib Tosylate, and/or Vandetanib.

Method of Determining Thyroid Cancer or Risk of Developing Thyroid Cancer

In an aspect, provided herein is a method of determining a thyroid cancer or risk of developing thyroid cancer in a subject in need thereof. The method involves:

- (i) isolating a thyroid nodule DNA molecule from a thyroid nodule of the subject thereby forming an isolated thyroid nodule DNA molecule;
- (ii) contacting the isolated thyroid nodule DNA molecule with a bisulfite salt (such as sodium bisulfite) thereby forming a reacted thyroid nodule DNA molecule; and
- (iii) detecting the presence or absence of uracil in the reacted thyroid nodule DNA molecule at a methylation site set forth in Table 1; thereby detecting the thyroid cancer in the subject.

In an aspect, provided herein is a method of detecting a thyroid cancer or risk of developing thyroid cancer in a subject in need thereof, comprising (i) isolating a plurality of thyroid nodule DNA molecules from the thyroid nodule of the subject thereby forming a plurality of isolated thyroid nodule DNA molecules, (ii) contacting the plurality of isolated thyroid nodule DNA molecules with the bisulfite salt thereby forming a plurality of reacted thyroid nodule DNA molecules, (iii) detecting the level of reacted thyroid nodule DNA molecules in the plurality of reacted thyroid nodule DNA molecules having a uracil at a methylation site set forth in Table 1; thereby detecting the thyroid cancer in the subject.

In an aspect, provided herein is a method of detecting a thyroid cancer or risk of developing thyroid cancer in a subject in need thereof, comprising (i) isolating a plurality of thyroid nodule DNA molecules from the thyroid nodule of the subject thereby forming a plurality of isolated thyroid nodule DNA molecules, (ii) contacting the plurality of isolated thyroid nodule DNA molecules with the bisulfite salt thereby forming a plurality of reacted thyroid nodule DNA molecules, (iii) detecting the presence or absence of uracil in a reacted thyroid nodule DNA molecule at a methylation site set forth in Table 1, thereby detecting methylation or unmethylation of the thyroid nodule DNA molecule of the subject.

In an aspect, provided herein is a method of detecting a thyroid cancer or risk of developing thyroid cancer in a

subject in need thereof. The method includes: (i) isolating a thyroid nodule DNA molecule from a thyroid nodule of the subject thereby forming an isolated thyroid nodule DNA molecule, (ii) contacting the isolated thyroid nodule DNA molecule with a bisulfite salt (such as sodium bisulfite) thereby forming a reacted thyroid nodule DNA molecule, (iii) amplifying the reacted thyroid nodule DNA molecule thereby forming a reacted thyroid nodule DNA amplicon molecule, (iv) detecting the presence or absence of thymidine in a reacted thyroid nodule DNA amplicon molecule at a methylation site set forth in Table 1, thereby detecting methylation or unmethylation of the thyroid nodule DNA molecule of the subject. In embodiments, contacting the isolated thyroid nodule DNA with a bisulfite salt comprises adding a solution comprising the bisulfite salt to a solution comprising the isolated single stranded DNA.

In an aspect, provided herein is a method of detecting a thyroid cancer or risk of developing thyroid cancer in a subject in need thereof, comprising (i) isolating a plurality of thyroid nodule DNA molecules from the thyroid nodule of the subject thereby forming a plurality of isolated thyroid nodule DNA molecules, (ii) contacting the plurality of isolated thyroid nodule DNA molecules with the bisulfite salt thereby forming a plurality of reacted thyroid nodule DNA molecules, (iii) amplifying the plurality of reacted thyroid nodule DNA molecules thereby forming a plurality of reacted thyroid nodule DNA amplicon molecules, (iv) detecting one or more thyroid nodule DNA amplicon molecules within the plurality of reacted thyroid nodule DNA amplicon molecules having a thymidine at a methylation site set forth in Table 1, thereby detecting methylation or unmethylation of the thyroid nodule DNA molecule of the subject.

In embodiments, detecting one or more thyroid nodule DNA amplicon molecules comprises detecting the level of one or more one or more thyroid nodule DNA amplicon molecules. In embodiments, detecting one or more thyroid nodule DNA amplicon molecules comprises detecting the level of reacted thyroid nodule DNA amplicon molecules in the plurality of reacted thyroid nodule DNA amplicon molecules having a thymidine at a methylation site set forth in Table 1, thereby detecting the level of methylation or unmethylation in the plurality of thyroid nodule DNA molecules of the subject.

In embodiments, detecting a level includes determining the number (e.g. quantitating) or molecules having, e.g., a thymidine or a uracil. In embodiments, detecting a level includes detecting the portion or proportion of a population or plurality of molecules having, e.g., a thymidine or a uracil.

In embodiments, contacting the isolated thyroid nodule DNA with a bisulfite salt comprises adding a solution comprising the bisulfite salt to a solution comprising the isolated thyroid nodule DNA.

In embodiments, the method of determining a thyroid cancer or risk of developing thyroid cancer in a subject in need thereof includes selecting a subject that has or is at risk for developing thyroid cancer. In embodiments, the subject (a) is a woman; (b) is about 20 to about 55 years old; (c) has a mutated Ret Proto-Oncogene; (d) has a grandparent, parent, or sibling who has been diagnosed with thyroid cancer; (e) self-identifies as being Caucasian or Asian; and/or (f) has or has had breast cancer.

In embodiments, the method includes detecting methylation or unmethylation at a plurality of methylation sites set forth in Table 1. In embodiments, the plurality of methylation sites comprises at least about 2, 3, 4, 5, 10, 25, 50, 75,

80, 85, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, or 550, or 5-550 methylation sites. In embodiments, the plurality of methylation sites comprises less than about 550, 500, 450, 400, 350, 300, 250, 200, 150, 100, 90, 85, 80, 75, 50, 25, or 10 methylation sites. In embodiments, the plurality of methylation sites is about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 50, 75, 80, 85, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, or 550, or 5-550 methylation sites. In embodiments, the plurality of methylation sites includes two or more methylation sites set forth in Table 1 and no other methylation sites.

In embodiments, a method provided herein is practiced for a subject more than once over time. In embodiments, methylation or unmethylation of thyroid nodule DNA from a subject is assessed using a method provided herein at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more times. In embodiments, the method is repeated at least once every 4, 6, 8, 12 or 18 months, or at least once every 2, 3, 4, or 5 more years.

In embodiments, the method of determining a thyroid cancer or risk of developing thyroid cancer in a subject in need thereof includes determining alteration in methylation at a plurality of methylation sites set forth in Table 1. In embodiments, the method comprises: (i) isolating DNA from multiple cells of a thyroid nodule of the subject thereby forming a plurality of isolated thyroid nodule DNA molecules, (ii) contacting the plurality of isolated thyroid nodule DNA molecules with a bisulfite salt thereby forming a plurality of reacted thyroid nodule DNA molecules, (iii) detecting the proportion of DNA molecules in the plurality of reacted thyroid nodule DNA molecules having a uracil at a methylation site set forth in Table 1.

In embodiments, the method of determining a thyroid cancer or risk of developing thyroid cancer in a subject in need thereof includes alteration, i.e., increase or loss of uracil level at plurality of methylation sites. In embodiments, the method of determining a thyroid cancer or risk of developing thyroid cancer in a subject in need thereof includes alteration, i.e., increase or loss of thymidine level at plurality of methylation sites.

In embodiments, the method of determining a thyroid cancer or risk of developing thyroid cancer in a subject in need thereof includes determining a uracil level which is above a threshold as set forth in Table 2. In embodiments, the method of determining a thyroid cancer or risk of developing thyroid cancer in a subject in need thereof includes determining a thymidine level which is above a threshold indicated in Table 2. In embodiments, the level is the proportion of molecules (e.g., in a plurality of reacted thyroid nodule DNA molecules or a plurality of reacted thyroid nodule DNA amplicons) having a uracil or thymidine as determined by a quantitation method.

In embodiments, the method of determining a thyroid cancer or risk of developing thyroid cancer in a subject in need thereof includes determining a uracil level which is above a threshold as set forth in Table 3. In embodiments, the method of determining a thyroid cancer or risk of developing thyroid cancer in a subject in need thereof includes determining a thymidine level which is above a threshold indicated in Table 3. In embodiments, the level is the proportion of molecules (e.g., in a plurality of reacted thyroid nodule DNA molecules or a plurality of reacted thyroid nodule DNA amplicons) having a uracil or thymidine as determined by a quantitation method.

In embodiments, the method of determining a thyroid cancer or risk of developing thyroid cancer in a subject in need thereof includes determining a uracil level which is below a threshold as set forth in Table 4. In embodiments,

the method of determining a thyroid cancer or risk of developing thyroid cancer in a subject in need thereof includes determining a thymidine level which is below a threshold indicated in Table 4. In embodiments, the level is the proportion of molecules (e.g., in a plurality of reacted thyroid nodule DNA molecules or a plurality of reacted thyroid nodule DNA amplicons) having a uracil or thymidine as determined by a quantitation method.

In embodiments, the method of determining a thyroid cancer or risk of developing thyroid cancer involves a candidate thyroid cancer patient. In embodiments, the subject is suspected of having thyroid cancer. In embodiments, the subject has thyroid cancer.

In embodiments, the method of determining a thyroid cancer or risk of developing thyroid cancer in a subject in need thereof includes determining a uracil level in which a threshold above the threshold set forth in Table 2 identifies the thyroid nodule as a cancerous thyroid nodule. In embodiments, the method of determining a thyroid cancer or risk of developing thyroid cancer in a subject in need thereof includes determining a thymidine level in which a threshold above the threshold indicated in Table 2 identifies the thyroid nodule as a cancerous thyroid nodule. In embodiments, the level is the proportion of molecules (e.g., in a plurality of reacted thyroid nodule DNA molecules or a plurality of reacted thyroid nodule DNA amplicons) having a uracil or thymidine as determined by a quantitation method.

In embodiments, the method of determining a thyroid cancer or risk of developing thyroid cancer in a subject in need thereof includes determining a uracil level in which a threshold above the threshold set forth in Table 3 identifies the thyroid nodule as a benign thyroid nodule. In embodiments, the method of determining a thyroid cancer or risk of developing thyroid cancer in a subject in need thereof includes determining a thymidine level in which a threshold above the threshold indicated in Table 3 identifies the thyroid nodule as a benign thyroid nodule. In embodiments, the level is the proportion of molecules (e.g., in a plurality of reacted thyroid nodule DNA molecules or a plurality of reacted thyroid nodule DNA amplicons) having a uracil or thymidine as determined by a quantitation method.

In embodiments, the method of determining a thyroid cancer or risk of developing thyroid cancer in a subject in need thereof includes determining a uracil level in which a threshold below the threshold set forth in Table 4 identifies the thyroid nodule as a benign thyroid nodule. In embodiments, the method of determining a thyroid cancer or risk of developing thyroid cancer in a subject in need thereof includes determining a thymidine level in which a threshold below the threshold indicated in Table 4 identifies the thyroid nodule as a benign thyroid nodule. In embodiments, the level is the proportion of molecules (e.g., in a plurality of reacted thyroid nodule DNA molecules or a plurality of reacted thyroid nodule DNA amplicons) having a uracil or thymidine as determined by a quantitation method.

In embodiments, the method of determining a thyroid cancer or risk of developing thyroid cancer in a subject in need thereof includes determining a uracil level in DNA of a thyroid nodule specimen obtained by biopsy or by surgical resection of a subject. In embodiments, the method of determining a thyroid cancer or risk of developing thyroid cancer in a subject in need thereof includes determining a thymidine level in DNA of a thyroid nodule specimen obtained by biopsy or by surgical resection of a subject.

In embodiments, the method of determining a thyroid cancer or risk of developing thyroid cancer is of a subject

who has previously undergone thyroid surgery, radiation therapy, radioactive iodine therapy, chemotherapy, thyroid hormone therapy, and/or administration of an active agent, before the determination.

In embodiments, a subject having thyroid cancer or at risk of developing thyroid cancer was administered an active agent: Cabozantinib-S-Malate, Caprelsa (Vandetanib), Cometriq (Cabozantinib-S-Malate), Doxorubicin Hydrochloride, Lenvatinib Mesylate, Lenvima (Lenvatinib Mesylate), Nexavar (Sorafenib Tosylate), Sorafenib Tosylate, and/or Vandetanib.

In embodiments, the method of determining a thyroid cancer may lead to changes in therapeutic regimen for treating the subject. In embodiments a subject identified as having thyroid cancer may be treated with tyrosine kinase inhibitors. In embodiments, a subject identified as having thyroid cancer or being at risk of developing thyroid cancer according to a method disclosed herein is advised and/or directed to receive additional screening and/or treatment for thyroid cancer.

In embodiments, the active agent administered to a subject after determining thyroid cancer is: Cabozantinib-S-Malate, Caprelsa (Vandetanib), Cometriq (Cabozantinib-S-Malate), Doxorubicin Hydrochloride, Lenvatinib Mesylate, Lenvima (Lenvatinib Mesylate), Nexavar (Sorafenib Tosylate), Sorafenib Tosylate, and/or Vandetanib.

Method of Treating Thyroid Cancer

Also provided herein is a method of treating thyroid cancer in a subject by administering to the subject an active agent for treating thyroid cancer, in which the subject is identified for treatment by a method including isolating a thyroid nodule DNA molecule from a thyroid nodule of the subject thereby forming an isolated thyroid nodule DNA molecule; contacting the isolated thyroid nodule DNA molecule with a bisulfite salt (such as sodium bisulfite) thereby forming a reacted thyroid nodule DNA molecule; and detecting the presence or absence of uracil in the reacted thyroid nodule DNA molecule at a methylation site set forth in Table 1; thereby detecting the thyroid cancer in the subject. In embodiments, contacting the isolated thyroid nodule DNA with a bisulfite salt comprises adding a solution comprising the bisulfite salt to a solution comprising the isolated thyroid nodule DNA.

In embodiments, the method includes detecting methylation or unmethylation at a plurality of methylation sites set forth in Table 1. In embodiments, the plurality of methylation sites comprises at least about 2, 3, 4, 5, 10, 25, 50, 75, 80, 85, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, or 550, or 5-550 methylation sites. In embodiments, the plurality of methylation sites comprises less than about 550, 500, 450, 400, 350, 300, 250, 200, 150, 100, 90, 85, 80, 75, 50, 25, or 10 methylation sites. In embodiments, the plurality of methylation sites is about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 50, 75, 80, 85, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, or 550, or 5-550 methylation sites. In embodiments, the plurality of methylation sites includes two or more methylation sites set forth in Table 1 and no other methylation sites.

In embodiments, a method provided herein is practiced for a subject more than once over time. In embodiments, methylation or unmethylation of thyroid nodule DNA from a subject is assessed using a method provided herein at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more times. In embodiments, the method is repeated at least once every 4, 6, 8, 12 or 18 months, or at least once every 2, 3, 4, or 5 more years.

In embodiments, the method of treating a thyroid cancer in a subject in need thereof includes determining alteration in methylation at a plurality of methylation sites set forth in Table 1.

5 In embodiments, the method of treating a thyroid cancer in a subject in need thereof includes alteration which includes increase or loss of uracil level at plurality of methylation sites.

10 In embodiments, the method of treating a thyroid cancer in a subject in need thereof includes determining a uracil level which is above a threshold as set forth in Table 2. In embodiments, the method of treating a thyroid cancer in a subject in need thereof includes determining a thymidine level which is above a threshold indicated in Table 2. In 15 embodiments, the level is the proportion of molecules (e.g., in a plurality of reacted thyroid nodule DNA molecules or a plurality of reacted thyroid nodule DNA amplicons) having a uracil or thymidine as determined by a quantitation method.

20 In embodiments, the method of treating a thyroid cancer in a subject in need thereof includes determining a uracil level which is above a threshold as set forth in Table 3. In embodiments, the method of treating a thyroid cancer in a subject in need thereof includes determining a thymidine level which is above a threshold indicated in Table 3. In 25 embodiments, the level is the proportion of molecules (e.g., in a plurality of reacted thyroid nodule DNA molecules or a plurality of reacted thyroid nodule DNA amplicons) having a uracil or thymidine as determined by a quantitation method.

30 In embodiments, the method of treating a thyroid cancer in a subject in need thereof includes determining a uracil level which is below a threshold as set forth in Table 4. In 35 embodiments, the method of treating a thyroid cancer in a subject in need thereof includes determining a thymidine level which is below a threshold indicated in Table 4. In embodiments, the level is the proportion of molecules (e.g., in a plurality of reacted thyroid nodule DNA molecules or a 40 plurality of reacted thyroid nodule DNA amplicons) having a uracil or thymidine as determined by a quantitation method.

45 In embodiments, the method of treating a thyroid cancer is in a subject who has undergone surgery, radiation therapy, radioactive iodine therapy, chemotherapy, or thyroid hormone therapy, before the detecting thyroid cancer.

50 In embodiments, an active agent administered to a subject for treating thyroid cancer: Cabozantinib-S-Malate, Caprelsa (Vandetanib), Cometriq (Cabozantinib-S-Malate), Doxorubicin Hydrochloride, Lenvatinib Mesylate, Lenvima (Lenvatinib Mesylate), Nexavar (Sorafenib Tosylate), Sorafenib Tosylate, and/or Vandetanib.

55 In embodiments, the subject has or is at risk of papillary thyroid cancer, follicular thyroid cancer, medullary thyroid cancer, or anaplastic thyroid cancer.

60 In embodiments, the method includes determining a papillary thyroid carcinoma (PTC) methylation alteration score for the subject, wherein the PTC methylation alteration score is equal to the number of methylation sites in Table 1 having a uracil level equal to or greater than the corresponding threshold level set forth in Table 2.

65 In embodiments, the method includes determining a PTC methylation alteration score for the subject, wherein the PTC methylation alteration score is equal to the number of methylation sites in Table 1 having a thymidine level equal to or greater than the corresponding threshold level set forth in Table 2.

81

In embodiments, the method includes determining a benign thyroid nodule (BTN) methylation alteration score for said subject, wherein the BTN methylation alteration score is equal to: (a) the number of methylation sites in Table 1 having a uracil level equal to or greater than the corresponding threshold level set forth in Table 3; (b) the number of methylation sites in Table 1 having a uracil level equal to or less than the corresponding threshold level set forth in Table 4; or (c) the number of methylation sites in Table 1 having a uracil level equal to or greater than the corresponding threshold level set forth in Table 3 plus the number of methylation sites in Table 1 having a uracil level equal to or less than the corresponding threshold level set forth in Table 4.

In embodiments, the method includes determining a benign thyroid nodule (BTN) methylation alteration score for said subject, wherein the BTN methylation alteration score is equal to: (a) the number of methylation sites in Table 1 having a thymidine level equal to or greater than the corresponding threshold level set forth in Table 3; (b) the number of methylation sites in Table 1 having a thymidine level equal to or less than the corresponding threshold level set forth in Table 4; or (c) the number of methylation sites in Table 1 having a thymidine level equal to or greater than the corresponding threshold level set forth in Table 3 plus the number of methylation sites in Table 1 having a thymidine level equal to or less than the corresponding threshold level set forth in Table 4.

In embodiments, the method comprises calculating a Composite Cancer Risk Score for the subject. In embodiments, the Composite Cancer Risk Score for the subject equals: [the PTC methylation alteration score for said subject]/[BTN methylation alteration score for said subject]. In embodiments, the Composite Cancer Risk Score for the subject equals: [(the PTC methylation alteration score for said subject)+1]/[(BTN methylation alteration score for said subject)+1].

82

In embodiments, the subject is identified as being at risk of developing thyroid cancer or diagnosed as having thyroid cancer if (a) the PTC methylation alteration score for the subject is at least 5, 6, 7, 8, 9, or 10; (b) the BTN methylation alteration score for the subject is at least 5, 6, 7, 8, 9, or 10; and/or (c) the Composite Cancer Risk Score for the subject is at least about 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, or 3.0.

¹⁰ In embodiments, the subject receives treatment (e.g., is directed or advised to receive treatment) for thyroid cancer or is directed to receive additional screening for thyroid cancer if (a) the PTC methylation alteration score for the subject is at least 5, 6, 7, 8, 9, or 10; (b) the BTN methylation alteration score for the subject is at least 5, 6, 7, 8, 9, or 10; and/or (c) the Composite Cancer Risk Score for the subject is at least about 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, or 3.0.

Target Sites for Methylation Level of Thyroid Nodule

²⁰ In another aspect, provided herein is a deoxyribonucleic acid 5 to 100, 5 to 300, 5 to 300, or at least about 5, 50, 100, 150, 200, 250, 300, or more nucleotides in length including a uracil-containing sequence identical to the sequence of at least 5 contiguous nucleotides within a sequence including SEQ ID NO:1 to SEQ ID NO:550.

²⁵ SEQ ID NO:1 to SEQ ID NO:500 are 300 bp length sequences that include the target sites (i.e., methylation sites of interest). The sequences provided are as modified after bisulfite conversion. Therefore "C" in the non-CpG context becomes "U", and C in the CpG context is designated as R or X (either "U" either "C"), where X is the target site. The DNA strands (sense and antisense) are no longer complementary after bisulfite conversion. Therefore, each DNA strand is identified with its unique sequence, and is designated as "forward" and "reverse" respectively, in Table 1.

³⁰ ³⁵ The sequences listed in Table 1 are provided below with their respective sequence identification number.

SEQ ID NO:	Sequence
1	TUUTTAGUUUTURGTGGGRGUUAGAGTTGGTGUUTUAGTAGRGRGTGUUUAUURGG UUUAAGUTGTTUTGUAGUTGGTUAUTGTGGGAGAAGAGAUTGGAAAAGTTUAAAG GTGGAGAGGRGUAGRGAUTGGAGUAUTTTTURGUAXGUTGTAAUUUUTGAGAAG AAUUAAGAGGAAARGAGGUTGTTTAGATAATUURGGGUUTGTTGUTTGUATTAA GAAAAATTAGGUUTUTGAAAAATTAAUAGAATTATGUTGUAGTGTUAGGTTUUU AGATAATGATGTTGUTGTTG
2	UAUAGAUUAUATUATTATUTGGAAUUTGAAUTGGUAGUATAATTUTGTAATTTT UAAGAGGGUUTAATTTTUTAAATGUAGUAAUAGGGUURGGGATTATUTAAUAG UTRGTTTUUTUTTGTUTTUTUAGGGTTAUAGXGTGGAAAAGTGTUUAGA TRGUTGURGUUTUTUAAUUTTTGAUTTTUAGTUTUTUTUUAAUAGTGAUAGU TGUAGAAUAGUTTTGGGURGGGTGGGUARGRGUTAUTGAGGUAAUUAUTUTGGRG UARGGAGGGUTAAGGA
3	GGGTGAUUAGTGUUAUTAAAAGUAGAGUTTGAGTTAUTUTUATAAUATRGGUTG TGGGUAGAUATTGGUTUTTGUAGGUAGAUAGGUTTUURGGTGACTUATGUT GUTTAAAATGUTGTUTGGGARGUAGAGAAAGTUTAAAGUUAAGARGUTGAGGA UAGUURGUAGGTGGAUTGUUATGUURGGUTRGGUUUUTTTGGTUUUUAGACTG GAUUUTTUTUUTUUUAUAGAGGGAGGUATUTGATGGTGUAGUAGAUAA UTGGAGAGAAUUAUTUAGGGT
4	AUUUTGAGTGGTTUTTUTUAGGGTGTUTGUTGAAGUAAUATUAGATGUUTUUU TUTGTTGGGAGGAGAAGGGTGUUAUTUTGGGUAAAAGGGGURGAGURGGGU TGGUAGTUUUAUTGRGGGUTGTUUUTUAGRGUTTGGXTTGAUTTTUTGRGT TUUAAGAUATTTAAGUAGUATGAUTUAURGGGAAGUUTGGTUTGUUTGUAAA GUAGGUAAAATGUTGGGUUAUAGURGATGGTTATGAGAGTAAUUAAGUTUTGUT TTAGTGGUAUTGGTUAAA

- continued

SEQ ID NO:	Sequence
5	CAGUTGGGGAGGGGAUAGGGTAGGTGGTGUAGAAGGGGGUTGGGTTGAGGTUTU AGGTGUAGARGAGGGGGUTGGRRGGAGGGGTGAGGAGGGGAGURGGGUTGGG GGURGGGRGRGUTGUTGGGTUUUUUTUURGUURGGGAUXGTURGUTUTGUUUA GAUURGTRGGTAAUAGARGURGTATGTUARGGGRGURGUTGAUUTGTGGUTGAA UURGGAGUTGTAATGAGATGUAAGGTGUUAGUAGUUTURGGURGUAGGGUATAR GAGUUAUARGRGUTUTURGURGG
6	URGGRGGAGGGAGRGRGTGTGGUTRGTAGGUUUTRGGUURGGGAGGGUTGUTGGUAIUT TGUATUTUATTTAUGUTURGGGTUAGGUUAUAGGTUAGRGGRGUURGTGAUATUA RGGRGUTGTTAURGARGGGUTGGGUAGAGRGAXGGTUURGGGGAGGG GGAUUUUAGUAGRUURGGGUUUUUAGUURGGUTUUUUUTUUTUAUUUUUTURGUU UAGGUUUUTUUTRGUTGUAUUTGAGAUUTUAAAAGUUUUUTTGAGUAGUAAU TAUUTGTUUUUTUUUAGUTG
7	TTTUTGTAATGGGURGUUUAUAAAATUATAAUAAAGTGTGAGGTURGAU AAGURGAAAATGTAAGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGG AGGATUTATTRGAUAGUTURGGGGAGUXGTGGGAGGGAGUTGAXGXGGUTUTT GUTGTTUTUUTAUUUAGUUTUURGGAAUTGAGAUATUTGAGUAGUTGGAGATUAAG GTGATTGGGUUTGUTGGUATGGAGGURGGUTRGGUAGAAUUTGUTUURGGU UUTGUUUAUUTUUUAAAUAU
8	GTGGGTGGGAGGTGGGUAGGGGGURGGGAUAGGGTTUTURGGAGGUURGGUUTUU ATGUUAGUAGUUUUUATUAUUTTGATUTUUAGGUTGUTUAGAGTUTTRGGGGGG GUTGGGAGGTAGGGAGAAUAGUAAGAGUXGUXTUAGUTUUUUTUUAXGGUTUU RGGAGUTGTRGAATAGATUUTTAAUUAUATGTAUAGUTUTGAGGTTAAUAA AGUTTTUAUAGGTTTRGGUTTGTRGGAAUUTUAAAUTTGTTATGAGTTTG GRGGUUUUATTTAUAGAA
9	TGAGUAGTGTUUAGRGUUUAAGAGAGAUAUTGGAGAGAGGTUUAUAGGATGUU TAUTGUUTTAUUAAGAGUUTAUTTGUUAUAUTGTGUUAUAUTGTGGAGAG UTGTTUTGGUURGGTTGTUTGGUAGGUUTGGGUUTXGAGUAGGGAAUTGG GUAGUTGGUTGUAUUTURGGUTATAUUUTGGTTTUAGTTUTGATGUURGUU UUTAGGTGUAGUATGAGGTGAUTUAGGGAUACARGUUUTTATRGTGARGUAA UUAGUUUUUAGTGGAGUUUUT
10	AGGGGUTUUUAUTGGGGUTGGAUTTGRGTUARGATAAGGGRTUTGUTUUTGAGTU AUUTUATGUTGUUAUUTGAGGGGGGGGUATAGAAUUTGGAAUAAUAGGGTATA GURGGAGGTGUAGUUAUTGTGUUUUAGTTUUUUTGUTXGGAGTAGUUUAGGUUTG UUAGAUAAURGGGUAGAAUAGUTUTUUUAUAGGTGTGUUAUAGGTGTGUUAAG TTAGGUTUTTGTAAGGUAGGTAGGUATUTGGTGGAUUTTUTUUUAUAGTGTUT UTGGGRGUTGAAAUAUTGUTUA
11	TUTTGTAATTTUAGAGUUAAGGTATAUUUAATUTGUAAARGTGTAGUTGUATGA UTGTAUAAAGTUUUUTAAUAGUAAURGGGUUTUAGTGAUATUATUTGTTAAATGG GGTGATGATAATGGTGUAGUATTATGGAGGAGUUUAUAXGGTGTUAGTGT AUATATUAGUTAAUTGAATUUTUATGUTGUUAATGAGAUAGGTAUTATTGAATUA GAGGUURGGAGAGATUUARGRGTTGGTUATAUTGGTGAAGAGUTTGGTTUA GUUTGGTGAUTUTRGGUAU
12	GTGURGAGAGTTAUUAGGUATTGAAUUAAGUTUTTUAAUAGTATGAAUUAURRG TGGAGUTUTURGGGUUTGATTUATAGTAAUTGTGTUUTGGUAGUAGTGAG GATTAGTTAGUTGATATGTGTAAGUAUTTAGUAUXGTGTGGUTUUTUUATA TGUTGAAUATTATUATUAAUUAUUTTTAAUAGATGTGTUUTGAGGUURGG UTGTTAAGGGAUTGTAUAGTGUAGUTAUUARGRGTTGGTUATAUTGGTATA GGUTUTGGAATTAAUAAAGA
13	TURGGAGUUAUTGTAUTGGAGGUAGTTAAUTTUAAUAGUTATGTG AGUAGUATTUAGGUAGRGUTGAAAGUAGAGUAGGGAGGGGGGGGGGG AGTRGAGGTURGGAGURGAAGUAUUUAUUAUTGAGXGAGGTUUUAUTTU UUTUUUAGGGTURGGUTGUUTUUUAUAGUAGUUUAUUAUAGGGTUUTGUT UAGARGTTAUTATTUTUTTTUAGTGTGUUAGUAGUAAUUTRGAUTGUUA AUAARTGAAAAATAAUTGUAG
14	UTGUAGTTATTTUARGTTGTTGGUAGTRGAGGTTGUTGUTGGAAUAAUTGAA AAAGAGAAAATAGTAATGUTGGAGUAGGUAGGGGGGGGGGGGGGG GUAGURGGGUUTGGGGAGAGTGGAAUUTXGUTUAGTTGGTGGUT GGUTTUURGGAAUTRGAAUTUUTGGGUURGTURGUUTUUTGUTUTGG RGGUTGGUTGGAATGUTGUAGUAAUTTAGUTGTGAAGTAAUTGGUTURGG UAAGTTUAUTGGUTURGGA

SEQ

ID

NO: Sequence

15 TTGUUAAAATGGAAAGUAUUAAAGATGUUUUTUAAAAGGTGAATGGAGGUUAGGT
GRGGTGGUTUARGURGATAATUUAGUAUTTGAGGAGGTGAGGUAGGTGGATUAU
TTGAGATUARGAGTTGAGAUUAGUURGGGUUAUATGGXGAAAUUURGTUTAUT
AAAAATAUTAAGATTAUURGGGRGTGGTGGUARGTGUUTGTTATUUUAGUTAUTG
GGAAGUTGAGGUAGGUAAATTGUTTGAAUUTGGGAGGTGGAGGTUAUAGTGAGUU
AAGATTGTGUUAUTGUAUTUUA

16 TGGAGTGUAGTGGUUAATUTTGUTUAUTGTGAUUTUUAUUTUUUAGGTTUAAGU
AATTGUUTGUUTUAGUTTUUAAGTAGUTGGGATAAUAGGUARGTGUUAAAARGU
URGGTTAATUTTAGTATTTAGTAGAGARGGGTTXGUUATGTTGGURGGGUTGG
TUTUAAAUTRGTAUTUAAGTGATUUAUUTGUUTUAGUUTUUAAAAGTGUTGGGA
TGTATRGGRGTGAGGUUAGUURGUAAUUTGGUUTUUAUATUAAUUTTTGAGGGGUATUTTGGT
TGUTTUUAAGTTTGGUAA

17 GGRGGGATURGAGURGAGAUAARGTGTGGAGRGAGURGUTTUUTUARGGTRGUUA
GURGUAGAUAAUTGAUUTUURGGUATRGRGTTTRGGGUUUTGUTGUTGGUTURGG
TGTUTRGGGURGGAAUTUUTGTGGUTUAGRGTTRGXGURGGUUAUTGGUAGRGU
TTGGGUUTRGGUUUTGUAGUTURGGGUUAUTAGGGUUAUAGUTTTGAAUUTUU
URGGTGUURGAAGGARGUUUAAGGRGAUUTUUUAAAATUUTUUUAAAUTTUTU
UUUATGTUUTRGGUUAUTT

18 AGTGURGUAGGAUATGGGGAGAAGTTGGGGAGGATGGGTGGGAGGTRGUUTTG
GGRGTUUTTTRGGAAARGGGAGGTUAAAGUTAAGUTGTGUUUTATGGUURGGA
GUTGUAGGGRGAGGUUAAGRGTGUUAGTGURGGXGRGAARGUTGGAGGUUAU
AGGAGTTURGGUURGAGAUAURGGAGGUAGUAGUAGGGURGRGAARGRGATGURG
GGGAGGTUACTGTGTGRRGUTGGRAURGTGAGGAAGRGUTURGUTUAGUARG
TGTUTRGGUUTRGGAUTURGUUU

19 UUAGUAGGGAGGUAGUUAUAGATGUAGAUTRGUTUTGUUTAUUTGTGGAGGUR
GGTGAGGUUAGGGUUTTGGGAUTTGAAUAGTGAGGUAGTGCGGTGTGGTGU
TGGGUUUUXGUTUAGGTUTUUAUGXTGUUAGTTUURGGAGUUTTATGTGUAGG
GTGTGGGGAGGGXGGGGUTGAATRGTTGGGTGGAGTUTGGGUUAAGUUUUAAGG
TGAGTCGAGGAATTGGGGRGGAUTGAACTAUTGTUTTGAAUTGGGUAG
UUTUTGGGUUTTGGuAGUTG

20 UAGUTGUUAAGGUUAAGGGGUUTGUUAGGTLTUAAUTTUAGUAGTAUTTUAGGT
URGUUUUAAATTUUTUAAUTUAAUTGGGUUTTGAGGUUAAGAUTUI TUAAUUARGAT
TUAGUUXGUUUTTUUUAUAAUUTGUUAUATAAGGUUTRGGAUTGGUAXGUTG
GGAGAAUTTGAGXGGGAGGUUAAGUAAAUAUAAAUTGGGUUTUAAAGGTAGGUAGA
GTUUUAAUAGGUUTGGUUTUAAURGGUUTUUAUAGGTAGGUAGA
TUTGTTGGUUTUUTGUTGG

21 UUAGAUTRGUUTUUTUUUAUURGGGUUTRGGAUTTUAAUAAAAGUTTUTUTUUTG
GUUAGTGATTAUUUAUAAAATUUUAAAURGUUURGURGRGUUAUTAUUTUUTU
UUTTUAUURGGAUTGGGAUATUATUUUAAUTUAAUTUXGUUAGTUTGGGAUTU
UAUTUTRGUTRGGUUTTGGGARGGUUAUTUAAUAGTTGGGUUTUAAAUAU
UAGTTUUTGGATGGATTUUU

22 GGGAAUTUATUAGGAUTGGTTGGAAUAAAATGTGAGAGTGGURGTUUUUA
ATAAGURGAGARGAGAGATTAGGUUAAGAGGAAGAGAUUAAGUAGAGATTAGTG
TGGGATTGGGAGGGAGGUAGGTGGAGTUUUAGAUTGGXGGAGTGGAGTGGGAT
GATGGTUUUAGTURGGTAAGGGAGGGAGGTAGTTGRGRGGRGGGRGGGTGG
ATTGGGGTGGGTAATUAUTGGUAGGGAGAGAGAAGUTGGGTGAAAGTURGAGG
UURGGTGGGGAGGGRGAGTUTGG

23 RGUAGGUURGRGUUURGUTUURGUUURGUUTGURGRGUUTUURGGGRGUURGUA
TTAAAGRGUATATGUAGGUATGAATTATUAAUTGAAAGGAGTUAATTAURGGUTU
TAAAARGAGTGTUTGRGUAGRGUURGGGUUATUXGUUTATTTARGGARG
ATUTAUUURGUURGGUTGGGGAGGGGUUTRGCCAGGGAGAGAGARGGAGAAARG
GAGUURGAGAURGGAGAGAGURGGAGGUAGGGAUTGGAGAGTUTGGGUARG
AAGGAGAGRGGGAGAGAURGA

24 TRGGTUTUUTUURGUUTUTUUTTRGTGUUUAGAUTUUTGUUTGUUTUTURGG
UTUTUUTURGGUTURGGUTURGTTUTURGTUTUTUUTUURGGAGGUUUUUTUU
UUAGURGGGRGGGAGATRGUTRGTAATAGGXGGATGGUURGGGRGGUTGRG
AGRGUAGGUATRGUTTGTGAGURGGTAATTGAUTUUTTUAGTTGATAATTUATG
GUTTGUATATGRGUUTTAATGRGGGRGUUURGGAGGRGGUAGGRGGGRGGGA
GRGGGRGRGGGUUTGRG

SEQ

ID

NO: Sequence

25 AUAGTRGUTGUAGGGAGGARGGGGURGTGAGAAUURGGGAUAGUUTUUUUTUT
TGRGGTUUTGUAGTUURGGAUUUAUTGGGRGGATUAGAAAGTTGUAGGGAGUUA
GGGAUTAGGAGAUAUAGAUAGRGUAGGGAUAGAGAAAGXGGAGGGATGUAG
AAAGAURGAGTRGGGAUAGAUAGAGAGAGAUUAGGGTGAGAUAGAGGAAGAGAT
AUURGGGUTGAAARGGTGGUAGAAAGTGAGUAUTTAGGGAGAUAGAAAGAGR
GUAGAAUTRGAAATTURGAGGUAGAGA

26 TUTUTGUUTRGGAATTTRGAGTTUTGRGUTUTTUTGTUTUUUTAAGTTGUTUAUTTT
UTGUUAURGTTTUAGUUURGGGTATUTTUUTUTGTUTUAAUUTGGGTUTUTUTG
TUTGTUURGAUTRGGTUTTUTGGUATUUUTUXGUTTTUTGTUUUTGRGUTGTU
TGTUTGTUTUUTAGTUUTGGUTUUUTGUAAAUTTTUTGTATURGUUUUAGTGGGTURG
GGAUTGUAGGAUAGGUAGAGGGGAGGUTGTUUURGGGTUTUARGGUURGRGTUU
TUUTGUAGRAUTGT

27 TUAGUUTGTAUURGGRUTGGUUTUUAGAUAGUAGGTGUTGUUTRGUARGGTUT
TGUTTGAGGUTGGGGUATGAAGUAAUUTCGTATTARGUTGGGATTGGTUTUTUUA
UTAGGGGTGGGGGGGTGTGGTUAAUUTGGUURGGRGXGURGUAGAGGGUTGGTUR
GGAGAAAGAUUTGGGRGUAGAAUTUAGAGGUUAGAGGTGUAGURGUTGTGUAU
TUATTGRGGARGGGRRGGUTGGGAGGAGRGUTAGUUUUTGTTGTGAGRGATTGA
GAGUUAGGGUUAAATUTGGGT

28 AUUAGATTGGUUTGGUTUTUAAAATRGUTUAAUAAUAGGGGUTAGRGUTUUTUU
AGURGUUURGTURGUAAATGAGTUAGUAGRGGUTGUAAUUTUTGUTUTTGACTUT
TGRGUUUUUUAGGTUTUTURGGAGUAGUUTUTRGGXGRGURGGGUUAGGTGAU
UAUAGUURGUUUUAAUUTAGTGAGAGAUUAUUUAGRATAAAUUAAGGGTGU
TTUATGUUUUAGGUUTGUAAGUAAGAURGTCRGAGGUAGUAAUTGGUTGTUTGGAG
GUUAGRGRGGGGTAUAGGGUTGA

29 GUUAGUUTUAAUAAAGGTGAGTGCCCCAUUUUAGUTGURGAGUTUUUUTAGTUA
GUAGUUTUATAUUTUAAUATTUTUUTGTGGURGUAAUTUAGUUURGUURGGUU
UAUAGGUATUUTTAAGAAGAAGTGTUTGUUUUAAUATUAGXGAGAGAGGUUTU
UTGXGGUTUUUUUTGGGUATGUAAAGGGTUTTUURGGGUTUTURGUTAGTAGTA
GGGUAGURGGGGAGGUUUUUUUTUURGUUUAURGUURGGUAGGUUTUJAGGA
GUAGUTGAARGGGTUATGUUUATRG

30 RGATGGGUATGAUURGTTUAGUTGUTUUTGGAGGUTUTGURGGGRGGTGGRRGG
GGAGGGGGGUUTUURGGGUTGUUTUAUTAGRGGAGGAGGUURGGGAAGAUUUTG
TGUATTCTUUAAGGGGAGUXGUAGGAGGUTGUTTUTXGUTGATGGTGGGUAGA
UAUUTTUTTAAGGATGUTGTGGGURGGGRGGGUTGTGAGGTGRGUUAUAG
GAGAATGTGAGGTATGAGGUTGUTGAUTAGGGAGUTRGGUAGUTGGGGTGUUU
UAUTUAUUTTGAGGUTGGGU

31 TUAGAATAATGGUTGGTTGTAGAGATUAGAAATGUUUAUTGUTGTTTUUTGTAT
UUUTUUAAAUAUAGAUTGAGUUTUTGAAGUTGTURGGGUUTGGAGAGAGAAG
UUAUTUAAGGAUAGUAGUTGUTGAUTUAGAXGUTUAATTUTXGGXGGAAAAGG
AUUTTAGAGAAUTGUUTAAATRGTCGUUUUATUUUTUATTGGAAUTGGGTURG
AAAAGURGGGUTURGAAAGUTGGGAGAGUAGUUAUAAAGRGTAUTGUUUAUTAA
ATGTGGATGUARGUTGGUARGU

32 GRGGTUUAAGRGTGUATUUUAUTTAGTGGGUAGTARGUTTGGGUTGUTUUAG
UTTTRGGAGUURGGUTTTRGGAGUUUAGUTTUAAUTGAGGGATTGGGUARG
ATTAGGUATTUTUTAAGGTUUTTTUXGUUXGAGAATTGAGXGTUTGAGTUAGU
AGUTGUTGTUUTTGAGTGGUTTUTUTUAGGUUURGGAUAGUTTUAGAGGUTUA
GTUTGGGTGGGTGGAGGATAUAGGAAAGUAGUTGGGUATTUTGTATUTUAA
AUUAGGUUATTATTGGA

33 AAGTTUTGGGUAGAAGTGGATAAUUAGGGUUTGAGAAATAAGATAAGAGGGT
ATATTUUTUUUUAGGAGAUAAGAGAGAAGGTGGATGGAGAAGGGAAAUTGGGU
UTUAGGUAGUAGRGAGTGTGRGUAAUAGUTTTGTUAGUAXGUTTGGGAGUATAU
AAUAGUTTGUUTTGGGUTGGAGGAGAUTGTGATUAAUAAUUTTUUAUAAUUTAU
UUUAAUARGUAGGGUTGGUATGGUUARGUUAUAGTGUUUUAAGTGUUTGUUT
TGUAGTGAUTUAUTTUUTUTGTA

34 TAUAGAGGAAGTGAGTUAUTGUAGGUAGGUAGUAUTTGGGUAUTGTGGGRGTG
GUUATGUUAUUTGRGTGTTGGGGATGGGTTGGAGGGTGGTATUAAUTGUTUR
GGTGUUAGGUUAGGUAGRGGTGTATGUTUUUUAAAGXGTGUTGAUAAAGUTGGTR
GUATUATUURGGTGTGGUTGGAGGUAGTGUUAGTTTUUTTUUAUAAUUTTUTUTT
TGTUTUUTGGGGAGGAATATAUUUTUTTATTTUTUAGGUUUTGGTTATUU
AUUTTGUUUUAAGAAUTT

- continued

SEQ

ID

NO : Sequence

35 TUAGAARGTGUUUUAUATGUUUATGUUUTUTATUUTGUTGAAATUUAAA
UTTUAAAGGUUAUTGUAGGGAGUUTUUAGGUUUAURGGAT TUAGTGTUAT
UTGTTUTGTUUTGTAUAAAAGRGUUUTTTGUUUTTXGTGTAUTTAGAGAATT
UTGAGUTTTGAUTGAUATUUTGTAUTTGTUTTUTUAGUUTUAAAAAUATGG
TGAGUTUAURGGTUTAUTUATTUTGUATGAGGAAGGGTUTRGUUUUAUAGG
TGUUAAAUAUTGUTTARGGU

36 URGTAAGUAUTGGTGUUAUTGGTGTGGGRGAGAUUUTTAUUTUATGUAGAAATG
AGTAAGAURGGTGAGUTUAUATGCGGGTGACGUTGAGAGAAAUAAGTAUAU
AGGTATTUAGTAAAATUAGAATTUTUTAAGTAUUAUXGAAAAGGGUAAAAGG
GRGUTTGTAUAGGAUAGGUAGGTAGAUAUTGAATURGGTGGGUUTGGGAAGG
UTUUUTGUACTGGUUTTTGAAGGGGGGTTGGATTUAGUAGGATAGAGGUATGG
GUATGTTGGGUARGGTUTGAA

37 UAUUTRGGUUUUTUAUUTGTAAGUAUTGTGAGGAGUAGUAGUAGGAAGAAAGGA
GAUTGGGTGUURGGTGTUATGGTGTGGTCAAATGGGTGGGGAGGGGUAGAAA
GATTUAGGUAGGGRGUTGGUTGUTTGAGAGGTGGAGXGGGUUAAGGXGUUTAURGU
TTTATAURGGTUUUUUAUTUUURGUURGUUUTAGGUUAUGRGAGUAGG
TGAUAGGTGAUAAAUAURGUUUUTUUUTAUUTUATUUTUTTUUTUUTUU
UUAUATTUUTGGTAGGTAUA

38 TGTAUUAUTUUUAGGAATGGTGGGGAGGAGGAAGAGGTAGGGAGGTAGGGGA
GGGGRRGGGGTTTGTUUAUUTGTAUUAUTGUTURGGUTGTGUUTAGGGRGGGRGG
GGGAGTGGGGGAURGGTATAAAGRGGTAGGXGUUTGTGUUXGUTUUAUTUTU
AAGUAGUUAURGGUUAUUAUTGTTUTGUUUUUTUUUAUUAUTTUUAUUAU
AUUAUTGUAUURGGUUAUUAUTGTTUTGUUUUUTUUUAUUAUTGUT
TAUAGGTGAGGGGUARGGAGGT

39 AGAGGGAGAAAUAAGAAARGGGAGTUAGGRGGGGAGUUTRGGGAUAGGUUTGGGA
UURGAGGURGGAAUURGUAGGGAGRGAGUUTGRRGGATGUAGTGTGGAGU
UAAAGGAAURGTUURGGUUTGTUUAARGRGGGGGUUTXGGUURGGTGUU
GAGRGAUURGTGUARGTGUUURGGUATUUATUUUUAUJUTUUUAGAUT
UTUUUTUUUAGUTUUTTUTGAGGRGGAAAGAAAAAUUUTAUATUTGGUUUAGU
UTGGGUUUTGUUUUTGUU

40 AGGAGGGGUUAGGGUAGGGAAUUAAGGUTGGGUUAGATGTAGGGTTTTUTTUR
GUUTAGAAGGGUTGGGGAGAGTGTGGGGAGGGGTGGGGATGGGATGRGGR
GGGGUARGTGUATRGGTGUUTAGGGUUAURGGUXGAAGGUUUUUURGRGTT
GGAUAGGURGGGARGTTUUTTGGUTUUATUATGUATUURGUUAGGUTRGUT
UUTUTGRGGTTURGGUUTRGGTUUUAGGUUTGUUURGGAGGUUTURGUUTG
UTURGTTUTGTTUTURGT

41 TUAAAUUUAGGTATTUTGGGTUTAGTRGGTGTUTTUTGUUAAAGAGTAUTTG
UTAAATTUAUTGGATGTGAUTAGTTTATUTTRGTUATUTTAGUTTTGUUTTA
TUAAAURGGATUAUTUTUTGUTTAGAAUTXGTTUTGUTUTTGTAUAGTGG
AUATAUTUTUATGUUTUTGUUAGAGTUUTTUTGUUTATGTTUUAU
TUUTUTAUTGGGAURGGUUTGGGTGTGUUTUAAUTGGAUATATTTGTTGGGU
UTUTUUTTUAUTUU

42 GAGTGAAGGAGAGGGUUUAAAATAGTGTURGATTGGAUAGUAUAAAAGGUR
GGTUUUAGTAGAGGAGGTGGAAUATGAGAAGGAAGGAUTGGGUAGGGAG
GUAGTATGAGAGTATGTAUUAUTGTAUUAAGAGUAGAAXGAGTTAAGUAGAA
GAGAGTGATURGGTTGGATAAGGUAAAGUTAAGAGATGARGAAAGATAAAAATG
AGTUAUATUAGTGAATTAGUUAUAAAAGTAUTUTTGGAUAGAGAAUURGAUTA
GAUUUAGAATAUTGGTTG

43 AAGTGTGTTAUUTUUTGACTGRGAUAAAAGTGUAGGAGGUAGGGGUTGAUTGAG
GAUAGGGAGGGGTGTGUUAUTAUAGUATGAGGUAGAGUTGTGTGUUAUATU
AAGUAGGAATGGGGURGGAAATGGGUUAAGGUUTAXGGATGAAATGGTGG
TTGGATGTGGGUUAUTTUTGUUAGGUUTGAAAGAGGAUAGGUATGTGGUT
GAATGGGUUTATGAGAATTGATTGUTRGAGATGTTUTTUTTUUTAA
ATAGAAAATGAUATAUUUU

44 TGGGTATGTUATTUTTTAGGAAGAAAAGAAAATUTRGAGRAUAT
UAATTUTUATTAGGUUUAUTUATGUUAUATTGUUTGGTUTUTTUAGGGUTGG
AAGAAGTGGUUUAUTUAAATUUAUATTUAATXGTAGGUUTTGGUUUUATATT
URGGUUUUATTUUTGUTGATGTGUUAUAGUTUTGUUTATGUTGTGAGTGT
GUATAUUTUUTURGTGUUUTUAGTGUUUTUTGUUTUTGAUTGGTRGUAUT
UAGGAGGTAAGAUAUT

45 GGATGTGUTUAGGUUTUAGGUUUAUUTGUATGTAUTUATGUUAAGGUUUTU
TGGAGGTGUAGTAGAGTTGGGUUAAGUTGTGTGUAGUAGUTGGAAGTT
TGUATAUUTUATTUURGGTUUUUAUAGUAGUTURGTUXGUTUUUATAUUAURGG
UUAUAGGUAGTGUATGTUUTUUTUUUAUTAGUAGGUUUAUAGUTGTTGGT

SEQ

ID

NO : Sequence

ATGUUATURGTGAAGRGTAGUATGGGAGAGGAUAGTGRGTGGTGGGTGGTGG
GGUAGGATUTUTUTGGTUTU

46 GAGAUUAGAGAGATUUTGUUUUAAAUAUAAAARGUAUTGTUUTUTUUUATG
UTAGRGTGGTGGATGUATUAUAAAAGUTGGTGGUUTGUTATGTGGAGGG
AUATGUAGGATGRGTGGTURGGGTATGGGAGXGGARGGAGUTGUTGGTG
GAURGGAGAATGAGGTUAGAAUUTTUAGUTGUTGRGAGUAUAGUTGTUUU
UUAAUTAUTGUAUUTTUAGAATGGGUTGTGUTATGAGTAUATGUAGGGTGTG
GUUUTCGAGUUTGAGUAUATUU

47 AGUUAGGAAGGGUTGUAUTUUUAGTGGTUAGRGUAGGUTGRRGTUUTGGUTGUT
GGRGUAGTUTUAGUTGUUUUTUUUTTUTAGUAGUATGGRRGTGTTGGTATG
RGGGTGUTGGGTGATGUATUAAUTURGGAGAUAAUTXGGUTUUUAAAUAU
TUTGAATGATGATUAAUTTATGAGGTGAATGUUTGTUUTUAGGGAGUTUUA
GUTGGAGUTGGAGGUAGUATATGGAGTGGAGAGAGUTUXGUAGTUAURGGG
UUTGTAUAGUUTGUAGGUAGAAU

48 GTTUTGUUTGUAGGUTGTAUAGGUUURGGGTGAUTGXGGGAGUTUTUUAUUTUU
ATATGUTGGUTUUAGUTUUAGUTGGAGUTUUTGGAGGUAGGGUATTAGUUTUA
TAAATGATTUAGATUATTUAGAGGTGGTGTGGGAGUXGAGTGGTUTURGGAGG
GAGTUGTAUUAUAGUAAUURGUATAUUUAUARGUUUATGUTTGUTAGAAGGGGA
GGGGAGUTTGAGAUTGRGUUAGUAGGUAGGARGUUAGUTGRGUTGAUUAUTG
GGGAAGTGUAGUUUTTUUTGGUT

49 GGGTGTGGTAAUTGUTGUUTUUTURGGAGAUUAUTXGGUTUUUAAAUAUUAUUTU
TGAATGATGATUAAUTTATGAGGTGAATGUUTGTUUTUAGGGAGUTUUA
TGGAGUTGGAGGUAGUATATGGAGGTGGAGAGAGUTUUXGUAGTUAUURGGGU
TGTAAUAGUUTGUAGGUAGAAUUTATAATGGAUTUUTAAAGUUAUTUUTUUA
GUUTGGAGATTGUTGAGTTUAUTUTGUTUTUAGAGUATUTGGAAUTUTAA
TAAAGUTGAGGAAUUUTTTGT

50 AUAAGGGTTUUTUAGUTTATGAGTTUAGATGUTGAGAGUUAAGAGTG
AAAUUAGUAGAATUUTUAGGUUTTGAGAGGGTGTGUTTAGGAGTUUAGTTATA
GGTUTGUUTGUAGGUTGTAUAGGUUURGGGTGAUTGXGGAGUTUTUUAUUTU
UATATGUTGGUTUUAGUTUUAGUTGGAGUTUUTTGAGGUAGUATUAGUUTU
ATAAATGATTUAGATUATTUAGAGGTGGTGTGGGAGUXGAGTGGTUTURGGAGG
TGAGTUAGTAUUAUAGUAAU

51 AGTUUATGAAGGUAUTTTTUAAGTTAGGTGGTUAUUAAAAAAUAGGTAAUAT
UUTGTUAAUAGURGRGGGAUAGRGGAGGUUTTGAGGGTGUUTTGAGGGGAGGATGURG
ARGATGURGAURGRGUATUAGATUTRGURGGAGGGXGRGGGRGUTUUAUTG
TTGUAAGAARGURGGGTUUTUTGGUUAATTGGGUTGURGUTURGGGGAGRG
RGGAAGGUTGGGUUATUAGGTAGUTTUAAUTTUAAUUTGUTGGTARGGTRGRGG
RGURGGGAAUUTAUTURGG

52 TURGGAGTAGGGTUUURGGRGURGRGAUURGTAAUAGUAGGTGAATGATTGAAGU
TAUTGAGGUUAGUUTTURGRGUUTURGURGGAGRGGUAGUUAATGGGUUAG
AGGAUURGRGGTTUTTGUAUAAAGTGGAGRGUURGXGUUUTUUTURGGRAGA
TUTGATGRGRGGTRGGUATRGTRGUATUUTUUUUTUAAAGUUAAGGUUTRGUT
GTUUURGRGGUTGGTGAUAGGATTATAUTGTTTGGTGAUUAUUTAAUTTG
AAAAAGTGUUTTUATGGAUT

53 GTUTGUAGGAAATGAATGAAGGTUAAGGATGAAGTAATAAUAAAT
TGGTTTGGGTGUUTTGTAUTGTURGGTTUUTGGTGUUTTGAGGTGAUAT
UTTUTUTGGGGAGAGAUAGAGTUAATGAGAAAXGTGAGTTGAGGUUAGGGGA
AAGGATUATURGGAGATGUUTGGGUTUAGGUATRGTAATUTUTGTUUTAG
UTGGAGAGTGGGUTGUAARGGUUAGUTGUTUTUTGGGUUTRGGUUTTG
TTUUUUTGAGGAUTTGAG

54 TUAAAGTUUUAGGGGAAUAGGAAGGAGGGAUTUAGAGAGGUAGUTGGURG
TGUAGUUUUAUTGUUAGUTGAGUAAGAGATTARGATGUUTGGAGUUUT
GGUATUUTURGGATGATUUTTGUUTGGGUUAUTUAAGTGUUTTGGAUT
GTUUTUUUAGAAGGAAGATGTUAUUAAGGAAUUTAAUTGGAAUURGGAUAGT
TAUAGGUUUAUAAAATTTGGTTATTAAUTTUATUUTGAAUUTTU
ATTUATTUUAGUTCUAGAU

55 UUAGTGUAGAAUAGGUAUTGUUUAAAATAUAGGUAGAGGGTGUUTUTU
AUTGGGUAUTGAAAUTAUTUAUTGGGUAGUAGTGGGTGUUAUTTGGAAAAAAGAT
GGUUTUUUUTGUAGAGGUAGGUUAAAUTGURGGAGGTGUUXGATGRGTGAGU
AGGGTGGAGGUAAUTAUAGGUAUTUTAGTGUUTTAAUAAAUAUTGAGTGT
GATUTTGGTGGTTUTTUAGAGAAGGGGAAARGGAAUTUAUAGAAGUAAUTAGAG
GAGTGGAGTAGAAGGUUAGGTATG

56 UATAUUTGGGUTTUTAUTUAUTUUTUTAGTTGUTUTGTGAGTTURGG
UTUTGAAAGAAUAAAAGATUTAUAUTAUAGTGTGAGGAGAGTG

- continued

SEQ

ID

NO : Sequence

UUTGTAGTGTGUUTUUAAAATGUTTUAUARGUAXGGGAUAAUTURGGUAGGGTG
 GUUTGmWGUAGGGAGGGUUAUTTGTUUAAUTGUTGUUAGT
 GAGTAGTTUAGTGUUAGTGTGGAGAGGGUAAUTUTTGGuUTGTATGGTGGU
 AGTGUUTGTTGUAUTGG

- 57 TURGUUATUATTUATGAGTUURGAGUUURGUAGTUUGTUTAUTTUTTTU
 TTTUUAGTGAATUUTUAAUTGUUTTGUATGTUTUTGUUUAAAATTT
 GAAGUUUUTUUUTTURGTUTUTTAAGAATUTUTAXGAAUURGAAAGUURGTGAGG
 UTGATGAGTGUARTGTGUUTTGUUTTUUUTUUTUAAUAAUAGUTUURG
 GGAURGGAUUUTUUUUAUTUAAUAGGTGUAGGGUUAAGGGUAGUAGGAGGA
 AUAGUUAUAGGTAGAGGTG
- 58 UAUUTUTAUUTGTGGUTGTTUUTUUTGUTGUTGUUUUTGGGUUTGUAAUTGGTGA
 TGCGGAGGGTURGGTURGGGAGUTGTGGGTATGGAGGGAAAGAAGGAGAAAGGA
 AUUAUAGARTGUATUAGUUTUARGGGUTTRGGGTXTGTAGAGATTUTTAAGAG
 ARGAAAGGGAGGGGUTUAGAAATTGGGUAGAGAAUATGUAGGGAAAGGGGA
 UTGTGAGGATTUATGGAAAGAAGAAGTAGAUAGGAUTGRGGGGUTRGGG
 AUTUATTAAGAATTGTGURGGA
- 59 AGUUTGTGUTUAGGAATAAUTAAGGAGTGGAGURGUATUAAUUTUUTUUUAAATU
 RGGRGATUTUUTURGAUTUAGGUUAGUUTGAGGUUATTUTGUUTTGATTUAAU
 TTGGAAAUAGAUUAAGUUAAGGGAGUTGTUTUUTGGXGTTGARGAGGATURGATT
 TAGGTUAGTATTUTAGTUUUUAUTUAAUAGGAAUTGTAUTGGAGGUAGUTGTG
 GTRGATGAGTUATURGGAAUUAAGUAGGUAGUTATTURGAUTAAATGGUATUT
 GATUTUUTUUTUAAUTTGGA
- 60 TUAAGGTGAGGAGGGAGATUAGATGUUATTAGTTRGGAAATAGUTGUUTGUTTGT
 GTTURGGATGAUTUATRGAAUUAAGUTGGUUTUAGTUAUTGAGGUUTUTGTGGAGTG
 GGAUTAGAAATAUTGAUUTAATRGATUUTRGTAAXGUUAGGAGAUAGUTUUT
 TGGUTGGTGTUTGTTUAAAGGGTGAUTUAGGAGAATGGGUUUTUAGGUTGGUUT
 GAGTRGAGGAAGARGTURGGATTGGGAAGGGGTTGATGRGGUTUUAUTUUTTA
 GTTATTUUTGAGUUAUAGGUT
- 61 GAUUTUAGGATUTGAATGGTTUTTGAGTTUTTGAGATGAGGTAAATGTTGGTT
 AAUTUATAGCTUAGAUUTGUTGTUUTTAGUTAAUTGUUURGGGGGTTTAARGG
 AAGGUUTGTGTTAGUAAAATUATATTGUUTGATGAXGAGUAGAGAUITGTGATUTG
 GTUTTAAAGAARGRTTUUAAUTTAAUUTGGGUUTTTTGAAATTAGURGGUUAU
 ATATAUAGGGTTUUTUAGGAGTTTTTUTUUTUTUTGTUTUTTG
 TTTUUTTAAUTAATT
- 62 ATTGAAATAGGAAAAAUUAGAAGAGAGAUAGAGAGAAAGGGGGAAAAATUUT
 UTGAGAAAUUUTGGTATATGGUURGGUTAATTUAAAAGTUUUAGGGTAAGTGG
 AAAARGRTTUTTAAGAUAGATUAAGGTUTUTGUTXGTTUATUAGGAAATATGAT
 TTGTGUTAAUAGGUUTTURGGTTAAAATUURGGGUAGTTAGUTAAGGAAUAG
 UAGGTGAGTAAUUTGAGTAAUAAAATUATUATGUUAAGAAGAUUAAAGA
 AAUATUAGATUUTGAGGTUU
- 63 GUUTGGAAUURGGRATUTUTGTTUTUAAUAAAGGGAAUTUTGUTTGAAU
 TTTAAGUUTUAGUTGAAAAGTGGTUTUUTGGGTGAAGTUTUAAUTGTGUUUU
 TGAGGGTGAUTGAGTUTGUUTUUTGGUTUTUURGXGUTGTTAGUATT
 RGGAGTUUUAAUTGTAUTATTGUUTUAAUUTUURGAUAAAATUAGGUTTU
 TGAAGGGUAGAGAUAGUATUATAUTUUTTAAUTUURGGGUUTAGTGUUTAGTGU
 TUUUAUTUUTAGTAAGUAT
- 64 ATGUTTAUTAGGGATTGGGAGTAGUAUTAGGUARGGGAGTTATAAAAGATGATT
 GATGUTGTUTGUUUTUAGAACUTGGAGGTTGTRGGGAGGGTATGGAA
 TGAGTUAUTGTGGAUTURGGTAAATGUTATAAUAGUXGRGGTGAGAGUAGGG
 GUAGAGUTGAGTAAUUTUAGGTGGGTGUUAAGGTGAGAUTTUAAUAGGAGAU
 AUTTTUAGUTGAGGUTTAAAGTGTAAUAGUAGAGTTUUUTTGGTGAGAA
 GAGATRGURGGGGTTUAGGU
- 65 AATUUTTUUURGGGATAGTUAARGAGGUTTUAATTAAUTGUATTGAGUTT
 GUAGAGAUTUAAUTGAUTTAAUAGGUUTAAUAAUAGUAGUTGTUTUUTG
 TTGRRGUAGGGTAGTGAAGGATAUAGGGUAGUAGGAAAXGAGTUUURGG
 GGATUURGGTUTTAAUUTGTAGAGUUUAGGUUTGAGGGUATAGGUU
 ATGUUAAGAGUTUAGAGAAATUTGTUTUUTURGTUUUUUAAUTAAGAUTGAG
 GUTGGAGGAAAGAGGUUAGG
- 66 UUTGGUUTTTUUTUAGUAGUTUAGTUTTAGGTGGGGAGGGAGAGAUAGAT
 TTUTUTGGAGUTUTGTGUUATTGGUUUTATGUUUTUAGGUUTGGGUUT
 GAGGTGGAGUARGGGATUAAUUTGAGAACURGGAUTXGTTUUTGUTGU
 TUUTUUTUAAUTGGRGUAAUATGGAGAUAGUTGTGTTAGGGUUTGG
 AGTGUAGTGTGAGTUTUTGUAGGUUTTAAATGUAGTTAAATTGAAAGU
 UTGAAAGUUTRGTTGA

SEQ

ID

NO : Sequence

67 AGGAATGTTAUTGAAGGAGTGAATGAAAUTATTGUATTAGATUAAGUUUAGGTGU
AGAGGAUTGGTTUAUATAGAAAGUATRGATTTGUUTAUAGAAUUAUTGAUTUA
GTTTUAGUAGAUAUUUTGGTGTGAAGAUAGAGGGXGGGAGGAAGGTAGGG
GUTGAUATTUUUAGUUUUTUUUAGGURGGTGGGGAGUTGAATAGUTAUGTGAUT
GTUAGGAGUORGAGGTAUAAGAUATAGAGUUAAGAGTUATGATTUAUTAU
TTGUATTUTUAGUATGAUA

68 TGTUATGGUTGGAGAAATGUAAGTAGTGAATUATGAUTUTGGUTUTTAGTUTGTGG
TTTUATGGGUTUTGGGUTUTGGGUAAGTGUTAGGUTATTAGUTUUUUAURGGUUTGGG
AGGGGUTCGGAAATGTUAGGUUUTAUUTTUUTUJGUUUTUTGTUTTUUAUUA
GGGTCTUTGUTGGAAATUTGGACTUAGGGTTUTGTAGGGUAAAATRGATGUTTUT
ATGTGAAAUAGTUUTUTGUAUUTGGGUTTGATUTAATGUAAATGTTUATTUAUT
UTTUAGTAAAUATTUUT

69 GUTGGGATTATATATGUAAUAAAATGUURGGUTAATTTTATATTGGTAGAG
ATAGGGGTTUUAUATGTTGGGUAGGGTGGUTTGAAUUTGAAUUTAGGTGATU
UAAUUAUTTGGGUUTUUUAGAGTGUTGGGATTAUAGGXGTGAGUUAUTGUAAUURG
GUAAUAGUUAUTTTAAAUAGUTTTTTTTTGAAUAGUUTGUUUTGTA
GUUAGGUTGGAGTGTAGTGTAUAATUTAGUTAATGUAAUUTUUUUTURGG
GTTUAGTGATTUTTGGu

70 GUAAAGAATUAUTGAAUURGGAGGTGGAGGTGUAGTGAGUTGAGATTGTAUU
AUTUAUATUAGUUTGGGUATUAGGGUAAGGTGTTUAAAAAAAAAAAAAGU
TGTGTTAAATGGUTTGTGURGGGTGUAGTGGGUATUAXGUUTGTAATUUUAGUAUTU
TGGGAGGUUAAGGTGGGATUAUTGAGGTGUAGGGTGUAGGUUAAAUTGGU
UAAUATGGTGGAAUUAUTUTUATUUUAGGUUTTGGUATTTGUUATGGGAGGUATGGT
GTGTGUATATAATUUUAGU

71 AAUAAATGUAAUAGGUUUTATTGUAGGUUUAAGGAGTTGAGATTUUTAUTGGG
GTTGUTGGAGGUAGGUUTUUAUTTGUAGGUUURGGAUUTGUUUTUUUAR
GRGGTURGUUAGGUAGGUATUAAUUTGGGUUAJAGAGXGUTUUAAGGUUTUAG
GTGTGATGURGGGUTGAUTUAUAGTGGTUTGGGUUAGGRGGAGGUUTUAG
AGGGRRGGAAGGGGUUUTUUUUTGGUATTTGUUATGGGAGGUATGGGAGGUATGG
GUAGGUUATGUUAGGUUTT

72 TGAAGTUTGGUATGGTUUTGGTAUTGAUTGUTUUUATGGAAATGGUAGGAG
GAGAGGUUUTTURGUUUTTGAGAAGGTUUTRGUUTGGGUUAGGUUATUTGG
TGAGTUAGURGUATAUAAUAUTGAGGUUTTTGTGAGXGUTUTGTGGUUAGGGTG
TAGUTGGUTGGGRGGGAURGRGTGGGGAGGGUAGGTURGGGUUTGAAAGTG
GAAGGUTTGUUUTGUUAGGUUUAAGTATGGAAUTUAAUTUUTGGAGGUUTGUA
ATTAGGUUTGTGUATTGTT

73 GUAGTGUTAAUAAUATGUUAAGGURGTGGGUAGUTGATGGTTGGGUUUUA
AUTUUUAGUAGGTGUTTGUAGGUUUAUTUTGUUUAUTGGGUUAAAUTTA
AATAAUTTTGAUTRGGUUTAUTUTTGUTUAAAGAXGTUAGGGGUUTUUUAAAT
UTUTTAAUUTGUUAGAAAGTUTTGUTUAAUTGUUATAGTGUUUTGGGUUT
GATUTTUUAUTRGUATUUTGUUATUAAUTGUUATAGTGAAUUTGGGUUT
UTUUAUAUTTGUUTGUT

74 AGUATGAGAAGTGTGGAGURGGAGUAGUAGGGGUAUTAGTGGUAGGTTATGAG
UAGGATGRGATGGAGATUAGGRGTGAAAGUTAAGTGGAGGURGTAUTATAGAG
AUTTUTGGUAGGGTAAAGAGATTGGGAGAGGUUTGAXGTUTTGAGUATAAGA
GTAGUURGAGTUAAGGTTATTAAGGTTGGGUAGTGGGUAGATGTGGGUUTGU
AGAAGUUAUTGGUTGGAGTTGGGAGGUUAAAATUAGUTGUUUUARGGUUTT
GGUATTGATGTTGAGUATGUU

75 AGGAGGCGARTGGAAAGTRGTGGTGUAGAGAAAGTGTGUAUURGUTGGAGGTU
TATTGUAAAGATAGGTGGGATGAGAAAATGTUTGGGRGAGGGGGGTGGGAGGU
RGGTGUUAUTGTGGATGGGUAAUAGGUUTGUUATGXGTGTTGUAAAGTTGUU
RGGUUURGUUATTGGGUAGGTUTTGGRGATGUUTRGUUTTGUUUTAAAGA
AGTGAGUTUATAAGGTTUAGGAGURGGGUUAAAAGRGGGACTGAAGAUTUR
GAGGGGUUAAATGAAGUAGA

76 TUTGUTTUATTGGGUUUUTRGAGAGTUTTUAUTUURGUTTGGGUUURGGUUT
AAUUTTATGAGAGUTUAUTTUTTGAGGRGAAAGTGRGAGGUATRGUUAAGAAU
TUAAAATGAATGRGGGURGGGUAAATTTGUUAUXGUUATTGUAGGGUTGTGGA
TUUATUUUAAGGTGAUAUURGGGUUTUUUAAAUUUUTRGUUUAGUATGTTT
UUUAAUUTTGTGAAATAGAUUTUUUAGRGGTGUUAUTTTUTUTGUUAAA
RGAUUTTUARGTUUUTUUT

77 UUTTTTGAGUTGRGAGTGUUUTUUUUTTUUTTGUUTTTTGTGUTTTTATGTT
UUUTURGGGUUTTUTUUUUTUUTAGGTUTTTUTUTAGUTUAGTTGGAGUTU
TUUTTUUAUUTTTUUAUTUUTUUTGUUAGGATTATUUUTGGGU
UATUUTGAGUTGAGUUTAUAGGUAGUAGUARGAAGATAGAGGTGRGRGGGGU

SEQ

ID

NO : Sequence

GGGTGGTATGGAGATTUTGGGUUTTGATTGAAUAUUURGGAGUTAURGUUAU
AGGUUTGUUUATTUAU

78 TGAAATGGGUAGGUUTGTGGGGTAGUTURGGGAGGTGTAAAATUAAGGUXGUA
GAATUUTUATAUUUUUUTGUUURGRGUAAUTUTATTTRGTGGUTGGUTGGUTGTA
GGUTAGUTUAGGATGGGTUUUAGGGATAATUUTGGGXGGAGGAAGGAGGAGGT
GAAAAGGGTGGAAAGGATGTGAGUTUUAAAATGAGUTAGAGAAAAGUAUUTAGGAG
GGGAGAAGAGGURGGAGGGAAAATAAAAGUAATAAAATGAAATGGAAAGGGA
AGGGAUTRGUUAGGTUAAAAGGU

79 GUTUAGTTGGAGUTUAUATUUTTUUAUUTUTTUAAUUTUUTUUTUXGUUUU
AGGATTATUUUTGGGUUUUATUUTGAGUTGAGUUTAUAGUAGUAGUARGAAA
TAGAGCTGRGRGGGGGUAGGGTAGGTGAGGATUTGXGUUTTGATTTGAAU
TUURGGAGUTAXGUUAUAGGUUTGUUAAUTTUAAUTGURGGGAAGATAAUUTTG
UTTUTCGTGGTGGGTGATTGAUTUTUAAAATUUAAGUATGGTTTTUTG
GTAAUTTUATGAUTGUT

80 AGUAGTUATAGGAAGTAAUUUAGAAAAAAUUAATGUTTTGGATTTGAGAGTUAT
UAUUUAAAUAUUAAGAAGUAAAAGTTATUTTUURGGUAGGTGAATGGGUAGU
UUTGTXGGTAGUTURGGGAGGTGTAAUATUAAGGUXGUAGAATUUAU
AAUUTGUUURGRGUAAUTUTATTTRGTGGUTGGUTGGUTGTAGUTUAGUTUAGG
ATGGTUUUAGGGATAATUUTGGGXGGAGGAAGGAGGAGGTGAAAAGGGTGGAA
AGGATGTGAGUTUUAAAATGAGU

81 UATTUAAAATUTGUAAAATGUAAUTGATRGATATTATAATTAAUUTTTTUUTT
UAUATGGUAAURGGGUUTURGARGAGUAGGAUTGAAGAAGGAARGAGGAATAA
AUTUTGGGAGTGGAAAGRGRGUUTRGUAGAUAGATURGXGGGRGUTGGGUAGU
AGGAGAAGUURGGUATURGUTTGTGAGGTURGGGUTGTGGTUTRGAGTUURGU
URGUUTRGGRGGGUURGUTUUUATGUURGUUURGUTATRGUUUURGRGUTTUT
URGUURGUURGURGAGUTGU

82 TGUAGUTRGRRGGRRGGAGAGAGRGRGGGGRGATAGRGGGGRGGGUATG
GGAGRGGGUURGRGAGGRGGGGRRGGAUTRGAGAUUAAGUJURGGAUUTUA
AAGRGGATURGGGGUTTUUTGGUTGUUUAAGRGGATUTGTUTGURGA
GGRGGUTTUUTUUUAGAGTTATTUUTRGTTUUTTUAGTUUTGUTRGTRGG
AGGAURGGTTGUATGGTGAAGGAAAAGGTATTATAATATRGATUATGTGU
ATGGTTGUAGTGGAAATG

83 TATGATGUUAGTGGTTGAATAUUTTAGTAGAGAAAAATUTGAAATAUUA
GGTUAAGGAGAUAGUTGGGTATTGAGAGUUTATGAGTUAUATAAGUAAAUTTGG
GUUAAGTTGATTUTUTGTTGGUUTUAGAGUJAGTUTXGAGUUAUTGUAGUJAGA
UTGURGGUAGAGAGATGTGAGUTGGUUTTGUTTAGGUUTGAGUAGGTRGT
GGAAGUUAGGTTUTGAAUATGGUURGUUAAGAGUUAUTGUTUAGUUTGGGT
UTUAGUAGGUAGGUAGGTGAG

84 UTUAUUTGGUTGUUTGUTGGAGAUUAGGGUTGGAGUATGGUTUTGTGRGGGUATG
GTUAGGAAUUTGGGUUTUARGAUUTTGUTUAGGUUTAAGUAGAATGUAGUT
UUUAUTUTTUTGURGGUAGTLTTGGUTGUATGTGUTXGAGAUTGGUTUTGAGGU
AAAAGAGAATAUAAUTTGGGUUAAGGGTGUUTATGTGAUTUATAGGUTUTUAAA
TAUUAAGUTGTUTUUTGAAUUTURGGTTGATTATTUAAGATTTTUTUTAAGGT
ATTUAUUAUTGGUATUATA

85 GGGGUTRGUAGTGUUTAGTUTGUTUTGGGUUTTGUTGGATGUUUTRGAGAATUA
URGRGUAAUUTUUTUAGAGGUUUAUATUARGTGUTGGAUTTUURGGGUUTGTG
TUTUUTURGGUAGAUTGAAGXGTTUURGGUTGAAGGTGAGGTUTGUUAAXG
AGTRGUAGAAGTURGGGUAGAGUTGGTGGGUAGUTUAGAGGUTGGGATTGGA
ATUTUTGAGUAGGAGGTGAURGUUURGGUUAUAGUTGUUTGUAGATUUTGAAGG
AGUAAGGUUTGRGAUATAUU

86 GGTATGGTRGUAGGUUTTGUTUUTUAGGATUTGGUAGUAGUTUUUKUUU
GTUAUUTUUTGUTUAGAGATGTUAATUUAGUUTUTGAAGUTGUUUUAGU
TGURGGUUTUTGRGAUTXGTTGGUTGUAGAAUTUAUTTUGURGGGAAXG
TUATUTGRGUAGGGGAGAUUAAGGUURGGGAAGTGUAGUARCTGGAGTGTG
UUTUTGAAGGAGGTGRRGGGTGATTUTRGAGGUATUAGUAAAGUUUAGAGU
AGAUTAGGUUAUTGRGAGUUU

87 GRGGGUUAGUAGRGTGUURGGGGAAAGRGGTAUAGGRGUTURGGAGURGRG
UAUAGUTGUTTUAGUAAUATGURGUTUAGGTRGURGTGUTUTUUTGRGARGGG
TGAAGATGRGGARGAAUTUTUURGGUAGUTUAAGUUAAGUAXGATUTUAGGUUTG
GGGUUTGGAGAGAGGAGARGUTGTGAGGAGATGRGGURGGUTUAAURGUUAAGU
TGRGRGUUURGUURGGAAAUAGUTUAGTURGGURGGAGGUTGGGTUATRC
UUUUTTAUUTUTGUAGGAGTTU

88 GAATUUTGUAGAGGTAAGGGRGAGTGAAUUAAGUUTURGGURGGAUTGGAG
UTGGTTURGGRGGGGRGRGUAGUTGTGRGGTGGAUURGGURGUATUUTUAAA

SEQ

ID

NO : Sequence

GRGTUTUUTUTUTUUUAGUURGAUAGGUUTGAAGATXGTGGUTGTGAGUTGURGG
 GAGAAGTTRGTURGUATUTTUAAUURGTRGUAGGAGAGUARGGURGAUTGAGRG
 UATGGTGTGAAGUAGUTGGTGRGRGGUTTUURGGAGRGUUTCTAURGUTTUURGU
 RGGGUARGUTGUTGGGUURGU

89 AGGAGTGTGGGTGUTTUUTUTGGUTGUAGTGGGAUAUAGGTGTGUUTTUUTA
 CGGAUTGGGUUTGAUTAUTTUUAUAAAUAUTUURGGGUUTGTGAUTGTGAU
 UTGTGTGURGGGATGGGTTTGTGGGTUTGUUUUATUUUXGUAUTGUTGGATUTGG
 UUAAGTGGTGAAGGUTAAGGURGGTUAAGAGTTGAGTTUTGUUTTGUTUUUTUTU
 UTGGUTAGATCUUAUAAAAGGUUUAJCTGAUTUATAGGUAGGUAGTTGGAAAT
 AUUAGGUAGAGGGGUAGGTUUTG

90 UAGGAUUTGUUUTGUUTGUUTGGTATTUUUAAUTGUUTGUUUTATGAGTUAUTGGGU
 UTGGTGTGGUATUTAGUUUAGGAGGGGUAAGGUAGAAAATUAAUTUTGAURG
 GUUTTAGUUTTUAAUAAAUTGGGUAGATUUAGUAGTGXGGGGATGGGUAGAUU
 AUAAAUAUATUURGGUUAUAGGTUUAAGTTUAUAGGUURGGGAGTGTGGGU
 GGAAGTAGTGUAGGGGUUAGTTUUTAGGAAGGUUAUUTGTGUUUAUTGUAGUUA
 AGAGGAAGUAAAUAUAAAATUUT

91 GUAGGAATUAGGUAGRGATGTAATGAAAATUTTGRGTTATUTTTAGAAGGAT
 GTGAUTGTATTTATGAGTATGUAGUAGGGGUUAUAAAUAUUTTTGUTUUTGGGU
 UUUTUUUUAUUTAAUATUUTGUAAUUTGUUTRGUTGUUTUUUTGTGTGATUTA
 RGAGGAAAATGGGAAUATAGGGURGTUTGGGUUTTXAGGUUAUAAAUXGGGUUT
 GGGTAAUAAAAGGGGAGGGGUUAGGAGUAAAAGGTGTGTAUUTGUTGU
 ATAUTUATAAATUAGTUAUATUUTTUTAAAAAGATAARGUAAGAGTTTUATTA
 UATARGUTGGUUTGATTUUTGU

92 GAATGTUAGAUAGGTTTATUUAGGUUAAGGGGTAGUAGTUTTGUTUURGGGTGUA
 UUUUTUUUUAUUTAAUATUUTGUAAUUTGUUTRGUTGUUTUUUTGTGTGATUTA
 RGAGGAAAATGGGAAUATAGGGURGTUTGGGUUTTXAGGUUAUAAAUXGGGUUT
 GGGTAAUAAAAGGGGAGGGGUUAGGAGUAAAAGGTGTGTAUUTGUTGU
 ATAUTUATAUUTGTUTGAUATTUURGAUTUTGAAGTUATUUATUATGGUTGRGUTGGU
 TUAGAUAUTTUAGGGUUAUTTT

93 TGAUTGTATTTATGAGTATGUAGUAGGGGUUAUAAAUAUUTTTGUTUUTGGGU
 UUTUUUUTGTGTAGUUUAGGUUURGGTTGTGUTRGAGGGGUAGARGGUUUTAT
 GGGUUUUAGTTTUUTURGTAGATUAAUAGGGAGGUAGXGAGGUAGGGTGUAGG
 ATGTTAGGGGTGGAAGGGGTGUAUURGGGAGUAAAAGAUTGUTAUUUUTGGUUTG
 GATAAAUUTGTUTGAUATTUURGAUTUTGAAGTUATUUATUATGGUTGRGUTGGU
 TUAGAUAUTTUAGGGUUAUTTT

94 AAAGTGGUUUTTGAAAGTGTUTGAGGUAGRGUAGGUATGATGGGATGAUTTUAGAGGT
 RGGAAATGTUAGAUAGGTTTATUAGGUUAAGGGTAGUAGTUTTGUTUURGGT
 TUAAUUTTUAAUUTAAUATUUTGUAAUUTGUUTXGUTGUUTUUUTGTGTGAT
 UTARGAGGAAAUTGGGUUAUTAGGGURGTUTGGGUUTRGAGUAAAURGGG
 UUTGGGUTAUAAAAGGGGAGGGGUUAGGAGUAAAAGGTGTGTTGUAUUTGU
 TUAAUATUATAAATUAGTUAUATUUTTGAGTGTGTTGUAUUTGGGAGGUAGGG
 AGUAGGTUUTGAGGUAGGUTTA

95 UAAUAAUUTTUAGTGTAGGGGRGUTGAGGUUUTGUTGTTGUTGTGURGTGTAU
 UTGTUUUUTUTUTGUAUAGAGAGUAGUTGUTGUURGGGAAUAAUTTUAAAATG
 AGTGUAAUATAUAGGUAAUTTUATGTGUAGUATGGAXGGTGUATUURGGGRGU
 UTGGUAGTGTGARGGGUTGUUTGATGUTGUUTRGAGAAGGTGATGAGAAGGAGTGU
 GTGAGTGGUUTGGGUUTTGTGGGTGGGGTGUAGGUUATUUTGGGUAGGGGG
 AGUAGGTUUTGAGGUAGGUTTA

96 TAAGUUTGUAGGUAGGUUTGUUUUUTGUUUUAGGATGGGUAGGUAAUAAAUAU
 AGUAAAGGGGUAGGUUAUTARGGUAAUTUUTTUATUATUUTTGTRGAAGUAGTU
 AGGUAGUURGTUAUATGUUAGGRGUURGGGATGUAGUAGGUATUUTGUTGU
 AGGUAGUAGGAGGGGUAGGAGUAGRGGUUAUAGUAGGUAGGGGUUTUAGRG
 UUUUTUAAUATGAAAGGTGTG

97 UATGUATTTGTGTTGTAGTGTGUTGGUARGGGAGUAUTUAAAUAUATTATGGG
 URGGGRGUAGTGGUTURGGUUTGTATUTUAGUAUTTGGGAGGUTGAGGRGGGU
 GATUATGAGGUUAGGAGTTXGUAGUAGGUUTGGGUAAAAXGGXGAAUUXGT
 UTUTAUTAAAATAAAAATTAURGGGTGTGATGGGRGRTGUUTGTATTUUA
 UTAUTAGGGAGGAGGGGUAGGAGUAGRGGUUAUAGUAGGGGUUTUAGRG
 GTGAGGUUAAGATTGTGUUAUT

98 AGTGGUUAATUTGGGUUTGUAGTGUUTGUUTUUAGGUAGGAGATTU
 TGUUTUAGGUUTGUUTGUAGTGUAGTGGGUAAUAGGUAGRGRGUUATUAAA
 UURGGGUUTAAAGTGTGATUTGUURGUUTUAGUUTUAAAAGTGTGAGGAT
 TGUAGGUAGGGGUUTRGGUUUTATGTGTTAGAGTGTGUTUURGGGUAGGU
 TAUAAAUAUAAAATGUATG

- continued

SEQ ID NO :	Sequence
99	GGAUTGTGGUUUUTGGTTGUTGAAAGUTGGGGTAUAGTTUTGUATGGTT GGUUUUTGUUTTAUTRGGAAGUTUUUAGAGUUTGUTGGUAGUUTGUUTUUTU UTUTUAUTUUTUXGTUTUUAUTUUUTUUTUAUUAUTTURGGUTUTUUUARGUR GGAGGUXGTGAATGGGUTGUTTGTGUURGGUUUAUAGGAGGATGGTGGUAG AAGAUUURGGUUAUAAAGTUAGUAUUAUTUTGTTUUUAGGUTGGTTUAGGGAGG UTGAAAAGUUAUTTUAGUTGTG
100	UAUAGUTGAAGTGGUTTTUAGUUTUUUTGAAUUAAGUUTGGGAAUAGAGTG UTGUTTGUTGUGGGUTTUTGUUUAUTUUUTGUTGUTGGGURGGUAAUAAA GUAGUUUATTAUARGGUUTURGGURGTGGAGAGURGGATCTGTCAGAGGGAG TGGAGARGGGAGGGTGAAGGGAGGGAGGUAGGUTGUUUAGUAGGUTUTGGGAGU TUURGAGGTAAGGUAGGGGUUAUUAUTGUAGAAUTGTAUUUUAGUTTUAGAU AUAUUAAGGGGUUAUAGTUU
101	TAUTUTUTTGATGTATGAUUTTGATGTGATTAGUUTUTGGUUTTGGUUUKUU TGAAUATGTGATUAGAGUUAUAGURGGUUTUUUARGUTGGUTGAGUTGUUA GGGUUATUTAGGTUUTTGTUUUAAGUAGAGCTGUUTUTUURGGUUAAGUR GRGGUTATGGGGTGTGTAUAAUAGAGAGUUAAGGGAUTTGGGAAUUAUAAU TGGTUATGAUUAUTGUUTGUUAUTTGGUTGUTGUAUUTTGUTU TUUTTGATGGGGAGT
102	AUTUUUUUATTUUAUAAAAGGAGGAGAUAGAGGGTUAAGGTUAGUAGUUAAGAGTG GUUAGGUAGGGTUAUTGUUAGTGTGTTUUAAGTUUUTGUTGUTUTG TAUUAUUAUUAUATAGURGGUTGGUUTTGTGUAGUTUAGGUAGRGTGGGAGGURGG AUAAGGAGGUTAGTGGUUTTGTGUAGUTUAGGUAGRGTGGGAGGURGG TGGTGUUTGATUUAUTGGTTUAGRGGGGUUAAGGUUAGAGGGUTAAUTUAUT UUAAGGTUATAUATUAAGAGAGTA
103	GUUATGGAGAAAATGUUATGTUUTUATGGAAUUAUUAUTATTGUTTAUTGAGGTTUTG GGGGTGGTTUTGUAAUTAGTGTUAAUAGGGGAGTUTGGUTGAGGTRGTUAGUAUTG GRGGTGTGUTGGGUUTGUUTUUUAAGUAXGUAGGUUTGUTGUAGUUTG AGGUAAUTGGGAAAGGTGUAGAUATGAUUAAGGUUTUAGUAUARGUATUUU GURGAGGUAUTUURGGTGUUATATGTTAUTGUUUAGRGUUAGGUAGU GUU
104	TGGGUTGUUTGGGRGUTGGGUAGAGTUAUAUTATGUUAURGGGAGAGTGUUTRGRRGGGGAG GGTGGATGRGTGTGUTTGGAGGUUTGGGUATGTGUUAUTGTUUAGTGUUTGG GGUAAGGUAGGUTGGUAGGUUTGXGTGXGAGGUAURGGUAGUURGUUATGTG GARAUUTUAUAGGUAGAUTUUUUTGGTAGUAUTGAGTGTUAGAAUUAU TUAGTTAAGUAAATAGTTGGTTUATGGAGAUATGUUATTTTUTUAUTGG GU
105	GAGUTGGUTGTGAGGTRGTUAGUUAUTGGGGTGTGURGGUTGUUTUUUARGUA RGGAGGUAGGUTGUAGGUUTGUUATUTGUAGGUAAUTGGGUAGGTGUAG AUATGAUUAAGGUUTUAGUUAARGUATUUUUUTUUUXGURGGGUAUTUUR GGGUUATATGTTAUTGUUUAGRGUUAGGUUAGRGUUUAUTUUU UUUAGUUTGGUUUARGUUAUTGGGUATGGTAGTGTGAGGAGTG GUATUTGUAGGUUUUTAGAAG
106	UTTUTAGGGGUUTGUAGATTGUUAUTUUTUAAUTAUUAGUAGAGGUUTAGAGUA UTGTRGTGGGUUAGGUTGGGGAGGGGGAGGTGGGRGUTGGGUUTGGRG GGGUAGAGTUAUAUTATGUUAURGGGAGAGTGUUTRGXXGGGGAGGGTGATGR TGTGUTGGAGGUUTGGGUATGTGUUAUTGTUUAGTGUUTGGUAGATTGG AGGUAGGUTGGUAGAGGUUTGRGTGRTGGGAGGUAGURGGUAGUUA UTGARGAUUTUAUAGGUAGAUTU UT
107	GURGAUTUURGAGGGUURGGAGUAAUUAUTUUUUTUAGURGUAUTGUAAUTGUURGTAG GTGAUUAUUAUARGGRGGAAUUAUTGUAGGUAAUTGGGUAGGTGG ATGGGUAGGGGUAGGGAGURGGAGGUUUTAUTGGGUURGGXGAAGGUATUTGG AAGUATUUAGAGRGTGUAGUATUUUTUURGGGUAAUURGUAGGUTG UTGGGUAGGUUUTAGUATUAAUTGUUAGTGUAGGGRGGATTAAGGAGTGGGAG AGGGAGURGGTGUUURGGGU
108	GGGUAGRGGGGUUAURGGUTUUUUTGTUTUUUAUTUUTTAATURGUUTGGAUTG GATGAGTUTGAGGGTUTGUUUAGGGTRGGTGUAGUUTGRGGTGGURGRGGGG GATGUTGGGARGUTGGTAGGUUTGUAGGUUTTXGUURGGGUAGTAGGG TURGGUTUUUTGUUUAUTGUUAGGUUTGGUTUTGGAGAGGATTGG GTURGUURGTGGGTGGTUAAUTARGGUAGGTGUAGTGRGGUTGAGGGAGGG UTRGGUUUTRGGGATRGGU
109	TTGUTTGAAUAAAAGAATGUAGUAGUAAUTAAUTTGAGAAGUTGGAGUTGG AGARGATTUUTGGTTTGTGAAUTTRGTTUTGAAAGAAAUAAGGUUA GGURGGGTGAGGUTGUUTGUAGGUUTGTGUAGGUAAUTGG GUXGATUUAAGGTGUAGGAGATRGAGGUAAUTTG TUTUTAUTAAAATUAAAAAAATTAGURGGGUAAUTGGRGG UUTGTAGTU UAGUTAUTRGGGAGGUTGGGU

SEQ

ID

NO : Sequence

110 GUUTUAGUUTUURGAGTAGUTGGGAUTAUAGGRGUURGUUAGTATGUURGGUTAAT
TTTTTGATTTTAGTAGAGARGGGTTTUAAUATGTTAGUUAGGATGGTUTRGATU
TUUTGAUUTTGTGATXGGUURGGUTXGGUUTUUUAAGTGTGGGATTAAAGGXGT
GAGUUAGUTUAUURGGUAUTTGGGUTTGTUTTUAGAARGAGAATTUUA
AAAAGGAAATRGTTUTTGTAUTAGUTUUAGGTUTUAAAGTATGTUTGUTGU
ATTUTTTGGTUAAGUAA

111 AGAATUTGUUTAGUAGGRGGUTUTUUUUTGUTUUUUUAURGAGUAUAUAKUIUU
GAGGGGAAUUTGRGGGAGGGUTGUTTUAUTGAGAAUUAUTUUUATUT
AUAGRAUTUUUATGCAURGTUUUUUAURGGTGTUTXGGGUARGGGAAGG
GAUAUTRGGUAAAGAUUAAGAGAURGGGAGGGTGUAGUTGGGUTUTTRGRGGG
AGRGGRGGGAGGUUTTUUTGTTAUTGTRGUAGUTGGGUAAUAGARGGUAGRGUT
UAAGGGTUUAUTTGURGGUTRG

112 RGAAGURGGUAAGTGGAAUUTGGAGRGUTGURGTUTGTGTTUUAUTGRGAUATGT
AAUAGGAAGGUUTUURGUURGUTUURGRGAAGAGUUUAUTGUAAUUTUURGGT
UTUTGGTGTUTTUUURGAGTGTUUUTTUURGTTGGUUXGAGAGUAURGGTGGGG
ARGGUATAGGGGAGTRGUTGTAGAGATGGGAGATGGTUTUTGGAGAUTGAAGUAG
UUTUUTUURGUAGGGTUUUUUTUUARGGTUTGTCUTRGTTGGGAGUAGGGGAG
AGURGUUTGUTAGGUAGATTUT

113 AGGUUAGGUAGGGTUAGAGUUUAAGUUUTGTUURGAAGGAATGTGTTUUA
GUTAAUTAUUUTAGUTGAGGUUTGGAGGGACTUAGGGAUUUTGGAUTGGTTA
TUUTGGUUTTGAUTUATTAUTGTTURGGAGAUUTAAAXGUAAUUTGAGUUAUAGA
XGTGGGTGTTAAUUAUTGGGTUAAAAGGUUTGAXGUTTURGGUTGUTGGAGGAA
GUTTGUTUUTUUUUTUUUUTUUTGTTTURGTGUUAGUUTGGTAUAGAGTUAAGGG
GUTTGUTGGGUTTGGUTGG

114 UUAGUUAAGUUAGGUUAAGUUUTTGAUTUTGTAUUAGGUTGGUARGGAAAG
GAGGTGGGAGGGAGGUAGUTTUTUAGUAGAGUURGGGAAGXGTUAGGGGTTG
AUUTUAGGTGTTAAUUAUAXGTUTGGTGGUTIAGGGTGXGTTAGGTUTURGGAA
UAGTAATGAGTUAGGUAGGATAAAUAGTUUUAGGTUUTGAUTUUUUTUAG
GUUTUAGUTATGGAGTAGTTAGUATGGGUAAUATTUUTRGGGGUAGGGUTTGG
GUTUTGAUUTUTGUUTGGGUUTG

115 UUATGUTAAUTAUUATAGUTGAGGUUTGGAGGGAAUTGAGGUUUTGGGU
TGGGTATUUTGGUUTTGAUTUATTAUTGTTURGGAGAUUTAAAXGUAAUUTGAGU
AUUAGAXGTGGGTAAUUAUTGAGGTUAAAAGGUUTGAXGUTTURGGUTGUTTG
GAGGAAGUTGGTUUUTUUUUAUTUUTGTTTURGTGUUAGUUTGGTAUAGAGT
UAAGGGGUTTGGUTGGGUTGGGUAGAAARGTGGUAGTUGAGGUAGUAG
UTGRGGGUAGRGGGTGTGGG

116 UUAGUUAUURGUTGUURGUAGGUTGGGUUTUAUTGUUARGTTUTGAGUUAG
UUAGGUUAAGUUAGUUUUTGAUTUTGTAUUAGGUTGGUARGGAAAGUAGGAGG
TGGGAGGGAGGUAGUTTUTUAGUAGAGUURGGGAAGXGTUAGGGGTTGAAUUT
UAGGTGTTAAUUAUAXGTUTGGTGGUTUAGGGTGXGTTAGGTUTURGGAAUAGT
AATGAGTUAGGUAGGATAAAUAGTUUUAGGTUUTGAUTUUUUTUAGGUUT
UAGUTATGGAGTAGTTAGUATGGG

117 UTUTUUURGUAGTTUATURGTUUTUUTUURGUUTUTGRGAGUTGGGTTGGGAR
GTUTGGGTGAATGTGAGAUUUUAAGGUTGTTUTGGTGUUTUUTUUTGTTUTU
UAGRGUUUUAGUUAUUAAGAUUAUAGTUUUUUAGRGGXAAAGUURGGAGRGU
TTUURGAAAGAUATUAGGGTGUARGRGGUUUTGUAGUAGUATUUUU
TUURGUUUUTGUUTGCAAAGUAGGUUUUTUUUTAAGUTUTGRGUUUTTUUUT
GGRGUUUTRGGAURGTGGUURG

118 RGGGUUARGGTURGAGGGGUUUAGGGAAGAACGGGRGUAGAGUTTAGGGAGGGU
UTGUTTUUGGUAGGGGGAGGGGGATGUTTUTGUAGGGUAGGGGURGRGTTG
GUAAUUTGATGTUTTTRGGGAAGGRGUTUURGGGUTTXGUURGUTGGGGAUTG
GTGTUTGGGUTGGGRGUTGGAGAAUAGGGAGGAAGGGGUAAUAGGUAGUUTG
TGGGTUTAUATTUUAUUAAGRTUUTUAAAAGUTRGUAGAGGRGGGGAGGA
GGARGGATGAAAUTGRGGGGAGAG

119 AGAGGAGTGGGAGGRGUAGUAGGGTGUUURGUTUURGUAGAGGAGUTGGU
UTTAAGGUUAGGUUAGGRGGTGGGUAAAGAGAUURGGGAATGTGGGUTGGA
UTGGGAGGUAGGUUAUAGUATGAGTUATTURGTUTXGUURGUTUTGRGU
UTGGUTUTRGUTTGUURGUUTUUUUTGGGUUTGGGUUTTGUAGUUTG
GUAGAGUTGGTURGGTGGGUTGGGUUTUUUAURGUUUAAGRGUAAUAGGGUT
UTGUUUUATUURGUUUUTTTU

120 GAAAAGGGRGGGAGTGGGUAGGUUUTGTGRGUTTGGRGGGTGGAGGURGU
UAGGUUUAURGGAUUAGUTGUAGGGAGGRGUAGAGGUUAGGGGUAGGGU
GGGAGGGRRGUAGRGAGAGGUAGRGGRGAAGAGTURGGXGAAARGGGAAUTGAU
TUATGUTGGGTGGUTUTGUTUUUAGTUUAGGUUUAUTUURGGGUTUTGTTUUR

SEQ

ID

NO : Sequence

GAUURGUUTGGGUUTGGUUTTAAAGGGUAGUTUUTUTGAGRGGAGRGGGGUU
AUUUTGUTGRGUTUUUUAUTUUT

121 GURGAGRGRGGTGGUTUATGUUTGTAATUUAGUAUTTGGGAGARGGAGGTGGT
GGTAAUUTUAGGTAGAAGTTGAGAAUTUTGUTUTAUTGAAAATAAAAAAT
TGGURGGGUATGGTGGGTGTGTTAGTTUAGUTAXGTGGTAAGUTGAGGUAG
GAGAATGAUTTGAUURGGGAGGRGGAGGTGUAGTGAGGUAGGATTGRGUUAUT
GUAUTUAGUUTGGGAGAUAGAGTUAGAUTUTGTUTUAAAAAAAGUTATGGGUU
TGUAGGATGUUTAATAAAG

122 UTTTTATATTAGGUATUUTGUAGGUUUAUTAGUTTTTTGAGAUAAGAGTUTGAUTU
TGTUTUUUAGGUTGGAGTGUAGTGGRGAUATUUTGGUTUAUTGUAAUUTURGUUTU
URGGTTUAGTUTTUUUTGUUTUAGUTTAAUAXGTAGUTGGAAUTAUAGAUAU
UUAAUAAUATGUURGGUUAATTTTATAGTTUAGTAGAGAUAGAGGTUTUAAAU
TTUTGAUTGAGGTGATUUUUAUTURGTUTUAAAAGTGUUTGGGATTAUAGGU
ATGAGUUAURGRGUTRGGU

123 UARGUTUUTGTTUAUTTUATGTTUTGUTUTGTAUAUUTGGUTURGUUTTAGAT
AGUAATAGUAGAATTAGTGAAGTATTAAAGTUTTGTATUTTGAGAAGAGUAT
AGAAGAATAATGARGTAAGUTGTUUTUTUUAUTXGGUTAUUTAAAGGGAA
GGUUUUUTGTURGGGAUARGTAUTUAUTGAUTTATTAAUTAUUTGGAGATGA
UTUAUTAUUTTAAUUTGUUUUUTTGUUTTGTAUAUAATAAAUAGRGRGAUUA
GGUATTRGGGUUAUTGUU

124 GGUAGTGGGUURGAAUTGUUTGGTRGRGUTGTTATTGTGTAUAAGGUAAAAGGG
GUAGGGTAAGGAGTGTGACTUATUUAUTGATTAAAGTUAUTGTGAGTUAUTG
GTUUAURGGGUAGGGGUUTTUUUTTTAGTAGUXGAGUTGGAGAGGGAG
UTTARGTUATTATTUTUTATGUTUTTUAGAAAGATUAAGAUTTAATAUTTTU
AUTAATTUTGUTATTGUTATUTAGAAGGRGGAGUAGGTGTAUAGAGUAGAAUATG
AAAGTGAAGAUAGGAGRGTG

125 AGUUUUUTGGRRGGGTURGGGAGUAGGUURGUATTGGAGGAUAGGGTGTGAU
UUATUTGAATUUTRGTTAAAGTAAAGURGAURGARGGUTUTGGAGGTTGAGGU
UTGRRGGRRGGUURGGGAAGTGTGATTTGUXGUTAGGXGRGXGUTGGAAAAAU
UTTUUUATUTGRGGAGUUAUURGGAGUTGTGATRGAGGAGGATTUUUUAGGU
AGGGAGGAURGUAGGGUUTTTUAUTRGTUUTGAGGGGUUTGGGUTTGGGAG
UAAAUTGGGTGAUUUATTU

126 GAAATGGGTUAUUUAGGTTGUTUUUUAAGUUUAGGGUUUUTUAGGARGAGTG
AAAAGGUUUTGRGGTUUTUUUTGUUGGGGAATTUUTUTURGATUAUTGUR
GGTGGGUTURGUAGATGGAAAGGGTTUUAUTGXGRGXGUUTAGGGUUAATAU
AUTUURGGGUURGUUAGGUUTUAAAUTUUAGAGURGTRGGTRGGUTT
TAUTTAARGAGGATTUAGATGGTUUAUUUTGTUUTUUAAATGRGGGUUTGUTU
UURGGGUUURGUUAGGGGUT

127 UATUUUAUUUUTUAGGUUUUUTUAUTUTTUURGUUAUTGUTGUUTURGGTGT
UUAGAAGAATGGAAATGAGGTGAGTUUTTGATUUUTGUUTGUUAUTGUAA
ATATUATGTCGTGUTAUTGUUUTUTGTUUUTUUTUUXGTUUUAGGUUAUTUUT
UUUUUUUTTAATTGUURGGGATUTUUAUTTAUTAAUUTTUUAUTGGTAUUTUT
UUTUUUAUAGGUUTUUTAGUTTTURGTUTTAAUUAUUTUUUTGG
TUUGUTAUTGUUAUTTUAT

128 ATGAAGTGGUAGTAGUTGGAGGUAGGGAGGTGTGGTTAAAGARGGAAAAGU
TGAGGAGGUTTGTGGAGGAGGATUUAUTGCGAAAGGTTAAAGTAATGGAGAT
UUURGGGUATTAAGGGGGTGGGAGGATGGGUUTGGGAGXGGGAGGGAGGUAGGA
GGGUAGTAGUUAUATGATATTGUAUTGGGUAGGUAGGGATUUAAGGGAGUT
UAUTUATTUUAUTGUTTTUTGGAGUUAURGGAGGUAGAUTGTGRGGGAAGAGTG
GGGUUTGGGAGGTGTGAT

129 UTTUUUAGGAGTGUUTTGUUUUUTGGGUUUUAGTUTGGAGGAUTUTGUTUAUTT
UUTURGUUUUAGGTGAGUTGAGAAUUUAUTGRGRGRGGGAUTUTGUTGRGUUTG
UUUTUURGGGUTGUAGAGGUAGGAGXGUAGGUAGGAGGURGRGGUTUTGXG
UTGATGUUAUTURGGAGGGGTGGUTGRGGGGAGGGAGGRGAUATGGAGGG
GGGUAGRGGAGTGTAGGGTGTGAGATUTAAUAGAGGGUTUUAUTGGAGGGUTTG
UUUAGAAGGRGGGUAGTUAUAUTGG

130 UUAGTGTGAUTGURGUUTTGGGUAGGUUUTUUAUTGGAGGUUTUTGTTAGATU
TUUAUUAUTAUAUTURGUUUURGTUUAUTGUTGUUTUUTUUURGUAGUUA
UURGUTUURGGAGTGGGUATUAGXGUAGAGGURGRGGUUTTGUTGRGGTG
GUUUTUTGUAGUURGGGAGGGUAGGRGUAGUAGTGUURGRGRGUAGTGGTT
UAGUTUAUTGGGGGGAGGAAGTGAAGUAAGAGTUUTUAGAUTGGGUAGGG
GGGUAGGUAGTUAUUTGGGAAAG

131 TTTAGGGTUTUTUURGUUTUTTGUUUTUUURGUUUTUTUUTUUTTGRGGUTGA
UTUAGUTUUUUUTRGGTGUURGTAAUUTUUTTGUUTTGTGUXGUAGTUTUXG

SEQ

ID

NO : Sequence

TUTUTUTTUUAUAGGGTUTUTUUUUUUUTUUURGTGGTTGUAGAUTTUU
 TGGAUTTTUTURGUUURGUAURGUUXGUUURGGATGURGAGRGTGGTAGAUTUTGU
 AGURGGGUTUUTRGUTGUURGUTGGRGUTGUUTAUUUUUUTGGGUTUUUUTUUA
 AGGTUUUUTURGUTRGU

132 GRGAGRRGGAGGGGAUUTTGGAGGGAGUUUAAGGGGTGTAGGUAGRGUUAGRGG
 GUAGRGGAGGUURGGUTGUAGACTUTAUUARGUTRGGUATURGGGXGGRGCGT
 GRGGGGRRGGAGAAAGTUUAGGAGAAAGTUTGUAUAAUARGGGAGAGGGGAGGG
 AGAGAUUUTGTGGAGAGAGAXGGAGAUTGXGGUAAAAGAGGAAGGGAGGGTTA
 RGGGUUURGAGGGAGUTGGACTUACURGUUAGGAGAGAGGGAGRGGGGAGG
 AAAAGAGGRGGGAGAGAGAUUUTAAA

133 GAGGGGUUUAUAGTAUUTGGUAUAGTTTUTGUUAGUUTAGGUTGUUAUUTGTAG
 GTUAUTGGGTUUAUGUTATGTGGUTGUUTUTTGUTGGGTGUUTTAUTUTGGUA
 GTGUICGTGGTTGUTUAGGGUARGGUAGAGUUTGUUXGUAGUATGUUTTGUTT
 UATUARGGUTGTGAUTUAGGUTTGGRGUUTTGUAUTGUAGUTGGAUUAGA
 GAGGUTTURGAGTUUUTGGUUAUGUTGUUTGUAUUTURGGGURGAGGAUTGU
 GRGGTGGUUTUUTUURGUU

134 GRGGGGAGGAGGUUAUURGUTGUAGGTUUTRGGUUURGGAGGGGTUAGGUAGUTG
 GUUAGGAUTRGGAUAGUUTUTGGTGUUAGUTGUAGTGUAGAAGGRGUUAAAAGU
 UTGAGTUAUAGURGGTGTGAAGAAUAGGUATTGTGUTGGXGGUAGGUTUTGURG
 GTUUUTGAGUAAAAGUAGUAGUAGTAAGGUAAAAGUAGUAGAAGGGUAG
 UUUAATAGUTGGGUUUAAGTGAUUTAUAGGTGGUAGUUTAGGUTGGGUAGAAAA
 AUTTGTUUAGTTAUTGTGGUUT

135 GTTUTGGUTTUATTTTTUUUAAAATGUUATTTUATTTUTTAGGTTUAG
 AAUATGTUAAGAGUTTUTTAAGUAGTAGGTGGTTTAUAGAGUUUAAGAGAAAG
 GAAAATAAATATAUATUURGGATGUAGTUUUATAXGATXGTGGAGGAGTAA
 UTUTURGGUTTGUTGTGTUTGTGAAAGGAAAGGUATTGTGUTGGXGGUAGGUTUTGURG
 GAGTUAUUTAUUTGGGUUUAAGUAAAATGUAUTARTGTAATATGGAGAAAATGTGA
 AGUAAGAGTTUTTTTA

136 TAAAAAGAAAATUTTGUTTUUAUATTTUTUUATATTUARGTAGGTGGTGUUTGG
 UUUAAAGTGGGTGAUTUATGUUTUAGTTUTUUTTGUTTGTTUAAGUAGUAA
 UAGUAAAGUURGGAGAGTAATUTGAUTUUTUUXGATXGTAGTGGAUTUATURG
 GATGATATTAGTTTUUTTUTUTGTGGUTUTGTAAAUUAAUTAUTGUTTAAAGA
 AGUTTTGUAUTGTUTGUAUTUTAAGAAUAAATGAAATGUUATTTGGGAAA
 AAAAATGAAGUAGUAAA

137 UUTUUTUUAGTUTTGUAATATAUAGGUTGGTATUUATTGUAGGTGGGUUUTU
 UTUTTGGuUTTGAGGUUUUUUUUTUUUTGTGTUTUTGTGTAURGGGAGUTTUTT
 UTGTGTUTUUTUUTTGTGUUTATTAATUUTUXGUTUUTTAAAUUAAUTUAR
 GTGTGTURGTGTTTATUTAAUURGGGUAGGATUAAGAAUUTGTGT
 GUAUTUATUAGAGURGTATGATAATUAAGAGUTGAUTAUUTGGGUUATTUATAU
 UATTAGTGURGUATT

138 TAAATGRGGUAUTATGGTATGAGAATGGUUUAGGTAGTUAGUTUTTGATT
 ARGGUTUTGATGAGTGUAGGAAUUAAGGGTTUTTGATUUTGURGURGGTTAGAT
 AAAAUAAUARGGAAUARGTGGACTGGTTTAACGGAGXGGAGAGTTAAATGAGUAA
 GAAGGAAGGGAGAAGUAGAGGAAGAAGGUUURGGTAUAGAGAUUAGGGAG
 GGGGGUTUUUAAGGUAAAAGAGGAGGTUUUUAAUTGUATGGATAUUAGUUTGG
 ATATATGUAAAAGAUTGGAGGGAGG

139 AAGGTAAAGTRGUTGUTAGAUUAAGGUTAAUURGTGGRGGAGGTAGTTGUTTGRGU
 RGUAGAGTGCGGTGTGAUAGUTGGAGTUAGTGGTTUUTGGGAGUTUAGGUU
 AUUTGTATTUUUAUATURGGUTUUUAAAARGUUAUXGUAGTATGAUUTGGTT
 UUUTTATAUAGTGGAAUTGUTAAGTGUUTAUAAUUTAGURGGGUAGUUAUTAT
 GGUTGTGGGUUAUUAUUTGUAGUUTGTTGAGUTAAGAATGTTGTGAU
 AUTTTAAAAGAGAAA

140 GTTUTUTGTTTAAAGTGTUAUAAAATTUTTAGUTUAAAAAUAGGUTGUAGGTG
 GGATGCTGGGUUUUAAGGUUATAGTGGUTGAUURGGUTAGGGTGTAGGUAUTTAGU
 ATTUUAUTGTATAAGGGGAAUUAAGGTUATAUTGXGTGTGRGTGGGTGGGAAGU
 RGGATCTGGAAATAAGGTGGTUUUTGAGTUTUAGGAUUAUTGAGUTUAGUTGT
 TUUAUUUAUAUTGRGGRGUAGUAAAUTAUUTRGUUARGGTTAGUUTTGGTUT
 AGUAGRAUTTAAUUTTG

141 GAGAUAGGGTTUAUTUUTGTRGUUUAGGUTGGAGTGUAGUUTUAAUUTGGU
 TUAGTGTGATUTUUUAUUTAGAUUTGAGTAGUAGRGGAUTAUAGGUUARGUUA
 UUAGGUUTAGUTATTTTGTTAGGGTGTAGAGAXGGAGGTTRGUTAGGTGU
 UAGGUTGGTUTUTAAUTUUTGGGUUAAGXGATUUAUUUAUUTAGUTUUUAAG
 TGUTGGGTTAUAGGUUTGAGTUAUAGXGTURGGUTGAAAGTGAAGTTGAATGAGA
 TGAUTRGTUAGGUUUAAT

SEQ

ID

NO : Sequence

142 ATGGGUUTGGARGAGTUAUTUATTUAAUTTUAUTTUAUGURGGAXGUTGTGAUT
UAGGUUTGAAUUUUAGUAUTTGGGAAGUTGAGGTGGTGGATXGUTTGAGUUUA
GGAGTTAGAGAUUAGUUTGGGUAAUTAGRGAAUTXGTUTUTAUAAAAAATA
AAAAAAATTAGUTAGGUUTGGTGGRTGTGUUTGTAGTUURGGUTAUUAGGAGT
TGAGGTGGGAAGATUUAUTGAGGUUAGGAGGTTGAGGUTGUAUTUAGUUTGGGR
GAUAGGAGTAAAAAUUTGTUTU

143 AUARGUUAUUAGGUUTAGUATTTTGATTTTTGTAGAGAXGAGGTTTRGOT
AGGTGUAUAGGUTGGTUTUTAAUTUUTGGGUUAUGXGATUUAAAUAUUTUAGUT
TUUAAGTGTGGGUUTAGGUUTGACTUAAGXGTURGGUTGAAAGTGAAGTT
GAATGAGATGAUTRGTUUAAGGUUAUTGGUAUTAGTGGUTGATGTGARGUUAAGT
TGATTUATTUTTUTUAATGGGUUTAGGUUAATTUTGGUAUTUAGAAGARGTT
GUTATTUTGGGUUAAGU

144 UTTGGAAUUAGAATAGUARGTUTUTGAGGTTUAGAATTGGAUTUTGAAUUA
TTGAGAAGAATGAAUAAUTTGGRTUAUTUAGGUUAUTGATTGUATGTGGUUT
GGARGAGTUAUTUATTUAAUTTUAUTTUAUTGGAGXGUTGTGAUTUAGGUUTGT
AAUAAAAGUAUTTGGGAAGUTGAGGTGGTGGATXGUTTGAGGUUAGGAGTTAGA
GAUAGUUTGGGUUAUTAGRGAAUTXGTUTUTAUAAAAAATAUAAAAAATT
AGUTAGGUUTGGTGGRTGTG

145 AGTAUTGUAGRG TUAGGUUAAGUTGGGUUAUTTAUATGTUTGGUATGAUAGTGGU
UTUAGAGT AUTRG TUAGGAAAGAGUTATUAUTGAGRG TUUTGGAGAAUTTAG
URGGAGUTTUAGGUAGTUTGGGAGUUTAATGGAGGXGTGTAGGUTTATGTUTUA
TGTUURGTTGURGGAGUAAAATUUTTUTTATTTAGAGUTGUUUAAAATG
UTGUUAJAGUTTUUTUAUTGRGGTGGUTTUAAUTTAGUATAUAGGTATGTGARGGU
UAUTGTGUTGGUTUAUUTT

146 AAGGTGAGGUAGUAGTGGGUUTGGGUUAUTTAUUTGTATGUTAAGGTGAAGUUA
GUAGTGAGAAGGGTGUAGGUAAUATTGGGUAGUTUTAAATAGAAAAGGATTT
GTUTUURGGGUAR GTGGUATGAGAUATAAGUUTAUAXGUUTUATGTAGGUTUU
UAGAUTGUUTGAAAGUTURGGUUTAGTTUUAAGAGRGUUTAGGTGATAGUTUTU
TTUUTUAGARGAGTAUTUTGAGGUUAUTGTUATGUUAGAUATGTAAGTGGUUAAGU
TGGUUTGARGUTGUAGTUAUT

147 RGGGUUAUTAGGTUTRGUURGUUTGUAGURGUUTGGGARGGGTTURGGARGGU
TGGRRGGGGRRGGGGGGGUUAURGAGUAGGAAGTUUURGRGGAAAGRURGUR
GGGUUAURGRTGGTGTGAGGAGTGGRGUURGGXGGGGGGAGGTTATA
AATAGRGGUUUAUTUTGUTTUTUAGUUAUTTAATTAGURGGUAGGUAU
ARGGATGUTTATTTAAAAAAAGAAUTTGTGTTATTGRGUTRGAGGTGAURGGGAA
GGTGUURGRGGGUAUTRG

148 RGAGTGAAURGRGGGUAUUTTUGGTUAUUTRGAGRGUAATAAAAAGTTUT
TTTTTAAAAATAAGUATURGTGTGUUTGURGGUTAAATTAAGTGTUTGAAGAGA
AGUAGGATGRRGGURGUTATTATAAUUTUURGUTGUURGGGRGUUAUTUURG
AUAGUAAAARGUTGTGUURGGGRGUUTURGRGGGAUTTUUTGUTRGGTGCTU
UURGUUURGUURGRGUUAGURGTURGGAUURGRGTUUUUAGGRGGUTGUAGGR
GGGRGAGAUUTAGGTGUURG

149 GAAGGTGRGGTGRGGTGAGGTGAGAAGAGAGAURGRGUUTAGAUAGGRGATGTUTT
AGGGARGGGAGAGGGGTGAGGUUUAURGRGGTGUUTGGGAGRGGUUUARGAURGG
UUUARGUAGAGUTGTAGUUAAGTGAAGAAGTATTGGXGAGAGGGAUTGAGAA
AUAUAAGAGAGTGTGGGTGAGGAAAAGGTUAAGGAAGGUUAGGUTTUUAGGAA
GGGUUTGGGURGGGGGGGGGGTGGTGGAGGUAGTGGTAGGARGGRGGGG
GTGGGGTGGGGTGGGGTAGGG

150 UUU
UURGUUURGUUURGGGUUAGGUUUTTUUTGGGUAGUUTGGGUUTTUUTGAAUUTTT
UUTUAAUUUUUAUTUTTGGGTTTUTUAGTUUUTUTXGUUAAUTTUUTGTTUAU
TGGUTAUAGUTUTGRGTGGURGGURGGURGUTUUUAGGAURGURGTGGGU
UTUAAUUTUTUURGTTUUTAAGAUATRGUUTGUTGTAGRGRGGTUTUTTUTUA
TTTTTATTAUTURGUUAUTTU

151 GAGAAAAAAAATAUTTTTAATTAAATTTAAAGTAAUAGAATGAATAAAAAGG
GGUTTUUAAAATGUTTTGGTAGATTTAGUAAAUTAUTGAAUTTTAGAAUTTT
ATTTTATAATTGTURGGAGATAGAAGUAGTGUUTUXGAATAAGTGGATAAUTG
RGGUUUUAGTAGGTGUUAATTGGTAGAGUUAUAGGGTTGUTTAAGTUTUTAAGT
TTUUTGAUTGTGGTTGAATUATGTUAAATATUTAUAGGGGUAGGUAGGTAU
TUAATGAAGTGAUAUAGG

152 UTGTUAUTTUATTGGTTAUUTGUUTGUAGGUUUTGTAGATATTGUAUTTGATTUA
AAUUAAGTGUAGGGAAATGAUTTAGAGAUUTTAAGUAAUUTGTGTGUUTUAAAATG
GUAAUTAUTGGGAURGGUAGAGTTATUUAUTTATTXGGAGUAUTGUTTUTATUT
URGGUAAATTATAAAAGTAAAGTTUTAAGTGUAGTAGGTTGUTAAATUTAUUAAA

SEQ

ID

NO : Sequence

AGUAGTTTGGAAAGUUUUTGTTTATTUATTUTGGTAUTTTTTAAUUA
TGTATTTGTTUTUT

153 GGAGGGUTTUURGTUAGRGTARGUTGRGGGURGGGGGGAGAGGAU
RGTRGRGTTTGTGURGUAGUAGUAGTGRGGGUUUUAGRGUAAURGGGUUUUARG
GTAGUUUUUAGGGAGTGGGAGTRGGGRGGGAAAUAGUTXGUURGGGUUTUUTARG
GGTGUUUTTURGURGRGUTUUUTURGAGGGTUUTTGUAUTRGGRGRTGGAAAGT
GGGATGAGUAAUURGUAGUAGUAGGUUTRGUUUUAGGAUTGUAAUUTAU
RGGUUARGGGARGTUUUTURGUAU

154 GTGRGGAGGGARGTUURGTGGURGGTAGAGGGTUAGGGTUUTGGGRGAAGGUU
TGTGUTGRGGGTTTGUTUATUUUATTUARUGUURGAUTGUAAAGGAUUTRG
AGGAGGRGRGRGAAGGGGUUAGRGUTGGGAGAGGAGACTURGUAGAAGRG
GAUTUUUUAUTUUTGGGGUTAURGRGTGGGUUURGGGTGRGUUTGGGURGU
GGTGUUTGRGGGUUAJAARGRGARGGTUUUTUTURGUUURGGUURGUAGRG
GUTARGUTGARGGTGAAGUUUTUU

155 AGAUAAAAGAGGGGGAGAGAUAGAUAGAAAGAGGGAGAUAGRGGGGUTGG
ATGGARGTGTCGURGGGUAGTGGGAGGGAGAGGAGACTURGUAGAAGRG
GAGGURGRGUTGUTGGGTGUTGAGURGTUURGGGTTUAXGGTRGUAGTTG
TTAUAAGGUAGGUURGUAGUAUTGCGTGUUTAGGGAGGAUTAUUTGG
TGURGGUTGAGAAGGGGUAGTGAGGUURGGTGRGGGTARGGGGGGUAGAT
GUAGUAGGAGGAGGGGGAGU

156 GUTUURGUURGTUUTUUTGGUTGUATUTGUAUURGUURGTAUURGUUA
AUTGGGUUUTTUTUAGUAGGUAGUAGGTTAGGUUTUUTAGUAAUUAAGG
TRGGGRGGUTGGGRGTTTGTAGGUAAAATGRGAUXGTGAAUURGGGARGGU
TUAGUAAAAGGUAGRGRRGUUTUTGAARGUTGTUTGRGGAUTRG
UAUTGGUURGGUUAUARGTUUTUAGGUUURGUAGUTGTUTUUTUTITUTGT
UTUTURGUUUTTTGTGTUT

157 GUTGTUAAAATGAGUTGTTAAUAUTTAAGATGTTGGGATGGUAAAGUTAAAAG
AGUATGTAUAAAATGAUUTUTGGGUTUURGGGAGTGAUTGGTAAUUTUTAGAU
AUAGURGTGGGUAAAAGAATTUTGUTUUTGUTGUXGUURGGAAAGUAUTUT
GGGUUTGUAAAATUATGUATUUTUUUTUUUARGAGGTAAAGAGUTGT
GGGATGAGTAAGGAGGUUTGTGAAGGATTUUTGTTAGUTTAUAGGTUT
GAGTTUUTUAGGAAATUT

158 AAGATTUUTUTGAGAAUTUAGAUUTGAATGTAAGAUTGAAAAGGAAATUUTU
AGGUUTUUTTAUTUATUUUUAAGUTUTTAAUAUTRGTTGGGAGGGGGAGGTG
GGTAGGTGGGTGUAGGAGUAGATGAGTGGUTTURGGXGUAGUAGGAGUAGA
ATUTGCTGGUUUUUARGGTGTUTAGAAGGGTAUTUATGAUTURGGAGUU
GAGGUATGTTAAGTGUUUTTAGUTGUUATUAAUUAUATUTTAAGTGT
AAAAGUTUAGTGTGAUAGU

159 UAGGGUTGGGAGAATAGGATGGAUAGRGTGGGUAGAGUUTUATGGGAAGUTUU
TTUAGGUAGUTGAUUUUTTUAGGGTAGGGAGUATGATUAGGGTTGGGUA
TTGUURGGGAGGGAGGATGAGGATGTTUAGGUUTXGGUTGAUTATGGTACTGA
GTATTAGTUAUTUUUTUAAAGAATUAGGUUUAUTUUTAGTGUUTUTTG
UUAGGAGGUUUTGUUUUATGTTAUUTGUUTGAAGUTUUTUURGGURGU
UUUAUTURGUUAUAGTTGG

160 UAAAUTGTGRGGATGTGGGTGGGGRRGGURGGGAGAGGAGUTTUAGGUAGGTAA
UATGGGUAGGGGUUTUTGGGAGUAAAGAGGUTAUTAGGGATGTTGGGUTG
TGTGAGGGAGTGAUTAATAUTUATUAAUTGAGTUAGGUAGGGGUUTGG
TUATUUTUUTUURGGGUATGTTUAAAATUUTGATUAGTGUUTUUTAU
ATGGGTUAGUTGUUTGAAAGGAAGUTUUUATGAGGUTUTGGUAAAARG
ATUUTATTUUTUUAUAGGUUTGU

161 GAGGAUTAAAAGAGUAGAGATGUTGGTUATTGAAUAAAAAATAAGAG
GGGAGGGTTGAGAGAGGGAGAGUATATUTATGGGTGUTGGAATT
UTUAGGGAGGGGGURGGGRGTGGTGUUTXGUUTGTTATUXGAGU
GGGGUUAAGGTGGGUAAAATUARGAGGTUAGGAGTTGAGAGUAGU
ATGGTGUAAAURGTUTAUTAAUAAAATUAAAATTAGURGGGTGT
UUTGTAATUUUAGTAAUTUAGG

162 UUTGAGTAGUTGGGATTAUAGGUUAUAAAUAUURGGUTAA
AGTAGAGARGGGTGUAAUATGTTGGTUAGGUUTUTUAAUTUUTG
GATTGUUUAUTGGGUUTUAAAAGTGUUTGGGATAAUAGGX
GAGGUAAUARG UUTUTGAGGUUTTAAAATUUAGGU
ATUUTUTUUTUAAUUTUUTUUTTAGUTUTTATTTGTGT
UUTGGUTUTTTAGTUUT

163 UUAGGAGUURGUUTGGGAGRGRGUAGRGUTUTAGGAGUR
GAGAGGAGURGUUTGGGUUTUUTGGGUUTUUTUUTAAGU
UUUTRGUTGGURGGTAAU
RGAGGGAGUTUUTGGGUUTUUTUUTAAGU

SEQ

ID

NO : Sequence

UTTATTGUTTGTGGGAAGGUUUTUUTAGGTAGGGXGAAGGAURGGGAGATA
AUUTUUUATGGGUUAUATURGUTGUATGGTUTGTGTRGTGUAGAAGGTAAUT
UTUAGUUUTUAGTGURGTAAAAAUTGUAAUTUAAGAAGGTRGATTGAUARGUUT
AARGTRGUUAUAGUATTTAGT

164 AUTAAATTGUTGTGRGARGTTAGGRGTGUAATRGAUUTTUTTGAGTGTUAGATTT
TUARGGUUAUTGAGGGUTGAGAGGTAAUUTTUTGUARGAUAAUAGAUATCGUAGR
GATGTGUUUAUTGGGAGAGTTATUTUURGGTUUTTXGUUTUTAUUTAGGAGGG
UTTUUUUAUAGAAGUATAAGGGUTTAAGGGAAAGGAGGUUAGGAGUTUUUUT
RGCTTAUURGGUUAARGGCCUUAAGUAGRGGUUTURGGUTJUTAGAGRUTGRG
RGUTUUUAGGRGGGUUTUTGG

165 GAGGUARGAAGUTGURGGAGUTAUUAGUTTAAUUTUTAGGAAAGATAUAGRGAAT
UAURGUUAATAAAAUAUAGUAAAAGUTRGUUAUTGUTGAARGGAATGGGA
AAATTGUTUTTGTUAAUTATTTGATTGAATTGAGTXGGUATUTGAAURGGT
TUAUTGATAUAAAATAGGAAAUATTTAAUTGTTUTTGUAUUTTAAUAAAATA
GTAGGTTTTAAGUAGTUAGTAGGRGATGTGTGATUAAGGTTUAGAUAGARGUAGA
UAUTGATUAUAAAATUAG

166 UTGAGTGGGTGATUAGTTGUTGRGTUTGTUTGAAUUTTGATUAUAAUTRGUUTAUT
GAUTGUTTAAAAAAUTAUTATTATGTTAAAGGTGUAGAAAUAUGTTAAATGTTU
UTATTGTTGATUAGTGAUARGGTTUAGAGATTGXGURGUUUTAUAAAATTA
GTGAUAGAGAUATTTTUUUTTURGGTTUAGUATGRRGAGUTTTTGTGUTT
TGTTTATTGGRRGGTGTGGUTGTATUTTUUTAGAGGTAAGUTGAGTAGUTURG
GUAGUTTRGTGUU

167 GAUUTUAGUTURGGGTGAUAURGGTGGGRGTRGGGTGTTGUUUTUAGAUAGUTUUUT
TUUTUURGGUTGGTGUAGGTUAAUARGGGGGGAUTAGUUTUTGGTGTGGU
AGTAGUUUUATGUTUURGGGUUTTTGGTTUTTGUAUTGXGURGUUUTAUUUTGG
UTGUUUTUTAUUTTURGGTTUAGUATGRRGAGUTTTTGTGUTT
AATTAAGGAUAGUAUUUUUUUAGUAGUUTGGGUAGTGUAGTUUURGGGATGGGRGU
TUUTAGTRGUUTAGATRGGGU

168 GUURGATUTAGGRGAUTAGGAGRGUUUAUTURGGGAUTGUAGUAGGRGGTUTGG
GAGGGGGTGTGUUTTAATTUTGGUTTGAGGAUAGGTGUAUURGGGAUAGGGGG
AGARGGAAAGTGAGAGGGGUAGUAGGTGATGGGARGGXGUATGUAAGAAUUA
AGGURGGAGUATGGGUTAUTGURGAUAAUAGGAGGTAGTUUUAUURGGTGTG
AUUTGGUAAUUAUAGURGGGGAGGAAGGGAGUTGTUTGAGGUUAUUAURGARGU
URGGTGUUAURGGAGUTGAGGTU

169 GTATUTGTTGUAUUAUAGRGGTTUTUAGUUTGGGUUTUATUAGGGUUTGAAGUUTAU
TAUAGAAUUUUUAUAGUAGUARGTGGGGTGUUAAGUAAAGATUAGGUUTGGAUUA
URGGGTGUUAGGGGGGTGAGGGGGUAGGAGGUAGGGAXGUAGGAGGTGAGUTG
TURGGRRGGGUAGGATGAGGGACTUUTGUATTGUAGAGUTAAGGGGAGAATUA
TUAGUAAUUTAATTAGUTTTGATGGUTTUAAAGUUTTTAAGTUUUTTTTTTT
TTTTTTTTTATUUUTAUAG

170 UTTGTAGGGATAAAAAAAAAAAAAAAAAAAGGAUTTAAAGGUTTTGGAGU
ATUAAGAGUTAATTAGGGTGTGATGATTUTUUUUTTAGUTUTGUATGUAGGAU
TUUTUUTAUUTGUURGGUAGUTUAAUTUUTGXGTTUUTGUUTUUTGUUUUU
TUAAUURGUUUTGAGUUAUURGGUTGTGUUAGGGUTGATUTTGUTGTGUUU
RGUTGUTGGGGTTUTGTAGTAGGUUTGGATGAGGUUAGGUTGAGA
AURGUTGGGTGUAUAGATAU

171 GATTAAUTGUTUUTGUAUAGTUAUAAUTTAGUTTAGTAAUTAAGGUAGAAGAG
AGUUUTGTTGAAGAGUURGGUTTGTTUTGTGTTAAAGAUAAAGGUUTAURGGUTT
UTUXGTGGGUUUAGTGTGAGAAGGGGUUAAGGUUTGGGUTGGAGAAGTGUUUTGU
TTGAUAGAUUUUUUUAAGUTRGGAUTUUAGTUTGUAGGUUAUUTGUAUTGG
TTUARGGAAGAGUTAGAATUTGTTTAATGTTGUAGTGUUUTAUATUTAGUTTG
AAAAGAAUUAAGAAUTTARG

172 RGTAAGTTUTGTTUTUUAAGUTAATGATGGAAAUTGGUUAUATTTAAAGA
ATTUTAGUTUTTURGTGAAUUAAGTGUAGGTGGURGGTGUAGAATGGAAGGTUR
AGXGTTGGAGGGGTUTGUTUAAGUAGGGUAUTGTUTUAGUAGUUTGTGUUUTTU
AGUAUTGGGAUUAAGGAGAAGURGGTAGGUUTGTGUUTTAUUAAGAAUUA
GRGGUTUTTUAAAGGGUTUTUTGUUTTAGTAAUTAAGUTAAGGGTATGAUTT
GTUAGGAGGUAGTTAATU

173 GAUUAUAGGTGTGUTATUATGUURGGTAATTTATATTTTGUTUAUTAT
GTTGUUUAGGUTGGTUTUAAUTUUTGGGUUTAAGTGTATUUTGUUTUAGGU
UUAAAGTGTGGATTAGAGGUATGAGUUAUUTGUAGXGTTGUUTUUTGU
GTUUUUAUARGGAGTTGTTUAGUAGGGUAUTGTUTUAGUAGUUTGTGUUUTTU
UATGUTRGATGATGAUUTGAGGAGUAGAAGGGTGUAGGTGAGTGUAAUTGAGGG
GAAUTGGGTUATGAUAGAG

SEQ ID	NO : Sequence
174	UTUTGGTUATGAUUUAGTTUUUUTUAGGTGAUTUAUUTGUAUUTTUTTGUTUUT UAGGTUATUATRGAGUATGAUTUAUUTTUAGUAURGGUTGAGRGAGGUUAGAAG ATGAUAAAATURGTGGGAUUTGAGGTUAGGAGGUAAAXGTGUAGGTGUTUAT GUUTUTAATUUAAAAUTTGGGAGGUTGAGGUAGGAGGATUAUTGAGUUUAGGA GTTGAGAUUAGUUTGGGUAUATAGTGAGAUUUAAAATATAAAAATTAUURGG GUATGATAGUUAUUAUUTGTGGTU
175	AGGAAGTRGAGGUTTAGAAGTTGGGTGAUTTGTAUAAAGGTRGUUAUUARGGTGAG GGUAGGTTUTGGGAGGUTGAGGGGUAGGUATGGTGAUUAAGTURGGUATGCA GGUAGGRGTCGUAGGUUTGGGGGUAAAAGUUAUAGUUXGTGTGAGGGGTGG GGGATRGAGGUUTTGGGAGGUUTGTGGATTUTGGUTGUAGTGTGGTGTGUAUUT GAGTGUTURGGGAUTURGAGTTAUUUAGGUAUTGGUAGGUUAGGUUARGUTUUU TUUTUAGGTAUTGGUTUUT
176	AGGGAGUUAAGTAUTGGAGGAGGGAGRGTGGGUTGGUAGTGUUTGGGTGATA AUTRGAGTUUURGGAGUAUTUAGTGTUAUAAAUAUTGUAGUAGAATUUAAA GGUTUUUAAAAGGUUTRGATUUUUUUUUUUUUUUAXGGGUTGTGGUTTTGUUU UUAGGUUTGUAGGUUTGUUTATGUURGGAUTGGUTUAAAATGUUTGUUUT UAGGUUTUUUAGUAGGUUTGGUUTUAGTGGGTGRRGAUUTTGUAAGTUAUUU AAUTTUTAAGUUTRGAUUTTU
177	AGUAGRRGUAUUAUUAUUTUATUUTUUUUAUUTUUTUUTUUTGUAGGTGGUU TTTTGCUUAGTGTUTGAGTGUUAUUTUTTGUTUTAGTGTUTGTGTUTURGGUT UTUUTUTTUUTUUTAUTUUTUUTGGGUUTGGGUUTGXGUTUURGGUUTUAGG UTAGAUAAAAGGTTGAATGAAUAGAUTGUTGGTUTGTTUAGTTUUTGTGGUUT RGGUUAUAAAAGGUUTGGUTGUUTUUUUAAAATUTUATUARGARGAGATUATA UAGTAAUTUTGUUUUUTUUUT
178	AGGGAGGGGUAGGTTAUTGTATGATUTRGTRGTGATTGAGAUUTTGGGAGGUA GUUAGAGUTGGGTGGGURGGAGGUUAUATGGAAUATGAAUAGUAGTUTGG TUATTUAAAATTTGTCTUTAGAUUTGGAGGUURGGAGXGGAGGGUAGGUUAG GGAGACTGAGGAGGAAGAGGAGAGURGGAGUUAUAGGUAUTAGAGUAGAGGT GAGUAUTUAGGUUAUTGGUAGAAGGUUAUTGUAGGAGGAGGTGGGGA GGATGGAUUTGGTGGTRGURGTGGUT
179	AAGGTGAATGUTGUAAUUTUTUUTUAGGUUTGUAGURGATUUUTGUAUTAAA TUUTTGAAGTGUAGTGUUTUTTGUATGUAAUUTAUUAUUTAUAAUTGUTGU AAGAAUAAAUAUATGGAUURGGAAUAGAAUTGAXGTGUAAAATGUUTGAGGA UAUTTUATXGAATGTTGGUTGGUTTGATGGGAUTGGUATGAAATGTUAGG AGTUTUUUTUTXGAGGTTUAAGUTTGTTUTGTTUTGAUTUAATGGTURGGATTGAG ATUAGATGAGTUAAGTTUA
180	GAAUTTGAUTATGATUTUAATURGGAUUATTGAGTUAGGAAUAAAAGUTTGA AAUUTXGAGAGGAAGAUTUTGUAUTTTUTAGTGUATGUAGUTUUUATUAAGU AGUUAUATTXGATGAAGTGUUTUAGGUUTTGUAXGTGUUAGTTUTGTTUURGG UUAGGTTGTCGTTUTTGAAAGUAGUAGGTGAGGTGTTAGGTGUATGAAAGAG GUUAUTGAAUTTUAAGGAGTTATGTUAGGGATRGGUUTGUAGGGUTGAGGAGAG GGTTGUAGUATTUUTTU
181	UAGGUUTGUAGURGATUUUTGAUATAAAUTUUTTGAAAGTTUAGTGUUTUTTUUA TGUUAUTUUAAUUTAUAAUTGUTGUUTTUAAAGAAAUAUAAUUTGGAURGGGA UAGAAUTGGAXGTGUAAAATGUUTGAGGUAUTTUATXGAATGTGGUTGGUTTGA TGGGAAGUTGGUATGAUTAGAAATGTUAGGAGTUTTUUTUTXGAGGTTUAAGUT TTGTTTUTGAUTUAATGGTURGGATTGAGATUAGATGAGTUAAGTTUAGATGAAU ATGUAAAATTTAGATGGG
182	UUUUAUTAAAGGTTGUATGGTATUTGAAUTTGATUATUTGATUTUAATURGG UUATTCAGTUAGGAAUAAAAGUTTGAAUAUTXGAGAGGGAAAGAUTUUTGUAUTT UTAGTUATGUAGUTUUUATUAAGUAGUUAUTTXGATGAAGTGUUTUAGGU TTTGUAXGTUUAGTGTGUUTGGGUAGGTGTTUTGTTUTGAAAGUAG GTGTAGGTGGTAGGTGUATGGAAAGAGGUUAUTGAAUTTUAAGGAGTTATGTUAG GGATRGGUUTGUAGGGUT
183	UUTAUAAAUAUUAUTGUTGUUTTUAAAGAAAUAUAAUTGGAURGGAAUAGAAUTGGA XGTGUAAAATGUUTGAGGUAUTTUATXGAATGTGGUTGGUTGATGGGAAGUTGGUATG AUTAGAAATGTUAGGAGTUTTUUTUTXGAGGTTUAAGUTTGTTUTGAUTUAATGGT RGGATTGAGATUAGATGAGTUAAGTGUAAUTGAAUUTTTAGATGGGUUTAAA UAAAATUTGTTUTTAAUAAAATGTGUUTAUAAUAGTTAGTT
184	AAATATAAUTGGTGTGAAUUAUTTGGATGGTTGAGAAUAGATGGTTTAGGU UUATUTAAAGGTTGUATGGTATUTGAAUTTGATUATUTGATUTUAATURGGAUUATTGA GTUAGAAAUAUAAAAGUTTGAAUAUTXGATGAAGTGUUTUAGGUATTGGUAXGTUUAGTT TGTGUURGGGUAGGTTGTGGTTUTTGAAAGUAGGAGGTGAGGTGGTAGG

SEQ

ID

NO : Sequence

185 GAGAGGGGAAGGGGURGAUUAUTGUTUURGAGUUATTURGGGUTRGGUUAGUU
 ATTGGGUTGGGAAUTGTUATUTGGTTGATUTTUUAATGAGUTGTGAAUTGGTUT
 TURGGGAGGAUTTAUAGGAGGUTGCGAARGGGUUTGGXGRGRGUTTUUTUTAG
 TGRGAGGUTGAUTGGTGGAUTRGURGGGUTUTAUTGTGGGUUUUARGUTATGTT
 AGARGUURGARGTGUUUUATTTTATTGAAUTRGTUUTGUUUUUUARGTAGGGARGA
 TTAAUTUUATTTUTAGAT

186 ATUTAGAAAATGGAGGTAAATRGTUUUTAUTTGGGGGUAGGARGAGTTUAATAAA
 ATGGGAUARGTRGGRGTUTAAUATAGRTGGGGGUUUUAGTAGAGUURGGRGA
 GTUUAUUAUTGAGUUTRGUAUTGAGGGAAAGRGRGXGUAGGUUURGTTUUA
 GUUTUTGTAAGTUUUTURGGAAGAUUAGTTUAUAGUTAUTGGAGATUAAUAG
 GATTGAUAGGTUUUAGUUUATGGUTGGURGAGUURGAGAATGGUTRGGGAGUA
 GGTGGRGUUUTUUUTUTU

187 RGGGGGUAGGGAGUAGAUUTGAUTUAGTGGRTUAGTGUTAUTTUAAGRGGUAG
 RGUATTUATTAAGGAAUTGATGTAGAAATTUUUTGGGUTTTGTTGUAAAGAGU
 ATTGUATAAGGAAATTAUAGURGGTTAATTUUUXGTUUAUTGGUAGGAAGA
 GAGAGUAGUUTTAAGAGAGTTGGAUTUTUTAUUURGGAGAATTAAAGUUTUR
 GAGAGUATUAAUTTAAAGTGTUTGGTUATRGTTTAAAGTGRGGTUAGAAGAU
 UUTTGRGTUTGAATGGTTG

188 UAAAUATTUAGARGUAAGGGTUTTUTGAURGUAUTTTAAGAARGATTGAUUA
 AUTTUTAAAATGGATGTUTRGAGGUTTTTAATTUTURGGAAUTGAGAGATUUUA
 AAUTUTGAGGUTGTUTUTTUUTGUUAGTGGAXGGGGAAATTAAURGGUTGA
 TTATTTTTTUTATGUAAATGUTUTTGUAAGGAAAGGGTAATTUTAUAT
 UAGATTTTAATGAAATGRGUTGURGUTTGAAAGTAGUAUTGARGUUAUTGAGTUA
 GGTUTGUTUUUTGUUURG

189 UAGTGTGTTAGAUUTTAAATTUAGGATAATTARGGARGGGAAUTUAGAU
 AGATAUUAUTAUAGTGUUUTUUTUUUUTUURGUUARGUUUUTUURGGTUTUUUT
 AUATUUTGGTGTGUAUTGTGTTUUTGUUATUTUAXGUTGRGGUTUUTAUTAGA
 UUUUUUUTURGGTGUAAAATGUUAAAAGGAAGGGUTGAGTUAUTGUTUTGGU
 GUUAGURGUATAGTUATGUTGUUAUTUUARGAAAAUTUUTTAAUUA
 UAGAGGTUTGAGAUUUUTAA

190 TTAGGGTGTUTUAGAUUTUTGGAGTGGGTGAAAGGGAGGTTTURGTGGAGTTGA
 GUATGAUTATTGRGGUTGGGUAGGUAGGUATGAUTGUUUTTUUTTGGGUATT
 TTGGUAGGUAGGGGTGGTUTAGTAGGAGURGUAGXGTGGAGATGGUAGGGGA
 AUUAGTGUUAUUAAGGATCTUAGGGAGAURGGGAGGGRTGTGRGGGAGGTG
 GAGGAGGGUAUTGATGTATUTGUTGGATTUURGTURGTAATTATUUTGATA
 ATTAATAGGTUTAAUUAUTG

191 GGAAGGAGRGAGGUTTTTATAGGAGUTUUAGTTUUTRGTTTGTTUTTRG
 TTATTUTUUAAAGAACURGGUTUTTGAGTUAGUTGGUAGGAGAGRGAGGRGAATG
 RGUTGGTGTGGURGUAATGGGUURGGTTUARGUTXGUTUUAGUTGGTURG
 TUUARGGGRRGGURGGGUUTGUUARGUTUTGUUAGGAGUUUAGGTUAG
 UUUTTGUUTRGURGGGURGGAGUURGTUAAAATUAUAAAGTUTTTGTGUUT
 UUTTGGARGUTGTATAATT

192 AATTATAUAGRGTUUAAGGAGAGGUAAAAGAUTTGTGATTGGARGGGUTU
 RGGUURGGRGAGGUAGGGUTGAUTGGUTUUTGGUAGAGRGRTGGUAGGUAG
 GURGURGGUURGGTGGAGGAGTGAUUAUTGGAGXGAGRGTTGAUURGGG
 UUATTGRGGGUAGGUUAGRGUATTRGUUTRGUTUTUUTGUUAGUTGAUTUAAGAG
 URGGUTTTTGGAGAATAAUURGAAGAGAAAARGAGGAUTGGAGUTUUT
 TAAAAGAAGUTRGUTUUTUU

193 UTGCTGTGAGGAGGAGRGAUTUTURGTUURGGAGTATGUAGTTUUUUUTU
 RGATUAUTTGGAGGGATTGGGRGGAGTTUTGTUATTGGAGAAAAGGGTUUTGG
 GUTTUAGGTTGTGAGGAGGGAGGGGGGGTTUTGXGTURGGUAGGTTGGU
 UTRGAGGAUUUAGRGUTUAAAATUUTAAUTGUTGTRGGATGTAGAAGAUTRG
 UATTUAUTGUTUTUUAAGTRGGTGAAGGGAGAARGURGAAAAGGGURGUATT
 TUUTGURGGTUUUUTUUUUT

194 AGGGAGGGGAURGGUAGGAGGGAAATGRGGGUUTTTRGGRTTUTUUUTU
 AUTGTGGAGAGUAGTGAATGRGAGTUTUTAUATURGAUAGUAGTTAGGAGGTG
 GGGARGGGUTGGGTUUTRGAGGGUAAAUTGGURGGAGXGUAGAURGUURG
 GUUUTAUUAUAAUTGAAGTUUUAGGAUUUTTUTUAAAATGAUAGAAUTUR
 GUUUAATUUUTUUAAGTGTGUAGUAGGUAAAATGUATAUTUURGGGARGGAG
 AGUTRGUTUUTTUUAUUAUAG

195 GGGTGUAGGUTAUUUTGAAGGGAUUTAUUTUUTUAGGUAUTGUUAUTGGAU
 UTUUUTUAGGUUUTUTAGUAAAGGUUUUATGUATGTUUTGAGATTGTUURGG
 AAATGTGUAUTUAGGGAGGAGAUTUTGGGUAGAGAGXGTATTATAAUAGUA
 AGAUAUTGUAGGUTGUUTAAUUAUTUARGAUAGAGATGARGGGAGUATTUARG

SEQ

ID

NO : Sequence

196 UAUUUUTGUUAAGAGAGTATTAAUAGUUATTAAGGATUAGUAGAGAURGG
TAGTGARGUTGAGTAATGTTTU

197 GAAAAUATTAUTUAGRGTUAUTAURGGTUTUTGUTTGATUATTTTAATGGUTGTGT
AATAUTUTTGGUAGGGTGURGTGAATTGUTRGUTATUTGTRGTGGAGTGTT
TAGGUAGUUTGUAGTGTUTTGUTTTATAAATAAXGGUTUTGTGUUUAAGAGTUTT
UUUUTUTGACTGAUAGTTTURGGAUAAUTUAGGAUATGUATGGGGUTGGAGGAGGTAGGUUUTT
GUTAGAGGGGUTGAGGGAGGGTUUAGTGUAGTGGUTGGAGGAGGTAGGUUUTT
UAAGGGTAGUUTGAUAAA

198 GUUUAURGRGGAGGGUUUUUUTATUUTUUTAUUTGGUTUAAAAGGU
UUAAUUAUTUUTUAGGAAUAAUUTUUTGUUUUUTATUTUTGGGTGTUTUAAA
TGGUAAUUTAUAGGUAGAAUAAAUAUTURGGGUUTUXGTTTUAGTGGUTGACT
AGGAGUTTUGTAGGTAGGUUTGGGUAGUAGAAURGAUAAAUTUTTUATUTTU
UAAAUAUUAUUAUAAUTUAGGAUTGGGTUURGGGUUTGUUAAAATTGUAGG
UTTAGAGTUAGGGTAGGGTGG

199 UAUUTAAUUAUTGAUTUAGGUUTGUAAAATTGGGUAGGUUURGGTAUUUAGTU
UTGAGTGTGTTGGGTGGGGATGGAGATGAAGAGGGTRGGTTUTGUTUAGGGGA
GTUTUUTAAAUTGAAGUTUUTAUTUAGGUUTGGAAAXGGAGGGUURGGAGGT
GGGTTUTGGUTGTAGGTGUUUAAGGGTGTAGAGUAAAAGAGATAGGGGUAGGG
GGGTTUUTCGAGGGAGGTGGTGUUUTGGGTGAGUAGTGAGGATGAGGAGGAT
AGGGGGGUUUTURGRGGTGGGU

200 UTTAATGAGAAGAAUATGTTTUTAUAGUATTGTGAAAGTTGGUTRGAGUTA
RGRGUTGATTAATATUAGATUTUUTUATRGUUTRGUUAUAUTUTGTUAAUATUTG
GUTGUAUAATUURGAGGAUTURGGUAAAAGUAGGXGGRRGGGUUTURGGTU
TGGGRGGRRGGUTURGGAGGAGUAGRGGGAGAUUURGUAGRGGUUTUUTUTU
RGUURGRGGUUUUUAUAGUUTRGURGURGURGUURGGGUUUAGUARGGAUARGARG
GGGRGUTUURGAGARGGGRA

201 TRGUURGTURGGAGGRGUUURGRGGTTURGTGUTGGAGURGGGRGGRRGG
GAGGUTGGGGURGRGGRRGGAGAAGGAGGAGGURGURGUTGRGGGTUTUURGUTGU
TUUTGGAGURGUUAGUURGGGUUURGURGUAGXGUUUTGGUTTTGURGGA
GTTUUTRGGATTGTUAGUAGATGTGUAAGATTGTGRRGAGGRGAGTGAGGA
GATUTGATATTAATUAGRGRGTAGUTURGAGUAAAUTTUAAATGRGGTGTAG
AAAATGTTUTTUTUATTTAAG

202 GTGGTAGGTUTGTGAGGAAUTGAATUUTGTTTUTUUAGUUTTTUUAAAAG
AUAAUUAAGGAGAGUAGGATATGGUAGAGGAGGGTGGTGTUUUUUTUTTGAUT
GGGUUUTGUTUTUAGGUUUAAGGTGATURGGAGATTXGGGTGAGUAGTTTUUT
GATGUUTURGGTAGUUTGGGUAGTGTGUUAGTTTTUAAUATUTTAGTGAUTUA
GTUTTGAUATGGGUAGGATUAGRGGUUAGTGGRGAGGTGGUAGGAGGTAAG
UUAARGAUAAAATGUUAAU

203 GGTGUUAGTGGTGTGGUTTAUUTGUUUAAUTRGUUAUTGGGRGUTGAT
UUTGGUUUATGTUAGAUTGAGTUUTAAGAATGTTGAAAAAUTGGUAAAAGU
TTUAGGUTAURGGAGGUATUAGGAAUTGUTUUAAUXGAATUTURGGATUAAUTG
TGGGGUTGAGGUAGGUUAGTUAAGAGGGAAUAAAUTUTUUTUTGGUUAAT
ATUUTGUTUTUUTGGGTGUUTTGGTGGAAAAGGUTGGGAGAAAAGGATTUAA
GTUTUUAUUAAGAUUTUAAU

204 TGUUTAUUAUUAUTRGTTGGTGAAGAAGATATTRGAGUATGAGUTTATTA
GAGGUUTGRGGRTGTTUUTGURGGGGTTAGAAATTUAAGGATGGGGTTG
AGGGAGGGAGGAGGATATGGUATGTGATGGUAAGGGXGGGUAGGAGGATGGAA
GTAUAGGTUUAAAATGTATUTTGTTGGUURGGUAGAGUTTGUATGGGTGAG
AATGGTAATTAGAAGAGUAGTUTUUTUTGTGAAGUAGAAGAAAAGTGG
AUTTAAGGAGAAGTTRGGGT

205 UAUURGAUTTUTUUTTAAGTUUAAUTTTTUTUTGUTTUAAUAGATGGGAAGA
UTGUTUTUUTAAATTAAUATTUTUAAUAAUTGUAGAGAGUTGURGGGUUAAAAG
ATAUATTGGAUUTGTTAUTTUUTUUTGUUXGUUUTGTUUAUATUAAUTGU
UUUAAUTUUTUUTUUTUAAUAAUUTUUTGUUTTGAAATTUTAAUAAUURGGUAG
AGGAAGRGURGUAGGGUTUTTAAGUAGTGUATGUTRGAAATATUTGTTUAA
UURGAGGTGTGGTAGGU

206 GAGUAAAUTUTUUTTUUTTUUTGGAGGTGGGGAUURGUUUTUATUAGGUUT
GAAGAGGGUTGTGTGAGTTUTUUAUTGTGTGGGTGAGUURGGGUUATGU
UAUAGUTAUUAUAAUATUAAUAAUAAUURGGAUAXGRGUUUTAGGTUUUU
AUTGUUUTTAUUAUATGRGUUUTUAAUATGUATGTGUUUUTTGUAUAUARGUU
UUUTRGUUAUARGUATGUUUTRGUUAUARGUATGUUAUAGGUTUATUTGUTGU
UTGTUUUTGGUTGUTGTGTGUT

207 AGUUAUAGUAGUAGGGAUAGGUAGUAGAGTGAAGUUTGTGTGUATGRGTGTGR
AGGGGUATGRGTGTGRGAGGGGRTGTGUAAAGGGAUATGUATGTGTGAGG

SEQ

ID

NO : Sequence

GGRGUATGTGTAAAGGGUAUTGAGGRGXGTURGGGTGGTG
 TGTGATGTGTGTAGUTGTGUATGGGURGGUTAUUUUAUAAGTGGAG
 AAUTUAUAUAGGUUTTUAGGUUTGAGATGAGGGURGGTUUUUAUUTUAG
 GAATGAAAGGAGAGGGTGGUT

207 UUUARGGGGUAGGUAAURGGAGGGGTGUUUUAUAGAGGATAGAGGARGURGAGA
 AGTGAAUTGGGAGGUATAGGATGAGGAAGAGAGATGAUAGUAGGGUTG
 TAGGAGGTUAUUTUUARGGAGGGGGTGARGGUAGAGGXGTURGUAGGAGUT
 GGTAURGGTGGGGTGUUUUUAGGGGGUTGAUAGAGGUAGUAUTGAGUAGGU
 AGGGTGGAGGTGUUAGUUTGURGTGAAAGGAGARGUAGUAGRGGGG
 UUUTUTGGGTUUUAGTUTGTUT

208 AGAGUAGGAUTGGGUUUUAGGAGGGGUUUURGUTGUTGGRTUTUUTTUARG
 GUAGGUTGGUAUUTRGUTUUUUUUTGUUTGUTUAGTTGUTGUUTUTGTUAGUUUU
 UUUTGGGGUAGUUUUAURGTAUUAAGUTUUTGRGGAXGUUTUTGURGTUAUUUU
 TUUTURGTGGAGGGTGAUUTUUTAUAGUUUUTGUTGTUATUTUTUTUTTUUT
 ATUUTATGGUTUUUUAAGGTUAUTTRGGRTUUTUTATUUTUTGTGGGUUAUUUU
 TURGGTGUUTGUUUURGTGGG

209 TGAAUTUAGGATUUAAAAGUTAGGUUUTGUUUAUUUUAGUUUUTUUAUUTUUTTA
 UUTGGGTGTGUAAUTGUTURGGGGGTGUTUUUUUAUTURGGGUUAAGG
 AUAGGUUTAGGGGAGAGTGAAGGUUTGUAGGAGGUAGGXGAGAAUAGGAGGGT
 GTUAGGGUTAGGGAGGTGURGGATGAAAUUAGUTUTGTGUAGGUTUAG
 GUTUURGUUTGAAUAAAAGGUAGGGAGUUAUAGTUAGGGUAATAAAAATTGG
 GUAUTUTGAAAGUAGUAUTTGGGAAG

210 TGTUUAAGTGTGUTTTUAGAGTGUAAAAGTTTATTGTUUUTGAUTGTGGUT
 UTGUUTTTGTGUAGGRGGGAGUUTGGAGUUTGUUAAGGGUAAGAGUTGGTTTUAT
 URGGUATUUUTAGGUUUTGGGGTGUUTUTGGGUUTTGUTXGUUTGUUTUTGUAGGUUT
 TUATUTUUUTGGGGTGUUTUTGGGUUTTGUTGUURGGAUTGTGGGAGUAUUTUUUURG
 GAGUAGGTGUUAUUAAGGTAAAGGUAGGTGUAGGGUTGGGTGGGUAGGGUTAGU
 TTTGGATUUTGAGTGTUAU

211 UAAAAAAGTAGTTAUUTUAGAAGTUAUTTARGTAAAGAUTATTUUUAAAARGU
 UAGGUAAUTGGATTATUATGTGTATTUARARGATAUAATGGUAAGAAATGTA
 TUATAUTGAGAAGTGAGTGUUUTUTRGGAUATAUTXGTUAGTGAGTUATUAGU
 AUTAGAAUUAUTGGAGATAAATAAAUUAUUTTUTTUTAAAGUTGTGAAATTU
 AAGTGTUATAAUUTAGGUATUTGGURGGGUATGGTGGGUATUTGUUTGTAAU
 UAGUATGAGGUTGAGATGGG

212 UUATUTUAGUUTUATGUTGGGTAAAGGUATGAGUUAUATGUURGGGUATGATG
 UTUTAGGTATGAAUATGAAUTTGUAGAUTGTTTAGAAGAGGTGGTATTATTAT
 ATUTUAGTGTUTAGTGTGATGAUTUATGAGTATGTUURGGAGAGGGUA
 UTUAUTTUTUAGTGTATGAAUATUTGTGUUATTGTATRGTRGTGAATAAUUAGTG
 ATAATUATGTGUUTGGRGTGGGGGUATGAGTUTTTARGTAAGTGAUTTUTGAG
 GTAAUTAUTTATTGAA

213 GTUUTUAAUTTGAUTURGGATAAAUUTUTUAAATATTUAGAUTUTGGUTTU
 TRGTTAAUAGUAGUTUAAUATATGTGTUUTAGUAGTGAUAGATGUTGGUUUAU
 UURGGAGGTGAAUTGUAGUAGGGATTGAGTTGXGGGRGTUATGUUTUAAGGU
 URGGAAUTAGGAGUTTGGGUUTTUUTUAAUTAGTGGGUAAATUUTAGGGUAGGG
 GAGGGGGGUATGUAGGAGAATGGGUUUUUTGGGGGTUTGARGGUAGAG
 ATGUAGAGAAAGAGGARGUUT

214 AGGRGTUTTTUTUTGUATUTGGURGTUAGAURGUUUUAGGTGGGUUATTU
 TUTGGUATTGUUUUUUUTUUUTGUUUTAGGATTGUUUUATATGTGAGGAATGAG
 UAUUAUUTUUTATTURGGGUUTTGGAGUATGARGUUXGUAAUTUATUUTGUT
 GAGTGUUTUAGUUTRGGGTGGGUAGUATUTGUUTGUTGAGGUAAUTATATGT
 GTGAGTGUUTGTAAAGGAGAAAGUAGAGTGUUTGTAAATATTGAGAGGTATU
 RGGAGTAAATGTGAGGAA

215 GAAAGUAGUUTUTUUUTGUUUTGTAAAGGTGATUURGGATURGGGUATTUUUATT
 UTGAAAGGAGTTUTGAAAAGTGUAAAGATTAUTGAGATTUUTGUTTUTGGATUA
 AGUAAUTUUTGAAUATATXGTURGATTTUTAAGGAGATTGTGGUAAAATUTA
 UUTXGTGAGATUAGAAAATGUAGUAGGGATGAAUTAURGGUUTUTUAGAUUTA
 UUAGUUTUAGGUATTUUTAAGGUUTUATUUTURGTUTGTGGUAGTGGGG
 AGGTARGGGGURGGATGGUA

216 TGUUATURGGUURGTAUUTUUUUAUTGUAAAAGAARGGAGGAGTGAGGUTUT
 TAGGAATGGUUTGGAGGUTGAGGTUTGAGGAGGGURGGTATUATUUTGUTG
 UATTTUTGATUTUAXGAGGTAGATTGUUUAATUTUTTTAGAAAATRGGA
 AXGAGATGTGUAGGAGTGUUTGAGTGUAGGUAGGUAGCAATUTUAGTTAATUTGTGUAA
 TTTUAGAARGTUTTUAGAAGTGGGUATTURGGATRGGGGUATUAAUTTAUAGG
 GUAGGGAGAGGGUTGUTTU

SEQ

ID

NO : Sequence

217 AAGAAAAGAGAAAAGUUUATUUAGGTAAAGGUAGUUTGGTGAUTATTAAUUTGGGAGAUTU
UUUAUUUAUATGUUAUTUUAGGTUAUURGAGGGUTGUAGUTTUUTURGGATGGATUUAG
GGXGGUTAUTGGTUUUAGAGUTGGGGUTGAGTGCUURGTGUXXAGGGUTGTGXGUTTG
AUAAGURGGUTUUUATGTGAGUAGGAAGGGRGATGGGRGGGUUARGGUTGUUUTGG
UTUUUUUUUUTGUTGTGUTTUTUTAUTUUUUTGUUUTGUUTUUTAAUAAAAGT

218 AUTGGGTGTTAGGAGGUAGGGUAGGGGAGTAGAGAGAAGUAUAGUAGGGTGGGAGUAG
GGUAGURGTGGUUUURGUUUAUTURGUUUTUUUTGUTUAUAGTGGAGURGGUTTGTUAGA
XGUUAUAGGUUUTGGGUAGGGGUUUAUTUAGGUUUAAGUTUTGGGUUUAAGTAGUXGUUUTG
GATUUATURGGAGGAAGUTGUAGGUUUTRGCGTGAGUUTGGAGTGGAGTGGGTGGGAG
TUTUUUUAGGGTAATAGTGUUUAUAGGUTGUUUTTAUTGGATGGUTTTUTTTTT

219 UTGAGGUAGGGUTGUAGGUTUAGGAGGAGGATGGGTGGAGAGAGAAUAAGUTT
AUURGGAGGTGAUTAUAGGAGAAATGGGUUUTUAAGTATGUTGATTUXGU
UTUATGUTGUUTGTUUTUXGUUUAUTURGGUTUTGGUTUATUTGUTUTTGTAAG
UAGGGTUTGGUTGGGTGUTGUAGGXGUATGGAGAAAGTGGGAGURGGGARGGG
GUAGUTUAGGGUARGUUUTUUAAUTGRGUTURGAGGAUTUAGRGGTTTAUTU
AGGGTGUUAUTGAGGUUAUAG

220 GUTGTGUUATUGTGUUAAAAGTGGAGTAAAURGUTGAGGTUUTRGAGRGUAGTGT
TGGAGGGRGITGUUTGAGUTGUURGTUURGGGUUUUTTGUUTATGXGUUTGU
AGUAAAAGUUUAGGUUAGGUUAGGUUAGGUUAGGUUAGGUAGUAGURGGAGGTGG
GXGGAGAGUAGGUAGUAGTGGAGXGGAAATUAQUATAUTTGAGGGUUUATTU
TUUTGAGTGUUATUURGGGTGAGUTGTGUTTUTUUAUUAUTUUTUUT
GAGUUTGUAGGUUUTGUUTAG

221 GUUAGGUTGGAGGTGUAGTGGGTGATUTGGGUUATGUAAUUTUTGUUTUURGG
GTGUUAGRGATTUTULTTGUUUTAGUUTUUAGATAUTGGGATTAUAGGTGTGTA
UAAUATAUUUAGUTAAATTTTGTTAGTAGAGAXGGGUATGTTAGTUAGGUTG
GTUTTGAAUTUUTGGAUTUAGTGAUTUAGGUUUTAGGUUUAAGTGTGUTGGTAT
TATAGTUAUTGAGGUUATGUUAGRGUUTUTGUTTTGUUTUUTTAGTGUUATUUUAU
TGUUTTGUTTTUAAUATT

222 AATGTTGAAAGUAAGGUAGTGGGTGUUAUTAAGGAAGUAAAAGUAGGURGGG
TGUAGTGGGUUATGAUTATAATAUAGUAUTTGGGGUTGAGGURGGTGAATUAU
TGAGGTUAGGAGTTUAAGAUAGUUTGAUTAAUATGGUXGTUTUTAUTAAAATAU
AAAATTAGUTGGGTATGGTGUUAAUAAUTGTAATUUAGGTATUTGGGAGGU
AGGUAGGAGAAATRGUTTGAAUURGGGAGGUAGAGGTTGAGUAGUUAAGATUAR
GUUAUTGUUATUAGUUTGGGU

223 GUUAUTUTATAAAATGAAGAGUAGAGUAGUTRGAGTGUTTATAUARGTUATTTAU
UUAAGUAGAGAAAARGAAAAGAGAGUUTGAGUATTUUTTGAUTUUTUUA
UUURGGAGGTATATTUAGGTUTUUAAGGUUTGUUTUXGUUUAUTUATGTTA
TGGUURGGTGAGAURGUATUTUUTTUTATUTGUTTGUUUTTTUTGGATGUAGGG
AUUAAGAATUUUUTAAGTGGGAAGAGUTTGAGTGAGGUTGTUAAAGTTUTGT
GGTATTAAATTATAUUTAU

224 TAGGTAAATAATTAUAAAAGAAUTTGAAUAGUUTUUAUUTUAAAAGUTUTTU
UAAUTAGGGGATTUTGTGUUUTGUATUUAGAAAAGGGUAGATATAGAAAGGGAG
GATGRGTUTUATGGGUUATAAAUATGTCAGTGCGXGGAGGUAGTUTGGAGAUT
UTGAATATAUTTURGGGTGGGGAGTUAAGGAATGUTUAGGUTUTTTRG
TTTTUTUTGUTTGTTGGTAAATGAGTGTATAGUUAUTRGAGUTUTGUTUTT
UATTTTATAGAGTGGUT

225 ATTAAGGUAAAATUUAGGUUAAAAGTAGGTTUAGTUTUTATAAGATAAUAA
AAGGTUUTAAATGUUAGGUUTGGGRGUAAUTGTGUAGUAAGRGGGTGGURGGA
GAAGGGGGGGGUUAAGGAAGAGAGGGAAUTUAATTGAXGGTTAUTTTTT
GAGTTTTTURGGTGCGTUTGUUUUUUUUUUUAUAAAATTGTTGUTUTGA
TUUAGGUATAAAAGTGGAGGUUUTGGAGGGGUUUTGAGAUAGRGTUUTGUUAAG
TGAUATGGGUAGTGAUATGG

226 UUATGTGUAUTGTGUATGTGUUUTGTGUAGGARGUTGGTUTUAGGGGUUUTUUAU
UUTUUTTGTGUUTGGGUUAGGUAAAATGAGTGGGGGGGGGG
UAGGUUUAUAGGAAATAAUTGAAAAAAAGTAAUXGTUAAUTGAGTTUUTUT
UTTUUTTGAAUUTUUTUTURGGGUUURGGUTTGUTGUUAGTTG
GGUUTGGUATTTAGGUUUTTGTTAATAGAGAUUGAAUUTAUTTGGuu
TGGAGTTGUTGTTAAT

227 GGUUTGAGAGTGUTGGAAUUAUARGGARGGGGUAGGUUUAUATGGGUUTGG
URGATGAGTGUATUTUTGAGTGGGGGGGGGG
GTUATUUUAUAGGGRATTGTGGGUUURGGGAGAUUXGUTGAGGGATGUTGUAG
TGTAGAAGUTUUUAATUTGAGTGGUTTUTUTUUTUAGTUTUTUURGGUT
TGUUUTURGGTTUATGUUUTGTGGUTGATUUATUAURGGUTUTUARGGUUTT
UTTGGGGGGGGGGATGGUTGGUT

SEQ

ID

NO : Sequence

228	AGUATUUAAUURGUUUAAGGTGAAGGURGTGGAGAGURGGTGTGGATGUUA UAGGGUATGAAURGGGGGUAGUAGRGGAGAGGAUTGAGGAGGAAGAGAAGUA GRGTAGATTGGAAAGUTTUTAUAUTGUAUATUUUTUAGXGGGTUTUURGGGTGU UUUAATRGUUUTGTGGATGAUAGTTAUUTUUUAUTTUAGAAGGGAGARG UUTAGAGAGATGAUTAUTRGGUUAGGTUUUATGGTGGGUTGAUURGTURGGT TGGTTUAGUAUTTUAGAGUUU
229	GURGURGUTTTUAGTUTTGUUAAAURGGTATTUTGRGUTTGUUTUAGUUAUR GUAGGAGGUAGGURGUUUTTRGTUUTUURGTUUTTRGUUUUAAGGAAUURGG GUUURGUUUAUTGRGUAGGTUURGUAGGTUUUUURGGXGTGTUTTUUTGGUUT RGAAUUAURGGGAUAGRGGUTGAGAAUARGRGRGAACGGTGGGAGGARGRGRGG GURGGGTUUUTGGURGTTUTRGRRGGTGUAGUUTGTGUUTGGAGTURGGURGTU UUAAUTUAGAAUAGAGUUAA
230	TTTGUTUTGGTTUTGAGGTGGGARGGGURGGAUTUUUAGGUUAAGGUTGUUAURGRGA GAARGGRGUUAGGGAUURGGGUUAGRGRGRGTUTUUUAUTTURGRGTGTTUT UAGRTGUTGTUURGGGGTRGUAGGGGUUAGGAAGAUAXGUURGGGGGUUTGRGG GAUTGRGGAUTGGGGGUUURGGGTUUTGTGGGRGUAGGAGGARGGGAGGARG AAGGGRGGUUTGRGUUTUTRGGGTGGUTGAGGUAGRGUAGAAATAURGGGTTG GGUAGAUTGGAAAGRGGRGGU
231	UUTGGGAUAGGUTUAATGGAGGUTGUAGGGGUUATUAGURGAUTUUTARGUAGGUT UAGTUAGUAGUUUUUTGGUAGUUUUUUUUTGAUTGURGGUUTUAGAAUTGGGA GUTGUTTUUTGGUAGGGUURGUUUTGUTGGAGAAGURGGAXGGTAGTUAGUUTTA AGUURGGUAUAGAUUUUTGAGGATGGAGUAUAGUTGGUTGUUUTGAGGUTG UAAAUTTUUTUUTRGAGGAGUAGGGAGGUUAUTUAGAUAUTUAAUURGGAUT UUUTTGAAUAGGGAUAGGGAGGAA
232	TTUUTGGGGAGGGGTGAGTGTGAGTGTUTGAGGTGUUTUUTGT UTUARGAGGGAGAGAGTGTGUAGUUTUAGGGGUAGUAGUTUUTGTGUUATUUU AGAGGGGTUTGTTGURGGGUTTAAGGTGAUTUAUXGTURGGTUTUUUAGUAGGG RGGUUUTGUAGGAAGUAGUTUUUAGTTUTGAGGURGGUAGTUGGGGGGG TGGUAGGGGGUTGUTGAUTGAGUTGAGTGTGGGUTGATGGGUUTGUAGUU TUUATTGAGUUTGTUUUAGG
233	AUAUTGTGGGGAGGGAGGGGUATUTTGAGAAUAAAAGATUUATTUTRGAU TUUAAAATGGAGAGUTTUTTGAGAGAAAAGAGAGAGAAGUAGGTUAJGGTUUARGU AUUAUAUAUAGUUTGTGUUAUAUAGUURGGGUUAAGGXGTUUUAUAGGUAGTTR GUAGUTGUUATTTGTGAAGTGAATGUTGATTGGGGURGGGGTTRGTUTG TAUATRGGUATGTUAGAUUUTTUTGAAGGATTGGTATTAUTGAAGTATUAGAAG GUUUTGTTUTAAGGTGGTG
234	AUUAUUTAGAAUAGGGUUTTUTGATAUTTUAGTAUAAAATUUTUAGGAAGG GTUTGAUAGTGUARGATGTAUAGARGAAUUUAUURGGUUUUAAAATUAGUAAU AUTTUAAAATGAGUAGUTGRGAUTTGUUTGTGGAXGUUTGTGTURGGTUTGT TGUUAAGGGUTGTGTGGGTGGRTGGGUUTGTAAUTGTUTUTUTUTU AGAAGUTUTUAGTTGGAAAGTRGAGAAATGGATUTTTGTTUTUAAGAGATGUU UUTUUUTGUUUUAUAGTGTG
235	AUUAUARGGGGUAGGGGTUAGAGTAATGGAGTGGAAATGGUAGGTTUUAATTTG GUTUAUAGUTGUUUTATUTUAGAAUAAAAGGUTURGGGTGGAGGGTGGRAAUU UUAAGATGRGGGUUTUAGURGGGUAGXGTGTGGUTUAGUAGXGATGAAGXGAGTG UAAAGGGUTGTAAUAAARGRGGGUAUTGAAUAAAATGAGRGTGURGTUUAGAT GTUURGGGGAGGGUTGAGGATUUUAUURGGGGAGTGTGUUTGUUUUATGGAGT GAUTGGRGUTGUUUTUARG
236	RGTGGAGGGRGCGARGUUAAGGTUAUTUATGGGGGUAGAGUAUTUUUARGGTG GATUUTUAGUUTUUUURGGGUATUTGGARGGUARGUTUAGTGTGTTGTTUAGTGU TRGRGTTGTAUAGUUTTGTUTTUTGUTGUUTAXGGUTGGAGUAAAAXGGUR GRGGUTGAGGURGUATUTGGGTGUUUAUUTUAAUURGGGUUTGGGGTGU AGAGATGGGAGUAGUTGTAGUUAUAAAATGTGAAUUTGUUATTTUUAUTTA UTGAUUUUTGTUUUURGGGGT
237	RGAGGTGRGGUTGUURGRGGUTTUUTRGGUUTUURGTUURGRGTGUTTUUTGG GTUUUUTUTRGAGGUUUTUUTGUUTUURGTGTGUUUTTUTUATGTUUAGUA TTRGGGRGUUTUTGTUTTUTGUTGUUTGGUTTXGGTAGTGAUTGGAGGTGTGA UTUURGUAGRGGGTGUAGUTTUTUUTGAGTGAUTGGAGGAGGUUURGU TUURGGGUARGTRGUUAGUUTTUTUUTUTUUTAGGUTATUAAGRGGAUTTAT GAUAAAGAAGRGGTGGAT
238	ATUUAURGUUTTUTGTUATAAGTURGUTTGATAGUUTAGGGAGAAGAGGAAGAG GUTGGRGARGTGUURGGGAAGGRGGTTUUTURGGTUAUTUATUUUAGAGGAAA GUTGUAAUURGUTGRGGGAGTUAUTUURGGGARGUXGAAGUAGGGAAUAGA AGAAAGAAAGAGGRGUURGAATGUTGGGUATGGAGAAGGGUUAARGTGGAGGU

SEQ

ID

NO : Sequence

GGAGGGUUTRGGAAGGAGGAUTUUAGGAAGUARGRGGGARGGGAAAGURGAGG
AAGURGRGGGUAGURGUAUUTRG

239 TGUAGTGTGTAUAGGAUTUUTGAAAGGGUTUUUTGGATGGAGGGTTTTGGGG
GGUUTCTGTTTUTTUUAGTGAAGTUAUAAAUAUTUUTUAUAGTUAUGRG
ATUAAAURGATTGAURGAGATXGGUTUTTUAAUTGXGGTUTUURGGGGTUUUR
GAGGATUTGGUTGAAUTTUAGACTAAUTGAGUAGAUAGUAGTAUUTUAURG
AUTRGAATAUAUAGTAGAUUUTGUUUTGTGGATUUAAGGUTAGGUATUUTGTGA
GUTGATAGTTAGGTGGGUTGT

240 UAGUUUAUUTAUATUAGUTUAUAGGATGUUTAGUUTTGGAUUUAAGGGUAGG
GTUTAUUTGTGATTURGAGRGGTGAAGGTAUTTGUTGGTUTTGUTUAGGTAUTUTG
GAAGTUUAGUAGATUUTRGGGGAUAAAURGGGAGAUXTGAAGAGAXGATU
TRGGUAATRGGTTGGATURGGUTGAUTGTGGAGGATGTGGTTGTGAUTUATGU
TGGAGAAGAAUUAUAGGUUUUUAAAAGUUTUATUUUAGGGAGUUUTTUA
GGAGTUUTGTGTAUUAUTGUAU

241 AGGAGUUTGTGAUUAAGAAATGGTAAGTAAGGTURGATTUTUAUAAAAGUAG
GUATGAUUTUAGAUAGTUUUTAUUUTGUTUTGGUUTUAGTTUTUUTTAGTGA
GGAGGTGGGTGAGGGTUTGTUUTUUTURGGGAUTGGXGATTTGGGAAGGUAGAG
AUATTUUUAAGAATUXGURGGAGTUTGAAAAAUUUARGUUUTTTGTUUUAGUAT
UUTGAGAAAGGUUAUATGATAAAGUTGTGGGTGGUAGATGAUAGUATTUTTGG
UUTUAGARGAAGTGGGAGGG

242 UUUUUUAUTRGUTGAGGUUUAAGAATGUTGUTATUTGGUUAUUUAAGUTTA
TUAGTGTGCUUTTUTUAGGATTGUTGGGAUAAAAGGGRGTGGGTGTTTUAGGAUTU
RGXGGATTUTGGGAATGTUTGUTGUUTTUAAAATXGUAGTTUURGGAGGGAGAU
AGGAUUTUAAUAAAUTUUTUATAAAGGAGAAAUTGAGGUUUAAGUAGGGTAG
GGAUTGTUTGAGGTUATGUUTGUTGUTTTGTGGTGAGAATRGGAUTTAUTTAAUATT
TUTGGGTUAUAGGUTUUTT

243 AGUUTGGUTGAGTGUUUUUUAUTTUUTGGUTRGAGTTUUUTUAUGAAAAAAUUT
GGTGAUTUUTUUTGUAUAGAAUAAAAGGUTGAGTGAGGUUAGTGUUUUAGGGATG
AGGAAGGUTGAGURGGGAUAGGUAGGGAGGAUUTGUXTGUAUTUAUTUAGAU
TUUTGUAGUAGURGGGUAGGTGUUTUAAUAGRGGGGUAGURGUTUAGRGUUT
UUTUATUURGURGUAGUAGTGGATUAAUUAAGUTGTUAGAGAGGUUUAUUAUTT
GGUUAURGGGTUTARGUUTGUAGA

244 TUTUAGGRGTAGAUURGGTGUUAAGTGGTGGGUUTUTTGUAUAGUTGTGGTGT
UUAUTGGUTGRGGGGGATGAGGGAGGRGGUTGAGRGUTGTGUURGUTGGTGG
UAUUTGUUURGGGTGUTGUAGGAGTUTGAGTGAUTGUAXGGUAGGTTUUTUUTGU
TGGTURGGUTGUAGGTTUUTUUTGUUTUUTGGGUAUTGTGUUTUAUTUAGUUTTG
TTUTGTGUAGGAGGAGTUAUUAUAGGGGUUTGGGAGAGGAGGTGAGT
GGGGGUUAUTUAGGUAGGG

245 UTUTGGGUTUTUUAUAGGGTGAGGUUAGAGUTATTUAGAATUURGURGGAG
GGGUUTTGUUTGGAGGGGUUAARGAUAUTTUTTGUTUUUAUAGUJGAUTG
AGGGUTGGGTTGGGUTGGGTUAUAGTTUAGTGUUTGUTUAGAGATGTTUUR
GGAATAGUTGAGTUAUUTGGGUUAGGGGUUTGGGAGAGGAGGTGAGT
GGGGTGAGGUAGGGGUUUAUUTUUTUUAAGUTAAGGGUTTTUUTGGGTG
GGUTGGGUUAUUAUTAGGGU

246 GUUUTAGGTGTGGUUUAUAGGUUUAUAGGAAAAGGUUTTAGUTGGAGAGGAGG
GTGGGGGUUTGUTUUUAUAAAUTUAAUTUUTUUTUUAUTGGGUUUUUUTG
GUUAGGTGAUTUAGUTATTURGGGAUATUTUTTAGAGXGAGUAUTGAAUTGTGT
GAUUTAGGUAGGUAGGUUTURGGGGATTUTGAGAATAGUTUTGGUUTUA
AAUUTGTGGAGAGAGGUUAGAGU

247 RGUUUTGGGUTUTGGGUTTUAAAURGUUTGGGUUUTGUTGGAUTUTGUAGUTG
TGTUUUAAGGUTGRGUUUTAGATTGTUTAUTUUTUUTGGGUUUUTGGGU
GUUTGGGUUTGGGATGUUUUATGUTUTGTUTGTGAUTGUUTTAUTUTTGAT
UAUUTGATGGUTGUAGGUAGGGAGGUAGGGGUAGGGGAGGTAGAUA
ATGTUUUUUUTTGUUAU

248 GGTGGUAAGGGGGAUATGTAGAGAAUAGAGGAUTTGGGGTTUTGUUTGUAGUTG
GAGUAGUUAUAGAGGTGATUAAGAGTAAGGUACTUAUAGAAUAGAGUATGGGU
ATUURGGGGAGGGAGGTGUATGGGUUUAAGGUAGGUAXGTAGGTGGAGGAGUAG
GAAGAUTAUAGAGGURGGGAGAAAGUAGGGAGGGGUAGGGGAGGAGTAGAUA
AATUTAGGRGUAGUUTGGGUAAUAGUTGUAGAGTUUAGUAGGGGUUUAAGGRG
GTGGTCAAAGGUUAGAGGUAGGGR

249 TTTUUTUUTUTTUUTTUUTUAGTTUUTUUTUUTUUTUUTUUTUUTGTTGA
TTTTAGGUUTUTGATTTTUTTUUTUUTUUTTATTUTTTUATUUTUT

SEQ

ID

NO : Sequence

UURGGTUUTTTTUTGUTTGUAUUTUUTTXGTTTUTTUTUTGGUTGAUTU
AGGGGAURGGAGGTGGGUATUTGGAGTGAGTGAGTAAGTGTGAGGTGAG
GGTAGGGGUTGGAGGGGUAGTGATUTGGUUTGAGUUUUTUAGTATTGUTUUA
GUUUUAGURGUAG

250 UTGRGGUTGGGUTGGAGUAATAUTGGAGGGUTUAGGUAGATUAUTGUUUUU
TUUAGUUTUAAUUTUAAUUTUAAUAUTTAUTAUAUTUAUTUUAGATAGGUU
UAUTURGGTUUTTGAGTUAGUAGAGAGAGAAGAAAAXGAAGGAGGTGAUAAA
GUAGAAAAAAAGGAURGGAGGGATGAAGAAAATAAAGAGTGAGAAGAGGA
AGAAAATUAGAGGUTAAAAATUAAAAGTGAAGGAGGAAACGGAGGAUTG
GAGAAGGAAGGAAAGAGAGGAGGAA

251 UTATAUTUTUAGGUUAGGUAGGGRRGUAGUTGUUUUUUTUAUTGUUUUARGU
AUAAATUUUTGTTUAGTUAAAURGUTAUTGTGAGUTUAGATUTGGTGGGU
URGGAGUUTUUTAATAGUAAUAGGTGGGATGGUUTTGXAAGATAAGUTUTG
TGUUUUAGUUUAGGUTGAGUURGGGUUTGUUUUAGGUAGUUTGUUAGGAT
GUTGIGUATGTTTGUAUUTTGUAUUTGUAGUAGATGGGUATUTGTGGAGU
TGUUUTTTUTUUTTAGAATGA

252 TUATTUTAAGGAGAAAGGUAGUTUUAAGATGGUUUATUTGGUTGUAGTGGG
UAAAGGTUAGAAATGGUAUAGUAUTGGGUAGUTGGGUAGGGUURGG
GGUTAAGUAGUTGGGUAGGUAGAGUTTATUTTXGUAGGUUATUUUAU
UTGGTGTAAATGAGGAGGUTRGGGGUUUAUAGATUTGGAGUTUAAAGTAGRG
GTTGGAUTGAAAUAGGGATTGTGRGTGGGUAGTGAGGGGGUAGUTGURGUU
UUTGGUUTGGGUUTGAGAGTATAG

253 ARGGGTGTUTGUTUUUAAGUTGGGUUUUUTUUUUAGGUTGTGGGAURGUTGG
GUUATTUTGAUTRGAAUAGAAATAGUUURGAUAAAATUTTUTUURGRGUU
UUAGURGGAURGUUURGGGUUUAUAGUAAAUAUAGXGTURGGUATAGGU
UTUUTUUTATTGUAAAURGUTAGGGGAGAUAAGAGAGGATGGGGTUURGGGAA
UATGUTGGGTRGUAGAUTATGGGARGTAGGGRGTAGUTUAIUTGTTGGAGAU
GGUURGUTUUTUAUTGGUTGAGTU

254 GAUTUAGGUAGTGAGGAGRGGUUTGUTUAAAAGGTGAGUTARGUUUUTARGT
UUUATAGTUTGGRGAUAAAAGUATGTTUURGGGUUUUUTUUTUTGUTUUUU
TAGRGGTGTGUATAAGGGAGAGGUUUTATGURGGAXGUTGTGGUTGGGU
TUURGGGGGRGGTURGGUTGGGGRGRGGGGAGAAAGAGGGGGTRGGGUAT
TTTGGTTRGAGGTUAGAATGGUUUAGRGGTTUUUAUAGUUTGGGGAGGGGG
UAGUTTGGGAGUAGAUAAURG

255 GAAGTAAAAGTUUTATTGTAUAAAATATAGRGRGGGUTGGGGGGGGGTUAA
UUURGGGTTUUTGGUARGGGAUAGGGRGRGUTGGGUURGGUTUTGUAGRGAUR
GGTGGGAGGGUUTAGTGTGGGUUAGGRGGTGTGAGUAXGGGURGGGGRTUA
TAGURGGGGAGGGURGGGUAGRGAGRGGGTGGRGAGGGGRGACTUATGUTG
UURGUURGGAGGGAUUURGRGGGTGAGGARGTGGGTGGAGGGAGARGTGGG
AGUTAGTRGGAGTAGATGATGAA

256 TTUATUATTAITURGAUTGAGUTUUUARGTUUUTUUAAAARGTUUUTUAAU
RGURGGGGTUUUTURGGRGGGGUAGARGATGAUTRGUUUUTRGUUUAAURGUT
RGUTGUURGGGUUUTUURGGUTATGARGUUUURGGUUXGTGUTUAAAURGUUTG
GUUAAGUTAGGUUTUUTUAAURGGUTRGUTGUAGAGURGGGUUAGRGRGUU
GTUUURGTGUAGGGAAURGGGTTGAURGUUURGGUUAGUURGRGUTATATT
TGTAUATAGGAUTGTTAUTGU

257 AGTTATTTAATAUATGUUUUAGTGGUAUTAALUTGTAUTAAGUUTATGTTU
UATUUTAAATGGAGAAUAAAATUATUUTGUTGUAAAATUAAAATUAGAGGT
TTUTAUAGRGTGAURGAUTGTGUUURGGAGAGTTXGGUUTUTUUTGGUTUTG
GUUUTGGAAUARGTGTGUUUAGGUAAAAGTGUUAAAATUUTGUTUTAUAT
GUUTUARGAGAGTUAUAAAAGATTGGTACTGAGUAGAGGAUATAGAGGAGT
GGGAUTGGTAAAGGGAGT

258 UTUTUXGTTAUUUAGTGUUUTUUTGGUTUTGGUUUUTGGAAUARGTGTGUUUAGU
TTGIGAUTUTRGTTGAGGUATTGTAGAGUAGGGTGTGGUAUTGTTGGUTGGGUAT
UARGTGTGUUAGGGGUUAGGUAGGGAGAGGGGUUGXGAAAUTUTURGGGUUAGT
GTRGGTURGUTGTAGAAAUTUTGATTTGGATTTGUAGUAGGTATGATGTTGG
TUTUUTTTATGGAGAGGUATGAGGUTTAGTGAGUAGGTTAGTGUAUUTGGG
UUATGTATTAATAAUTG

259 GAGTTXGGUUUTUUTGGUTUTGGUUUUTGGAAUARGTGTGUUUAGU
UAGTGUUAUAAUUTGUTUTAUATGUUTUARGAGAGTGUAAAAGGATTTG
AGTUAGAGGAAATAGAGGAGGTGGGAUTGGTAAAXGGAGAGTGUUT
TGGAGGTGGGUUAJGUURGGAGTGATGAGGGGUUAGAGTTGUAGAGGAUARGA
ATATAGATUTGTTGTGAAGUUTUAGATATTUTAATGTTGAUARGAAUTAAAATT
GAAAAAAATAAAATUAATA

SEQ ID NO :	Sequence
260	ATTGATTTTATTUUUATTGATTTGTGUAAUATTAGAATATUTGGAGGUT TUUAUUAUAGATUTATATRGTTUTUTGGAAAUTUTGGGUUUTUATTUAUTURGG GUTGTGUUUUAUUTUAAAAGGUATGGAUTUTUXGTTAUUUAGTTUUUAUUTUT UTATTGTUUTUTGAUTAAAATUTTGTTGTAUTUTRGTTGAGGUATTGTAGAG UAGGGTGTGUUAUTGTTGGGUTGGGUATUARGTGTUUAGGGGUUAGAGUAGG AGAGGGUXGAAAUTUT
261	RGGGTGRGGAUURGUUAUUTGURGUAAUUTUUUTUUUAUUTGUUUTTUUUU AUUUUAUUAUUTUUUAUUAUUAUUTGGGUUTRGGGUUUUAUTUURGAUUT GUUTGUURGGGUAUUTRGGGRGTRGUTRGCGUTTXGUUTUUAUTGUUURGG UAGGRGRGRGTTGGGUTRGGRGTUURGRGUUUUTUUTRGAUTGTGRGGUTUURRG UTGURGGGTTUUTGTTUAAAATATAAUAGGGAGGUUURGGGGAGAGRGRGURGG GUAGAAUTTUUTUURGGAUTG
262	UAGTURGGGAGGAAGTTUTGUURGGRGTUTURGURGGTGUUTUUUTGGTTATATT GTTGAAUAGGAAAUURGGUAGRGRGGGAGURGUAAAGTRGAGGGAGGRGRGGG ARGURGAAUURGRGRGUUTGURGGGUAGTGAGGXGAAGURGRRGAGRGGA RGUUURGAGGGTGUURGGGUAGGGTGGGAGTGGGAGTGGGURGAGRGGGGTTG GGGGTGGAAAGTGGGTGGGGTGGGAAAGGGUAGGGTTGGGAAAGGGAAAGGGT RGGUAGGTGGRGGGTURGUUAURG
263	GGUAAGGUAGTUTGGGRGURGTUTURGGTUTRGGGGUUTRGGRGGGUURGRG GTGURGRGTTAGGGURGGTUGUTUUUTRGGAATTAUAGGGGRGUUTRGGRGUUTG RGGRGRGUUUUURGGGUAGRGUURGGUTGGTTGGAGGXGTTAAATTGAAAGUAG UTTGGGAGAGGGGGGARGRGGGURGURGAGUAAGGGAGGGGGRRGUURGG UAUAGRGAAUUAUTGUTGTGUURGURGAGGGTGGAAUUTTGRGGTGAGUTRG RGGRGUUUUUTUURGAGU
264	GUTRGGGGAGGGGGGRGURGRGURGAGUTUARGUAAGGTUUUUUTRGGRGGG UAUAGUAATGGGTRGUTGTGUURGGGUUUUUTUUUTTGUTRGGRGGUURGR GTURGUUUUUTUUUAAAAGUTGUTTTUATTAAAXGUUTUUAUAGRGGRG UTGUURGGGGGRGRGAUURGAGRGURGAGRGUUUUUTGTAATTURGUAGGGAG UTGAURGGUTUAARGRGGUAURGRGGTGUUURGAURGUAGGUUURGAGAURGGA GARGGRGUUUUAGAUTGUUTTGU
265	GGAGGGAGUUTGUAUTUTGGUAGTGATGTGGAGTUAGAGATTUUAAGTTUATGG TGUAAGTUTGTGGAGAGUAGAAUTUAUTTTAUAAAATTGTTGAUAGURGGTGTG TTAGAGRGAAAGGGAAUAAAURGGUTUUTUUAAGGXGTGGAGTUTGTGGGAT GTGUTUUAAGAAAATGUAGGGTTAACGUAGGAGUTGUAGAGTAGAAUTUAATGAUA ATGAUTUAUTGUTGUAUTAAUAGGUTUTTGUTGGGUTGTAGGTGGAGGRGAT ATGGURGGUAUTTRGUUAAA
266	TTGTGRGAAGGTGURGGUUAATRGUUTUUUAUUTAUAGUUUUUAAGAGUUT GTTACTGAUAGUAGTGAGTUATTGUTTGTGUAGUTUUTGUTTAU UUTGUATTUTGGAGUAUATUUUAUAGAUTUAXGUUTGGAGAGGAGURGG GTTGTUUTTTURGTUTUTAAUUAUURGGUTGUAUAATTTGTAAAGTGAGTTU TGUTUTUUUAUAGAUTGUUAUATGAUUTTGAAATUTTGUTGUAUTUAUATUAUTGU UUAGAGTGUAGGUTUUUTUU
267	GTTUTGGTTRGGUAGAGTGGGGUATUTGUUTUTUTUTAGAAUAUUTAAAGA AGUAGTGAAGTGAGUTGUATGUUAUURGGGAGAUUTAUAGRGGAUTUAGGA GGAGRGGGAGUTATGUTGUUAUUTGUAGGGGGTGUAGGGGGTGTGAGAAGTGAGG UUAAUTGUUAUTGGTGUURGGGGGUAGGGGGTGUATGGAGGAGGGGGRRGGGG AGGTGTUTGGAAUAAGGGATGUTGGTUTUAGGTGGUAUAGUTGGGAGAAAAAA UTATUUATTGUAAAATUATTAG
268	TAATGATGTTTGUATGGATAGGTTTTUTUUUAUAGUTGTGUUAUUTGAGAUAG UATUUUTGTGUUAUAGUAAUTGUUURGGUUUUUTUUTUUATGGAUUUUUTGUUU URGGGUAAUTTAGGAGGGTGUUTUATTTUUTATUAXGURGGGTGAAAGTG AGTUAATGAGUTUURGUTUUTTGATURGTUTGTAGGTUTUJGGTGUATG AGUAGUTUAUTUATGGUTUTTAGGTGTTUTAGAGAGAGGUAGATTGURGU UAUTUTGURGAUUAAGAAUA
269	RGTGATUAGAGAGUAGAAATUAGUTUUUUUTUUTUUTAUTGAGUTGTGUUAUTT TAAGTATAAUUTGTGUUTGTGUAGTTUUAUATAAUAGUUTGAGTTTATUR GGGGUTTATUTGUTGUAAAATUAGTTGXGGGAATGGGUUAGGGAGAG AGUURGGAUTTAUTURGGUTGTGGTGAUTUARGUUTTGGAAGGGUTGAGGTAT TTGTUUTTGGATGTGGGATGUTGTGGUUTUTGGTTGGAAUUAUAGUUTRGTTTGT UTGUTGGUTUTGGUTTU
270	GGAAGUUAGAGUUAUAGAUAAAARGAGGUTGTGUUUUAUAGGGGUUAJGU ATUUUUUAUTUUAAGGAUAAATAUTUAGGUUUTUUAAGGRGTGAGTUUAU AGURGGAGTAAAGTURGGUTUTUUTGGGUUATTUUXGUAAUTAATGAAGGTT TTGGUAGUAGAATAAGURGURGGATAGAAUTUACGGGUTGATTATGGTGGAAUTGG

SEQ

ID

NO : Sequence

UAUAGGAUAUAGGTATAUTTAAAGTGGUTAUAAGUTUAGTGAGGGAGGAGGGAG
GUTGATTUTGTUTGTGATUARG

271 UAGTATGUATGTG TUATTAAAGGUATUTGAGUUUTGGUUTTGUTGTTUTTUUTTU
UTTUTTImURGTRGGGTGUTGAGUTUAUATUUUAURGGGUTUTGUTUUTTAGU
TAGUAGTUAGTGUAGAGUTGUTGGGTUUTTUUGUUTXGUTTGGGUAGGUTTUTGTU
AATAGGTUAAAAGUAUARGGAAATAAGTGUAUAGGAAGGAGUAGGTGCUAAGAU
UUTGTGGAGGTAGAGAUAUTTUATTUAGTGAGTGAGUTGTGAUTGUAAAATTGG
AAGGTTUTGGGGAGAAGUAA

272 TTGUTTUUUUAGAAUUTTUAAAATTGUAGTUUAAGUTUAUTUAUTGAATGGAA
UTGUTUTAUUTUUAUAGGGTUTTGUUAUTGUTUUUUTGTGUAUTTATTUURG
GTGUTTGTAUTGUAGAAGAAGUTGUUUAXGAGGUAGAGGUAAUAGUA
GUTGUAGUTGUTGUTAGUTAAGGGAGUAGGAGUURGGGTGGGATGTTGAGUTUAGU
AAUURGARGGAGAAGAAGGAAGGAAGAUAAGUAAGGUUAGGGUTUAGATGUU
TTAAATGGAUUAUTGUATAUTG

273 RGGURGRGGGGGRGUUTGGAGGAGGAAGUUTUTRGAGGAGAAGAGUTGGGR
GGURGURGTAGGAGGAAGRGGAAAGATAAGGGGUUUTRGUTRGGRGGGURGUR
GGARGUUUAGGAGUUTUATGGGAUARGTRGGGTGGGAXGGAGGUAGUTUUTG
TURGGAAURGAAUURGRGAGGUUAGGAGAGRGGUAGUAGRGRGGUAUAGU
RGCGAGUTRGGGGUUARGURGGGUUTARGGAUATGGGUTRGGAAGGGUAUAAA
URGGURGGAGTUAGRGUTGGAGGU

274 GGUUUAGRGUTGAUTURGUURGGTTTTGTUUTTURGAGUUAUTGTURGTAGG
UTURGGRGTGGGUAGUTUURGGUTGTGURGRGUTGGUTGURGTUTUUTGG
UUTRGRRGGTTTRGUTGTURGGAUAGGAGUTGUUTUXGTUUUUUAURGARGTGTUU
UUATTGAGGUTUUTGGGRGTURGRGGGUURGURGAGURGAGGGUUUUTTATUTT
URGUTTUUTUUTARGGRGGURGUUAGUTTUTTUUTURGGAGGUTTUUTUUT
UUAGGRGUUURURGRGGURG

275 GUATUAUAUATUUUTUUTGTUTUUTGUTGUUAUUAUTGTTUAAUUAUTGTUUAAU
TUTGUUUUAATTUUAUTUUUARGUUTGUTGUTGUUAUUTGGAUTTGTUTTUUTGAA
ATTGUATGUATUAUTUUTUUTUTAUTUTGUTGXGTUUUTUTGUUUTATUAGG
AUUTGTTGAUTAGGAUTUURGGGUTTTUTUUUUUATUTUTUTUUURGTTGGGUU
TUAUTAUUATTUAGUUAUTTUTGUAGUTUAUTUUTGUUUUAAGAUUUUAGU
UTTUAUUUTUUTGGTTUT

276 AGAAUAGGAGGGTGGAGGUTGGGGTUTTGGGUAGGAGTGAAGUTGUAGGAA
GTGGUTGAAATGGTAGTGAGGUUUAARGGGGAAGAGAGATGGGGAGAAGUURG
GGAGTUTGAGTUUUAAGGTUUTGATAGGGUAAGAGGGAXGUAGUAGAAGTAGAA
GGGAGAGTGGATGGUATGUAAUTTGUAGGAAAGAAGTUUAGGTGUAGUAGUAG
RGTGGAGGTGGGAATGGGUAGGGTGUUAUTGGTGGAAUTGGTGGUAGUAG
GGAGAUAGGGAGGGATGTGTGATGU

277 GGTGGRGATGUTUTAGUUUAUTGUTTUTGTUUTUTTUUAUAAAATGTATUUTGU
TTUTTUUAAGATGTURGGUTTAATGGGATGGATTATUTUAAAAGTUUUTGGTTTG
UUTUTGATTAAAAAUAGTGTGUTUUUATGGTAXGGARGGUTGTGUAGGTTTTG
TTTGTGAAGGGAAUTGGUTUAUTUTGAGTGUAGURGTGUAUURGGGUTGUTGATGT
AGTUTUAGTGTGATGGTAAATTAAAGTGTUATTGUAUTGGGUTAAGGAATGUUA
GAUATTATTURGG

278 UURGGAATAATGTUTGGUATTUUTAGUUUAUTGUAUAAATGUAUUTTAAGTTAA
UUATUAUAUTGAGTAUATUAGUAGUURGGGUAGUTGUAUTAGAGTGA
UAUTGTTTUUAUTGAGGUAAUAGGAUTTTGAAGATAATUUAGTUUUATT
AAGURGGUAUTGGGAAAGAAGUAGGATAUATTGTGTGAAAGAGGAUAGAGAAG
UAGGGUTAGAGUATRGUUAUU

279 GGTGTTGGGTGTTGGAUATUUUTGGAGGGUTGTTTAGTGUUUUAUUAUTGUUUTAG
TTAAAGAAUUAUUTGTTUUTTAGUUTTGUTGUAGGAGGTGGGAAAGGGURGG
GTGTUTGGTUTGUTGUUAGGGGUAGGTGUAGGTGTGAUXGTURGGGUAGAGATGA
GTUAAUUTUUAUTGUTTGUTGUURGUTUURGAGUUTAGTTTAGUTRGTTGGT
UAAGAAGGGGRRGATTUUTUUAUTAGAAUUAUTGGGUUAATGUTAUUTTGAAA
ATGGAAUAAAATAAUUU

280 TGGGTATTGTTTGTUUTTUAAGGTAGUUAUAAATGGATTGGTGTGAUUU
AGGAATRGUUUTTUTGAUUAUARGAGUTAAAATAGGRGTGGAGARGGGUAGU
AAGAUAGTGTGGAGGGTGAUTUATUTGUURGGAXGGTUUAUAUTGUAUTGTUUU
UTGGUAGGUAGGUAGAUUURGGGUUTTTUUUAUTGTUUTGUAGAAGGUTAAG
GGGAUAGGGTGGTTUTTAAUTAGGGUATTGGTGTGGGUUAATAAAAGUUUUA
GGATGTUUUAUAAAATAAUUU

281 UAGAAUUTGAGRGATGAAGTGARGGGATTAGTGUAGGUUTATGAAGAGTUAATGGU
AUTGUUTUUUATAUUTUAGTUUUATGGGUUAUURGTUTGTUUUTRGRTG

SEQ

ID

NO : Sequence

ATUTTTGGATUTGAAGTGGTGT TUAGGAUURGGAGXGTGGUUTGUATGUUTTG
 TTUTGTTGTTGTGUAU RGATTUATRGTAUTAUUTGAGTUATUUAGGUAGTA
 TGGAAAGAAUTTGAGTTATTTAAUUAUTTGUTUAGAAUUAUTTGAGGAT
 ATTAUATGUAAGATAA

282 TTATUTTGUAUTGTTAATTUTAGAAGAAATGGGTTUTGAGUUAAGGGTTAAAATA
 AUTUUAAGTTUTTUATAUTGUUTGGATGAUTUAGGATGAGTGAUTRGAAUTRG
 GTGUAAUAAAAGAAUAGGUAGTGUAGGUAXGUTURGGTUUTGAAUAA
 UAUATUAGATUUAAAAGATUARGRGAGGAAUAGRGAGGTTGGUUAATCGGAUTG
 GAAGGATTATGGAGGUACTGUUATTGAUTUTTUATAGGUUTGAUTAAATUURGT
 UAUTTUATRGUTUAGGTTUTG

283 GTUUUTTGUUAUAGGUATUAUUAUTUUUAUTUTUUAGAUUUTTUUTTGAAU
 TUTTAGAGUAGUUAUTUUTGGAGTTGUTUAARGUUTGRXXRGGAAAGGTTGAAUR
 UUAJAGUTTGGUTUATUTAUTURGGTTAGUTUAXGUUUTUTUTTTUUUG
 TGAAUUAUAGUTGGUATUATAUTURGGTTAGUTUARGUAUTUTTUTUTU
 UUTUTGAAUUAUARGGUTTGGUATUATAUTUTGGTTAATTAGGUTTUTUUAAG
 ATAGTUTGAAAAGGGA

284 TUUUTTTUAGAUTATUTGTGGAGAAAGUUTAAUUUAGAAGTAGATGAGUU
 AAGURGTGGTTUAGAGGGAGAAGAGACTGCTTGAGUTAURGGAAAGTAGAA
 TGAGUUAAGGTTUAGAGGGAGAAAAGAGGGXGTGAGUTAAUURGGA
 AGTAGATGAGUUAAGUTGTGTTUAGAGGGAGAGAGAAAGGGRGTTGAGUAAU
 TUUAGGATGGUTGUTUAAAGAGGTUAAGGAGAAGGGTUTGGAGAGGTGGAG
 GGTGATGTUUTGGTGUUAAGGGAU

285 UTGAGTUAUAAGGUTGUAAGGUTGTGTTUTGGATGUAGGUURGGUAGATGTTG
 AGGGGAGGTTGUAGUUTGGAGGUUTUAGGAGUARGGGUUTGGTGRGGGTGUR
 GAGGUUUAATGAAGGTUATRGAUUTGURGGAGGTGGGUUXGUUTTTGTGATGGAGU
 ATTGAAGATGAAGAGUTTGAGUAGGTTGAGTGTGAGUUAUATATGRGUUAUT
 GTGTAUAGGUAGAGAGAUTAGAGUAUAAAGAGAGAGAUAGAGAAAGGGAT
 AGAGATGGGAGGGAGAUAGAAA

286 TTTUTGTUTUUUTUUUATUTATUUTUTGUTUTGUTUTGTTGTUTUTGAG
 TUTUTUTUTGUUTGTAAUATGTRGUATATGGTUTUAAUUAUTUAUTGUTU
 AAUTUTTUATUTTAAATGUTUATUAUAAAGGXGUUUUAUUTUURGGUAGGTR
 GATGAUTTUAUTGGGUUTRGGUUAUURGUAUUAGGUURGTGUTUUTGAGGUUTU
 AGGUUTGGUUAUTUUUUUTAAUATUTGURGGUUTGUATUAGAAUUAUAGUUT
 TGTUAGUUTTGTGAUTUAG

287 TTRGTGUAUTUTGRGGURGGRRGUAGUAGURGRGGRRGUAGUTUUURGGT
 UTARGTGUUAUUAUURGRGTGGTTUATGUTGUURGGUUTAURGTAAUUAUTGU
 AGGGTRGGGUAGTGGGUUAUUAUARGRGGGGXGRGGGRGUAAUURGG
 UTGGUUTUAGGUUTRGURGAUAGGUUTUATARGGUAGRGGAGGRGGRRG
 GGRGGRRGGGURGRGGGUUTGGRGGRGUTGGGUUTAGURGRGGGUARGTUTRGGR
 GRGUUTUUUUTAUTUUUAUAGU

288 GUTGGGAGAGTAGGGGAAGRGRGURGGAGARTGRGURGRGGUTGAGUAGRGURG
 UUAGGUURGRGGUURGRGURGUUAGURGRGURGUUTURGUTGURGTATGGAGGGU
 TGTGRRGGAGGUUTGAGGUUAGURGGGGTGRGRGUURGXGURGUURGRGTGGTTG
 GUTGGGUUAUTGUURGUUUUUTGUAGGTGGTARGTAGGGGUAGUATGGAAU
 UUARGRGGGTGGGGUARGTAGAURGGGAGUTGGURGUURGRGGUTGUTGU
 RGURGRGGURGUAGAGTGUARGAA

289 TUTTGTTGAGTUTGTTATATUUAUAAGTAUTUAUAAAAGATTTTTTT
 TTTTTTAAGATGGAGTGTGUTUTGUTUAAUAGGUTGGAGTGUAGTGUATGATUT
 TGGUTUATGUAAUUTGUUTUURGGTTUAAGXGATTUTUTGUUTUAGGUTU
 TGAGTAGUTGAAUTGUAGGUATGUUUUAUUAUURGGUTAATTTTATATGTA
 TAGAAUUAAGGTUUAUUAUTGTTGGUUAAGGUAGGTUTTGAAUTUUTGAUUTUAG
 GATUUAUUAUATRGU

290 GURGGGTGGGTGGATUAUUTGAGGTUAGGAGTTUAAGGUUTGUTGGUUAUTG
 GTGAAUUAUTGTTUTATTAUATATAAAATTAAGURGGGTGTGGGUATGUUTG
 TAATTUAGGUATUAGGAGUUTGGGUAGAAGATXGUTTGAAUURGGAGGUA
 GAGGTGUAGTGGAGUAGATUATGUUAUTGUUTUUAUAGUUTGGTGAUAGAGRG
 AUUAUTUATUTAAAAAAATUTTTTGAGTAUTTGTGGATATA
 AGAUATGAUTUAUUAUAGA

291 AUUAUUUUTGAAUUAUTGAUTUAUUAAGGUUTAAGTGUUUUTGGUUAUUA
 GTTUTTGTCGUATGGURGCTGUAGTTUTATGAGAGUAGAGAGAUAGGGA
 GGGAGGUURGGGUUTGGGUUTTGGAAAAGATGUUXGTUTUAGAUAGUAAA
 AGGAGGUAGUTGUTTAGGAGUURGGAAAATGUUATUAUTGATAGTATTATT
 ATTTUUUATTTUUTTGTGTTTAAATGAAAAGTTUAGGUATUATGGGTAGG
 GTAGAGTGGGUUTGGAGGGAG

SEQ

ID

NO : Sequence

292 TUUTUUAGGUUAUTUTAUUUTUUUATGGATUTGAAUTTTUATTTAAAAAU
AUAAGGAAAATGGAAAATAATAATAUTATUAGTGATGGUATTTUURGG
UTUUTAAAGUAGUTGUUTUTTGTGUTGGUTAGAXGGUATUTTUAAAAG
GUUAGGAGUURGGUUUTUUUTGUTUTGGUTUATATAGAAUTGUAU
RGGUUATGUUAAAAGAAUTGGGUUUAGGGUAUTAGGAGUTGGGTGAGTU
ATGAGGGGTUAGGGGTGGTT

293 GUAGUARGUAGUUUAGGGGUUTAAUTUAAAAUTTUUUTAUAGGGUTTU
UUTURGGTGUAGTGTGAGAAGGTGAGGGGAUTGTAGGUURGGATGGAG
GTGUAGUAAAARGAGAGAGUTURGGUUTGTGGAGGGAXGUTUAGGUUTAGGTU
AAAGUAGGAGUTURGGAAAATGGGUAGURGUUARGGUUARGGAGGGAU
AUUUUTTUUTGUUTGATGGUAGGGUUATGGTAGAUAAAUUATGAUUTAU
UTUTUTGGGUUAGGGGUAGUU

294 GGUTGAGUUUTGGAGGUAGGAGAGGTGAGGTUATGGGTTTGTUTAUUATGGGUU
TGUUATAGGUAGGAAAGGGTGTUUUUTURGTGGGRGTGGGGUTGAAUUA
GGTTUURGGAGGUUTUGGUUTTGAAUUTAGGUUTGAGXGTUUUUTUUUAGGURGG
AGUTUTTRGTTGGUTGUAAUUTUARGGGUTAUATGTUUUUTUUUUTTUT
UAUUUAAAATGGGUAGGAAQUUUTGTGAGGAAAGGGGGTAGTTAGGG
UUUTGGGGUTGRGTGUTGU

295 ATTUTTTUTAUUTGTUATTGAAGTGAATUATUAGTATAAGTAGRGAGUTGGGRUA
TTUUTTUTUAGTTGTAAAAUTGTGTTATTUUUURGGTATUAGUAGGGTGTG
TARGGUUAUTGUTTTAAUTGGAAAGGAGGAAGAXGAGGUUAGGGAGURGGAGG
GTUAAAAGGTAGATTUAGUAGRUTAGTUUAGUTGAAUATTTUAGUUTTGT
TTTAAUAGGUTTGAGGAAAAGTATAGGTAGAAUAAAAGAAUAAAATGTATGTT
GUTATATGAATGUATAAAA

296 GTTATGUATTUATAGUAAAATAUAGTGGGTUTTTGTUTTAUUTATAUTTTUU
TUAAGUTGUTGAAAAGGUAGGUTGGAAAGTGTUAGUTGGAUTAGRGTGUTGGA
AATUTUUUTGGTGAUUTURGGUTUUUTGGUUTXGTUTGAATTUUUGGUUATTA
AAGUAGTGUURGTAAUAAAUTGUTGATAURGGGAAUUAAGUAGTTAAU
AUAAUTGAGAAGGAATGRGUUUAUTRGUTAUTTATAUTGATGATTUATTAATG
AUAGGTAGAAAGAAAT

297 ATTGGTUTGGTUUTTTUTAUAAAUTUUUUAURGGGATGUAGUAAGAGTGGUTG
UAGUUTAATTTUTAUATGAAAATGAUUTUAGTGATGUUURGGGUUUTUT
UTGUUTTUUUUUUTGGAAAAGAUTGAGTTURRGAXGGGUATUUUUTUUUUTU
RGGAUAAAAGGGUTUTGGATGTTGAUAGUUUURGUUAUTUTGAGAAGGGUAGG
URGTGGAAAUAUTUUTUUUTTGUUTUTGUTUTUUTAGUTGGGUU
UTGUUAATGUAGUTGGGUUA

298 TGGUUUAGUTTGTGUAGAGGUUAGUTAGGAAGGUAGAGGGGGAGGAA
GGGAGGAGATGGTTTUUARGGUUTGUUTUTUAGAGTGGGGGGUTGTUAU
ATUUUAGAGUUTTGTTURGGAGGGGGAGGGGTGUUXGTRGAGAAUTUAGTUTT
TTUAGGGGGAGAAGGUUAGAGGGGUUURGTGGUATUAUTGAGGTUATTGT
TTAATGTGAAATAGGUUTGUAGUUAUTUTGGUTGUATUURGGTGGAGGTG
TTAGAAAGAGGUUAGAUUAAT

299 TTGUUUTUATUAGGUTTGGAGGGGGTAGGTGUUTGGUAGUAGAGTGGUUA
UTGUUAUTGGGUUAGAGGUAGGUAGGUAAUAGUUTGATUUUUTUUTUR
GGGUUATUTUATUUUUTUUTUAAAGUUXGUAAAATAGAGAUUU
RGGUUTTGUUUUTGUTGUAGGAAGGGAGAGUUAURGUUAGAUUTGUUTGU
GGGUUUTUTGGGUAGGTGAGUAGTGGUUAUTUTGUTGGUAGGUATUURGGTGG
UTRGGGATARGTGTATTTUTTT

300 AAGAAAATUAGTATUURGAGAGGAAGUAGGTUUTUTTGATTTUUAAGUAURGG
GTGAGATUAGAAUAGGAGGUAGGUAGGUAGTGUTGGGGGTUTUTUUTU
UTGUAGUAGGGAGUAAAGURGGGGTUTUTATTTGGXGGGGUTGTGTTGAGG
AGAGGGGAGTGAAGATGGGURGGAGGGAGAAGTGGGATUAGGUTGGUUTTGU
TTUUTUTGGGUAGGTGAGUAGTGGUUAUTUTGUTGGUAGGUATUUTUUTU
AAAGUUTGGAGATGAGGUUAAG

301 GUUAGATUAGGUAGRGGGTRGUUUTUTUAGGAUTUTUAAGGUAGUTAAGGU
GGAGGRGURGGRGAGUUTGGAGAGGGAGGTUAUTAAATTGTGTTGGATGGAAG
GRGTRGAGGAURGGAGGAATTATURGATGTGGGAAGGXGGARGGGGUTARGAG
GAAAAAGAGGGGUATGTAUAUTUAGUUTTUTUATUATRGGRGGGGAGATGGA
TGGTTTURGGAUURGGRGTUUUAGRUUURGGTTAGUTATAGGGAGARGTUAGAG
RGUTUTGGTURGRGATAGAAGA

302 TUTTUTATRGGGAUAGAGRUTUTGARGTUTUUUTATAGUTAURGGGRGUTG
GGARGUURGGTURGGAAAUAUTUATUUTUURGURGAGTGATGAAAAGGUTGAG
TGTAUATTGUUUUUTUTTTTUUTRGTAGUURGUTUXGUUTUUUAUTRGGATT
AATTUUTURGGTUUTRGARGUUTTUATUAAAATTTAGTGAUTUUTUUTU

SEQ

ID

NO : Sequence

UUAGGUTRGURGGGUUUTUAGUUTTAGUTGUUTTGAGAGTUUTGGAGAGGGRGAU
UURGUTGUUTGATUTGGGU

303 ATTTGGUTTGTATUTTATTTTAATATTTTAUAUTTUTUTUTAAAGAAAA
RGAGTGAATAATRGATGGTGUAGTTATGUTGAATAATTGGATGGGAGGARGTGU
UAGGRGATUUAGGUUUTGGGAGURGGARGUUUAXGUTTUUUTUTGUUTRGTUT
UAUAGAUAAUATTGTTGGGTGATTAAUTUAGGAATTUATGUTGUTUAAGTAAUTA
UAGTGGTGAGTGTGTTGAURGGTTGATGTAGAAUATUAGGAAAUUAGAAAA
TUAGGGGRGGAGGUUAAA

304 TTGGGUUTURGUUUUUGATTTTGTGTTTUUTTGATTTUAUTUATGTT
AAAAAUAUTUAAUATGTAGTTAUTTGAGUAGUATGAATTUUTGAGTTAATUAAU
UAAUAAATGTGTUTGTGAGAARGAGGUAGAGGGCGXGTGCCRGTURGGGUUUAG
GGGTGGAGATRGUUTGGUARGTUUTUUUATUAAATTATTUAGUATAUTGUAAU
ATUARGATATTUATRGUUTTTTUTTAGAGAGAAAGTGTAAAAATATTAA
ATAAAGATUAAGUAAAAT

305 TGAAUTTTTUATTUTUAAAGATGATUATTAGGAGTGGTTUAAAUAAUTGAAUA
UAGAATTTGAGGGUUUUAATUATGAUTUAAAAGAGUUUTUUTGAATTUTTUT
GAGTUAGUURGGUUUTUUUUAUTGAUTTUAAUUTAGXGGGUAUUTGTUTTUTT
TUTTATUAAUTTTGUTUTUTTTGGTTTUAGUTUTGGTTTUTUUGAATA
UAUUTUUAATTUURGGGUUUUUTUAGGGAAAUUAGAGGUAAATTGAGTGU
GGGAGRGGGGUTRGU

306 GRGAAGUUUURGUTUTGUAUTUAAATTGUUTUTGGTTTUUTGAGGGGURG
GGAGAATTGGAGGTGTTGGGTUTGAATTUAGTUAGAGUTGGAAUAAAAGAGA
AGUAAAAGTGATAAAAGAAGAAGAAGUAGGTGUUXGUTAGGTGAAGTUA
GGGGAGGGURGGGUTGAUTATGAAGAATTUAGGGAGGGUTUTGGTTGAGTUA
TTGGGUUUUTAAAATTUTGTGTTUAGTGGTTGAAUUAUTUATAUTGATUA
TGAGAGAAATGAAAAAGTUA

307 GGTGTUAGGAGTGGUUUAGGAGAGUAAUURGTTUURGGUURGUAGGGTGGT
UTGGUTUUAGUAGGGGUUAGGAGGUAAUTGUAGUUTGGTGUUJAGAUTGATGT
AUURGGGURGAGTGTGUUTURGGUUAUATTGAUAXGUUTGGTUUAAA
UUUUAUURGGGAAUAGATUAAUUTUUTRGUTTTTGGGUUTTGUUAUTGU
UUUTGUAAAGGTGAGAAUUTUAGGUAGAAGUAGGGUAGARTGUTUAGT
UAGGUAAAAGTUAUTGGTGGT

308 AUUAAUATGAUTTTGTGGUTGGTUUTGAGUTGAGARGTUTGUUUTGUTT
UTGAGGTUTUAAUTTTGUAGGGAGGUAGTGGUAUAGGUUUAAGAAGURGAG
GTTGATUTTGTUUURGGGTTGGGTGAGGTGGUAUAGGXGGTGUUATGTTGUR
AGGUUAAGUAUTRGGUURGGGTGAUATUAGTGGAGUAAUAGGUTGUAGGTGG
UTUUTGGGUUTGAGGUAGUAAUUAUTGRGGGURGGGAARGGGTGU
TUUTGGGUUAUTUTGUAUAAA

309 GUAGUUUTTUUAAUTGUUTGGTGAUTUAUTAAUAGUUUTGGGAGGAAGGATGG
AGTGUUUTTUUAAUTTAUTGUUTUTGGGUUAATGGUAGGTGAUATAAU
AUUTGUAGGUUURGGGAGGUATXGGGUUTUTTGUAAXGTGUUATTAGTGGUT
TGAGGAGRGUUTGUUUUAUTGUUUUAXGTGUUUUAXGTUTGGUUAUTUAGGG
TUUATAGRGUTAATRGGUAAATGUUTGTGUTUTUATUTAURGGAAAATUTUU
UTTUUAGAGRGAGGUAGUAG

310 UTGGUUTURGUTUTGGAGAAGGGAGATGTTTUURGGTAGATGAGAGUAAAGGU
TTGURGATTAGRGUTATGGAAUUTGGAGTGGUAGAXGTGGGUAXGTGGGU
GGTGGGGUAGGRGUUTUUTUAGAAGGUUAATAGGUAXGTGUUAGGGUUXGA
TGGGUURGGGUUTGUAGGTGGTTATGTUAAUTGUUATTGTGURGUAGGGUA
GTAAAGGTGAAGAGGGUUAUTGUUATTUUTUUUAGGGUTTGAGTGA
AGGUAGGTGAAGAGGGUTGUT

311 GTGGUUUTTUUAAUTTAUTGUUTUTGRGGUUAUAATGGGUAGGTGGAUATAAU
UUTGUAGGUUURGGGAGGUATRGGUUUTUTTGUAAXGTGUUATTAGTGGUT
GAGGAGRGUUTGUUUUAUTGUUUUAXGTGUUUUAXGTUTGGUUAUTUAGGG
UUATAGRGUTAATRGGUAAATGUUTGTGUTUTUATUTAURGGAAAATUTUU
TTUUTUAGAGRGAGGUAGUUTAAAAGGUURGUAGGUUTURGAGGUTUTGA
AAAUAAGRGGUUTGTUTGGT

312 AUUAGAAUAGRGUTGGTTTUAGAGUUTRGAGGAGTGGGGUUTGGTTTAG
UTGGUUTURGUTUTGGAGAAGGGAGATGTTTUURGGTAGATGAGAGUAAAGGU
TTGURGATTAGRGUTAATGGAAUUTGGAGTGGUAGAXGTGGGUAXGTGGGU
GGTGGGGUAGGRGUUTUUTUAGAAGGUUAATAGGUAXGTGUUAGGGUUXGA
TGGGUURGGGUUTGUAGGTGGTTATGTUAAUTGUUATTGTGURGUAGGGUA
GTAAAGGTGAAGAGGGUUAUT

313 ATGGGUUUTGGGURGURGUUUTUAGTGTUTTGUTGUAGURGGGUAGGGUR
AAUUTGGGUUAAGGUUTTGUTGAGTGUUUTUTAAGGUTGTUTGTGGRRG

SEQ

ID

NO : Sequence

UTUTGURGGUUUUTUUTGUAAUUTGUUUAAGGUUUTGGGXGGAGGUUTUUTUURG
 GGGGGGUTGTGUUTUAGUAUAGAUAGGGGAUAGAAGGTGGUTUTTUTTGUUUTT
 GGUTGGGTGAAUAAAAGAUTTUUTGTAAGAAATUUUUTUUTUUTUUTUUT
 TRGUUUTUATUTUTUUTU

314 GGGAGAGAGATGAGGGAGRAAGGGAGGGAGAGGGAGAGGGGATTTAUAGGA
 AGTUTTTGGTTUAUAAAAGGUUAAGGUUAAGAAGAGGUUAUTTGTUUUUTGGTU
 TGTGUTGAGGUUAUAGUUUUURGGGAGGAGGAGUUTUXGUUUAGGGUUTGGUA
 GGTGUAGGGAGGGURGGUAGAGGUUUUAAGAUAGUUTTAGAGAGGGAGAUTUA
 GUAGGAACUTGTGRGUUAAGGGTTRGGUUUUTGUURGGUTGUAGUAUAGAAGUAU
 TGAGGRGGRGGUUUAAGGGGUUAT

315 UAUUTGGAUUATUUAAAUAUTTTGAGGATUAGTGGAAATGAAAAUARGGTGUUR
 GGUAAAUAUATATTUATAGUTTGGTTAGGUUAUAGUAUAGUATUARGUTGAGR
 GURGGGAAUUTTUTGAGTGUAAGGXGGTGGXGAAGGUURGGAGTUAUAAAUAU
 GAXGURGGGUUTGUTUUUAAGGGGUUTUTGGGTAGRAUTGGTATTAUUTGUA
 TTUARGAGGGAGAAUTGAGGUARGAAUTGTTUAGAAGUTGUUUTGAGGTUAU
 AAGTGAGUTAGGAAGAGGRGT

316 RGUUTUTTUATAGUTUAUTTGGTGAUUTUAGGGUAOUTTUTGAAUAGTTRGTGUUT
 UAGTTTUUTUUTRGTAATGUAGGTAAUAGGUUTGGTGAUTUUUAGAGGGGURGUT
 GTGGAGUAGGGURGGXGTRGTGGGTGTGAUTRGGGUTTXGUUUUAUXGUUT
 GUAUAGAAGGTUURGGGUTUAGRGTCATGUTTTGUTGTTGUUTUUAAAAGT
 ATGAAATATGTTTGTGURGGGUUAURGTGTTUATTUUAUTGATUUTUAAAAGT
 TGTGTCATGGTUAGTGT

317 UTUAGTGTGUUTUAGTGGTTATUTGTAAGGAAATGGGUUAGGUARGAUTGGTG
 TTUUUTTAAUAGAGAAGUAUTUAGGUAGGGGTGGGTGGGGGTGAAUTRGTTTU
 AATGGGUUURGGGAUAGGUUTGUAGUAUAGGGTAUTXGGGTTGTUTGRGGATUT
 TTUURGGGUUTUUTUUTGUAGGUAGGUUTGUAAATGGGUUUTUUTUUTU
 AAARGUATGGUUTTGTGUUUUUAAAAGUUTTAARGGUAGUATTUUTUUT
 UUTURGGGGUTGAAAAAUUA

318 GGTTTTUAGUUUURGGAGGGAGGGAAATGGUTGURGTTAAGUTGGTTGGGG
 GAUAGGAAGGUATGRGTTTTGGGAGGGAGGUUATGUAGGGUTGUUUTGA
 ATGGAGTGGAGGURGGGAAAGATURGUAGAXGAAUXXGAGTUAURGGGUTGU
 GGGUTGUURGGGGUATTGAGAARGAGTTUAAAAAAUJAAUJUUTGUUTGG
 AGTGUUTUTGTAAGGGAAUUAAGTRGTGGUUTGGGUUUTTTAUAGATAA
 AUUAUTGAGGUUAUTGGAGG

319 UAUUTARGGGUTAGUTURGTUAGGTGTTGARGGATGTUAUTUAGGTGTGAGUTUG
 UAUUTGAGGUUUTGGGUAAUAGGUAGUUAUAAUAGTGUAGAGGTGAG
 UTTTGTGGGUAGTGAGGAGURGGTGAGTUAUUTUUTUUXGUUTARGGGUUTGAG
 ARGURGGUTURGTGAGUTTRGGGTRGGGRGUUTATATAGGUUAAGGTGAG
 GUAGTGAUAAUUTUTTATGGGUUTGUTURGGUTGUUTGGGUUTGGTUT
 UTUUUTUTRGATGGAGGTUA

320 TGATUUTUUATARGAGAGGGAGAGAUAGGUAAATGAAGUAGGGAGRGAGAGUAG
 GUUUTAAGAGGGTGTGTAUTGUUTUAGGUUTGGUTTAATATAGGRGUUUTRGAU
 UURGUAGGUUTUAGGAGURGGRGTGTAUTGGGUURGTAGGXGGGAGGGTTGAUT
 UAURGGUTUUTUAGGUAGGUUTUUTGUAUTGATGGTGTGGUTGUUT
 GTGTGUAGGGGGAGGUAGTGUAGAGGUUAUTGAGTGAUTURGTUAUTA
 UUTGARGGAGUTAGUURGTGAGTG

321 UUAGGTGUUTGGTTTGGTUTUUAAAATGUTAGUTGGTGTURGAUUTGTGAGAUUU
 TUUUTGUUTUTGGUURGGGTGUTUUUATUUAGUAATGGGUAGGTGAAUAGGXGTTGTA
 GGGAAAXGGGUTGAAXGUURGRGGGUUXGXGATGTUTGXGATAUTUUTUUTXGUUU
 GUTUUTTAAGGAURGGAGTAGUUAAGUURGURGTRGRGUUUURGUURGRGTUTU
 GGTAUAAUAGUUTUTUUUTUURGUUATAAGGAGUAAGRGGUUAATRGGG

322 UURGATTGURGGUTGUTUUTTATGGGRGAGGGAGGGAGGGUTGGTTAUUAGGGAGA
 RGRGGGGRRGGGGRRGRGARGGRGGGUTTTGUTAUTTURGGTUTTAAGTGAGXGGGGX
 AGGGAGGTAGTXGXGAGAUATGXGXGGAGURGRGGGTTUAGGUUXGTTUUTAXGAAX
 GUUTGTTUUAAAUTGUUTTGUTGGATGGGUAAUURGGGUUAGGUAGGGAGGGTUTU
 AAAAUAGGTRGGAAUUAAGUTAGUATGGGGAGAUAAAAGGUAGUUTGG

323 UAAUTGGGUUTUTTUTUAGGUUTRGGTGGGRTGGUTGGGGAAUUUAGGGGG
 GGGGGGUAGGGGGTGTGUTGAGTUAUAAAAGUUTGGUAGGTUUTGUUTGUAG
 UUUUUTGUUUUUAURGUUTAGUURGUURGGGATUTAXGAGGUUAGGUAGU
 UTUTGGAUTUTGAGAUXGAATTGUAAATGUURGGGUUTGGGUUTGAAUTUUTGU
 TGTTAGGGGUAAAGTGUUTGTTGUTUUUAGGGGGUUAAGTGTGATUTUAGUTGA
 GUTGGGUUTAGGUUTUTGUAU

324 TGUAGAGGUTTGAGGUAGUTUAGUTTGAGAGATUATGTGUUUUUTGGGAGU
 UAUAGGAUTTGGGUUUTAAAAGUAGGAGTTUAGGUAGGUURGGGUAGTTGU

- continued

SEQ

ID

NO : Sequence

AATTXGGTUTUAGGGAGTUUAGAGGTGGUTGGUTGGGUUTXGTAGATURGGGRGGG
 UTGTAARGGTGGGGUAGGGGUTGGUAGGUAGGGAUUTGGUAGGUTGGGTGAU
 TUAGUAUUAUAAAATGUUUUURGUURGUUUTGGGTTUUUUUAGGUAGGGTGGTTA
 GAGGUTGAAGAAAGAGGUUATTGT

325 AUUUTGTGUAGGGUUTGUATUURGGAAAGGUUTUUAAAAGUURGAUUTGGUURGT
 URGUUUTAGATGGGUAAATRGGRGTTTUURGGGAUAGUUTUUTUUUTGGUUTUU
 TGGGUUUTRGUTGUATTGAGAGGUTGGUUTUTGGTUXGUATGUTGUUUTUURGT
 GUTGTGCUUTTGAGUAGGUUTGUUTUUTGUTGUUTUUTTGUTUTGGUUTGGU
 UUUTGGGUUUTGACTAUAAAAGGAGGTGAUTAGUAGTUUTTGAAARGUATGUR
 GAGGARGUAAUUTGUUTGGU

326 GUUAGGUAGGGTGRGTUUTRGGUATGRGTTTUAAAAGGAUTGUTGAGTUAUUTUAGG
 GGTGAUTUAGGGGUUAGGGGUUAGGUAGGUAAAGGGGAUAGGUAGGGAGA
 GGURGGGUTGUAGGUAAUAGUARGGGAAAGGUAGUATGXGGAUAGGGUAA
 GUUTUUTAATGUAGARGAGGGUUAGGAGGUAGGGAGGAGGTUURGGGAGAA
 ARGURGATTGUUUUATUTAGGRGGARGGGGUUAGGTTTRGGGUTGGTGGAGGUUTTU
 RGGGATGUAGGUUUTGUUAUAGGGTT

327 GGAUUATTGTTUTGUTGUUUAAAAGUTGRGTGGAGGGATTURGGTUUTRGGTTUA
 GTTGGTGAUAGTGRGGTAGGUUTGGGUAGGTGGAGGGTRGTGAAGUUUTTG
 UAGGUUAUTGGURGUTUATUTGGUAAAAGGGGUAGGGGUAGUURGGUURGG
 UAGTUUAGGAUTGUTTTUUTTUTAUURGGGGGUUTGTGGAAAGATATG
 GAAGTRGGGTGAATGAGURGTGUUAGTGAATTTAAAAGUAGATAAAATAAUAT
 AGAAAATGTUAGAGUTAUATTG

328 UAATGAGUTUTGAUATTTUTATGTTATTTAAUTGUTTTAAAATUAUTGGUAR
 GGUTUATUAUURGAUTTUUAUTATUTUUAAAAGGUUURGUURGGGTAGGAAGGG
 AAUAGUAGGUTUTGGGAUTGURGGGUUARGGGUTGXGUUTUTUUUTGGUUAGAT
 GAGGGGUAAAGTGUUUTGUAAAAGGGUTUARGAUUTUTUUAAAUTGUUAGGUUT
 AUURGAUATGTUAAAATGAAUURGAGGAURGGAAUTUUUTJARGUAGUTGTG
 GGUAGUAGAAUATGGTTUU

329 GUATUUTUAAUTGRGTURGAAGRGRGUAGATGGAGGUAAAAGGGAAAGGUUUTGTAGA
 GGAAUURGTGTGAUTGGGUAAAAGRGTGGUUTUUAAAAGGGGTGRGTGGGUAGRGG
 GARGUUUATGGGTGAURGGGTTGTGUUTUUTAGGGAUXTGTGUUUTGTGUAG
 AGAGUUUUTGGGGXGGAAAGTGGXGAGUAGURGGUAGGGGUUAGUAGA
 UAGAAGUAGGGGGTUAGGGAUATGGGAGGTGGGGGUUAGUAGTGAUTGAGTUAGAR
 GTGAGGAUTTUAGTGUUAAGGAUTG

330 UAGTUUTTGGUAUTGAAGTUUARTGTUTGAUTUAUTGGGUUTUTUUUTGGTTUU
 ATGUUUTGAAUAAAUTGUTTGTUTGUTGGGUUTGGGUUTGGGUUTGGGUUTXGUUA
 UTTGUUAAAAGGGGUUTUTGUUAAGGGUAGAXGGGUUUTATGGAGGUAAA
 AAUURGGTUAAAATGGGRGTUURGGGUUARGUAAUAAAUTGGGAGGUUARGUT
 TTGUUAAAAGTUAUARGGGGUUTUTAUAGGGGUUTTGUUUTGGGUUTUATUTGRG
 UTTRGGARGUAGGTGAGGATGU

331 AGGTTUUUUAUTAGTUUURGGATUTUUTAGGGAGTGTUUAGGGAUUUTUAAT
 UTUAGGGGUAAUTTUTGUAGGAGUTRGGGTRGGAGGTUUARGTGGUAGAAGAGU
 TUAGTGTUTGAGGAGUTGGTGTGUURGGGTAAUUTUXGUATUAUTGUTUTUUTU
 TGUTGGUTARGUAAAAGGGGUAGTGTGARGGTGGGUAGGTGUTGTGUUTUAGGGU
 AGRGAGGTUTTGUTGUAGUAGGUAGGGAUTUTTUTATGGGUUAAAAGTAUUU
 UAGTGGGRGGAGGRGUUUT

332 AGGAGRGUUTURGUUUAUTGGGTTAUTGGTGGGUATGAAGGAGTGUUUTGUTGUTG
 TUAGAAUAGAAGAUUTRGUTGUUUTGAGGUAAAGUAUTTGUUAAAURGTUAUTU
 AGUUTGGGRGTAGURGGUAGGGAGGAGGUAGTGTGAGTGGTAUURGGGU
 AAUAGUAAUUTUAGAGAUUTGAGUTUTTGGUUARGTGGAAUUTRGAAUURGAG
 UTUTGUAGAAGTGGGUUTGGGAGTGGAGGTUUUTGGGUAAUTUUUTATGGGAGATU
 RGGGGAGUTAGGATGGGAAUUT

333 TUUTTUUTTUTTUUTTUTTUUTTUUTTUTTUUTTUTTUUTTUTTUUTT
 UATTTGAGGAGTAAUTGGGUUTGTRGUUUAGGGUTGGAGRGUATGGRGUUATUT
 RGGRGUUATGUAAAATUUAUTUUTUURGGGTTUAAGXGATTUTAUTGUUTUAGUUTUU
 RGAGTAGUTGGGUUTUAGGRGRGUAAUTUAAAAGUURGGGUATTTTTTGATT
 TTTAGTAGAGAATGGGTTUARGATGTTGGURGGGUUTGGTUTGGGUAGTUTTGGAUUTU
 AAGRGTGRGUUUTU

334 GAGGGRGUARGUTTGAGGTUAAGAUUTUAGGUAGGUUAAUTRGTA
 UUUAGTUTUTAATAAAATUAAAATAGURGGGUUTGGTAGTGRGRGUUAT
 GTAGTUUUAGTUTRGGGAGGUTGGGUAGTGAATXGUTTGAAUURGGGAGGT
 GAGGTGUAGTGRGURGAGATGGGUUATUTGRGUUTUAGGUUTGGGRGUAGGU
 AGAGTARGTUTUAAAATGAAAGAAGAGAAAAGAAAAGAAAAGAG
 AGAAAAGAAGGAAAGAAGGAAGGA

- continued

SEQ

ID

NO : Sequence

335	AGGUUTUTGUTGAUTGTAGAAUTTGTGAUURGGATTGTGATGTUAGTUTUATTGG GUUTGURGTTGUTUTTUTGGGAUAGAAGATUTTGTGATURGGUAATTRGGTAGG GUTUAGGGGUATUUAAGGTTGUTGUUTTGATGATGXGGAGTATTURGGTAGTGT UTGGGTAUAGGTUUTUATUUAARGGGUUTTURGTGGRTTUARGGGAUTGGAU AGUTTGATGUTGUAGAGAAGUAUUUAUTTGAUATUAATGAAUUTUUAUUTTGUAG TGGTUAGTUAAGGUATGA
336	TUATGUUTGAUTGAUUAUTGUAAAGGTGGAAGGTTUATTGATGTUAGTGGGTGUTT UTUTGAGGUATUAAGTGUAGTGUAGTURGGTAGAAARGGUUARGGAAGGGAGUURGTGG ATGAGGAUUTGTAUUAAGAGUATTAURGAAATAUTXGAUTAUATUAAGGUAG UAAAUTGGATGUUUTTGAGGUUUTAURGAATTGGURGGATUAAAGAGATUTTGTU UUAAGAAGAGUARGGUAGGUUUAATGAGAUTGAUATUAATURGGTUAAUAA GTTTUAAGGTUAUGAGAGGUU
337	GGGGGGGGGTRGGURGGGGGRGGGUAGGAUTGAGUAGUAGUAGGGGUTGGGGGA GTUAGGTUAGGURGGTGGUTAUURGGURGUTGGAGAGGGURGGATGGUARGTGGUAAAG UAAAAGGAGGUTGAGUUAAGGUAGGGAXGGGUTAGRGAGUAAAGUTGGUAGGAGG GRGAGTGGGAGGGGURGGAGURGGUTGTGRGTGGTUUTTGGGAGGAGGGGTG GUUAAGUAAAAGTTRGGAGGTUAUTGUAAGGUAAGAUAGUUTGGGUAAARGAGUAG
338	UTGUTRGTTTGUUUUAGGGUTGUTTGTUUTTGUAUTGUAUTURGAUTGTTGGUTTG UUAUAAAUTUUTUUAAGGGAUARGUAGUAGURGGUTFRGGUUUUTUUUAUTRG GUUUTTGUUAGUTTGUTRGUTAGUUUXGTUUUTGUTTUTGGUTAGUUTUUTTGT UARGTGUUATURGGUUTUTUAGRGGUURGGGTAGUUUARGGUUTGAUTGAUT GUUUTUUTGGUTGUTUAGGTUUTTGURGURGUUUUURGGUAAUURGUUU
339	RGAGTTGGGAGGGGURGGAGURGGUTGTGRGTGGTUUTTGGGAGGGGGTGTGG UUAAAGUAAAAGTTRGGAGGTUAUTGUAAGGUAAGAUAGUUTGGGUAAA RGAGUAGGGGRGGAGRGTGAGAGUAGAUTGUAGRGATXGTGUTAGGUAGUAAA GUTGAAGAGGUAAGGGUAAGTUAAGAAGUAGGGGRGGGURGAUAAAUTRG GATUTGUTRGRAAGAGUAGUAGUTGGGUAGUJURGAUTGUTGURGGGUAG TAGTUTRGAGGGUTGUUUAGGGGU
340	UUUUTGGGUAGUUTURGAGAUTAUUTGUUURGGUAUAGUATRGGGUTGGUUUAGU TGUTGUTUTTRGUUUAGUAGATUTRGAGGTTGCTRGGUURGUUUUTGUTTUTGG AGUTTGUUUUTTUUTTUTUAGUTGGGUTGGGUUTTGAGXGATURGGTGUAGTUTG UTUARGUTURGUUUUTGUTRGTTGAGGTGUTTGUTUUTTGUAUTGAUTURG AAUTTTGUTTGUTTGGUUUAUUUUUTUUTUAAAAGGGAUARGUAAUAGURGG UTRGGUUUUTUUUAUTRGU
341	AAUAGGUUUAAGGUUTGTGGUAGGTGGGGGUUAUUAAGGUUAGGRGUTUUUAAA URGGGUUTGGGUAGGUUAGGUUAGGAGUTGGUTGRGGURGGTTTUUUUUAAA UTUTGGGGATGUUUTAGGUUUTGGGUTGGGUTTURGUUTTAGUUTXGUUAGGU UUTUTGTTGGUUTTAGUUTTAGUUTTAGUUTTAGUUTTAGUUTTAGUUTTAG GUUUUATGAGGGAGGGUAGGTUTUTTGUTRGTAUTGTUAGUAAUTAG TTAGUATTUTGUUUAAAAGU
342	GUTGGGTGGUAGGAAATGUTAAATTUUTGATGTGUTGGUAAGTARGUUAAGAG AUUTGUUUTUUUTUAGTGGGUUTURGAGUUAUTGUUUUAAGTUUAAURGGTUA ATTGAUTAAGGUAAAAGAGGUUTATTGGGUUTGGXGAGGUTAAGGRGGAA UUUAGGUUTGGGUATUUUAGAGTGGGTGGGGGAGAAURGGUURGUAGUAG UUTGGGUTTUTGGGUUAGGUURGGGUTGGGAAGRGUUTGGGUUTGGGTGA UUUTGUUUAUAGGUTTGGGUUTGTT
343	UUTGAUAAAUAUTUTUUAGGGGARGTGGGGGUAUTGGAGUUUUAUARGUA GGGGTAGUUTAATGUUURGRGTRGGAGTTUUTUUURGRGAGRGTRGGUAGG UAGGGAAGTUUURGGGUUUTGGGAGGGGUUTTGURGXGUATUTGTXGUAGGA AURGRGGGUUUTTUTTURGRGGGAAGXGGUTGGURGUUUURGUUURGU GGGUUTTGGGGTTTURGGTGUURGGUUAURGTGGGUTGGGAUTGAAGTGA TGGGAUTGAAGATGGGUTGG
344	TTUAGUAAAATUTTUAGTUUUATUAUUTTUAGTGUUUUAGGUUARGGTGGURGG UAUARGAAAUAUUAAGGUAGGUURGGGGGGGGGGTRGGGUUAAGUXGUTTUU RGRGGAGGAAGGGGUURGGGGTTUUTGXGUAGGATGXGRGGUAGGUUUUTU UUUAGGGGUURGGGUUTTAGUUTTAGUUTTAGUUTTAGUUTTAGUUTTAG ARGRGGGTGUATTGAGUTAURGUUTGRGGTGTGGGUUTUAGTGUUUUARG UTGGGAGAGTTGGGTGGGUAG
345	TATUAAAATGTGTTTATATAAAATGAATRGTTTUAGTGUAUTGAGGAAGTTTUT ATTAAGAAGAATUUTGUTGTGAUTUTTTGTGAAGAATGUTTUTAATGGAG GTUAAAATGAGTUAUTTGUTGUAAUTTUAGGTTGXXGGTTTGUUTAAGUAG TGGURGGAGAGTGAAGATAATTAGATGTRGUTAATAATTAAGGATTAUT AGGUAAAAGAGGAAAGAAAAAAATTGAUTRGTTATATGAUURGAATTGAGT UAGGGGTUTUUAURGGU

SEQ

ID

NO : Sequence

346 GURGGTGGAGAUUUTGAUTUAATRGGTTUATATAUARGAGTUAAUTTTTTTT
 UTTTUUTUTTTGUUTTGAGTAATUTGTAATTATTAGRGAUATUTATAATTATUT
 UAUTTUTURGGUUAGATUTTGUTTAGGUAAAUXGUAAAUTGAAGTTGUAGAAA
 TGAUTUAGTGGTGAUTAATTUUATTAGGAAGUATTUTUUAAAAAGAGTTUAUAG
 UAGGATTUTTAAATAGAAAATTUUTUAGTGUAUTGAAAARGATTUATTATAT
 AAAAUAUATTGGATA

347 TGGGAGTTUAGTTRGGGGUAGAUUAGTGTUAGAGTURGGUTUTGUTAUTUAG
 RGURGGAGGUAGRUUTUUUATTUARGGGGURGTGUAAATTUUTGUAUTGAT
 TUATGAAUUAATAAUATUURGGAAATTUTUJUAUXGUUTURGTUTGGURGT
 RGUUURGGUUTGGGAGAUUAGTGTUAGAGTUTUTGUUUUARGGGRGTATUA
 GTGUTGUUAGTGGAAAATAATGUUAGURGRGUUAUAAAATTAGGTGTAAAATT
 AUATTTTTGGAGUAAUTTT

348 AAGTGGUTTUUAAAAAAATGTTAATTUUAUUTAATTGGTGRGRGGUTGGUATTA
 TTTTUUAUTGGGUAGUAUTGATRGUURGTGGGGUAGAGAUTUTGAGAUUTGGG
 TUTUUAGGURGGGRGARGGUUAGARGGGAGGXGGTGGAGAGAAGTTURGG
 ATGATTATGTGGTUAUTGAAUTGUAUAGGAAATTGUUARGGUUURGGTGAATGG
 GGAGGRGUTGUUTRGGRGUTGAGTAGUAGAGUURGGAUTUTGAAUAUTGGTUTGU
 UUURGAAUTGGAUTUUUAT

349 RGGRTGUTTUTGGUAAAATUTUUTTGAGGATGURGUTGUAGUAUTTGAGUTGU
 TURGAGAUTTTGUTGUTUTUTGUTGGTGTGUTGAGAGTRGGGUARTUU
 TTUTTGGAGGTTUAUAGGURGGUTGUTUTUURGUXTGUTGGUUAUGUTTGGTGGT
 UTGGGUTURGGGGUAGRGGAGGGTGGUTRGTAATGGGTUAATGGTGGGG
 TGGTGTGTUTGUTTUTUUTTUAUTUUUTUTTGTUTGUUAAGAAUARGGARGUU
 AAUAGGUUAUTGUAAGAAG

350 UTTUTGAUTGTYUTGTTGGRGTURGTGTTUTTGAGGUAGUAAAAGAGGGAGTGAAG
 AGGAAAGUAGUAAAUAUAAAUAUAAAUAUATGAAUAAAATTUARGAGUUAUUT
 RGUTGUUUUURGGAGUAAAAGUUAUAAAAGUTGGGUAGXGGRRGGAGAGUUR
 GGUUTGTGAAAUUTUAAAAGAAGGARGTGUURGAUTUTAGUAGUAAAAGUAAU
 AGAGAAGAGUAGUAAAGGTUTRGGAGUAGUTUAAGTGTGUAGRGGUATUUTAAG
 GAGATGTTGUUAAGAAGUARGURG

351 TGGTUTGUTTUAAGTUUTAUUTGGUUUUTGGUAGTUAAAATTGGTGAUATUTTG
 GUUTGGTUUUTGAGGUTGUUUUAGATURGRGATTGTUUTGGGUAURGTACTTU
 UTUURGGATGUUAGUAAAAGUTUUUTUAGUUTUAXGUUTGUUAAGTUTUUAGT
 ATGUUTTUAUAGUUATTAGTUAAUUTUTGTGACTGUAGGUUURGGTUTGUUAGG
 UUAAUTGUTGGGUUTUAGUAGRGGGGUTGGRGAGGUAGTTTUTUAGRG
 TTUTAAGURGUTRGAGGGTGG

352 UAUUUTRGAGGGUTTAGAAURGUTGGAGAAAATGGUUTRGUAGUUURGUTG
 UTGAGGUUUUAAGUAGGTTGUUTGUAGGAURGGGUUAAUTUAAUAAUUT
 GAUTATGGUTTGAAGGUAUTGGAGAUTGTGUAGGXGTGGAGGUTGGAGGG
 GUTTGTGUUTURGGGGAGGAUTAURGGTUUUUAGGAAATRGRGGATUTGG
 GUAGUUUTUAAGGUUUAAGGUAAAGATGTUAAUAAAGTGGAUTGUUAGGGGU
 AGGTAGGAUTTGAAGUAGUAAUAG

353 AAUTGGTRGUUAURGGUAGUTRGGGGAAGAAGGGRGRGTGGRGRGUUUAAUTU
 RGGTGTGAAGAGUAGURGRGURGUAGUTRGUUAUARGTTGTRGATGUUAGUAR
 GRGURGRGURGUAGUTRGGRGATUAGTTRGGUAURGGUTGUUURGGGAAGAGGT
 TURGURGUTGUUAUTGURGUUAAGRURGAGUURGGGGGUTGUURGAGGAGRG
 GUUARGGUAAUAGGUAGRGAGTGU

354 GUAUTRGUTGUUTCTGTGURGTGGUURGUUTUUTRGGUAGUUUURGGGUTRGGRGU
 TGGGGUAGTGGRAGRGRRGGAGAUUTUTUURGGGUAGURGGTGTURGAAUTG
 ATRGRGUAGUTGUTGRGRGUTGAGGUUTAUUUTRGGXGGURGGGUTTRGGGU
 AGGGGGRRGRGRRGGRRGGTGTGGGUATRGUAUARGTGTGRGAGUTGGRRG
 RGRGGUTGUTTUTUAGUAURGTGGAGTGGGRGRGUUARGRGUUTUTUURGAG
 UTGURGGTGGURGAUAGGT

355 TGGUAGAGATAAAATTUUTGATGGUAGAGGGAGAGAGAGTGTGGGTGARGA
 TGAAUATGAAUTGAGUUAAAAGGAGGTAGGGAGGUATATGGGRGTUTUTGG
 AAGATGTTUURGGAAAGGUAAAGUUTTTAGAUAGGUUUXGAGGUAGGAGUUTGT
 UTGAUTUAURGGAGGAGUTGGAGGAGGUTGAGGTGGGUUTAAGTRGATTAAGUAG
 GTGGGGAGGGAGAGGRGATGGTGURGTGAGGUUAAGUAGGGGUUTTGAGGTUTGG
 GGGGAGAAUTTGGUTTTAUTUT

356 GAGTAAAAGUAAAAGTTUTUUUUUAGAUUTUAGGUUUTGUTTGGTUTUARGGU
 AUUATRGUUTUTTUUUUUUUUUUUTGUTTAATRGAUTTAGGUUAUUTUATGGT
 TUUAAGUTUUTURGGTGAUTAGGUAGGUTUUTGUUTXGGGUUTGTUTAAAGGUT
 GTGUTTTUURGGGAAUATUTUAGAGGARGGUUATATGTUTUUUUTAUUUTT

SEQ

ID

NO : Sequence

TGGGTUTUAGTTUATTGTUATRG TUAUUUUAUTUTUTUUUTUUTGUATUA
GGAATTGTATUTUTGUAG

357 AGAGGAGGGAGAGAGAGTGTGGGTGARGATGAUATTGAAUTGAGAUAAAAGGA
GGTAGGGAGAUATATGGGRGTUTUTGGGAAGATGGTUURGGGAAGUAUAGUU
TTTAGAUAGGUUURGGAGGUAGGAGUUTGTUTGAUTUAUXGGAGGAGUTGGAGGA
GGUTGAGGTGGUUTAAGTRGATTAAGUAGGGTGGGAGGGAGAGGRGATGGTGU
RGTGAGAUUAAGUAGGUUTTGAGGTUTGGGGGAGAAUTTGUTTTAUTUTGA
GGAAGGTGGGAGUUAAGAGGUTT

358 AGUUTUTGTGGUTUUUAUTTUUTUAUTAAAUAUAAAUTUUUTUUTTAGGAU
TUAAGGUUUTGUTGGTUTUARGGUUAUATRGUUTUTTUUTUUUAUUTGUTTA
ATRGAUTTAGGUUUAUTUAGUUTTUUTUAGUUTUTUXGGTGAUTUAGAUAGGUTU
UTGUUTRGGGGUUTGTUTAAAGGUTGTGUTTUURGGGAUUAUTTUUAGAGAR
GUUUAUTATGTUTUUUAUTUUTTGUTTGUTUAGTUAATTGTUATRG TUAUUUAU
AUTUTUTUTUUUTUUTG

359 TGGGRGTUTUTGGGAAGATGGTUUURGGGAAGUAUAGUUTTAGAUAGGUUURG
AGGUAGGAGUUTGTUTGAUTUAURGGAGGAGUTGGAGGAGUTGGTGUUTA
AGTRGATTAAGUAGGGTGGGAGGGAGAGGRGATGGTGUXTGAGAUUAAGUAG
GGUUTGAGGTUTGGGGGAGAAUTTGUTTTAUTUTGAGGAAGGTGGAGUUA
UAGAGGUTTUTAGAUAGAAGAAGUAGURGGAUTAGGATAUAGGGTGGGG
TATUTGTGGGATAAAGGGAGAA

360 TTUTTUUTTATUUUUUAUGATAUUUUUAUUUTGGTATUUTGAGTURGGUTTGU
UTTUTUTGTUTAGAAGUUTUTGTGGUTUUAUUTTUUTUAGAGTAAAGUUAAG
TTUTUUUUUAUAGAUUTUAGGUUUTGUTTGUTTUAXGGUUAUTGGUUTUUUU
TUUUUAUUTGUTTAATRGAUTTAGGUUUAUTUAGUUTUUTUAAGUUTUTRG
GAGTUAGAUAGGUTUUTGUUTRGGGUUTGTUTAAGGUTGTGUTTUURGGGAU
UATUTUUUAGAGARGUUA

361 GGUUTTGTGAAUAUAGGAAGAACATGAAUAUAGAGUTGGTURGAUAAAAGU
TRGAGGGAGGGGGGURGGGAAGUTTUTGGAGTTGGUTGUUUUTAAGUAGGGGUUA
UTUTAGGUUUAAGGUUAAGTGGUAGAGGUAGAXGAGGGGAUTUTGXGGUTUAA
GTUARGGGGUAGGGGUURGUAGUTGGGUTGAAAGGTUAGAGURGGUTUTGR
GTUTGGUTGRGURGGUAAGAUUAATTARGUAGGUAAAAGAGUURGGGATT
AGUUUAGUUAUTGGGUUUTGAAT

362 ATTUAGGGTUUUAGGTGTGGGUTAATUURGGGUTUTTGUTGRGTAAATTGT
GUTTUTTGURGGGUAGUAGARGUAGAGURGGUTUTGAUUTTTUAGUURGGUAG
UTGRGGGUTUTGGUURGTGAUTTGAGUXGUAGATGUUTUTXGTUTGUUTUTGUUA
AUTTGGUUTTGCGGUTAGGTGGGUUUTGUTTAGGGGUAGUUAUTTUAGAAGU
TTURGGGUUUUUUUUUTRGAGUTGGGTGTRGGAUAGUTUTGTGUTTUATTUTTU
GGTGTGUTTUAAAGU

363 AGGUTGAARGGAATTGGGAGUAGAGGUUTGRGGTAGGAUAGAGAATTRGUAAAAGU
URGGAGUUAUAGUAGUAVUURGTUTTUTAAAGGUAAATTGGAAAATUTTG
UTAATATTGUAGGUUTAAGGATUATTUTGUUAUTUUUXGUTUTGGAUTUAAGU
TGUAAGUUUUATURGGGUAGGGTTUUTUATTUUTGTGUAGRGGAAGUUTGT
UUTGUUUAAGGGUUTGGUAUTTG TGTGAUTTGAAAUUUTRG TG GGAGTAAGAGA
GGGTGTGATGTGUAAAGGUUT

364 AAGGUUTTGUUAUTAUUUUTUTTTAUTUUAUARGAGGTTTUAAGTARGTAU
AAGTGUAGGUUUTGGGUAGGUAGGGUTUARGGTGUUAUAGGAATGAGGAGU
UUTGUUURGGATGGGGUTTGAGGUTTGAGTGUAGAGXGGGGATGTGAUAGAAATG
ATUUTTAGGUAGAATATTAGGUAGAGTTTUAAAATTGTUUTTAGAAGARG
GGGTGTGUTGTGTGUTURGGGUTTGRRGAAGTUTGTUUTAURGUAGGGUTUTGU
TUUAATTURGTUAGUUT

365 AGUAGGUTAAUUAURGGTGTUUUAATGAGGGGUUTGGGUTGAGTGGAGGAAT
GGGTGRGGTGGAGGTGGGUTGGGUUTGGGUUAURGGGUARGTGTGGGTAAGRGG
GGGGURGGTGTGRGGGTGGUUTATUTGGGUUAAGUAGUXGAGGURGAUTGTG
GGRGTGTGGTGAUGRGGUAGGTGTGUTGGRGTGAUUTGUAGRGUTGGT
AUUTGGGUUUTGGGTUTGARGTGGGURGRGUUTGGGUTGUTGGRGGAUAGTGT
TUTGUUTGRGGARGUTTURGG

366 URGGAAGRGTURGUAGGUAGATAAUUAUTGTUURGUAGUAGUUAURGKUU
UARGTUAGAUUAGGGGUAGTAAAUUAUAGARTGUAGGGTUAGGUAGUUA
UTGUURGTGUTUAAUUAUARGURGGGUAGTRGGUUTXGGGUTGUTGUUUUAGAT
AGGUUAUURGUUAUARGGGGUUUUAURGUUTUAAAARGTGUURGTGTGU
GUUAAAUAUUTUUAURGUUUUATTTUUTUUAUTUAGUUUAGGGUUUUTUATT
GGGAUARGUTGGTTAGUUTGGGU

367 UUTTGUTUAGTTGGGGAGGGRTUATGAGTUATGAGGTGGGRTGUATTG
AGTGTGUAGURGRGUAAAURGAGTAGTGTGGGUAGRGRTURGRGTTRGATT

SEQ

ID

NO : Sequence

GRGTUTGGUURGUAGGAGGUURGGTUUAGUAGUUUTTUXGUAAUAGGGTUAURGG
 RGRGRGATAUUUTGGGGRRGGATRGGGGUTRGTGUTUTGUTTURGAAAUUUTTU
 TUUUTUUAUTUAGRTTUTTUUTUUTUUTATIUTTUAUTTGAGTTAUT
 TUUTUUUTUUUTUUUTUU

368 GGGAAAGGAGGGAGGGAGGGTAGGTGAAAGTGAAAGGATAGAGGGAGGG
 AAGAARGUTGAGATUTGGAGGGAGAAGGGTTRGGGAAGUAGAGUARGAGUUURGA
 TUURGUUUUUAAGGGTATRGRGRGURGGTGAUUUTGGTXGGAAGGGUTGUTGGAUR
 GGGUUTUUTGRGGGUAGARGUAATRGAARGRGARGRGUTUURGUUAUAUT
 RGGTGTGRGRGGUTGUAAUAUTGAAUATGUARGUUUAUTUATGAUTUATGAR
 GUUUTUUUUAUUTGAGUUUAGG

369 UAGGUTGGAGTGUAAUTGGRGRGATUTRGGUTUAUTGUAAUTTUTGUUTTRGGGTT
 UAAGUATTUTTUTAUUTTAGUUTUUTGAGTAGUTGGGATTAUAGGTAAUTGURGU
 UATGUURGGUTAATTTTAATTGTTTTAGTAGAGAXGGGTTUAAUATGTG
 UUAGGURGGUTAUAAUTUUTGATUTUAGGTGATUTAUURGUUTRGGUUTUUAAA
 TTAUAGGTGTTATUATTAGGATTUTTGUAGUAGGAGTGTGAGGGATGGAAGT
 GGATAGTAGGAGGUTUTG

370 UAGAGUUTUUTAUTATUAAUTTUATUUATUUUUTAUAAUAUTUUTGTUTGUUAAGAATU
 UTAATGATAAAUAUTGTAATTGGGAGGURGGRRGGTAGATUAAUTGAGATUAG
 GAGTTGAGAUGGUUTGGGUUAUATGGTAGGAAUUXGTUTUTAUTAAAAAAUAAAT
 TAAAATAGURGGGUATGGGGUAGGTAAUTGTAATUUUAGUTAUUAGGAGGU
 TAAGGTAGAAGAATTGUTTGAAUURGAGAGGUAGAAGTTGUAGTGTGAGGAGATRG
 RGUUATTGUAUTUAGUUTG

371 TGAATGAUUTGGGUAGUATTUTUUAUUTGRGUUTGUATTGUTAGAUAGTUTGTGA
 UTUTUTGTTGGGAGAAAUAAGAAAURGGGUUUTUTGUTGGTTUUUUAUUTGGU
 UTGUTUTUUTGTTUTUUAUUTGUAAUATGUUTGXGAAUUTGUTTUTUUT
 GAGUTUUTUUAUAGTGGGUUARGGGUUTTAATUTGUUUAUATUAGAGU
 UTUUAUUTURGGUUTATGGGUUATUAGAGGUAGTGGAGURGGGUATUUTUUUA
 RGTGGGUUTTGAGGATGGGA

372 TUUUAUUTUAAAGGUUUARGTGGGAGGATGUURGGUTUUAUTGUUTUTGATGG
 GUUATAGURGGAGGTGGAGGUTUTGATGTTGGGUAGATTAAGGUARGTGGUR
 GGGGUUATGTGAGGGAGGUTUAGAGGAGAAGUAGGTTUXGAGGUATGAGTGTGU
 GGGTGGAGAAUAGGAGAGUAGGUUAGGTGGGAAUUAUAGAGGGGURGGTTU
 TTGTTTTUTUUUAUAGAGTGTUUAAGAUTGTUTAGUAAATGUAAAGRGGUAGGTTG
 AGAAATGUTGUUUAAGGTUATTUA

373 GGGRRGGGUUTGRRGTUTGRGGGRGGAGURGAGTGGGUTGRGGGATGRGGG
 GAUAGUTGRRGTGGRRGGRRGURGAGAGGUUURGGAGGRGRGGGUTGAGRGAG
 GGURGRGGGGRRGUTGGUTGRGUUTGGUTURGGTATGXGUUTAUTTUUTUTGRGT
 UTXGUTAGUTGURGTGUTGURGRTGTAUTARGTUTUATUTGGGTUUUARGR
 GGTUTUURGRGGUAUURGURGGUUUAUAGUUUAGRGRGURGTUUUUTURGTGTG
 GTTURGUUTRGGRGTGURGUU

374 AGGRGGUARGUURGGGRGGGUAGUAUARGAGGGGUUARUKUKGUTUUUUTUU
 URGGRRGGTURGRGGGAGAURGRGTGGGUUUAGATGAGAURGTAGTAUARGG
 RGAGUAGUARGUAGUTAGXGAGARGUAGAGGAAGTAGGXGUUTAURGGAGUUA
 GRGUAGUAGRGUUUURGRGGGUUUTRGGUUAGUURGRGUUTURGGGUTUTRG
 GRURGURGUUARGUAGUTGGGUUURGUATUUURGUAGUUUAUTRGGUUTURGR
 GURGUAGAURGUUAAGGUUURGUU

375 AAGTGTATTTUAAAGGTATGAGGGGUUAGAGGAUAUTGTTUAAAAGUAGTGG
 GTGAGAGTGGUTTGGAGTAGGUAGTUTGGAAAUTTUUAAGGTURGUTUTGA
 AGTGURGGUTGUATGAAUAGGUUTUAGGUUTGTTGUTGXGUTTRGGUUTTGTG
 AAGTGGAGAGUATTGUTGATUUUURGGGTGGRGGAGGGGRGUARGTGAUT
 RGUATGGGUUTGUAGGUARGTGGTURGTGTTUATGATTUTTGAGAGUTTGG
 GUAGUTUUAAGAAGAUT

376 GAGTUTTUTGGAGGUTGUUAAAAGUTUTUAAAAGAATUATGAAUARGGUUARGT
 GUUTGUAGGUUAUTGRGAGGTUATGARGTGRGUUUUUTRGUUAUURGGGG
 GATUAGUAGUTGUUTUUTGUAAAAGAAGGURGAAGXGGUAUAGGUTGGAGG
 GUTGGGUATGUAGURGGUAUTUAGAGRGCGGUUTGGAAAGTTUUAAGAUTGT
 UGUUTGAGGAGUTGUAGGUARGTGGTURGTGTTUATGATTUTTGAGAGUTTGG
 TUATAUUTTGAAUAAUTTT

377 TAATTTAAUAAAATTTUATGAGUAAUTAAATTTAAATGTGTTTUATA
 AAAGTGAATUAGUTUAGTGTGUAGGUTGAAATAUAAUAGAGGGATURGGG
 UAGAAAGUAGAGGGGUUAAUTAGAURGTGTGUTGAGAGAXGGGAGAAAGUAGUT
 UTGUTGTGUAAUAGGGGUUTUTAGGGGUUURGGUAGUAAUURGTGGGGGU
 AUTTGGGAGGUTGATTGTTTUAGAAUAAUAGUTAAGUUAUTGAGGUAGGAGU
 TGTTATUATTUAAAGUUA

SEQ

ID

NO : Sequence

378 TGGGUTTGAATGATAAUUAGGUUTUTGGUTUATGTGGUTTAGUTGGGGTUTGA
AAAUAATUAGUTUUUAAGTGTGGUURGUARGGGTTGUTGURGGGTUUUTAG
AGGUUTUTGGTGUAAAGUAGUTGUUTTUUXGTUTUTAGUARGGTUTA
GGTGUUUTUTGGTGUAAUURGGATUUTUUTGGTGTATTUAGUUTGUAGA
AUTGAGUTGATTUATTTATGGAAAAAUATTAAATTAGTGTGUATGG
GAGTTTGTAAATTAA

379 GUUTUAGAUURGAAATUUUUAUTGAAGUATTUUUAGGAGGGGUUTUAUT
GGGUUTUAGGUAGUATUAGUATTURGGTGUAGGUAGUATTTATUAGU
AUTGGUTUTAUTGAGAAUAGGUAGURGGGUUTGUAGGGTATGAUAGGU
AGGGACTGATGGGUURGGGUUAGGGUAGGAGGGAGAUAGAAATGGGUAGGAAGA
GGAGGUTGTUUUUAGUAGUAUTTGAGAGGAGGAGAUUUTTRGGGUAUTUT
GGARGGUAUUUUAAAGUAAAGUU

380 GGGGUTGTGUTTGGGGGTGURGTUUAGAGTGTUUURGAAAGGTGUTUUTUTUA
GAAGTGTGUTGGGUAGUUTUUTTUUTGUUUTTTUTGTUTUUTUTGUU
TGGUURGGGUUUTAUAUTUUTGUUTGTUATAUUUTXGGUAGGUURGGUTTGUUT
TGTUTUAGTAGAGGUAGTGAUTGATAAATTGTGUTGTGUUTGTUAURGGAAATG
UTGATGUTGUUTTGGGUUUAAGTGAAGGUUUTUUTGGGAATGGGUTTUGTGG
GGGATTTRGGGTUTGGAGGU

381 TGAGAGUAGUAGAUARGTAGTGTUAGGGAAAGTRGAAAGTGUAGATGGGTRG
UAAARTGGAUTUTUTAGTTGGGTUTGUAGATGGGUURGGUAAUAXGTGUTUT
UTGAGTTUTUTTUUAAGTAUAGATUUTURGGAGARGGAAUATTGTTURGUUTTAA
ATTUTTUUAAGGAGUTGRGGAGGAAGGXGTGAGAAURGGAGUURGGGGAUTTGR
GGGGAGGGGATRGUTTUUURGTRGUUUUAUUTGUUTAAUURGUUARGRG
GURGUAAAGGRGAUURGRGT

382 ARGRGGTGTGUUTTGRGGGURGURGTGGGTAGGUAGGTGTGGGRGARG
GGGAAGRGAUTUUTUURGUAGTUAUURGGGUTURGGTTUTUAXGUUTTUUT
URGUAGUTUUTGGAGAATTAAAGRGGAAUATGTTURGTUTURGGAGGGATUT
GTAUTTGGAAAGAGAAUTAGAGGUAXGTGGTGGUURGGGUUUTUTGUAGAUUU
AAAAUTAGAGTGUARGTTGRGAAUUUATUTGUAUTTRGAUTTUUTGATUA
UTARGTGTUTGGUTGUTUTUA

383 AUAAGRGGTTGGATTTRGAGAGGAUATUAAGAGUARGTUAAGAGUARGTUAAG
UAUARGGAAUAGGUATGGUARGURGGUAGGTUATGAURGGUAGAAUAGAGTTG
GUAGGGUTGTAGAGAAGAGTRGGGURGUUAAGUUXGAUTTUUARGGGAAA
AAUATUTGUUTTUTGGUTUUTUATUTGUTGAGAGUTAUTTUUAUTUAATAAAAU
TTGUAUTUATUTUUAAAUAUATGAGATUUAATTUTURGGTAUAAAAGGUAG
GAAUURGAGATAUAGAAAGUU

384 GGGUTTUTGATUTTRGGGTUUUTGUUTTGGTGTUURGGAAGAATTGGATUTUATG
TGGGTITGGAGAATGAGTGUAGGTTTATTGACTGGAAAGTAGUTUAGUAGATG
GAGGAGUAGAAGGUAGATGGTTTURGUTGGAACTXGGGUTGUTTGGGGUURGA
UTUTUTUTGAUAGUUTGGUUAATUTGTTUTGUTGUTGGTUAATGAUUTGURGRG
TGUAGTGUUTGTURGTGUTUTTGARGTGTGUUTTGARGTGTGUUTTGATGTUUT
RGAAATUUAURGGUTTG

385 AUTTGAAAGTUGGGAGTTRGTGAAUAGUUTGGUAAAATGGTAAAAAUUTGTUTUTA
UTAAAAAAAGAAAATTAGURGGGTGTGGGUUTGTAAUAAAAGUAUTTGG
GAGGUTGAGGTGGGGATUAUTGAAAGTUAGGGAGTXGTGAAUAGUUTGATUA
ATGGTGAUUUUTGTUTUTAUTAAAUAUAAAATTAGURGGGTGTGGGG
TGUUTGTAUUTUAGUUTUAGGAGAUTGAGGUAGGAGGATUAUTTGAAURGG
GAGGUAGAGGGTGUAGAGAGT

386 UTUTUTGUAAUTUTGUUTUURGGTTUAAGTGTATUUTUTGUUTUAGTUTUUTGA
GTAGUTGGGATTAAAGGUAAAUAUAAAUAUURGGUTAATTGGTTTAGTA
GAGAUAGGGTTUAUUAUTGATAGGUTGGTGUUTUAGGUUTUAGTGA
TUUAAAUAUUTAGUUTUAAAAGTGTGUTGGGGTAUAGGRGUUUAUAAAURGG
UTAATTTTUTTTTAGTAGAGAUAGGGTTUAAAATGTTGGUUGUTTAAA
GAUATGUTGAUTTGAAGTG

387 AAATUTTTTUUTGUUTGUATTUTTAUATAAGUAATUTAUTGUUAUTRGGTT
UATTUAUTUARGAAUUTGTUTGUAGGUUTGUAUTUAGUAGAUTGAGTUA
UUAGUATUATUUTGGGUUAGGTUTGUATUUXGUTTURGGGUUUAAGUAAA
UTGTTAGUTUATUAGGTUUTGGGUAAAAGGAGGAGURGTUTL TUUUTT
TTUTGAATTAGATUUUAAGAAAAGAUATUAGGUTTUTGGGGAAUTAATTT
GUTUATGAAATTGAAUAT

388 ATGGTUAATTAGAGUAAAATTAGATTUUUAGGAAGUUTGATGTUTTGTTUT
GGGAGTUAATTAGAAAAAGGGAGAGAAAARGGUUTUUTGGTGUUUUAAGAG
GAUTGATGGAGUTAAUAGTGGGUTGGGURGGAGXGGGATGUAGAUUTGGGU
UUAAAAGGATGATGUTGGTATGAUTAGTUTGAGGTUAGGTUUTGGUAGA

SEQ

ID

NO : Sequence

UAGGTTURGGTGAGTGAATGAAURGATGGUAGTAGTAGATTGUTTATGTAAGAAA
ATGUAGGUAGGAAAAAGATTT

389 UAAGGTUUAGGTUUAGUUTUUUAURGURGUURGRGUUUTUUTAGGUUTRGAG
RGCGUTTUTURGGGUUTRGAACGTGGGGTGGAAAGTTGGGAGTUURGGUT
TUUAUGUUTTRGAGAAUTGUUURGGGAATTRGTUXGURGTARGGAAAAAUT
GGURGGAGUAGAGTRGTURGRGGTURGRGGTGGAAAGGTGAAGGTRGAG
GGAGGTUAGGUTGUTTUTGRGTUUTGARGUTGGRTGTTUTTGAGATGGGUT
RGCGUTAUTGGUAGUTT

390 GAAGUTGGUUAAGTAGUURGAGUUUATUTUAAGAGAAUARGUAGURGTUAGGAU
ARGUAGAAGUAGUUTGAUUTUUURGAUUTTUAAUTUUURGRGAURGRGAA
URGRGGARGALTUTGUTURGGUAGTTTUTRGAGTARGGGGARGAAUTUURGGG
GUAGTUTUARGAAGGUTGAGAGURGGAUTUUAAAAUTTUUAUUUUAU
UTTRGAGGURGUAGAAGGRGURGTURGAGGUUTAGGAGGGRGRRGGRRGGT
GGGGAGGUTGGGAUTGGAUUTTG

391 URGAGGGAGGUAGGUUAAGUTGAUAGGAAGGUAGAAGGTGGUAGGGAGGGAGG
TTGRGUTGUAAUTUTGGGTGUUAGGUAAUUTGUUAGGUAGGAGGGGAAGU
RGGUUUAUTTAAUATGAURGGAGATGATGGUAGGUUAUXGTGGATTGAGGAT
UUAGAGUARGGUAGGUAGAGGATUTGUAAUAGGGTGAAGAGGGTGGATURGG
AGRGGUARGTGUAGGUAGGUAATGGTURGGUTGGTGUUTGGGUATUAGGAA
GAGUTGUAGRTTUUAAGGAAUT

392 TAGTTUTGGGARGUTGUAAAGUTTUTGATGUUAGUUAAGUAAUAGURGGUAUA
TGUUTTUUTURGGGARGTGUURGGTGUURGGATJUAAUUTTUTGUAAUUTGGTGUAGA
TUTTTUTGUUTGGGGTGTUTGGATUUTUAAATUAXGGTGGUTGUUATUATUTTU
URGGTUATGGTAAAGTGGGUARGGGUTUUUUUTUUTGUUTGGUAGGTTGGUUTGG
GUAAUUUAGAGGTGUAGRGUAAUUTUUUUUTUUTGUUAUUTTUTGUUTTUUTGTUAG
UTGGGUUTGGUTUUUTRG

393 AAATAUURGGGRGGTGGTGGTGGGUUTGTAATUUAGUTAUTUAGGAGGURGAG
GUAGGAGAAURGUUTGGAAUURGGGAGGUAGAGUATAGGTGGTGGAGGGTTGAAG
GTGUAAUUAAGUAGAGGAGTGUUTAUAGGGAGGUUTGUUAAXGGGUUUAAGGAAAUUT
UTGGGUUUAAGAGGUTGUAGGUAGGAGGTAGAAUUAUTGGGUAGGAGTGUUT
GGAAGGUTTAAAGGUUAUTUUUTUUAAAGTLTrGGGUUUAUUTUAAUTGTUAG
GUTGTTAAAGGUUATTTAAAGGUT

394 AGUTTTAAATGGUUTTTAAUAGUUTGAGTGTAGGGTTGGGUUAGGAUTTGG
GGGAGTTGUUTTGAGGUUTTUUAGGUAUUTUUTGUURGGTATGGTUTAUUTUUTG
UTGAAGUTUTAUTGGGUUAGAGGTTTUUTGGGUXTGUAGGUUTUUTGTAT
GUAGTUTUTGGGTGUAAUUTTAAUUUUTUUAAUAAUTATGTUTGUUTUURG
GGTUAAAGRGGTUUUTGUUTRGGUUUTGUACTAGUTGGGATAUAGGUAAUUA
UUAAUARGUURGGTAATTT

395 AGGAAAAAAUAGUAGGUAAAAGAATRGGUUUTUUUTGTTAUAGUAGGAGTRGUATU
TATTATATATGTATGTUTTATGUTUAGUAAUAGUTUTRGURGGGRGTGGGU
RGGAAGAGGGTUUUTGGTGUAGXGGGTTGGGTGAUTUATUURGURGXGUAU
TUTGGUUTUTGGGUUTAGGTAAUAGAUTUURGGGTTUAGGUTGGGUUUAAGGRGG
UUAGGUUUTUUUTGUUTGGGAGGAAUTUTGGGTTGGGUAGGTGUUAGUTUUUTGUTT
AUUTGGGUUAAGAAGGGTA

396 TAAUUTUTGTGGUAGGTGAGAAGUAGGGAGUTGGUAUTGUUUUAUUAGAT
TUUTUAGUAGGGGGGUUTGURGUUTGGGUUUAAGUUTGAAAUURGGAGTUTGT
TAAUUTGGGUUAGAGGUAGAGTGTGRRGGGTGATGAGTGUARGUUAUUXGUT
GUAAUAGGAGAUUUUTUTGUURGGGUUARGUURGURGGAGAGUTGGTGTGAG
UAATAAGAUATAAATATATAATAGATRGRAUTUUTGUUTGTAAUAGGGAGGUURG
ATTUTGGGUUTGUUTTTTTTUUT

397 AUUAGGAATTUTTTTUUTTTTGAGARGGRGTUTUTGTRGUUUAAGGUTGGAG
TGUAGTGGGUAGUTRGUUTAATGUAGUTURGUUURGGGTUATGUUATTU
UUTGUUTUAGUTUTTGAGTAGUTGGAAUTAUAGGXGUUTGUUAUUAUURGG
UAATTTTTGTATTTAGAGCAGGGGTTUAURGTGTTAGUTAGGATGGTUTR
GATUTUUTGAUTRGATUUAAAUAUUTUAGGUUTUTUAAAGTGUUTGGGATAUAG
GUTGAAUUAUTGRGUUU

398 GGGRGUAGTGGTTUAGUUTGTAUUUAGUAUTTGAGAGGUTGGAGGTGGTGG
TUARGAGGTUAGGAGATRGAGAUUAUTUUTGGUTAUARGGTGAAAUUURGTUTUTA
UTAAAAATAAUAAAATGGUURGGGTGTGGTGUAGGXGUUTGTAGTTUAGUTAU
TUAAGGGUTGAGGUAGGAGAATGUATGAAUURGGGGRGAGUTGUAGTAG
GRGAGAUTGRGUUAUTGUAUTUAGUUTGGRGUAGAGARGURGTUTAAAAAA
AAAAAAAAGAATUUTGGG

399 AAATAUAGUAGGGAGAGAATTUUTGAGAUUTAAGATAURGTGUUUTUUUUUTG
GUUTUAGUTGUURGAGTUUUTGGAGAAAATRGGUATUTGAAUAGGGURGTG

SEQ

ID

NO : Sequence

TTTGTUUUTGUTURGGUUTTGTTUTUATTUUTGUUAAGGUATATGGATAATGAA
 AGTTGAUTGGUTGURGGGTTTUUTTUTUTGUUUUTGTUATTUATTTGUUAG
 GTUTUATGUUTTTTGUAUAGAGTTGTGTGUTGGGUTUTAATTGUUAGGUAGT
 GATAAATTUUAAGAAAA

400 TTTTUTTGGAAATTATUAUTGUUTGGUAAAATTAGAGUUUAAGUAUAUAAUTUTGT
 GUAAAAAAGGUATGAGAUUTGGUAATGGAATGAUAGGGUAGAGAAGAGA
 AAUURGGUAGUAGTUAUATTUATTATUUAUTATGGXGTGGUAGGAATGAGAAU
 AUAAGGGAGGAGGGUAUAAAARGGUUTUTGTUAGATGUURGATTTTUTUAG
 GAUTRGUAGUAGTGTAGAGGUUAAGGGGAAGGGUARCGTATUTTAGGTUTUAG
 AGGAATTUTUTUUTGUTGTATT

401 GUUUTGAGAUAAUTAAATGGRRGGGGGGTGGGGGGAGGAAAGGGAAAGGRGGUAGAG
 UTUUURGGAGURGGGAGUAGTUAUTAUTUTAUAGGUAGTGGGUURGAAUAGAU
 GRGRGURGUUURGGUAGUAGUUTRGGUARGUUTRGGAAGXGUAGGUTUURGGRU
 TGRGUTGGAGGGTTUURGGUAAAAGGUUTUURGTUUUAGUURGUTGUAAUUTU
 RGGGUUUUUUTTAUUTTGAGAGGUUAURGGAGTTGTRGRGGGGGUUTRGGA
 AATTUUURGGAAUUAUTGTGUAGAGA

402 TUUTGGUAUAGGGGTURGGGAATTUURGAGGUUUUURGRGAUAUTUURGGT
 GUUTUTUAAACGGTAAGGGGGUURGGAGGTGUAGRGGGUTGGGARGGGAGGUTG
 GGGTURGGGGAAUUTUAGRGUAGRGURGGGAGUUTGXGUTTURGAGGGRTG
 RGAGGUTGGUTGGGGGGGGRGUTGTUTGTGTRGGGUUUUAUTGUUTGTAGAGT
 AAGTGAUTGTUURGGUTRGGGAGUTUTGURGUUTTUUTTUUTUUUTRTAUUU
 UURGUATTTAGTGTUTUAGGGU

403 AUUAUAGUAUTGUAGGAGGATGAGGUUUTGUAGGAAGGAATGUTGGUTUTUTGG
 GTAGATAAAAGAGGTUTGGGAAGGGAGGGAGGAAUAGGAUATGGUTU
 GUUAGGUTGUUAGGTURGGATGUUAUTRGGUAGTGGXGGGUAGGUUTGG
 GTAGATGAUATGGTAGTGTAGTAAGTGGGAGGUAGGUAGAGGAGGUAGG
 UAUUTUXGUUAGGUUAAUTRGGUUAUAGRGAGGGTRGGAGGUAUTGRGTT
 GGGTTGATGAGUAGARGAUTGUUA

404 TGGAUGTRGTUTGUTUATUAUUUUAARGUAGTGTURGAUUUUTUURGGTUTGT
 GURGAGGTGGXGGXGGGAGGTGAGUUTGUTUUTUTGUTGGUTGUUTUU
 UTTAUTUAUTAUATGTUATUATUUAGGUUTGTUUUXGUUUAUTGURGATGGUA
 TUURGGAUUTGGGAUAGUUTGGUAGGGAGGUUATGTTUUTGTTUUTUUUT
 UUUAGAAUUUUTUUTUATUTAUUUAGAGGUAGUAGUATTUUTGUAGGGGUTU
 ATUUTUUTGUAGTGTGUTGGT

405 AGGGAGGGAGGAUAGGGAAUATGGGUTUUUTGUUAGGTGTUUUAGGTURGG
 TGGAUTRGGUAGTGGXGGGAUAGGUUTGGTAGATGAUATGGTAGTGA
 GTGGGGAGGUAGGUAGGGAGGUAGGAGGUAGGUUTUUXGUUUAUTRG
 UUAAGAURGGAGGGTRGGAGUAUTGRGTTGGGTTGATGAGUAGARGAUTGU
 UAGGUAGUATTUAAAGGAATGGUAUAGARGUAATTGTTUAGUTAUUU
 TUUTUUTUAGGGUAAGTGAATG

406 ATTUAUTTTGUUUTGAGGGAGATGGGGTAGUTGGAAUAATGTGRGTUTGT
 GUUTTUUTGTGAATGGUTGUUTGGUAGTGTUTGTUATUAUUUUAARGUAGT
 GUUTGGGGGUUTGUUUTGGGTUTGGGAGGTGGAGUUTGGUT
 UTUTGUTGGGUUTGUUUTUUUAUTAUTUAUTAUATGTUATUTAUUAGGUUTGT
 UUXGUUUAUTTGURGATGGUATUURGGGUUTGGGUAGUAGUUTGGUAGGG
 GUUUT
 GTTUUTGTTUUTUUUTUUUT

407 GGTTUTAAUAUAUAUUUTTGATGUATUTGGAAATTAAUUTTAATUUU
 ATTATUAATGGGUUATATTGGGGATTTUTGGUATGUAUTGAATGT
 TATTAAUTGGUAGGGAGGATTAUATUAAGAUUAURGGUTXGAGAAA
 UAGUAGTGTUUTGGGUUATGGGUUAGUAGTGT
 GAUTUATTAUTGTGTAGGUATUTGGGUUATGGGUUAGUAGTGT
 TTTUUUUUATTATT

408 AAAAAATGGGGAAAATUUUAUTUTRGGTAGTGGUUAAGAGUAURGGATT
 TAGUAUTGAATGAGTUAUTGUAGGAGAAATGAGATUTUTGTGGAGGGGUUT
 TGUAGRGTTGGGGGAGGGAAUAGAUTGUTGTUTXGAGURGGTGT
 TAATUUUTGUAGTGTAAUATTAUTGUUAGTGUUATTAAUATG
 AAAAUUUU
 TATTGAGUATTGATAAAATTGTAGGAAATTAGGTAATTUAGATGUU
 AAAGGTTGTGTAGGUU

409 TTTGGGGGUAGGGAGGGTTUAGTUUUUTUAGGUUTGGUTGTGUUUUTGU
 UUUUAUTAGGUUUAGGGTTGGGGGTGUUAUUAAGGAGGGGUAGGAAGT
 GTGUAGAAGUAGAURGGUTUTGTGUUUUAGTGGXGGXGGGTGT
 UUAGAAGUAGAAGUAGGGGUAGUUTGGGUUATGAUUTGU
 UTGUUUTGGGUAGGA
 GGAGGUTATUTGTGUUUTUUUUTGUUUTGGGUUUTGGGU
 UTGUUUTGGGUUUTGGGU
 TRGUUUTGUUUTGGGUUUTGGGUUUTGGGU
 GGGTAGGUAGUAAUUTGGGU

SEQ

ID

NO : Sequence

410 AGUUUAGGGTGTGGUTAUUUAGUUAUTGAAGGAGGAGGGAGGGAGGGAG
GGAGGGAGGGAGGGAGGGAGRGAGGGAGGGAGGGAGGTUATGGURGGGU
GTGGGAAGGGATUAGATAGUUTUUTGUUUUAGAUAAUXGXGUUAUTGGG
AUUAAGAGURGTTUTGUTTUTGGUAUTTUUTGUUUUUTUTGGTGTGUAU
UUAAUUTGGGUUTGATTGTGGTGCCCCGUAGGGGAAUAGUAGGUUTGAGGG
GAUTGAUUUTUUUTGUUUUUUAAG

411 UURGUAGUUTRGUUUUTUAGGUUTRGUUUUTUUTGUAGAGAGTGGU
AAGTGTGTTUAGAGGGATAGGAGATTGTGRRGAAGUURGAUTATGUTTTGAG
UTUTCGGAAGAGUURGGAGAUUTCGAAGAUAGAGXGUAGAUAGGAAGAG
UUAAGAUATGUAUAGAUAGAUUUTGUAUTGAURGGURGAAGAUAGUUTR
GGAUAGUUUUUAURGUUUUAGUUUURGRGUUURGRGUUURGAUTUURGGU
GGUUTGGGAGUUTTGAGGGTTA

412 TAAUUTUAGGGUTUUAGGUUTTGURGGAGTRGGGRGRGGGGGRGGGG
UTGGGGGRGGTGGGGUTGTURGAGGUTUTGTTRGGURGGTUAGGTGUATGG
UUTGTUTGTGTAGTGTUTGGUUTUTTGUTTGGTTUUGTAAGRIT
URGGTUTTAUUAAGAGUTUAAGUATAGTRGGGUTTURGUUAAAAATUUT
TUAGUUTUTGGAAUARGAGUTGGUAUTUTGUAGGGAGGGRGAGGUUT
GGAGGGGRGAGGUTTGRGGG

413 UAGATUAGGTUUTUAGAUTTGURGGAGGGAGGGGUUTGUATAUTGUUAARG
UUTGTTGUTGGGAAGGGGUTGATGTTGUATGAGGTTAAUAGUAAUAGGAU
ATTGAUTGGUATUTGUAGUTGAGUTUAGUTUAGAGAGGXGAGGAGUAAAGGG
GGAGGGAAAATUURGGTGTGGATUTUAAAARGGUUAUTGGGTGUUTTG
AGARGGAATTATGGGTGUTTTAUTUTUATTTTAAAATGTGUTTTATGTGT
TGAAAAGTAUAGATTUUA

414 TGGGAATUTGTTAUTTAAUATAUAAAAGUAUATTTAAAATGAGAGAGT
AAAAGUUAAGAAAUAUTGATGTGUAGGUAGUAAAAGTGGGURGTGTTGGGAG
UUAIAURGGATTTUUTUUTUUTGGTGTGUUTXGUUTUTGAGUTGAGUT
GUTGUAGATGUAGTUAATGTUUTGTTGUTGTTAAUUTGUTGUAAUATAG
UUUUTUUUAGUAAAAGGGRTGGUAGGTATGUAGGGUUTUUTURGGU
GTUTGAGGAUUTGATUTG

415 UAUTGGUTUTRGGGUTGGGAUAGATTGUTTUUTTUTUUTGGTGUAGGT
AGGUUAAGAAAUAUTGATGTGUAGGUAGUAGGUUAAAUTGGTGGGAGGA
AGTGGGGGGTGUAGGUAGATGAGURGGGUAGAXGTGUUTGAGGUAGU
AGTUAGGGGUTGARGGGUATTATGUAAUUTRGGGUTTGUAGAGUTGG
URGGTGUUUUAUTUAGUAGGTUAGAGTGGAGAGGGGUAGGGRGUTGGG
AGGUATGUAUTGAUAGGRGTU

416 GARGUUTGGTUAGTGUATGUUTTGAAUAAAAGRUUUUTGGGUUT
UTGUTTGATGGGUAAARGGGAUURGGAGGUAGUTUTGAAAGUURGG
AATGUUUAUTGUAUUTGAUTGTGUTGUUTUAGGUAXGTUTGUURGG
GTUUTGGGUAAURGUUAAUTTUUUUAAAUTGGTGGUAGGUUTTG
UATUAGGTGTTUTGGGUUTAUTGGUAAUAAAAGGAGAGAGGAAG
GTUUUAGUUAUTGAGAGGUUAAGTG

417 AUUAUAUTGAAUATAUAGAUATUUTTUUAGGGTGTGUTRGATAU
AATTUUTGTUTGUATUUAGGUUTGUUUAGUUTTUTGGGUUUUAGU
UTGTTUUTTGURGUUTGUATUUUUAAAUTXGTGTGUAAAGUAGGG
UAGGTAGGGAGAAGGUAGATGUTGUTUTGTGUUTGGGTTUTT
TAGTGTGUUTUUAAAARGRGTGUTTTAATTAUTGUUAUTUAGGU
GGGAGAGTGUAGAAATAG

418 UTATTTUTGAUTUTUUUUAUTGAGAAAGUUTGACTGTGUAGTTAA
UTGAGTGGGTGTGGGAGUAAAUTAAGAAAAGAAAAGGUAGAGAG
UTGURGTTUTUUTAUTGTTUUTGUTTGUAUAAUTGXGAGAG
GGGAGGURGGAAAGGUAGGUTGGGAGUAGGAAGAGGGUTGG
UUTGGAATGUAGAUAGGAATTAAGGTATRGAGUAAUAAU
UTGGAAAAGGA
TGTUTGTATGTTUAGTGTGGATG

419 TUUUAGUUAUTURGUAGTUAUTUUTGAAUAGAAAAGAA
UAGUAAUURGGGUUAUTUUUTGUAGUTGUUUAAUATUTGG
AGUAGTGTGATGTGGTTUTTAUATUTGAATUTGXGT
TATGUATGTGATGTGGTTUTTAUATUTGAATUTGXGT
UTGUAGTGTUTUUTGUAGUTGUUURGGGATGAU
TUTUUTGRGTUUTGGGAGUTGGGAGUAGGUAGGG
GGGGUAGGTUAGAGUTUAGUA
GGGGUAGGTUAGAGUTUAGUA

420 GUTGAGUTUTGAAUUTGUUUmGUTGUUATUAGUUUUTGUTG
UTGUUAGGARGUAGGGAGAUUUTGGGAGAGTGAGGT
GUAGTGUATUURGGGUATGG
AGAUAGTGTUTUUTGUAGUTGUUURGGGATGAU
TUTUUTGRGTUUTGGGAGUTGGGAGUAGGUAGGG
GGGGUAGGTUAGAGUTUAGUA
AGAAGUUXGATUUAATTGUATAAGTGG
GUUAGUTGUAGATGTG
GGGUAGUT

- continued

SEQ

ID

NO : Sequence

GUAGGGAGTGGUURGGGTGUUGGGUUUAGUTGTTGTTUTTTUTGGGTUAGG
AGTGAUTGRGGAGTGGUTGGGAU

421 UUAAARGRGGUAUARGGGARGGUUUUUTUURGGGTUAGGUTUAUTGGTUUTTU
UUTTUAGRUUUAUAGGUAGGGGUUAARGGTUAAUAGGAGGUAUUUTUAAUUT
GUUTTGUAUUAUAGGUAAAATAAAGTGUATUUUATTXTGTGAGXTRGGUURGGTG
AGTUAGUUUTURGGGUUUTTUUTGTTUAGGUAGGGGGRTGRGUTGAGUUA
GAGGTAGATUTGUAGAAAGGGUUUURGAUTGGGUUTRGGUAGGGURGGGUUUUA
UAUAUTUTGGGGTUAGUTATGU

422 GUATAGUTGAUAAAAGAGTGTGGTGGGRGURGGUUUTGUURGAGGUUAGTRGG
GGUUUTTUTGUAGATTTAUUTTGUTUAGRGUARGUUUUUTGUUUTGAGAAUAG
GAAAGGGUURGGGAAGGGUTGAUTUARGGGURGXGUTUAAAXGAAAATGGGATG
UAUTTATTGTGUTGGGUAAAGGUAGGTGAGGGTGUUTUUTGTGTAURGTTGGUU
UTUUTGUUTGGTGGRGTGAAGGGAGGGGUACTGAGUUTGAUURGGGAGGGG
URGTUUURGTGTGURGRGTTGG

423 GUAGGAAGGGUUUAGARGAUUUUUUAAGAUATATGUUAGUUUUTURGGTGAU
UAAAATUATUTUAGTAAAGGUAGTGAGGUAAACRGAAAAGGGTGGGTGGAAGA
AURGGUTUTGAGTUTUAGGUUAUAGAUATRGGAUAUTXGTRGGUURGGTAGGU
GGGGTTUUTGGTGUUTUAGGUTGUAGGURGUUUUUTUURGUAGUTGTUTUUA
GUTUAAAUTUUURGUUUUAAAAGGUATUUTATTUAUTGAGGAGATTAAG
AUUAUTGGRGAGAAUUUUUU

424 GGGAGGGTTUTRGUAGGTGGTUTTAATUTUUTUAGTGAATAGGAGTUUTGGGG
GGTGGGRRGGGGAGGTGGGAGUTGGAGAAGUTGRGGGAGGGGURGGGUUTGAU
AGUUTGAGGUAAAAGGUAGGUUTGUUTAURGGURGXGAGTGTURGAGTGT
GTGGGTGAGAUTUAGAGURGGTTUTUUAUUAAAUTTTTRGUTTGUUUTUAT
TGUUTTAUTGAGATGATTTGGTUAUURGGAGGGUTGGUATATGTUTGTGGGG
GTRGTUTGGGUUUTTUUTGUT

425 AGGTGAGATUTGGAGGTGRGGGUAGTTAGUAAGTGGGAGAGAGUTGUATGRGGG
GAAGGTGGGAGGRGTGUAGGAAGGTGAGGGAAUAGUTGAGUTGTGGTGT
GGUAGUTGGGUUTATURGGGUAUTGTGAXGGGUAUTAAUAGGGTT
AAGTAURGGAAUTGAUTGATRGGAATTGTAATTAAUTAGATUUTUTGAUTGUTGT
TGGGGAAUAGAUTGTUAUUAUAAUAGUAUTGTUAGUTGAGTATTAGAUAAAT
GATGAAUUTGGGUUAGGGAA

426 UUUUTGGGUUUAAGGTUATUATTGTUTAATAUTUAGUTGAUAGTGTGTTGTGAGGT
TGAUAGTUTGTUUUUUAUAGUAGTUAAGAAGGATUTAGTTAAATTAAUATURGA
TUATGTUATTURGGTAUTAAAAAUUTGTTAGTGUXGTUAUAGTGUURGGATAAGG
RGUAAAGGUUUUAGTGGGUAGUAAUUAUAGUTUAGUTGTGTUTUUTUAAUTTT
GUARGUUTUUUAUUTUUURGUATGUAGUTUTUUAUUTTGUTAAUTGUUURGU
AAUUTUUAAGATUTUAAUTG

427 TGTGTTAUUUUAGAAAGUAAGGARGUTTUAAAAGATGTTUAGAGUAGTGTUAAAG
GGATGUUUUAUTGGTUAGTUUAAAURGGUTGTGAAUURGGAAAATUTGAGAUTGGT
UAGTTAATTAGAAAGTTATTGTGUUAAGGTTGAGGXGTATGUUTGTGUAUAGU
UTUAGGAAGTUTGATGUAUTGTGUUUUAAGGTGGTGGGTGTAGUTTGATTATA
UAUTTAGGGAGUATGAGAUATUAATTAAGTAUAUTTGAGAAATAUATRGGTTGG
UTAGAAAGGRGGGAAUAA

428 GTTGTLURGUUTTUTAGAUAAAURGATGTATTUTUAGTGTAUTTAATTGATGT
UTUATGUTUUUAACTGTATAAAATUAGUTAUUUUUAAAUAUTTGGGUUAUTG
TUATUAGGAUTTUUTGAGGUTGTGUUAAGGUUTAXGTUUTUAAUUTTGGUAAAAT
AAAUTTUTAATTAAUTGAUUAUAGTUTUAGATTTURGGTTUAUAGRGTTGG
AUTGAUAGTGGGUATUUUTTGAAUAUTGUTUTGAAUATUTTGGAAAGRGTUUTT
GUTTUTGGGTAAUUA

429 TGAGAATAATGTUTGGTATGRGAGGAGUAAUAGUAAAATRGTGUTUATUUTUAGR
GGAGUAAAATGGTGTGUTUTUAGTGAUUAUURGGUTTGGGTAUTGAGGUTGUTATT
AAAGTGTGGTTGTGAUTUATTAAGGTUATGAAATXGGTAGTGTAGUAAU
AGUUTTAAAGAAATGAAUURGGGURGGURGGRGGTGGTTUAUUAUTGTAATUUAG
UAUTTGGGAGGURGAGGRGGGTGGGATUARGAGGTUAAGAGATRGAGAAUATUUTG
GUUAAUATGGTAAUURG

430 RGGGTTUAUATGTTGGUAGGGATGGTUTRGATUTUTGAAUUTRGTAUUAUURG
UUTRGGUUTUUUAAGTGTGGGATTAAGGTGTGAAUUAUURGRGUURGGUURGG
GTTUATTTUTTAAGGUTGGTTGUTUAAUUTAUAXGATTUATGAAUUTAGTAATG
AGTUAAUAAAUAUTTAAATAAATAGUAGUUTUAGTAUAAAAGUURGGTGAG
AGAUAGUAAAATTGUTURGUTGGAATGATGAGUARGARTGUTGGTGLTTUUTRG
UATAUUAAGUATTATTUTUA

431 AGGATGGGAGGURGGGGAGGUAGRGURGURGGURGGGGGGGGURGRGURGUAG
GRGGUTGGGUAGTGGGTGRGGUTUAARGTGGGGGUARGGTUUTGAUUAU

SEQ

ID

NO : Sequence

RGGUAGARGUTGTGURGRGAGUAGAAGTUUUTTUAGUXGUUTGTGUUAGGGGG
AAGAGUTGUAGTRGGAURGGGTGAGGUUUURGGGTGGGRGAGRGGGRGGTG
GGTUUUTURGUTRGUURGARGRGGGUTGTRGGGUUTGGUTRGUURGUUAGGUUTGG
GAUURGGURGGGTTUATTTURGA

432 TRGAAATGAAUURGGURGGGTUUUAGUUTGGRRGGAGGUAGGUURGAUAGU
UURGRGTRGGRGAGRGAGGUUUUARGUURGUUTRGURGUUUUURGGGGGUU
TUAAUURGGTURGAUTGUAGUTTUUUUTGGUAUAGGXGGUTGAGGAAGGAUTTU
TGUTRGRRGUAARGRTGUTRGGGTGGTAGGAAUARGTGUUUUUUARGTGTAG
URGUAAUUAUTGUUUUAGURGUUTGRGGRGCGURGUURGUUURGURGCRGR
GUTGUUTUUURGGUUTUATUUT

433 TUTAUTGATGRGGAGAGAURGAGGUUAGGUAGAGUUTAGUTTRGRGUTAUA
RGGUTGTGGRGUTGRGUUUUAGGUARGGURGGGUUAGGTRGTGGUUUAUTRG
GAUURGGGUTUARGGTGRGGTTGARGRGGUARGGGAGXGGTAGGTGUTUAGU
AUUTUUTUUTRGUTUTGUTRGTRGATGAUURGUAUTGGRGUAGATARGRG
UTGGURGGGTTUAGGGRGAGGUAGURGATGURGGARGGUUUTRGATRGUTUU
AUAGRGRGTUUTUUTURGUUTUA

434 TGAGGRGGAGGAGGARGRGUTGGGAGRAATRGAGGGRGUTGGUATRGGUTGG
UTRGRRGUUTGAAUURGGUUAAGUTUARGURGTATUTGRGUUAGTGUURGGGT
GARGAGUAGGARGAGGAGGGAGGTGUTGAGUAAUTAUXGUTTUURGTGURGR
AURGUAURGGTAGURGGGUURGAGTGCGGUUARGUAGUTGGURGGURGTGU
UTGGGRGUAGRGUUAUAGURGTTAGRGRGAAGUTAGGGUTUTGUTGUUUTGG
GGUTRGGTUTURGUATUAGTAGA

435 UTUAUUTTUUTAGTTAGAAAATUUUTUAUTGUTUUUUAATGGAGGUTGUU
GGAGTGUUUAAGTGGGUUAAUAGUTGTTUTATGUUAGUAGUTURGGAGTATGTA
UATTUUAUTUTGTTUAAUUTTUTTUTATTUAXGGUUUUTTAAGAAA
TUATGUAGGUTGGGAURGGGTGGGATGUAGUAGTTGGTGTGGUTAUTURGAGT
GTGTAUAAUATGUAGGGGUUTTGAGUAGTGGGAGGGUUAQUATGTTGATTU
UUAGGGUTGGTGGUTUUT

436 AGGAAGGUUAUAGGUUUTGGGAATUUAUTGUTGUUUTUUUAUTGUTUAUAGGU
UUUTGUAGGTGTGUUAUAAUTRGAGTAGUUAUAAAAUTTGUTGUATUUUAAU
URGGTUUAGUUTGUAGATGAATGTTnTUTTAATGGGUXTGTAAGATAAGAAUAA
GTTGAAUUAAGAGTGGAAATGTAUATAUTURGGAGUTGUTGGUATAGAAUAGUTGG
TTGGUUUUAUTGGGUUAUTUTGGGUAGUUTUUTGGGAAGUAGTGAGGGATT
TTUTAAUATAGGAAAGGTGAGA

437 AARGUTGAUATUTTURGGGTGTUTGAAAAUAGAAUTGGUUTTUUTAAGAAUTAAU
AARGAUTATUTTUAUAGUARGTTUUTTGUTUTGUTGUTAUARGUTUTGUTUAAT
AGGTGGGUAGGGGUURGGGTGUAGATGUAGTGGUTUAXGTUAGTAATUUUAGU
TUTGGGAGGUTGGTGGGGATUATTGAGGUAGGAGTTAACAGAUUAGUTTGG
UAAUATGGTAAUUAUTGTUTUTAUTAAAATAAAAAATTAGURGGGTGTGGTG
GUAAUAAUUTGTAGTTUAG

438 UTGGAAUTAUAGGTTGTGUUUAUAAUURGGUTAATTTTGATTTTAGTAGAG
AUAGGGTTUUAUATGTTGUUUAAGUTGGUTTTAAUUTGGUUTUAAGTGT
RGUAAAUAUAGTGUAGTGTGGGATTAUTGAXGTGAGUUAUTGUATUTG
UURGGGUUTUTGGGUUAUTTTGAUAGAGRGTTGAGUAGAAUAGGAAGGG
GTGGUTGAAAAGTATRGTTAGTTUTAGGUAGGAGTTUTGTTUAGUAA
UURGGAAAGATGTUAGRGTT

439 GAGGUUAAAARGGUUUUAGUTUARGATATUTGUAGAGAGGUAAAAGGG
GAGGAUTUAGGUATGTTGUUTGUUGUTGUUUTUUTUUTGUUUTGG
GUUTGAGGUAGGGAGGUUAAGUTGGGUUUTGUUUTGUU
UUTGTGUUUAAGGUUURGGGUUARGUAGCTGUAGTGTGUAGGU
UTAGGTGUAGGUARGAUAAUAAUAGGUAGGAGGUAGGU
GUUUTUTGRGGUTUTGUUTUU

440 TGGGAAGGUAGAGURGUAGAAGGGUUUAGAAGGTGUUTTGUTUTG
GGTGTGTRGTTGUUTGUAUTAGTAUATGTGGGUUTGUUAUTGAGUAAUTGUR
TGGURGGGTGUTGGGUUAAGGGTGGGUATTGGXGGATGGGT
GUUTGGUTUUTGGGUAGGGUURGGGUAGGGAGTGGAGGAGTGGAGGU
AAGUAUTGUUTGAGTTUUTGUUAGGGTTGGUATUTGUAGATATRG
UTGGGGGRGTGGGTGGGUUT

441 GGAGGUAAAARGGGAAUURGGUTGRGGGGUTGRGAGURGGTAGGGARG
UAGGGUTGUAGGUAGGUUURGUUUTGTAUUTUTUUUATAUTGU
GTURGAAATAGGUURGGTAATUUUAGGGRGAGGUAGTXGG
GUUUTGGGUUTGGGUAGGGAGTGGAGGAGTGGAGGU
GAUUAAGRGUAGACTUUAUTGUAGGUAGGU
GUTUUAGGGRGGGTURGRGRGGU

SEQ

ID

NO : Sequence

442	GURGRGRGGATUURGUUUTGGAGRGGGUUTGGGTRGUTTGRGGGTGRRGGTGUUU TGGAAATGGAUTUTGRGUTGTGUAGTURGGGARGRGUAGAGUJUTUTTUTGTGGA RGUUTUXXTUTUTTAUTTUAGGUTGGGGTTAGTTGGAAUUTTUUTTUUGUT TAURGGGGUTATTTRGGAUUUAGGATTAAGTGAGGGATGGGGAGAGGTAUAGGR GGGGUTGTUUAGUAGUUUTGGAUUUAGRGTUUUTAURGGUTRGUAGUURGUAG URGGTTUURGTTGUUTUU
443	UATGTGUTGAGATGGAGAAGGRGUUAGTGUTGUAGUAUTAGAUAGGUTGAGATGTUA AGTGGAAATCTUAGGAGGTGGTGGAGGAGUTGAGGAGUTGUAGGGUTGTGAGGUU RCGGAGAGGGUUAAGAGUTGUAGUTTTAATTCGAGGGTUAEXGUATGTGAGGUU AAGGAAGUAGATGGGATGTURGGGGAGAGGTATGGAUTGAAGUAGUTAAAGAAT TGUAGUATUTAATGGAUAGGAAGAGGGGUAGRGAUAGRGAUTGGAGUUTGAGAAGG AGGGTGUAGTGTUUUUAAGUATG
444	AUATGGUTTGGGGAUAUTGUAUUUTUUTTTUAGGUTUUATRGUTGTRGUTGUUUU TUTTUUTGTUUATTAGATGUTGUAAUTTUTTAGUTGUAGTGUUAUTAUUUTUU RGGUAAUTUUUATUTGUUTTGUUTUUATGUAGXGTGAUUUUTUAAUTTAAGU TGUAGUTUTGUUUUUUUURGGGUUTUAAGUUTGUAGUTUUUAAUUTUUAAU UAUTUUUUUUTGAUATTGUATUTGUAGTGUUTGUAGTGUUTGTGUTAGTGUAGUAUTGGRG UTTUUTUUATUTUAGUAAUTG
445	UUUTUAGGTTGGTTUTGTGURGUTGTTTUTTTUUAUATUATAAGUUTUT TUUTTATUTTTUUAUTGTUTGUAAUAGGAAGRGGUATUAUTGTTTUTATGTUUTG RGUATRGAGGUAAUTTUUGUTUUTTGTGUUGURGGGUUAGGUUUA GATGGTAGGUTTGGUUUUAGGUTGUTGTGAGTGUAGAGTGUAGGUAGGAAGUAA ATGCUAAUTTUAUURGGGTGAUTGAGGAATGUTTAARGAAGGRGURGUUUTTGUA ARGGTGTGGTTGGTAA
446	TTAUAAAUAUAUARGTTGUAAGGGRRGUUTTRGTTAAGUATTUUTUAGTUAU RGRGGTGAAGTGUUATTGUTTGUUTGAUTUTGAUTUAUAUGUAGUUTGG GUAAIAAGTUUUAUTTGTGGGUUTGGGURGGUTGGXGUUAAGAGGAGUAG AAAGTGUUTRGATGRGUAGGAUTGAAAAAAAGTGTGUTGURGUTTUUTGTG AGAUATGAAAAGATAAGGAAGAGGUTTATGATGTTGAAAAGAAAUAUAGRG AAAAGAAAUAUAAAATGAGG
447	TGUTUUTUTTGUTGURGUAGURGGGUUAGGUUAAGATGGTAGGAUTTG UAGGUTGUTGTGAGTUAGGUAGGAAGUAAATGGUAAUTTUAUURGRGGT GAUTGAGGAATGUTTAAGGUAGGRGURGUUUTTGUAUAAXGGTGTGGGTGGTAAA GGAAAAGURGGGAGUUTGUAGRGURGGTGUURGUUAURGTTAGTUTGAUTGTG ATTGAUTAAGTUAUAAGAGGUUAGGUUTGTGUTTGAGGGAAAAAAU AGAAAAGGUAGGTGTGGGUT
448	AGUUUAGUAAUUTGGTTUTGGGTTTUUUTRGGAUAAGTUAAGGUUTGGU UTUTGTGAUTTAGTUAATGUAAUTGUAGTGUAAUTAARGTGGGUUURGG UAGGGUTUURGGUTGTTUUTTTAUUAAAUAUXGTGTAAGGGGUUAGGU TRGTTAAGUATTUUTGUAGTUAURGRGGTGAAGTGUUAATTGUTTUUTGU TGAUTUAUAAGGUAGGUUTGGGUUAAGTGUUTAUUATUTGTGGGUUTGG TGGRGGUAAAGAGGAGUA
449	UTGTGUTUAAGAGUUAUTTUTTAUARGGGTGGGAGGAAGUAGUTUAGGAUTGU TGAGAGAGUAGAAUTUARGUTUAGGUAGGUAGGGTAGGGTGTGRGGUA AGRGTGGUURGGAGUAGGUAGAGTGGGUUUTGGTUTXGGGUAGGATGTTUTGA UTUAUATTTUUTGGAGAGAGAAGUTAAGUTUUTGUUTAATGTUTUTGT TUUAGAAAATGUUTUAGUTTUTRGGUUTGAAGGAATGGGUUTUUTUmGGGU ATGATTUTTUUTGTGTGGG
450	UUUAUAAGGAAAAGAATUATGGGUURGGGAGGGGUUATTUUTUAGGURGGAA GAGUTGAGGUATTUTTGAAAGGGAGAGUAGAGUATTAGGUAAAGAGUTTAG TTUTUTUUTUAGGAATGTGAGTUAGAAAATUUTGUUXGAGGUAGGGUUUAUTU TGUTTUTGTURGGGUUAGRGGUTTGURGUUAUUUUTAUUUTUTGUTUTGAG AGRGTGAGTUTGUTUUTUAGUAGTGUUTGAAGUTG AGAAGTGGUTUTTGAGUUAAG
451	TTTTTTTGAGAUAAGAGTUTRGUTUTGTUAAUAGGUTGGAGGTGUAGTGGRG TUTRGUTUAUTGUAGUTUAAUUTTURGGGTTUATGUUATTUUTGUUTUAG TUUTGAGTATUTGGGAAUTUAGGUAAUTUAAUAXGUURGGUTAATTTU TATTTTAGTGGAGARGGGGTTUATTGTGTTAGUAGGATGUTRGATUTU UTRGATGUAGUURGUUTUAGGUUTUUAAAAGTGUUTGGGATTAUAGGTGT GUUAUTUUTAUURGGGUUTGUT
452	AGUAGGURGGGTGAGGTGGUTUAAUUTGTAATUUAGUAUTTGGGAGGUTGAG GRGGGUTGATUARGAGGTGUAGGAGATRGAGGUAAUTUUTGGUTAAUAGT UURGTUTUUAUTAAAATAAAAAAATAGURGGXGTGGTGGTGAAGTGU GTAGTUUUAAGATAUTUAGGAAGUTGAGGUAGGAGAATGGUATGAAUURGG AGG

SEQ

ID

NO : Sequence

GGAGUTTGUAGTGAGURGAGATUARGUUAUTGUAUTUUAGUUTGGGTGAUAGAGR
GAGAUTUTGTUTUAAAAAAA

453 TTGUUTUTTTGATTTTTUTTGGGUAGGAGTTAGAATGUAAAATAUAGATTUTAT
UTGUTATAAGUUAUAAAGAGATGUTTGGGATUTGGTGTGUTGUUAURGGAGATTU
AAUTTGTUUAAAGTGAUTTUAGGGAGTGTGAXGATUTUAAUTUTTGGAGT
GAUTTGTUUAAAUATGAGUATGUTGAGTTUAGUUAAGTAATATGAGGRGAGUA
AGGUAAAGTGGGTGAGTAAGGAGGAAGUAGUUUAGATGAGURGUAGAGTGUUUUA
TGGGAGTGAGGUATGATG

454 ATUATGUUTUAUTUUAGTGGGUAUTUTGURGGUATUTGGGUTGUTTUUTUUTT
AUTUAAAUAUTGUUTTGUUTRGUUTUATATTAUTTGTGUTGAAUTUAGUATGGUTU
ATGUTTGTGUAAGTUAUTTUUAAAAGAGTTGAGATXGTUAAUUTUUTAGGAATUA
UTTGTGAGGAAAGTGAATUTURGGTGUAGUATUAAUAGATUUAAGUATUTUT
TGTGUTTGTGATTAUAGATAGAATUTGTATTGTGUATTUTAATUTGUUUAAAAGAAA
AAAATUAAAAGAGGUAAU

455 AUAGAGATGUTTGGGATUTGGTGTGUTGUUAURGGAGTTUAAAUTGTTTUAA
AGTGAUTTUUTAGGGAGTGTGARGATUTUAAUTUTTGTGAGTGAUTTGTUAAA
TGAGUATGUTGAGTTUAGUUAAGTAATATGAGGXGAGGUAGGUAGTGGGT
AGTAAGGAGGAAGUUAAGATGAGURGUAGAGTGUUUUAUTGGAGTGAGGU
TGATGAGGATTAUTRGTRGTGGGAGGUATGAGGGUAUTUTUTGGUAGGTTUUTT
UATUAAAATGAGGTUA

456 TGAAUUTUATTTGGTGTGATGUAGGAAUUTTGUUAGAGAGTGUUUTUATGUUUA
RGAGAGTAUTTUTUATGUUTUAUTUUAGTGGGUAUTUTGURGGUUTAUTG
GGUTGUUTUUTUUTAUTUAAAUAUTTGUUTTGUUTXGUUTUATATTAUTTGTGUTG
AAUTUAGUATGGUUTATGGTTGAAUTGUATUUTUAAAAGAGTTGAGATRGTUAU
AUTUUTTAGGAATUAUTTGTGAGGAAATUTURGGTGUAGUATUUAUAG
ATUUAAGUATUTGTG

457 AGUAAAAGAGGGTATGGTUAAAUTGUUTATGAAURGGGAAGUATAATATTTAA
TATTGTGUUTTAAGAGTTGTTTATTTAAAGUAAUAGGAATUUTGTUTTTTU
TGTGAAATUTUAAAAGUATGGGAAAGATUTXGUAGGUAGTGGTTTUAA
AGTGGGTTUUAGAAUTAGUAAAAGUTGAATUATURGGGAUTGGTTAGAAATGUA
AAGTURGRGUUAUUUUUUUUUUAGAUUTAATGAAUAGAAATTUTGGGG
TGTGGUUUAGTGGUUTGR

458 RGUAGGUUAUTGGGUAAAUUUUAGAATTUTGGTTUATTAGGTUTGGGGGGTTGA
GGGGTGGRRGRRGAGAUTTGUATTUTAAUAGTTUURGGATGATTUAGUTGTTGUT
AGTTUTGGGAATRTUAUTTGTGAAAGGAAUTGGUUTGXGGAGATUTTUUAAUTU
TGTAAAGATTTAAUAGAAAAGAUAGGATTUUTGTGUTTTAAGTAAA
AUTGUTTAAGGUAAAATATTAAAGTGUUTUURGGTTUATAGGUAGTTGA
UUATAUUUUTUTGTGUT

459 GUUUTAUUURGUTUTURGAUTUUUURGGGUURGGUUTGRGUUTTUUTGRGGTGU
RGAGGAGRGTCGGRGUUUTGGGTGAAGAAGTURGRGAGTRGAGGGGRGUATG
GAGGAGRGURGGAAUAGGTUTUUTATTURGAGTAGUTAUXTGTTGUATGTRGAGT
GTAAAAGTUAUTUUUUAURGGTUTUAGTGTUUAAUUTUAGTTGAAGTGAGGAG
TTGGAUTGGAGGTTUTGGGTUAUTUUAGTGAGGUTGGGGTTUTAGTUUUAA
TUAURGTGGUAAAAGGU

460 GUUTTGGGTGUARGGTGAGATTGGGAUTAGAAGUUTAUTGGAGTGGAU
UUAGAAAUAUTTUAGTUUAAUUTUUTTUUTTAUTGAGGTTGAAUAAAUTGAGA
URGGGTGGAGTGAUTTTAUAUTRGUUAAGTGUAAAXGGTAGUTAUTRGGAAUTGAG
AGAUUTGTTURGGUTUUTUATGRGUUUUUTRGUATRGGRGGGAUTTUTTU
UAGGRGUUAURGUUUTRGGUAGUAGGAAGGRGUAGGURGGGUURGGGGAG
TRGGGAGAGRGGGTAGGGU

461 GGAAUAAATUTGTUTTUUAAAGTTGGUAUTAAGAGUTUUTUUTGRGGTTUUUUTT
UUTUTUUTRGAGUAGUAAAAGGRGTTGUUAATGUUUUUUTUTGTGGGTUTAGG
GTGUURGGUTGUTGAUTTUAGGUAGTGUUAGGUAGUATGGAGAUUUTAAGU
TGGGUAGGUUUUTUATUAUTGGAGUTGUUAGGUAGUATGGAGAUUUTAAGU
AATAUTATTGGUUAATATTAAAGUATTGTAAAAGUURGGGTATGUTGGUA
AATUTTTAAAAGAG

462 UTUTTATTTAAAAGATTGGUAGUATAUURGGGUTTTAUAAATGUTTGATAATT
ATTGUAAAATAGGTATTGGUTTAGGGTUTUAGTGTGUTGUUTGGUAGUTUAGT
GATGAGGGGUUTGUUAUTGTATGUAGTUUAAAATGUUAGAGGGGUUTGG
AGGUAGUAAGURGGGUAAAAGGUAGGUAGGGTGGGUATTGTGGGUARGU
UTTGUTGUTRGAGGGAGAGGAAGGGAAURGUAGGAGGAGUTUTTAGTGUUAAUTT
TGAAGAAUAGAGATTGTGTTU

463 AUTGAGRGUTUTUUUUUAGUAGGUURGGUTGUUATUAAGGGUTTAUUTGTGG
GUTGUUARGUTGUTGTAAUUAAGUTURGTGGTGTGAGAAGUUAUT

SEQ

ID

NO : Sequence

GTUTUUTUUUARGGUTGTGTAGGTURGGTUUUTAXGGUTUAGUUAGTUUUU
TGUTUAGGTTAAUAGGURGGAATUAAGATGUUAGGGUUTGGUTGTGUTTGGA
GGUTUTTGGTGAGAAUTGUTTUTGGUUTGGTGUAGGGTGTGUAGAATURGATG
UTTGAGTTGAATGGTCAA

464 TTTAUUATTAUAAAATUAAGUATRGGGATTUTGUUAUAAUUTGUUAUAGGUAGAA
GUAGGTTUTAUAAAAGAGUUTUAAAAGUAUAGGUAGGUUTGGUATUTGATTUR
GGUUTGGTTAAAUUTGGAGUAGGGGAUTGGUTGGUUXGTAGGAUTURGGAUUT
AUAAUAGURGTGGGAGGAGAAUATGTGUTTUTUAUAAAUAUARGGAGUTTGTGGTUAU
TGGTAUAGUAGRGTGGUAGUAGGUAGGGTAAGUUUTTGATGUAGRGGGUUTG
UTGGGTGGAGAAGRGUTUAAGT

465 AAAUTUARGUTGGGUAAAAGAGGGAGAAUAGAGAAGUTTUUTGGUTGAGGUUAGU
RGAUTGUTGAUURGGAAAAGTTTURGAGGTGAUTUAUATUUUAGUUTUTGUUA
TGTGGGTGAGUAGTGTGAGUTUTGUUTGUATGGTGUAGURGAGTGAURGAA
TGUAGTUUUUTAGUUUUTAUATUUUUTAGGGTUUTAGTGGAUTGTAAGUTGGTGA
AAGAGTTGTGUTGUUUTUAUT

466 GTGAGGGUAGUAAAATUTTATUAUAGUTTAUAGTUUAUTAGGAUUTAGGGATG
TAGGGGUAGGUTGGGAGATTGGTGAUTGGUTGAGUAAUTGGGAAGTAGGUAGA
TAAUUTAUTGUUTGATGAATAUTURGGXGTUUXGTGUAGTUAAGGGAAUAGAG
UTAAUAUTGGGUAGUAAAATGTGAGGAGGAGGGATGTGAGTUAUUTRGAGAA
AUTTTTRGGGTUAGUGRGTGGUTGGGUUTUAGUAGGAAGUTTUTGTTTUTUU
TUTTGGGUAGRGTGAGTTT

467 AUTTGAGGRUTTUUUAAAAGUAGGUURGUTGUUATUAAGGGUTTAUUTGTGG
GUTGUUARAGUTGUTGTAUAAAAGTGAUUAUAAAGUTURGTGGTGTGAGAAGUAAUT
GTTUTUUTUUTARGGUTGTGTAGGTURGGAGTUUUTAXGGUTUAGUUAGTUUUU
TGUTUAGGTTAAUAGGURGGAATUAAGATGUUAGGGUUTGGUTGTGUTTGGA
GGUTUTGGTGAGAAUTGUTTUTGGUUTGGTGUAGGGTGTGUAGAATURGATG
UTTGAGTTGAATGGTCAA

468 TTTAUUATTAUAAAATUAAGUATRGGGATTUTGUUAUAAUUTGUUAUAGGUAGAA
GUAGGTTTTAUAAAAGAGUUTUAAAAGUAUAGGUAGGUUTGGUATUTGATTUR
GGUUTGGTTAAAUUTGGAGUAGGGGAUTGGUTGGUUXGTAGGAUTURGGAUUT
AUAAUAGURGTGGGAGGAGAAUATGTGUTTUTUAUAAAUAUARGGAGUTTGTGGTUAU
TGGTAUAGUAGRGTGGUAGUAGGUAGGGTAAGUUUTTGATGUAGRGGGUUTG
UTGGGTGGAGAAGRGUTUAAGT

469 GRGAATAAAAGUAGTGTGAGUAGAAGTUTGGGAAGATGUATGUAGAGTGTGA
UAGGAGAGTTAGGGUTGTGTGAUAAATURGTGAAATGGAATGTTUTAAAGGRGAGGGT
ATGTGTGTGGGTGAGGAUURGGUTGGATTTAXGTATTAAUTAGUAG
ARGGAGUTAAUTUAATGUAGTGUAAUAAAATTAUTAGTGGGTATGATTG
AGGAATGAGGAAGGGAGAUAAGGTUTGGTGAATUATUTGTGGGATTATUTGT
TGTATTGUTGGTTGTGA

470 TAUAAAAGUAAAATAUAUAGATAATUUUAAGATGATUTUAUAGAUUTGT
TTTUUTTUUTTUUTTUUTUAAAATUATUUUAUTAATAUTGTTUUAAGGU
AATTGAGTATTAGTGUURGTATUTAGUTAAATAAATAXGTAAAATUUAAUAGURG
GGTUUTUAUAAAUAUAAAATUUUTRGUUTTAAUATTTUARGGATTGTUA
UARGAGUUUUTAAUTUTGTUAAUATTTGUATUTGUUTTUUUAUAGAUTGTU
AUUAUTGGUTTTATRGU

471 UAGTGAGUTGAGAGUARGUUAUTGUAUUAGUUTGGGGATAGAGTGAGAUT
GTUUUAAAAGAAAAAGAAUTGATUUAAAATGTGTGGGGAGAUTGATTUAG
TAATAATAAAATURGGTUUUAAAUAUTGUAGUTUTGXGTGAATUUUTTTU
TATTGRGATTUUUUTGATTGAGTGAUAGTAAATURGGTUTUUTGUUAAGUAG
UTUTGRGTTGAGTUATUTTTUTUUTGTAAUTUUUUUATTTGGTUTTGATU
GTUTGGGUAGUAGGUAGGT

472 AUUTGUUTGUTGUUUAGUAGAGAGUTGATGGATUAAGAUAGGGAAUTAUAGGG
AGAAAAGAATGAUTUARGUAGAGAGUTGGUTGTGUAGGAGAURGGAGTTTAUTGTUA
TUAAAATUAGGGGAUTGUAAATAGGGAAAGAGGGATTUAXGUAGAGUTGGUTGT
GGGAGAURGGAGTTTATTAAUTGAAATUAGTUTUUUUUAUATTTGGTATUAGT
TUTTUTTUTUTUUUAGUAGAGUTUAUTUTATUUUUUAGGUTGGGAGTGAG
GRRGTGUTUAGUTUAUT

473 GGATGTRGGTGTGUUAUUUAGUTUUAUUUAUTGUTAAAGUTTAAGUTUTUU
TUUUURGTTAAGUTGTATGAUTTGAGTUUTTGUTGUUTAUTGTUUTATUTGTUA
AGTAAAATGUTUUUAGTUUUUUAUTURGGAGTTGXGTGGGAGGUAAUATGAA
UAUAGGAAAGTGAATTATGUAGUURGGGUACGGAUTURGGUTUTGUUTUTGU
UUTAATUUUARGGUUTGGGGAAARGTGUAGGGUTGAGGAAGRGUAGUUTU
TGGAATUTUAGRGGAAAGUTU

SEQ

ID

NO : Sequence

474 GGAGUTTURGAGATTUAAGGAGAGGUTGRGUTUUTUAGUUUTGUARGTTUU
UUUAGGURGTGGGATTAGGUAGAGGUAGARGAUURGGAGTUUTGGUURGGGUTG
UATAAAUTAUTTUTTGTGTTUATGTGTTUUTUAXGUAUTUURGGAGGTGG
GGAUTGGGAGUATTTUATUTGAUAGATGAGGAUAGTGAGGUUAAGAAUTUA
GGTUATAUAGUTTAARGGGGAGGGAGAGUTTAAGGUANTAGUAGTGGGTGGAGU
TGGGTTGGUUAURGAUATUU

475 TAATTGAATUAUATAATTUATTUATTATUTGAGTTUURGGUTTAGGUTUTTGAG
TAUAGGAGGUATGGGAGTGAUTATGUTUUAUTUUTRGUTAGTUAAGAAUTGU
UAGGAGGUURGGGTTCTGTTATTUARGTTAUAGAXGTAAGGUUTUUTGUUUAU
UUAGUAUTUUAATTTUATGAUATATGAAGGUTUTGAUATTGUAAAURGGAUTA
RGUAAGUUTTGAUTTUURGGGTTGTGAGGAGTTTAGAAAATAUTGAGAAGU
AAUTTTTGAGGATGATG

476 UATUATUUTUAAAAAGTTGUTTUTUAGTTATTTUTAAAUUTUUTUAAAURGGA
GAAGTUAAAGGUTTGTRGTTAGTURGGTTGUATGUTAGGUUTTUATATGTUATGA
AATATTGGAGTGGGTTGGUAGGAGGUUTTAXGTTGTAARGTTGAATAUUA
UAAAURGGGUUTUTGGUAGTUTTGAUTAGRAAGGGTGAAGTGGAGUATAGTU
ATTUUTGATTRGTTAUTUAAAGGUUTAAGURGGGAUTUAGATAATGGAATG
AATTATGTGATTUAAATT

477 UAAUATTUTTGATUUAGUATUUTTGTUATGTUATTUTATAGTGTUTUAUTAA
AGTGATGGUUAATTUUTAUUUTTRGAATURGGUTUTGGUAATGGGATGTTAAU
AAUAGUTUUAAAAGAGGATUAUATAGTAUTTGXGTGAGGUUAAAUTTUTTAT
GTTUTUAGUATGUATGAGAAUAXGUUTGGGUAGUUTGUTGAAGGAGUTGAGU
TGAGTUATURGGTGAUAGUAGUTGAUTUTTAGUAGTGAAGGAGUAAAUA
AGUTGUTUTGUTGAUUAU

478 GTGGTUAGUAGAGUAGUTTGTGGGGTGUUTUTUAUTGUTAAGAGTGUAGUTGGUT
GTUAURGGGATGAUTUAGUTAGUUTTUAGUAGGUTGAUUUAGGXGTGTTUTUA
TGGUAUTGGUAGAAUATAAGAGGGGAGTGGGUUTUAXGUAAGTAUTATGTGATUU
TUTGTTGGGAGUTGTTGTTAAUATUUUATTGUAAAAGUURGGATRGAAGGGTAA
GGAATGGUUTAUTTACTGAGAGUATUTAGAATGUAUTGGUAAAGGATGU
TGGATAUAAGGAATGTTGU

479 GUTUTUAUTAAAGTGTGGUUAATTUUTTAUUUTTRGAATURGGUTTGGUAAAAT
GGGATGTTAAUAAAAGUTUUAAAAGAGGATUAUATAGTAUTTGXGTGAGGUUA
TTUUUUUTTATGTTUTTUAGUATGUATGAAUAXGUUTGGGUAGUUTGUTG
AAGGAGUTGAGUTGAGTUAUTURGGTGAUAGUAGUTGAUTUTTAGUAGTGA
GUAAAUAAGAGUTGUTUTGUTGAUAAAAGUAAARGAGUAAAAGAATG
TTAUUATTAUATGTUAUTGAG

480 TUAGTGAUATGTAATGGTAAUATTUTTGTGUTRGTTGUTGGGTGGTGUAGUAG
AGUAGUTTGTGGGGTGUUTUTAUUTGUTAAGAGTGUAGUTGGUTGUTUARGGGAT
GAUTUAGUTUAGUTUUTTUAGUAGGUTGAUUUAGGXGTGTTUTUATGGUATGUTG
AAGAAUATAAGAGGGGAGTGGGUUTAXGUAAGTAUTATGTGATUUTGTTGGG
GUTGTTGTTAAUATUUUATTGUAAAAGUURGGATRGAAGGGTAAGGAATTGGU
UATUAUTTTAGTGAAGAGUA

481 UUUUAGUAAAUAUTRGAUTGUUUUUUATUAUUTATAUTGGURGTTTUUTGG
AGUUTGUAAAUAAGTGGUAAAUAUTTGTGGUURGGAGGUUUTUTTUAGUTTGGT
AGTGGUUTAGTGAUATGAGUAAAUAUURGGUUTUXTGTTUUTAGUAAAATU
UAGRGGUUTUTURGUUTURGUUTUUAAGAGGUUAAAUTGAGUTGRGUAGTGU
ATUUAARGAUAGUATUUUATTTAUTUAGRGGUAAAUAUTUUUARGGURGAAU
AUTGAUATTUUUTGAGUUAU

482 TGTGGTUAGGAAAATGTUAGTGTGGGTGGGAAGGTGGCTGURGUTGAGTA
AATGGGAUTGUTGTTGGGATGGUAUTGRGUAGUTUAGGGGTGGUTUTGGGAGG
RGAGGRGGAGGAGGURGGUTGGAGATGGTGTGAGGAXGAGGAGGURGGTGGGT
GGTUATGUTUAUTAGGUUAUTGAUUAAGUTGAAGAGGGGUTRGGUUAAAAGGT
TTGUUAUTGTTGGGTGUAGGUTUAGGGAAAAGRGGUAGTATAGGTGATGGGG
UAGTRGAGTGGTTGGUTGGG

483 GUAGTGGUTGGGUUUUUUUUUUAGGAAUTUAUUUUTGGGUAGURGRGGG
TGGRRGGTTGGGUAGGUAAAAGAGGGUUTUTGTRGGGURGGUTGGGUU
UAGGATTUTGGGGAGGGAGGURGGAGUTGTTUXTGTTUURGGUTGGGU
AGGUTGRGGAAUTGUURGGAGUTUTGGGUAGUUTGUUURGGUTGGGU
GUUUTUUUATTUUTTUAGGGUUTTGGGTAAUTG
AGGGGUUTGAGAGUUAUUUUA

484 TGGAGGGTGGUTUTUAGGGUUUTGTTGUAGAGAAGTUTGUAGUTGTAUUUAAGGU
UUTGGAAAAGATGGGAAGGGGUTGRGGTGGGUAGARGGGGUAGGUTGGGU
GAGUTURGGUATTURGUAGUUTURGUAGGAAGUAGAAXGGGARGGAAAURGG
URGGUUTUUTUUUAGAATUUTGTTGGGUAGGUUAGURGGURGUUAAGAGGUU

SEQ

ID

NO : Sequence

UTTGTGUUTGUUUAAAURGUUAURGRGGUTGGUUUAGGGTTTGAGTTUUTG
GGGGTGGGGUUUAGGUAUTGU

485 AGGUAUURGTUAAARGGUAGGUTATTTTTGTATTTTAGTAGAGARGGGTT
TUAURGTGTTAGGUAGGATGTTAGTUTUUTGAUUTTGATUUAUUAAUUTUA
GUUTUAAAAGTGTGGGATTAAUAGATGTGAGUTAUXGUAUURGGUAAAGTTUATG
ATUTTUTGTAUTGAGUAGTGTAAUTGGUAAGAAATGUUUTGGUATTGTGTTG
TGGATGGAAGUAGGUAAUTGUATUUTTUUTTAGAUTAAGTTGUUTGGUUT
GTGGAUUTTUTUAGGUAG

486 UTGGUTGAGAAGGTUUUAAGGUAGGUAAUTTAGUTAGGAAGGAATGGATGUAA
TGTGUUTGGUTTUATUUUAUUAATGUUAGGUATTUTTGUAGTAAUAT
GGUTUAGAGTAUAGAAAGATUATGAAUTTGURGGGTGXGGTAGUTUAAUTUTGTA
ATUUAUGUAUTTGGGAGGUTGGGGTGGGATUAAGGTUAGGAGAUTGAGA
UUATUUTGGUTAAARGGTGAAAUUURGTUTUTAUTAAAAATAAAAAAATTAG
URGGRGTTGTGARGGGTGUUT

487 TTURGTGGGGATGUAAUUTRGTTGUUUUTUTGAUTUUUUATGAGATUTRGUTT
UUTUUAUUAUUTUUTTATUUUUAAAAGGUAGGTGUAGUT
GGGTUTGRGGTAGGGGUATTUTAGGTUTTGAXGUUAGGUAAURGGTUUAGT
UURGGUUAUAGUUTTGGGUUAATGAGGGUTGGGUUTGGGUAAGURGAAATUA
GGGUUTGGUTGTATUUAGAAAGAGAAUTGAGAUURGTTGUUTUUUAUTGGGUUA
UUUURGUUUUAUUAUATA

488 ATGTTGGTTGGGGTRGGGGTGGGUUAGTGGGAGGUAAARGGTUTUAGTTUTT
UTGGATAUUAUAGGUAGGUUUTGATTTRGGUTTGUUUAGGUAGUUTUAAUTTGG
UUAAGGUTGTGGURGGGAUTGGAUURGGGTUTGGXGGTUAGAUUTAGGAAT
GTUUUUTAUURGUAGUAGUAGUTGUAGUUTGGTGGAUURGGUAGGGGGTTGGG
GATAAAGGGAGGTGTGGAGGAAGRGGAGAGATUTATGGGAAGTUAGAGGGGUAA
ARGAGGTTGUATUUUUAUARGGAAT

489 UTTATAUURGGTUUTRGUUUUTUAGRGURGGUUTRGUURGRGUTUUTGAGAAAGU
UTGGUURGUTRGUTUARGGURGTGUUUTGGUUAUTTUTGUTGRGGURGGGG
UUUTGGGAAGGUUTTUUUTGUURGGGUUTXGAGGAUTTUUTTGGUA
GGRGTGGGGGUUTUTGAGAGUAGGUAGGGUURGGGUUTTGTUTURGRGAGGUUA
UUURGGUURGUUAUTRGUTTGRRGTUTGAAUUAUARGGUUUUTGUAGGGUTG
GGUURGGGTGAGGGAGUTT

490 GAAGUTUUUUTUAURGGGUUAGGUUUTGUAGGGGGGRGRGTGGGTUAGAURGU
AAAGRGAAGGTGRGGURGGGTGGGUUTRGGRGGAGAAAGGGURGGGUUTGUU
GUTUTUAGAGGUUUAAGRGUUTGUUAAGAGGAAGTGUUTXGAGGUURGGUAGGG
AAGGGGUARGGGUUTUUAAGGGUURGGURGGUAGUAGGUAGTTGGUUAAGGG
ARGGURGTGAGRGAGRGGGUAGGGUTTUTUAGGAGRGRGGGRGAGGUURGGGU
TGGAGGGGRGAGGAUURGGGTATAAG

491 AGUTUUTTATUAGAAAGGGUAGURGUAGAGUURGRGTGTRGRGATGTGGUTGRG
GGTGGGAGRCGGGRGGGUURGGGAUURGRGGUUAUTGTTUTAGUUURGUUT
GGURGUUTGAURGRGGUTURGUURGUAGUURGXGUUUTUTGGUTUUTGT
TUURGGGRGGGGAGAAAGGRGGGGRRGUUTGGGUURGRGGGTGRGAAR
GRGAGGTUTTUUTGGGTUTUUUAGGTRGGAGGATTUUUAGGRGGGGUUATUA
GGTGGRGAGGAUURGGUAGGG

492 UUUTGURGGTTUUTRGUUUAVUUTGATGGUUUURGUUUTGGGAATUUTURGAUUTGG
GAGUAAAAGGAAAGGUUTRGRTGTRGUUURGRGRGGGUUUAAGRGRGUUURGU
RGUUTUTUURGRGUURGGGAUURGGGUAGGUAGGGGGXGRGGGGUTGRGGGU
GRGGAGURGRGTUAGGRGGGUUAGGRGGGGUTGAAUAGTGGURGRGGTGUUR
GGGUURGUURGUURGUUTUUUUAURGUAGUUAUTRGGRGUUAUARGRGGGUUTGR
GUTGUUUTTUTGATAAAGGAGUT

493 TGGAAAAGUAAAATGTGUAAAATRGUTTUTAURGTUAAAGGTGAAAGGAAAA
ATGUUAAAAGGAGAGUTGGAAUUAUAGUAGAAGAGUAATGAUUUUTGUAG
AAUATGAAATAAGTURGGUAGTGAUAAAUAAGAUAXGGAAAATAAGGTUUA
AAUUAGAAUTGGTUAAGGAAUUAUTGTGUTTAGACTAAUAAATTAAUAAAGGA
AAGAGGAGTRGGGUAUTGTAATATUURGGGUAGUTTGTAUTUTGGGTGG
GUATTUTGTAATTAAATTAAATU

494 GATTAATTGAATTUAGAATGUATTUAAAAGAGAGTAAAGUTGUAGTGUURGGGA
TATTAUAGTGUURGATUUUUTUTTGUUTTGTAATTGTTAUTUTAAGGUAAUTGG
GTTUTGUAUAGTTGGGTGGGUUTTATTTUXGTGUTTTAGTGGGGTTUAUTG
URGGATUTTATTUATGTTUTGUAAGGGGTUATTGUTUTTGUTGTGTTUUA
GUTUTUUTTTGGUATTUUUTUTUTTUTTGARGGTAGAAGRAATGTTGUA
UAGTTGGUTTTUUA

495 UTGAGUAGATTGAUATGTTAATUAUAAAAGGUUAGGGTTGTGTTUAGAGAUAAAG
TUAGTGTGAURGGTGAUTGTTAUAGUAATAUAAAATAATGGUAGUAGTUUUAUTAG

SEQ

ID

NO : Sequence

URGAGGUUAGUATRGAATAGGGUAAGTTAUTUAAAUXTUAAUUTAGRAUUAU
TUUAAAUAUUTGTGUTTAAUTAAUTTAGGGAGUURGGTTTGUAGGATGTGUAAU
UARGTGTGUUUUUTAGGGUTUAUAGAUTTACTAUUTAATGUAGUTAUUUTAU
RGTCGUUUAGGTTUUAGGGA

496 UUUUTGGGAAUUTGGGUUARGGTGAGGGTAGUTGUATTAGGTAUTAAAGTUTGGTA
GUUUTAGGGGGUAUARGTGTTGUAUATUUTGUAAAURGGGUTUUUTAAGTTAG
TTAAGUAUAGGTGTTGGAGTGGTRGUTAGGGTAXGTGTTGAGTAUTTGUUUT
ATTRGATGTGGUUTRGGUTAGTGGGAUTGUTGUUATTATTTGTATTGUTGTAUAA
GTUARGGTUAUATGAUTTGTUTUTGAUUAUAAAUTGGGUTTGTTGTGATTAA
UAGTGTAUATUTGUAGG

497 AAAUAUAGGUAGTGTUTAGUUTUTGTUUTUATTTUUAUAAAAGGTTG
UUAGTTUUTTGUUUUAUAGTGATGGGUTTGGAUTATGGGTGTTUATTURGGGUTT
UUUTGGUTTGUUTTAUTTUTUATGGGTGUTTGAGXGUUTTTTUGAGRGGUUTAG
GUTTUUUUUUUAUAAUUTIUTUUTUTGUTTUTAUAGGUAAAAGGTTAGATT
TRGGTUAUTGAGTUAUTUUAAAUTGGGTGGAAGUAUUTGGGUAAAUAUUTTGT
TTGGGUTUUTTTAGUT

498 AGUTAAAAGGAGUAAAATAUAAGTGGTGUUUAGGTGUTTUUUAUAAAAGGTTG
GATGAUTUAUTGURGAAGUTUTGAAUUTUAUTGUUAGATAGAAGUAGGGAGGA
AGGGTGGGGGGAAAAGUUTGAGURGGUTUAAAAGGXGUTUAAAGUAAAATG
AGAAAGTAAGUAAGGUAGGGAGUURGGAAUTGGGUAAAAGGGAGGGGAGAAAATGAGGA
GGUTAGAAUAGAUTGGGUTGTGTT

499 GTUUUUAAAAGGUTGAAUUTTGATUAATGUAGUUUAAGUTGUARGGGUAGAGAAA
GGGTGRGGGGTAGGGGURGGGGTTGGGRGUTGAGUTUUTUTGAUARGGTGTTGUAGG
UAAAAGAATGGAAATTUARGGGGRGGUTAAATGGAGUTUXGUUAAAATGTTUTGTG
GUAAAURGGAAUAGGUAGTGUUATTRGUUUTTUUUUUUUUUUUUUUUUUU
TUTIAUTGTAATGAGAAGGGTGUAGAGAAGAUTUTTTUTTRGGAGTUAUT
URGGTTGUAUTGUTTTUA

500 TGAAAAGUAGTGUAAAURGGAGGUATGAUTURGAAGAAAAGAGTTUTUTGUA
UUUTUTUATTAUAGATGAGAAAATUAGTGGGTGGGAGGGGAGAAAGGR
GATGTGAUTGGGTGUURGGTTGUUAAGAAUATTGTGGXGGAGUTUATTTAGUR
GUURGTGAATTUUATTUTGTGUUTGGUAAAURGGTTUAGAGGAGUTUAGRGUUUA
AAUURGGUUUUTAUURGUUAAUUTTUUTGUURGTGUAGUTTGGGUUGGUUUU
UAAAGGTTUAGUUTTGGGAU

501 UTUUAURGRRGUUTRGUUUUUTGAGGAGGGGGUTGGGUUAGGGUUTRGGUTGAUR
GGGAGGAAGGGGGAGUAGAGAAAAAAUATGACTUAUAGURGTGTTUAUTGCA
GRGUUTTUAUUTGUATUAUAGGAGGTGTGGAGGUUTRGGGGAURGG
RGRGGGAGGTGRGUURGGAGGUUTRGGUTGUAGGGRGRGURGUTURG
UUTGRGUUUTTUUTUUTUUTGUURGUUATUTUUUTTGUTTUUTTU
TRGUTRGGTGUAAAAGTUTT

502 AAAGAUTTGTGUURGAGRGAGAAGGAAGUAAAAGGGGAAGATGGRGGGGAGGG
RGGTGGGGAGGAAGGGRGUAGGRGGAGRGGRGUUUTGUAGGURGGUURGG
GUUTUTRGGRGUATUTUURGRGUURGGTUUURGAGGXRGGUUTTUUAAA
TGTGATGUAGGAATTGAATGRGUUATGGAGTGAUAAURGGUTGTGAUTUATGTTT
UTUTGUUUUTTUUTUUTUURGGTGUAGRGAGGUUTGGGUUAGUUUUTU
AGGGGRRGAGURGGRRGGTGGAG

503 UUTGAAGAGUATTUUTGAGTGUUTUAATGATGUAGAGUATGTUTUATGR
GGAGGATGGGAGGURGGUTUUUTGUAAGATUTUATGGAGAAGUTGUTUUAGU
RGGUUTTGTTGUURGTUUUAGGAGGAGRGAAAAGAGUXGAAGGUAAA
GGGUUAGGUUAGGUUTTUUAAAGTURGGAGGUUAGGUUTGUUUTRGGU
UTTUTGUUUTUUTUAGUAGTGUUUTTUTTGUTGUATTUUUATUUTUR
GUUUUTUUUTGTGUTGUTGT

504 AUAGAGUAGUAUAGGGAGGGGGAGAGGATGGAAATGUAGAGAUAGAAGAAG
GGAGGCTGTUTGGAGGAGGATGAAGGAGURGGAGGGGUAGGUTGGGTGAGUTURGG
AUTTGGAGGGUTGGGUUTGGGUUTGGGGGTGTGGGUTTXGGUTUTGTTURGUT
UUTUTCGGARGGGUUAUAAAGURGGUTGGAGTGUAGGUUTTUUATGAAGATUTGU
GGGAGURGGUUTUUUATUUTURGUATTGAGAUATGUTGGUATATUATTGAGU
AUTUAGGGAGAATGUTTUTUAGG

505 ATGTUTGGGAGGUAAAAGUATUTUAGAUAGTUTUTAUAGGAUTUTUAGGTU
URGGAGGUURGAGRGAGUTTUUTGGAGGAGGTGGUTGGGGAGACTGGAGGAGURG
GTAGGGGTRGUTGTGUTTGGRGRGUURGTUUAGGAUTXURGGGGUTGTGGGA
GGGGGRGURGGUUTGGAGGAGGAUTGTAAUTGUTGTTUTAAUAAA
UAAARGUUAUTTUUUAAAURGTUTUTTGUTGUUUTUUAGGUUURGGGUTAGAU
GGGGUTRGGGURGUUAUTUAU

SEQ

ID

NO : Sequence

506 GTGAGGTGRGGUURGAGUUUTUAGGGTUTAGUUURGGGUTGGGAGGGUAAGAG
ARGGGTGGAAAGTGTGRGTTGGAGTGGGTGGTAGAAUAGAUTGTAUATTG
TUUTUTUAGGURGRRGUUUUTUUUUUAGUUURGGXAGTTUUTGGARGGRG
RGRGUAGUAUAGRGAUUUTAURGGUTUUTUAUTUUUAGUUAUUTU
AGGAAGUTRGUTRGGGUTTURGGAUUTGGAAGAGTUUTGTAGAGAUTGTUTGAGA
GATGUTTTGGUUTUUAGUAT

507 GGAGRGUTAARGRGRGUAGTGGGAGGGAGAGGAGAUTGAAGAGAGARGGGGAGG
GGAGAGGGGGTGGGUTGUAGGUUTAGGTGGGTGAATURGUAGUTGGGUTGA
UTUAGRCGGAGCAGURCGAAGGAUAVURGRGAGGUTTXGGGRGRGUUTTTAGG
GAGGRGURGUUTUAGUTTGTGUUAGAAAGTGCGGGTTGRGGUTUAGGUUTGAAT
UUAGAGAAAGGUTURGGGTGGAAUTUUTGGGUAUUTGGGUUTTAUTTGUUTTUA
GGRGUTGGGUUAURGTTGGGAUTT

508 AGTUUUAARGGTGGUAGRGUUTGAAGGUAGAGTAAGGAAUUAAGGGTGUUUAGGA
GTTUUAURGGAGUUTTUTGGATTUAGUUTGAGGURGUAAUUAUUGGTT
UAUAAAGUTGGGAGRGGRGUUTUUTAAAAGRGRGUUUXGAAGUUTRGCGGGGT
TUUTTGUTUUTGUTGAGTUAGGUUAGUTGRGGATTUAAUUAUUTAGGUU
TGGUAGURGAUUUTUUTUUTUUTGGGUUTTGUTUTTGUTUAGTUTU
UUAUTGRGRGTTAGRGUTUU

509 TATUAGAATUUUAATAUUUAGGTGGTTAGGAUUTUTAGGUUTUTUUUTUAGGU
UATAGGAGUAAUUAUURGGUTLUTUTGGAGGGGUAGUUUAAGGAUUTGTG
GGTAUUTTGTGUTUUUAUURGGGAATGTGXGUUTTUAGGUURGUUU
AUURGGATTUUTGTGUAGGGAGTUAGURGAUAAUAGUATGTTGUATGTCGUUTTG
GGAGAARGTTUTGUUTUUTGTUAGGGGGAGGAGGUUTGGGURGTGUUTGTCGU
GUAAUUTUAGUTUUUAUURGAA

510 TRGGTGGGGAGUTGAGGTGRGGUAGUAUAGGUARGGURGUUAGUUTUUTUU
GAUAGGGGUAGAARGTGTUUUUUAAGGGGUUAUTGUAAUATGUTGTGRGGUTGA
UTUUTGUAAUAGGAATURGGTGGGGGUUTGAAGGAXGGUAAUTUURGGG
TGTGGGAGUAAAAGTTAAUUAUAGGTTUUTTGUTGUUUTUAGGAG
AGUURGGGTGGTGTGUUTATGGUUTGAGGGAGGUUTAGAAAGTUUTAAU
UAUUTGGGTATGTGGATTUTGATAU

511 AGAGGATTTAAGAATUAAUUAAGGGUAAAUAUTGGGUUAUTGTAAGAGRUTGGA
AUATTUTGUUTTGTAGTGAAGGGGUUTTUTTAGUUTUTAGGUUTGAGGGGT
GRGURGGUTGGTGGAGGUAGTURGATGGAGUUTGXGTTUURGGGUUAUAG
GGUUAAGUTTGAGGTTGGAAAGTTUTGGGUUTGAAUAAAGGAGAGTUTGT
TTTUTTUUTAAATTGGAUTUTGTUTGUUAUAAUTGUTGTTUTGTTGUARGGTT
TGTGTGUUTTTTUUUT

512 GGGAAAAAAGGUUAUAAAURGTGUAAAAGAUAGAGTTGTGUAGUAAGA
GTUUAATTTAGGAAGAAAAAAGAUTUTUTUUTGTTGTTUAGAAUAGAAAU
TTTUUAUTUAAAGUTTGGGUUTGTGUUUTGGGUAXGUAGGGGUUTAATRGGAUT
GUTUUTUUAUAGURGGGUAAUUTUAGTGUUATAGGGUTAGAAAGAAGGUU
UTTUAUTUAAAGGGGUAGAATGTTUAGRGUTUTAUAGTGGTUUUAGTGTGUU
TGGGTGAGTUTTAAATUUTT

513 TGUUTTGAGTUTAAARGGUAGTGGUUTAGGAGUAUAGGUUTGGGUUAUGGU
UAGTGUUAUAUTAAUTGAGATATGTGUAGAGUTGAGGTUTAGGUUTUAGUATUT
GTGTRGTRGGGGAGUTGGTGUARGGURGGTGUAGXGGGUUAAGGAGTUU
UAAGAGUAGTAAUUTGGGUUAUUAUAGUTURGGGUATTGGAGAGGGGUUU
AGTUTAGGUUTGAGTTGGGGAGGUUTGGGUAGGUUTGGGUUAUAGRGUAGGA
UAGAGGAAAGGUUTUAGUTUUT

514 AGGAGUTGGGGGUUTTUUTUTGUTUUTGRGUUTGGTGUUUAGGUUTGGGU
UUUUUUAAUTTUAGUUTAGAUTGGGUUUUTUTUAAATGUUAURGGAGUTGTGGT
GTGGGUUAAGGTTAUTGUTTGTGAUTUUTGGGUXTGUTGUUAURGGURGTGAUR
UAGGUAGUTTUURGARGGUAAAGATGUTGTGAGUTAGAUUTUAGUTUTGGGU
UTUAGGTTAGGTGTGGGUATGUUUUTGGGUUAUAGGUUTGTGUUTTAGGU
URGTTTAGAUTUAGGGUA

515 GUAGUUUTGGGGRTGGGGGGGGUTGTTUUTGUTGUUUUTGGGUUTGUUAU
UURGAGUTGUAGGUAAUTGGGUUTTUUTGUUUUTGGGUUTGUATT
UUAAUATRGAGGUAGGUAGTGAGAGGGAGTGAGGGXGATGATGUTGUAGU
UAAGAGUUTURGGGUAGTAGGUUAGGUUUTUUGUTGUAGUUTGUTGUUTGG
UUAGUAGGGGTGUTATGGGUUTGGGAGGUUTGGGUUTTGUTGUUTCGGG
UUUTGRGUUTGUTGUTGTG

516 AUAGUAGAGUAGAGRGUAGGGUAGGGGAGGAAAGGGGUAGAAGGUAGGU
UUAGGGGUATAGGUAAUUTGUTGGAGGUAGGUAGGTUAGGUAGAGGGGU
TGGUATGUURGGAGGUTUTGGGUUTGUAGGUATUATGUUUUTU
TUATGUUTGTURGAATGTGGGUAGGUAAUURGGAGGGUTGGAGGAAGTU

- continued

SEQ

ID

NO : Sequence

UAAUTGTGGUTGGUAGUTRGGGUAGGTGGUAGUUUAAGGGUAGUAGGAAAUAGU
RGUUUUUUARGUUUUAGGGUTGUU

517 TUTUTUUTGGGUAAAGUTTTGTGGATGUUAGUUTGGGURGRGGGAGUTGGUAG
GTUACTGGUAGAUATGGTGGUAGAUUTAGTGATGUTGGTAGAAUAGGUATUAAGG
AAGTGGTGAURGGAGGAAAGUUAAGTGUAUTUAAAATXGGGTGAGTUATUAUR
GURGGGTUTTTUAUGUTGTAAGTGAAGUAAUAGTGATGAAGGTTGTGAGTT
UTGRGTGAGRGAGTGAATGGAUUAGTAGUAGTTTUAGGTTGTGGAAGAGRGTUU
UTUUURGGGATGGGAAUTTG

518 UAAGTGTUUUUATUURGGGAGGGAAARGUTUTUUAAAATGGAAAUTGUTAUTG
GTUATTUAUTRGUTUARGUAGAAATTUUAUAAAATUATUAUTGTTGUTUAUTTT
UAGUAGUTTGAAAGAUURGRGGTGTGATGAUTUAUXGAGGGTTGAGTGUAUTTG
GUTTUUTURGGTUAAAATTUUTTGATGUUTGTTTUAUAGUAAUTAGGTUTGUU
UAAAAGTGTGUUAUTGAUTGUAGUTUUURGRGGUUUUAGGGUTGGGUATUUA
UAAAGUTTGUUUUAGGAGAGA

519 GGTGGTUTTGAAUTUUTGGGUTUAAGAGUTUUAAUUTGUUTUAGUUTUUAAAAGTG
AGUUAUAGGUUTAUURGGTUUTTUUTUATGUTTGTGGUUTTUUTUUTGTT
TAGXGAGUTUTGAAUTUAUTUATAGTAGGAAUAAAGUUTUUATTGGTAGT
GGGTGAGGTGGXGTGTGTTUTGTTAUAGTGATUTGTTTURGGUAGGUUTUT
UUUTGAGGGAGAGUTGGTAGUTTUUTGTAAGTGUAGGUAGUATAUTUAA
AAAAGATGTGTGGGTGAG

520 UTUAAAAUAAAATUTTTTATTTAGTGAAGTATGUUUTGUUAAUTAUATGGAAGUTA
UUAAGUTUTUUUUUUTAGGGAGAGGUUTGURGGAAAAGATUAUTGATAUAGAAA
AUAAJXGUUUAUUTAGUUUUAGAUTAAUUAATGGAGGGTTTGTUUTAUUTATGA
GTGAATGTUAGAGUTXGUTAAAAGGAGGAAAGGUUAUAGAUATGGAGGAAA
GGAURGGTAGGUUTGGTGGUUTATTTGGGAGGTGAGGUAGGTGGAGUTUTTG
GUUAGGAGGTUAAGAUUAGU

521 UAAGUATUTTAGTGTGAGTUATAAAATUUTUUTGGGTUTGUTTGAGUU
UAUUTTUUTUUTUUTGUAGTUATGTTTUTTAGUUTUAGGGUUUTGGGRGGAR
GGAUAUTUUUAGUAGUAGUUTGUTGUAGGUUAUTGXGUTGUTUAGUTURGG
GGUURGTUUTURGGATUUUTUAGGUUAGUAGAGTGTGTTGAUARGGGUUTGA
URGGAGGGAGARGUUAUUTUUTGGGAUTTGUAUAAAUAUAGUAAAATG
ATGAGAUAAUURGGAGGUAGUA

522 TGUTGGUUTURGGGTUTUATGAUAGTGGTGUUTGGGTGUAGTUUUUA
AGGTGGRTUTUUUUTUURGGTUAGGUURGTGGTAAUAAUTUTGUTGGGUUTGGA
GGGATUUAARGGAGGARGGGUUUURGGAGUTGAGUAGXGUAGTGGUUTUTGGA
UAGGUTGUTGGGAGGTGUTGGGRTGUTGUUAGGGUUTGAGGUTAAGAGUTA
TGATGUAGGAGGAGGAAGGTGGGUTUAAAGUAGAUUAGGAGGAAGTTTGAT
GAUTUAAUTUATAAGATGUTTG

523 TGATGAUUAAGGUAGUTGUTATTUTTAGGURGGGATTUUUUUAAGUUTGGTATTTT
AAAAATARGTTATAGTTUUTGAAAUTUTUUTTATUAAUTUAAUUTGTTT
TUATUUUUUATUUUTGGUAAUUTGTTUUTUUUAXGGTGTUUUATGARGUTG
GUATGUUUAUTGGUUUUAGUUTGGAGUTTUTUAGAGARGUURGGGUAGAUAT
GGUTGUAGATAGAGUUAAGGGGTGGUUTRGGGTGGUTGGTGUAGTUTUTGG
GTGGGGGUAGAAGTGGGG

524 UUUUUAUTUTGUUUUUUAAGUAGGAGAUTGUUAUAGUUAUURGGAGGUAAA
TUTTGGGUTATUTGUAGUAGUATGTGUTGGUURGRGGTUTGAGAAAGUTUUUAGU
TGGGUUAATGGGUAGGUAGRGTUATGGGAUAUAXGTTGGGAGAUAGAGGG
TGUAAGGACTGGAGATAAAAAAGGAAGGTGGAGGTGATAAGGAGAGTT
AAGGGAAUTATAARGTATTTAAAAATAUAAAGGUTGGGAAATUURGGUUTAA
AGAATAGUAGTGUUTGGTUATUA

525 GUUTAGUUURGRGRGUUAUAAUARGTGTGUTUTURGRGRGGAUUTRGGGAAUTTG
UUUTUARGUURGRGRGGTGUUTUURGUURGUURGGUUTUAAAATGGT
ATGUUUUTUUUAGURGGTUTUUTUUTUURGGUTXGGGAAGAAGUUTGUTGG
GUAGGGGUUUTGAUUAUUTUURGGAGGURGGUAAAUTGUUTGAAURGUUU
AGAGGAATRGGUAGGGGUUTRGUUAUAAAURGGUAGGAGGGUURGGAGA
UURGGGURGGGUTURGUAGURG

526 RGGUTGRGGAGGUUURGGUURGGTRGGTUTRGGGGUUUTUUTGURGGGTGGGT
RGAGGUUUUTGUURGATTUUTUTGGGRGGTTUAGGUAGGTTGURGGUUTURGAGG
AGGTGGTUAGGRGUUUTGGGUUAGUAGGUTTUTUUXGAGURGGGGGGAGGG
GAURGGUTGGGAAGGGGUATUTRGAGGGGTGGAGGURGGGGRRGGAGGU
AAGRGRGRGGRTGAGGGUAAAAGTTUURGGAGGTURGRGRGGAGAGUAA
TGTATGTGRGRGRGGGUTAGGU

527 GAAARGGRGGTRGUAGUUUURGGURGGGUARGRGTGGGURGTTRG TGGAAGGGTG
TUTTGUTAGGURGGTGGGTAUTURGGGUURGGATGGGUTTGAGGTGAGXGG

SEQ

ID

NO : Sequence

GGUTGGGGUAGGUTGUUAAGGUURGGGTGGATUTGUTTGUTTTGAATGUUTTGAT
 GGTUTUUAGAGGGTAATAGGGGXGGGTGAUURGGATGGGTUUATGUUUTGG
 AAGGGUTTGTGUTURGAATGGAGUUATGTRGTGGGTGGTAGAGGTTGTA
 GTUAGGAATUATGGGAAGAG

528 UTUTUUUUATGATTUUTGAUTAUAUUTUTAUUAUUAUUAARGAUATGGGUTU
 UATTURGGAGUUAAGUUUTTUUAGGUATGGAUUUUATURGGTUAUUXGUU
 UUTATTUUUUTUTGGAGAUATUAAGGUATTUAAGAUAGUAGATUUUURGG
 GUTTGTGUAGUUTGUUUUAGURGURXGUTUAAUUTUAAGUUUATURGGUURGUA
 AGTAUAAAUAURGGUUTAGUAAGAUUARGUTUARGAARGGUUUUARGRTGUUR
 GGURGAGGGUTGRGAURGURGTTU

529 TGUTUAGGUTGGAGTGUAGTGGUAAAATUTTGUTUAUTTUAAUUTURGUUTUURG
 GGTUAGUAATTUTUUTGUUTUAGUUTUTUAAGTAGUTGGGATTAUAGGUATGUA
 UUATUAUAAAAGUTGATTGATTGTTAGTAGAGAXGGGTTUAAUARGTTGTT
 UAAGUTGGTUTAAUUTUUUTGAAUTUAGGTGATUAAUURGUUTTGGUUTUUAAAAG
 TGURGGGATTATAAGGTGTAGGUUARGUAAUTGGUAATTAGTATTGATTAAAGA
 GTTATATTUATATUUATA

530 TATGGATATGAATATAAATUTTAAATAAATAUTAATTGUUUAGGTGRGGTGGUTU
 AUAAUTTAATUURGGUAUTTGGAGGUUAAGGRGGGTGGATUAAUTGAGGUAG
 GAGTTGAGAUUAAGUTTGAAUARGTGGTGAUAAUUXGTUTUTAATAAAATAUA
 ATUAGUTGGGTGATGGTGUATGUUTGTAUUTUUAGUTAUTTGAGAGGUTGAGG
 UAGGAGAATTGUTTGAAUURGGGAGGRGGAGGTTGAAGTGAGUUAAGATTGUUA
 UTGUAUTUUAGUUTGGUA

531 TGTTAUTTUATTGAATTUATAATAGUTTAATGUTATRGGTTTUTTUTTAATTTG
 GGGGUATAGTGGGAGATAAGUAAUTGATAUUURGGAGGTTGAGTGAUTUATTUA
 TGGAAATGUAGUAGGURGTGAGTUAAGXGAGTAUTGGUAAGAUXGAGTGAAGU
 TGGGAAUAATAGUUAAGUUAAGAGRGTGTTAAAGATAUTTAGUATUTTUATUA
 UTGAAUTTUTTAAGGTGAUAGUAUTUUAUTRGAAUAGUAAAATGTUAGATTUAUTGT
 TTUTTURGGTUTTUAAA

532 GTTGAAGAURGAAAGAAAAGTTGAATUTGAUATTGUTGTRGAGTGGAAAGTG
 UTGTAUAUTTAGGATTAGTGTGATGAAGATGUTAAGTATUTTAAARGUTUTG
 UTTGGUTATTGTTUUUAGUTTUAUTXGGTUTGUATGTAUTXGGTUTTGAUTARG
 GGUUTGUTGUATTUATGAATGAGTUAAUTUAAUUTURGGGTATUAGTTGUTTATU
 TUUUAUTATGUUUUUAAAATTAAGAAGAAAURGATAGUATTAAGUTATTGAG
 ATTUAATGAAGTAAUA

533 TTAGTATTUAAAATATRGAGTGUAGGGUUTGATUAGUUAAAAGAATGAGGUUA
 TTTAATGTAUAAAATUUTGGUAGTUTUAGGTGCGGUUTUUUAGGUURGGAT
 GUAGATGGGUTTAGGGGUTGGUUAUTUUTATUUAAXGGTUUTTGGAGGUUA
 TTTUAGGGUATGUATGTAUTGUUTTURGGTAGGUATGUTGAUTUAATRGTAG
 AUTGTTATTUATGTTUUUAGTAAUTGTGUAGGAAGGGAAATGAGTAATA
 GATGTTAUAGTUUUATTUAA

534 TTGAATGGGAUTGATAUATUTTAAUTUATTUUUTTUUTGUUAAGGGTAUT
 GGGAAUATGAAATAAUAGTUTARGATTGAGTGUAGUATTGUTUARGGAATGTTAGT
 UATGGUATATGUUUTGAAAGTGGGUUTTUAGGAUXGTTGAGATGAGGATGGUUA
 GUUUTAAAGUATUTGUATURGGGUUTGGGAGURGAAUUTGAGAUTGUUA
 GGAATGCTGTTAUATTAAGTGUUUTATTGTTGGGUTGATUAGGUUTTGGAUT
 RGATATTGGTAATAUTAA

535 AGTGGTGGUTGUTTTUTRGGTGGUAGAGATGATGUUTGGTTATTUTTAGTAAAG
 TGUTTAGGARGUTGAGGUUTGAGGGGUTUTGGAATGGAAAAAAAUA
 AUAAAURGGAGGUURGUTUTGUUTGGGUUTTAGAGAUAXGUAAAGUTGGGUAAAG
 GAAGGAGATTGAGGTGGGAUTGAGAUATTGTTGUATTGTAATGUUURGGTTUU
 AUUTUTGUUUUUURGAATUTGTTGTTTATGRGGTTATTTTUUTTGGTGAAG
 AAAATGGGATGTGGTGUAA

536 TTGAUAAAATUUTUUTUAAUAAAAGGGAAAATAAURGUATAAAUAUT
 ATGATTRGGGGGUAGGAGGTGGGAAURGGGUATTUAAAATGUAAAATGTUTU
 AGTUUUUTUUTUUTGUUAGUTTGXGTGTTUUTAGGAGGUAG
 AGAGRGGGUUTURGGTTGTTTGTGTTTGTGTTTUGATGGTTGGAAGGTT
 GUTUAGRGTUUTAAGUAUTTAUTAAGAATAAAUAGGUATUTUTGUUAURGA
 GAAAUAUAGUUAUUAUT

537 GGGGTRGGUATGGGUTGGAGUTUAGAGARGGUAGUTAGGAUTUAGGAUUA
 GUAAAATAGUTGRGUUURGUTGAGGGTUAGRGUUAAGURGUUUAUAAGGTGTU
 UTUTUUURGGGUTUTGGGURGGGUUTUTGUTTGUUXGTGURGUAGAURGG
 TTAGAUTGTGGARGRGGGAAGGAAGGGGRRGTTGRGARGGGATUTTGAGGGAG
 AGGAUTTGUUUUTGUUUUTGRGGRAAGUTUTAGGUUUTGGUAAAGGTTRGGTA
 RGAGGGGURGUTUUTUUUAGGG

SEQ

ID

NO : Sequence

538 UUUUTGGGGAGGAGRGGUUURGGTGTGTAURGAUUTTGUAAGGGUUTAGAGUTTRG
URGUAGGGGUAGGGGUAAAGTUUTGUTUUUUUAAGATUURGTRGUARGUUUUUT
TUUTTUURGRGTUUUAUAGTUTAATUURGGTUTGRGUAXGGAGUAGGGAGURG
GRGGUUUAGAGAGUURGGGAGAGGAAUUTTGTTGTGGGGUTGTGRGUTGAU
UTUAGRGGGRRGUAGUTACTTGTGTGTUUTGAAGTUTAGUTGGURGTUTTG
AGUTUAGGUUATGURGAUUU

539 GTGUARGUAGGGAAATAUUTUAUAGGGTAAATTGGATURGATTGAGAAUAGGAAG
UUAAUAGGUUATAUAGAGGAGUTGTGAGAAUAGATGAAUAAUUAAGURGG
GAGGGAGGAAAGAGUTTTGCUUTGGGUATGGGGATCGGXGAGUURGUUAU
UAUAUAAAGUTGRGUUTGGGUUTAGTAATUAAAUAUATUATAUAGAUUTGARGT
TTGGUTGUAGUTGTAAGAGATAAGUATGTTGAAAGAGAAAAUAGGUUURGGT
AUURGGUUTTAGGGTUTGAGR

540 RGUTUAGAUUUTAAGGURGGGTUAURGGGUUUTGTTTUTUTTUAAAATGUTTA
TUTUTTAUAGUTGUAGUAAAURGTUAGGTUTGTAATGATGGTTTGATTAUTGAG
GUUAAGRGUAGUTGTGTGTGTGUTGGGGUTXGUUUTUUUUUAGGUUAG
AAAGUTTTTUUTUUUUUUURGGGUTTGTTGTUATUTGTTUTUAAUAGGUUT
UUTGTATTGGUUTGTGGGUUTUTTTUUUAATRGGATUAAAATTAAUUTGTCAGG
TATTUUUTGRGTGUAAU

541 TGTGRGGGUAGTGGGTTGTGRGGGUAGTGGGTTGTGUATURGGATGTTAGUAUT
AUAAUUTTRGGGTAUTUTTUUTGGGUAGUTGTGATGAGTGGGGGUAGUATU
TGURGTGAUTUATTUTUUTUTTUUTUAAUAGUXGGGTGGGGAGTTGGGATT
TUUGAGUAAGGUUTGGGUUUUUUUTGGUAUAGAGGGTGGGAGTGGGATGGGAGG
GAGGAGGGAAAGGGTUAUTGGGAGGTGGGUUATGTTGTGUTUAATGAAUTGAGA
AGGGGAGGGTTUAGUTGG

542 UAGUTGGAAUUUTUUUUUTTUTUAGTTUATTGAGUAUAAAUAUTGGUUUUAUTTU
UUATGAUUUTUUUUUTUUUUUUTUUUUUATUUUUUATUUUUUATUTGCUUAGGGG
AGUAGGUUTGGAAUTUUUUUATUUUUUUAUXGGUTGGAAUTGAAAGA
GGAGAGAAUTGAGTUAURGGUAGATGUTGUUUUAUTUAUATUUUAUTGU
GAAGAGTUAUURGAAGTGTGTGAGTGUUAUATURGGATGUUAUAAAUAUTGU
RGUUAUAAAUAUTGUURGUUA

543 GUAAUTGGRGUTGGGTAGGUAAAGURGGGAGAAUTGUTGAGARGAGGTTAGGAT
TTAAUUTTAAATTUTGGGUUATRGAAUURGAGGGGGAGGARGARGGGTGTGGT
GUTAATGGAGUTGGGGGGGGGGATGRGRGGTGGGUUTUXGAGTURGGGUAGGT
UTRGGGGGTTUURGGGAAAGGUUUTGGGAGUUTGGGUUUTGGGUUUTGGGUU
ATUAGUTGGAAUTGTTUTGATTGGGTGUUAAGGAGGGTGGGUUUTUUTUURGG
UUUAGUTGAGGGGTGTRGTUTTU

544 GAAGARGAUUUUTUAGUTGGGGGGAGGAGGGGUUAURGUUTUUTGGUUUAAA
AATUAGAGAUATTUUUAGTUTGATGGRGGAGGURGUUAGGGUUAAGGGUTUU
GGUUTTUURGGGAAUUUURGAGAUUTGUUURGGGUUTXGGAGGUUAURGR
GUUAGUURGUUUUAGUUTUATTAGUUAURGUAAUURGTRGTUUTUUUUTRG
ATGUTUUAAGAATTAAAGGTTAAUUTAAUUTRGTTUTUAGUAGTTUTUURGG
TTGUUTUUUAGRGUUAAGTTGU

545 GGGUAAUUTUTGGTGUUTUAGGUUTGTGAAATTGGUAUAGUAGGUUAAGAU
UUAAGGTGUUUUAUTGGGGUTUAGAAUUAUTGGGGAGGTUAGTGUATUU
AURGGAGAAGAGAUUTAGTUTAGUTGGGUUAGXGGUAAGGAGGAAAG
ATGAAUATGUUAGUARGGUUTGGGUUAGTGUUAUAGGUAGGUUTRGUUUAGUU
AAGAATGTTUTGTTUTAAGAUUTTTTUTTTGTATTTAGAGAAAGTUU
AAATGTUAAUUTGAGAUURGG

546 URGGGTUTTUAGGTGAUATTGUUTGTGATAATTUTAAAATUAAAAGAAA
AAGTUTTAGAAUAGAAAATTUTGGGUUTGGGRGGAGGTUAGTGUATUU
TGUAAGRGRTGUTGATGTTUATUUTTUUTTTGTGUAGTGUAGGUAGGG
TAGAUTAGGTUTUTTUTURGGTGGGATAGUUAUTGUAUUTUURGUUAGGG
GUUUUAGGTGGGUUATUTGGAGGTUTGTGUUUTGUTGTGUUAATTUAGGU
GGAAGUUAUAGAGGGTGUUU

547 UTUATGGAGAGGAGUAGAGATGUAGGAARGUAAUAGUAGUARGGUAGAARG
GGAGAAAAGUUURGUUTUAGAGURGUUUAUTUUTGUUATGUAGGAAGGG
UUAGTGUUUUTUAGRGURGGTGUTGTUARGTUAGGUAXGTGARGTGTGG
GUUUAGATTUTTGGRGGTGAGUURGGGAGGGAUUUAGRGGTUTUURGG
GTTAGGGGGGATUTURGUAGAUUURGUURGUARGTGGGUUTGTGAGGG
TGRGRGRGAAGGTGTGGT

548 UAGAUUAUAGUUTTRGRGRGUAGTGUUUUTUAGGAGGUUARGTGRGGGG
UTTGRRGGAGATUUUUUUUTAAUAGARGURGGAGAURGUUTGGGUUUTRG
GGGUUTUAGGUUAAGAATUTGGGUUAGGUUARGTUAXGTGTUTGARGTGA
UAGURGGTUTGGAGGGGUAUTGGGUUUTTUTGGGUATGGGGAGGGTGGG

- continued

SEQ

ID

NO: Sequence

	GUTUTGAGGRGGGGUTGTTTUTUUTGRGTTUTGURGTGUTGUTGTTGRGTTU UATUTUTGUTUUTUATGAG
549	UTUTUUAUTGTGUAGGUUAUTGTAGGGAUAGTGUUAGTGCGGTAGGAGAGGTGG RGAGGUTGUAGUAGTGRGGGATGGGUTUUUUAAUAAAATAUUUUATGG GTURGGGGUTTUUUUAGGAUUTGGGUAGGTGXGUAXGUUTGGXGGGUAGGU AGUTRGTGUTGAGTUAUARGGTGURGTUAGTGACGGGUUTGGUUUAAAUTRGGGAA UUAUARGGTGUTGGTTTUUARGGUTGUTGUURGTGTCGGUUTTGUTGUAUAAA UAAGGUUUTGGGAGGUUUTGUU
550	GGUAGGGUUTUUUAGGUUTTGCGGTGAGUAGUAGGUUAUAGRGGGUAGUA GURGTGGAAAAUUAGUAURGGTGGTTUURGAGGGTGGGUAGGUUTUAUTG ARGGUAAURGGTGAUTGUARGAGUTGGGUUXGUUUAGGXGTGXGUAU UTGGUUUAGGTUUTGGAGGUURGGGUUUUATGTGGAGTATTGGGGTGTG GGGAGGUUUAUTURGUAGTGUAGUUTRGUUAUUTUTUUTAUAAAATGGUA UTGTUUUTAUAGGTGGUUTGUUAAGTGGAGAG

20

Also provided herein is a deoxyribonucleic acid identical to 5-10, 10-20, 20-30, 30-40, 40-50, 50-60, 60-70, 70-80, 80-90, 90-100, 100-110, 110-120, 120-130, 130-140, 140-150, 150-160, 160-170, 170-180, 180-190, or 190-200 of contiguous nucleotide sequence of the sequence including a sequence of SEQ ID NO:1 to SEQ ID NO: 550.

In embodiments, provided herein is a deoxyribonucleic acid which includes a methylation site set forth in Table 1.

In embodiments, included herein is a deoxyribonucleic acid in which a plurality of methylation sites set forth in Table 1 are methylated or unmethylated. In embodiments, the plurality of methylation sites comprises at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 50, 75, 100, 150, 200, 250, 300, 350, 400, 450, 500, or 550 methylation sites. In embodiments, the plurality of methylation sites comprises between 1-50, 50-100, 100-250, 100-300, 100-400, 100-500, 100-550, 250-550, or 350-500 methylation sites.

Compositions for Detecting Methylation

Also provided herein are probes and primers that are complementary to one or more of SEQ ID NOS: 1-550. In embodiments, pairs of primers complementary to nucleotide sequences on either side of a methylation site of interest listed in Table 1 are provided. In embodiments, a plurality of probes and/or primers are provided to detect and/or amplify a polynucleotide (e.g., a polynucleotide obtained by bisulfite treatment of DNA) comprising a methylation site of interest. In embodiments, a probe or primer is complementary to a polynucleotide sequence that encompasses the methylation site of interest. In embodiments, the probe or primer is complementary to a sequence that is proximal to the methylation site of interest (e.g., within 1000, 900, 800, 700, 600, 500, 400, 300, 200, 100, 75, 50, or 25 nucleotides of the methylation site of interest in a genomic or bisulfite-treatment-derived polynucleotide).

In embodiments, a deoxyribonucleic acid selected from SEQ ID NO:551 to SEQ ID NO: 782 is included. In embodiments, the deoxyribonucleic acid selected from SEQ ID NO:551 to SEQ ID NO: 782 is hybridized to a complementary DNA sequence having uridine or cytosine. In embodiments, each of the nucleic acids is different. In embodiments, each of the nucleic acids does not simultaneously have the same sequence selected from SEQ ID NO:551 to SEQ ID NO: 782.

In embodiments, aspects include a deoxyribonucleic acid selected from SEQ ID NO: 551 to SEQ ID NO:782, hybridized to corresponding a complementary DNA sequence

having uridine or cytosine, and in a complex with an enzyme, e.g., a thermostable DNA polymerase. In embodiments, the thermostable DNA polymerase is Taq DNA polymerase.

In some aspects, the method includes deoxyribonucleic acid that has a sequence that is at least 50%-55%, 55%-60%, 60%-65%, 65%-70%, 70%-75%, 75%-80%, 80%-85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical or homologous to a nucleic acid having a sequence of at least one of SEQ ID NO:551 to SEQ ID NO:782.

TABLE 5

SEQ ID NO:	Sequence, 5' to 3'
551	GGGAGAAGAGATTGGAAAA
552	CTAAAAACCTAACACTAACAAACATAAT
553	TGTTGTTAAATGTTGTT
554	AACCCTAAATAATTCTTCTC
555	GGGTTGGGTTGAGGTTT
556	ACACCTTACATCTCATTTACAACTC
557	AATTGTGAAAAGTTGTGTA
558	CCCAATCACCTTTAATCT
559	GTTGGGATTGAAAATAGTGA
560	CCTCCACTCACCTAAACCT
561	TTGGTTAGTGATTATTATT
562	AAAAATTAATATAAAATTAAAA
563	TTTGTAGGGAGTTAGGGAT
564	TCCTCTATCTCACCTAAAT
565	TTTGATTGAATTATTGTGTATT
566	ACTCCCTTACTCCTAACACT
567	AGTGGAGATEGGTAGGGAGA
568	CCCAAAACTAAACCAAATATAA
569	TTGTGGTTAAATTATTG

187

TABLE 5-continued

SEQ ID NO:	Sequence, 5' to 3'
570	ACCCAACAAAATAATATC
571	TGAGGTAGAGTTGTGTATAT
572	ATCAATCAATTCTCATTAAAC
573	GGAAGTTAGGAAGGGTTGT
574	CTCCAACCTCAAACAAACTC
575	TTEGGGTATTGATTTATTT
576	AAATTCTACCTACAAACTATACA
577	AGGATGAAGTAATAATTAAATATTG
578	CCCACTCTACCAACTAAC
579	AGGTTTGTGTTAGTATAAAT
580	TTCTTACCTATATAATTAAATA
581	GTTGGGTGAATTTATTAG
582	TCAAAACCTAAACTCTAAC
583	GGATTGGTTTRATATAGAAAGTAT
584	CAAATAATAATCATAACTCTTA
585	TGGGGTAGTTGATGGTT
586	CTTTCTAACAAAATAAAAAATTAA
587	TTGTATTTGAAGTTGTAGAGATTATA
588	TTTCCTCCAACAACTCAAT
589	TTATGAGTATGAGTAGGGTTATTATA
590	AAAATATCAAACAAATTATCC
591	TGGTTGTTGTTTTATGTATT
592	TCCCTACCTCCAAATTCC
593	TATGATGATTGTTGTAGTGTAGA
594	CCTCCCTAACAACTAAAAATAC
595	GGTGGTTTGATATTAGTG
596	CCCAATTACCTAACAAATTAA
597	TGGGATAGGTGTAGATATG
598	CAACAAAAACTAAACACTATAC
599	TTTGGGATTGGTTATTTT
600	AAACCCCTTAACCTATACC
601	GATTTTTTGAGAAGAGTATAG
602	AACCACTACCACCTAAATATA
603	GGAGGATAGGGTGTGATT
604	ACATTTAACCTAACAAATAAA
605	TGGAAATGAGGTGAGTTT
606	AAAAAAAAATAAAACAAATAACTA
607	TGGAGAGTTAGTTGTT
608	CAAAAAAAATCTAACAAAC

188

TABLE 5-continued

SEQ ID NO:	Sequence, 5' to 3'
5	609 TGGGTTTAGTTATGTGGTT
610	ATCAATAATATCCAACAAAATAATAT
611	TTTTTTAGTTTGATATATATTAG
612	ACCCAAATAATCAACTCTT
10	613 GTGGTTTTGGAGATTAA
614	AAACAAACTACAAATAAAATAATAC
615	GGGTTATAGGTTGAGTTA
15	616 CCATTTAAAAAAATAAAATC
617	TTGGTAGATTTAGTAAATTATT
618	AAACTAAACAAACCTATATAC
20	619 ATGGTTTAAAGAGTAGTAGTATAGTT
620	AAATTTACTCATCCCACTTC
621	AGGGGTTGGGATATTGTT
25	622 AAAAATTCTCCTTACAAAAACTAA
623	ATGGGTGTTGGAAATTTTTA
624	CTACCTCAACCTCCTAAATAACTAA
30	625 GTGTTTGTGGTANAGATATAG
626	ATTCTAAATTAAATTCAACTACAT
627	TGGGGTAAAGTTATAGTT
35	628 AAAAACAAAAACCAAATAC
629	GTTTTTGGTTAGTGTGTT
630	CCCCATACTCTATACTATAAT
40	631 TTGTTGTTTTAAAGAAATTATA
632	ATCATCTAAACTTAACCTCATCTAA
633	ATTTTTGGGTGTTTATATT
45	634 AACCTCAAACAATAACA
635	ATTAAGGATATTAGGAGAGTAAG
636	ACACCCACCTCAAACACTAC
50	637 TGAGGAAGAGAGAAGAGATGATA
638	AAAACTAAACTATAAAACAAACAAACTA
639	GGTGGAGGTGTTTTATAG
640	CCAAATACTACTTCAAAATACA
55	641 ATGGATTATTATGTGTATT
642	CATCTCAACCTCATACTAA
643	GGATGATTAGTAGGGATTGAG
60	644 CCAAAATAAAACATTCTAAC
645	TTGGATTAAGTATTTGATATTA
646	TCCCTAAACCATATATTACTAA
65	647 GGGTAGTTGGTGATTATTATT

US 12,391,993 B2

189

TABLE 5-continued

SEQ ID NO:	Sequence, 5' to 3'
648	CCCTCCCTACTCACAAATA
649	ATTTGGTTAGTGATTTAGTTATT
650	TCCCACCTAAAAAATTCTATA
651	AGTGGGGAAGGTAAATTGTTAT
652	CTTTCTAATAAAAATTACTAAACCTCTA
653	TTTGGTTAGTTTATTTTGATTG
654	ATTCCTCCCTATCCCTATTC
655	GGGATAGGGTTAGAGTAA
656	TCCATAAAAACAAAACACTC
657	TTTTTAGTATGAGTTATAAATTAT
658	AAAACAAAATCTACCTATATATT
659	TTTTATAATAAAAGTAGGTATGA
660	ACCTTTCTCAAAATTACTAA
661	ATAGGGTTGAGGTTAGAGTTAT
662	CCTCCTCTCCACAATAAA
663	TTTAAGTTTTTTAGTTTGTAGT
664	CCCCATCCTCTCTATCTC
665	AAATTAAAATTTAGAGGTTTTATA
666	AAACTTCACACACAAATCTATATT
667	TTTTTATTTATTTTATTTTAA
668	ATACCTCCCTAAATTATTTTAA
669	TTTTAGAATATTTAAAGAAGTTAGT
670	TAACCTCACTTTCCATCA
671	AATTTAGTATAAGATTGATTGTTA
672	CCACCTACTCCTCCATAC
673	TTTTTGAAATTGTATGTTAT
674	CAAATCCTTAAATTCTATAA
675	TTTGAAGTGGTTTTAG
676	CCAAAATTCTTCCATACT
677	TGGGTATTTAGTYTTTGTG
678	AACAAcTACCTCCTTTACTAAT
679	TATGGTAGGAGGTGGAGTT
680	CCCAATTAAAACAATAC
681	AGAGGAAGTAAGGTTATTAGTT
682	ACCAAAACAACAAATATCTAA
683	GGTTTTAATTATGATTTAATTAGA
684	CCTACACTCAAATTACCTCTA
685	AATGGGTAGTTGATATAATTATT
686	CACAAAATCCTAAAACAAAAA

190

TABLE 5-continued

SEQ ID NO:	Sequence, 5' to 3'
687	AGGATTAGTGGAAATGAAAATA
688	TAACCTCAAAACAACCTCTAAC
689	TTTTTTTATAGAGAAGTATTTAG
690	CCCATTACAAAACCTATCC
691	GGTGAGTTGTGGTTAGTG
692	TTTCTAAAAAATCCAATCTA
693	AATGGATAGGTTGGAATAG
694	AAAAAAAAAAAAAAACTAATTAC
695	GAGTTATTTAGTTGGTTAGGT
696	ACTCAACTAAAAATCACTATAC
697	TTTYTTTGGYTTTTGGYTTT
698	TCCCCCACACCCATATAA
699	TTAAAAAAAAGTATAATGAGTAGGA
700	CCCACAAAACCTCTACAA
701	AAAGGAGGTTGAGTTAGAAAGTAG
702	AACTATTTAACTTACTTAACCACACC
703	GGTGTGGTTAAGTAAGTAAATAGT
704	TACCCCTCCTCTTCAC
705	TTTGATATGATTATGATTATAT
706	TTTCCACTAAACAACACTA
707	TTTGAGGGTTGTTTAGAT
708	ACTCACAAAAATAACTAATAACTAT
709	AAAGGAGGTAGGGAGATATA
710	TCAAAATAAAACCAAAATTCTC
711	AGGTAAAGTTGGTAGAGGTAGA
712	CAAACCTCTAAACTCAAAATATATT
713	TTTTTATTTAGTTTTGAGTAG
714	CCCTACAAACACTCCTATCTA
715	TTTGGAGTTAGGTTGATAG
716	CAACAATACTCTCACTTACAC
717	AGAAAGATTTAAATATTTAAAT
718	AAACCTCTAATACACAAACAAA
719	TTTTGAGTTTTTTTTAAAGTAT
720	CAAACAAAACAACACTTAATAC
721	GGTTGAGGTGGTGGATT
722	TTTTTTTTTTTTTTAAATAAAATCT
723	GGGTGTTGTAATTTAGTT
724	ACCTETTAACACCTAACAAAT
725	GGGTAGATGATAGGTAGTGA

191

TABLE 5-continued

SEQ ID NO:	Sequence, 5' to 3'
726	AAAAAATAAAAAATAACTAAAACAATAT
727	AGGAAGTGTAAAGAAGTAGAA
728	CCTAAAACCTAAATACAATCTC
729	TTTTAATTTGTTGTATT
730	AAACCACAATCTATTCTAA
731	TTAGAAAAGAATAATTATAGTTG
732	ACCCCTAAAAAAATAAAC
733	TTGTATTAGTAAATAAGTGTATT
734	AACCCCTTCTACAAATCTAC
735	AGGGTGGGTGGAAGAAT
736	CTCCTCAATAAAATAAAATCCTAAAAATA
737	GGGTTAATTAGTTGTTTAT
738	CCTACAAATATCACACACT
739	TTTGTAAATAGGTGGTTAGA
740	ACCTCAACCTCTAAATAAC
741	TAGGGTTAGAGTAGGAGGTAG
742	CAAAAATATAATCAAAACATC
743	GGGATTATAGGTATTATTAT
744	AAAAAATAAAAATCATACTTA
745	AAGTGATTTTAGGGAGTGT
746	TCCATAATAACCTCATTTAATA
747	TTTTGGTTGAGGTTAGT
748	AAACAAACACAACCTCTTATCAC
749	TATGGTGTAAAGTATAATAGTT
750	TCCTAAATAAAAACACATCA
751	TGAAAATGTTTAGTTTATT
752	AAATACCCCTACCTCTTATCTAA
753	GATGGTTATTTTTTATT
754	ACTCCTCAACAAACTAAC
755	AGGGGATATTTTAGGTT
756	CCAATCTATTCTATATAATTAA
757	AGGAGAGTTGGAAATATAG
758	CAATTCTAAATTAAACCTTATT
759	ATAATGGTAGTAGTTTATTAG
760	TTCCTATATTAACAACTTACA
761	TTTTGGTAGTTTTTAT
762	AAATTAAATTCTATTATTTATTTA
763	AGGTGGTGGGGAGAGTG
764	CCCTAAAATAATCAAAAAACCTTAA

192

TABLE 5-continued

SEQ ID NO:	Sequence, 5' to 3'
765	AGGTTAGGTGGGGTGAAT
766	TAAAATCATCAAAATCCCTAAAA
767	TTTTTTTTAGTTTACGTGAGTATT
768	ATCCCCACAAACACATA
769	TAGGGTAAATATTGGGATTATT
770	TTTCCACCTCAAAACTTAAC
771	GGGTGTTGTATTTTATATT
772	ACCTCCAAAACCATAAC
773	GATGTGAGTGGTGGAGGTGGT
774	CAAACCCCTCCAAAACATAAAC
775	TGGGATTATAGGTATGTATT
776	CAATTCATTTATAATATAATAT
777	AGGGGTTGGTTATTTTATTT
778	TTTTAATATTAATTTTACCTTCAACT
779	GGTAAGTTGGATGTGAGT
780	AAAAAAACCAACCTTATCTA
781	TTTTAGGATTTGGGTTAG
782	AACCTTATAATAACAAACAAAC

Kit for Detecting Methylation Level of a Thyroid Nodule
 35 Also provided is a kit including a plurality (e.g., at least about 10, 20, 40, 50, 100, 150, 200, 225, or 232) nucleic acids each independently comprising one sequence selected from SEQ ID NO: 551 to SEQ ID NO:782, in which the nucleic acids do not simultaneously include the same sequence.

In some aspects, the kit includes deoxyribonucleic acid that has a sequence that is at least 50%-55%, 55%-60%, 60%-65%, 65%-70%, 70%-75%, 75%-80%, 80%-85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 45 more identical or homologous to a nucleic acid having a sequence of at least one of SEQ ID NO:551 to SEQ ID NO:782.

The kit provided herein may include enzymes, reagents for deamination of cytosine, buffers, vials, plasmid vectors, 50 control DNA, devices for collecting thyroid tissue samples, reagents for isolating DNA, reagents for labeling DNA, labels, or any combinations thereof.

The kit provided herein may include enzymes such as thermostable DNA polymerase enzymes, restriction 55 enzymes, and combination thereof.

In embodiments, the kit(s) may further include enzymes, reagents for deamination of cytosine, buffers, vials, control DNA, devices for collecting blood and/or tissue samples, or reagents for labeling DNA, or any combinations thereof.

60 In embodiments, a kit provided herein may include a solid carrier capable of adsorbing the nucleic acids containing in a sample of a body fluid, for example blood (whole blood, plasma, or serum). The kit may also contain other components for example, reagents, in concentrated or final dilution 65 form, chromatographic materials for the separation of the nucleic acids, aqueous solutions (buffers, optionally also in concentrated form for final adjusting by the user) or chro-

matographic materials for desalting nucleic acids which have been eluted with sodium chloride.

In embodiments, a kit provided herein includes materials for purifying nucleic acids, for example, inorganic and/or organic carriers and optionally solutions, excipients and/or accessories. Such agents are known and are commercially available. For solid phase nucleic acid isolation methods, many solid supports have been used including membrane filters, magnetic beads, metal oxides, and latex particles.

In addition, a kit can also contain excipients such as, for example, a protease such as proteinase K, or enzymes and other agents for manipulating nucleic acids, e.g., at least one amplification primer, nucleic acid bases (A, T, G, C, and/or U), and enzymes suitable for amplifying nucleic acids, e.g., DNase, a nucleic acid polymerase and/or at least one restriction endonuclease. Alternatively, a commercial polymerase chain reaction kit may be used to amplify the DNA samples. Exemplary Techniques for Detecting Specific Sequences

Specific sequences, such as the sequences listed in Table 1 (or portions thereof containing a methylation site of interest), can be detected by numerous methods that are well-established in the art (e.g., PCR-based sequence specific amplification, isozyme markers, northern analysis, sequence specific hybridization, and array based hybridization). In embodiments, the presence or absence of methylation is determined through nucleotide sequencing of the site of interest (e.g., the site in bisulfite-treated DNA or an amplicon thereof). Any of these methods are readily adapted to high throughput analysis.

Some techniques for detecting specific sequences utilize hybridization of a probe nucleic acid to nucleic acids corresponding to the methylation site of interest (e.g., amplified nucleic acids produced using bisulfite-treated DNA as a template or the bisulfite-treated DNA itself). Hybridization formats, including, but not limited to: solution phase, solid phase, mixed phase, or in situ hybridization assays are useful for sequence detection. A non-limiting guide to the hybridization of nucleic acids is found in Tijssen (1993) *Laboratory Techniques in Biochemistry and Molecular Biology—Hybridization with Nucleic Acid Probes* Elsevier, N.Y., as well as in Sambrook, Berger and Ausubel.

Nucleic acid probes complementary to a methylation site can be cloned and/or synthesized. Any suitable label can be used with a probe. Detectable labels suitable for use with nucleic acid probes include, for example, any composition detectable by spectroscopic, radioisotopic, photochemical, biochemical, immunochemical, electrical, optical or chemical means. Useful labels include biotin for staining with labeled streptavidin conjugate, magnetic beads, fluorescent dyes, radiolabels, enzymes, and colorimetric labels. Other labels include ligands which bind to antibodies labeled with fluorophores, chemiluminescent agents, and enzymes. A probe can also constitute radiolabelled PCR primers that are used to generate a radiolabelled amplicon. Labeling strategies for labeling nucleic acids and corresponding detection strategies can be found, e.g., in Haugland (2003) *Handbook of Probes and Research Chemicals Ninth Edition* by Molecular Probes, Inc. (Eugene Oreg.). Additional non-limiting details regarding sequence detection strategies are found below.

PCR, RT-PCR and LCR are in particularly broad use as amplification and amplification-detection methods for amplifying nucleic acids (e.g., those comprising a methylation site), facilitating detection of the nucleic acids of interest.

In embodiments, real time PCR or LCR is performed on the amplification mixtures described herein, e.g., using

molecular beacons or TaqMan™ probes. A molecular beacon (MB) is an oligonucleotide or peptide nucleic acid (PNA) which, under appropriate hybridization conditions, self-hybridizes to form a stem and loop structure. The MB has a label and a quencher at the termini of the oligonucleotide or PNA; thus, under conditions that permit intra-molecular hybridization, the label is typically quenched (or at least altered in its fluorescence) by the quencher. Under conditions where the MB does not display intra-molecular hybridization (e.g., when bound to a target nucleic acid, e.g., to a region of an amplicon during amplification), the MB label is unquenched. Details regarding standard methods of making and using MBs are well established in the literature and MBs are available from a number of commercial reagent sources. See also, e.g., Leone et al. (1995) "Molecular beacon probes combined with amplification by NASBA enable homogenous real-time detection of RNA." *Nucleic Acids Res.* 26:2150-2155; Tyagi and Kramer (1996) "Molecular beacons: probes that fluoresce upon hybridization" *Nature Biotechnology* 14:303-308; Blok and Kramer (1997) "Amplifiable hybridization probes containing a molecular switch" *Mol Cell Probes* 11:187-194; Hsuih et al. (1997) "Novel, ligation-dependent PCR assay for detection of hepatitis C in serum" *J Clin Microbiol* 34:501-507; Kostrikis et al. (1998) "Molecular beacons: spectral genotyping of human alleles" *Science* 279:1228-1229; Sokol et al. (1998) "Real time detection of DNA:RNA hybridization in living cells" *Proc. Natl. Acad. Sci. U.S.A.* 95:11538-11543; Tyagi et al. (1998) "Multicolor molecular beacons for allele discrimination" *Nature Biotechnology* 16:49-53; Bonnet et al. (1999) "Thermodynamic basis of the chemical specificity of structured DNA probes" *Proc. Natl. Acad. Sci. U.S.A.* 96:6171-6176; Fang et al. (1999) "Designing a novel molecular beacon for surface-immobilized DNA hybridization studies" *J. Am. Chem. Soc.* 121:2921-2922; Marras et al. (1999) "Multiplex detection of single-nucleotide variation using molecular beacons" *Genet. Anal. Biomol. Eng.* 14:151-156; and Vet et al. (1999) "Multiplex detection of four pathogenic retroviruses using molecular beacons" *Proc. Natl. Acad. Sci. U.S.A.* 96:6394-6399. Additional details regarding MB construction and use is found in the patent literature, e.g., U.S. Pat. No. 5,925,517 (Jul. 20, 1999) to Tyagi et al. entitled "Detectably labeled dual conformation oligonucleotide probes, assays and kits;" U.S. Pat. No. 6,150,097 to Tyagi et al (Nov. 21, 2000) entitled "Nucleic acid detection probes having non-FRET fluorescence quenching and kits and assays including such probes" and U.S. Pat. No. 6,037,130 to Tyagi et al (Mar. 14, 2000), entitled "Wavelength-shifting probes and primers and their use in assays and kits."

PCR detection and quantification using dual-labeled fluorogenic oligonucleotide probes, commonly referred to as "TaqMan™" probes, can also be performed. These probes are composed of short (e.g., 20-25 base) oligodeoxynucleotides that are labeled with two different fluorescent dyes. On the 5' terminus of each probe is a reporter dye, and on the 3' terminus of each probe a quenching dye is found. The oligonucleotide probe sequence is complementary to an internal target sequence present in a PCR amplicon. When the probe is intact, energy transfer occurs between the two fluorophores and emission from the reporter is quenched by the quencher by FRET. During the extension phase of PCR, the probe is cleaved by 5' nuclease activity of the polymerase used in the reaction, thereby releasing the reporter from the oligonucleotide-quencher and producing an increase in reporter emission intensity. Accordingly, TaqMan™ probes are oligonucleotides that have a label and a quencher, where

195

the label is released during amplification by the exonuclease action of the polymerase used in amplification. This provides a real time measure of amplification during synthesis. A variety of TaqMan™ reagents are commercially available, e.g., from Applied Biosystems (Division Headquarters in Foster City, Calif.) as well as from a variety of specialty vendors such as Biosearch Technologies (e.g., black hole quencher probes). Further details regarding dual-label probe strategies can be found, e.g., in WO92/02638.

Other similar methods include e.g. fluorescence resonance energy transfer between two adjacently hybridized probes, e.g., using the "LightCycler™" format described in U.S. Pat. No. 6,174,670.

Amplification and Sequencing Primers

In embodiments, methylation sites are detected using primers, e.g., to amplify and/or sequence polynucleotides comprising the methylation sites.

Suitable primers can be designed and is not intended that the present subject matter be limited to any particular primer or primer pair. For example, primers can be designed using any suitable software program, such as LASERGENET™, e.g., taking account of publicly available sequence information. Flanking sequences for the methylation sites identified herein are publicly available; accordingly, suitable amplification primers can be constructed based on well understood base-pairing rules. The sequence of any amplicon can be detected as has already been discussed above, e.g., by sequencing, hybridization, array hybridization, PCR, LCR, or the like.

In embodiments, the primers are radiolabelled, or labeled by any suitable means (e.g., using a non-radioactive fluorescent tag), to allow for rapid visualization of differently sized amplicons following an amplification reaction without any additional labeling step or visualization step. In embodiments, the primers are not labeled, and the amplicons are visualized following their size resolution, e.g., following agarose or acrylamide gel electrophoresis. In embodiments, ethidium bromide staining of the PCR amplicons following size resolution allows visualization of the different size amplicons.

It is not intended that the primers be limited to generating an amplicon of any particular size. The primers can generate an amplicon of any suitable length for detection (e.g., by sequencing or hybridization). In embodiments, amplification produces an amplicon at least 20 nucleotides in length, or alternatively, at least 50 nucleotides in length, or alternatively, at least 100 nucleotides in length, or alternatively, at least 200 nucleotides in length. Amplicons of any size can be detected and/or sequenced using various technologies described herein and known in the art.

Detection of Methylation Levels Using Sequencing

Sequencing is the process of determining the precise order of nucleotides within a DNA molecule. The advent of rapid DNA sequencing methods has greatly accelerated biological and medical research and discovery. Non-limiting examples and descriptions are provided below. However, embodiments are not limited to the use of a particular sequencing assay, technology, or approach.

Sanger sequencing is a method of DNA sequencing based on the selective incorporation of chain-terminating dideoxynucleotides by DNA polymerase during *in vitro* DNA replication (Sanger F; Coulson A R (May 1975) *J. Mol. Biol.* 94 (3): 441-8; Sanger et al. (December 1977) *Proc. Natl. Acad. Sci. U.S.A.* 74 (12): 5463-7).

In embodiments, next-generation sequencing is used. Non-limiting examples of next-generation sequencing methods include massively parallel signature sequencing

196

(MPSS), single-molecule real-time sequencing, ion semiconductor sequencing, pyrosequencing, sequencing by synthesis, sequencing by ligation, chain termination, DNA nanoball sequencing, helicos single molecule sequencing, single molecule real time sequencing, nanopore DNA sequencing, tunnelling currents DNA sequencing, and sequencing by hybridization.

Many commercially available sequencing technologies, devices, and services are available. In embodiments, an Illumina sequencer is used. In embodiments, PCR products are ligated with a linker and sequenced using a high throughput sequencer, such as an Illumina sequencer. In embodiments, the ligation step can be avoided, omitted, or eliminated by adding a linker to amplification primers.

15 Array-Based Sequence Detection

Array-based detection can be performed using commercially available arrays, e.g., from Affymetrix (Santa Clara, Calif.) or other manufacturers. Reviews regarding the operation of nucleic acid arrays include Sapolsky et al. (1999) "High-throughput polymorphism screening and genotyping with high-density oligonucleotide arrays." *Genetic Analysis: Biomolecular Engineering* 14:187-192; Lockhart (1998) "Mutant yeast on drugs" *Nature Medicine* 4:1235-1236; Fodor (1997) "Genes, Chips and the Human Genome." *FASEB Journal* 11:A879; Fodor (1997) "Massively Parallel Genomics." *Science* 277:393-395; and Chee et al. (1996) "Accessing Genetic Information with High-Density DNA Arrays." *Science* 274:610-614.

A variety of probe arrays have been described in the literature and can be used for detection of methylation. For example, DNA probe array chips or larger DNA probe array wafers (from which individual chips would otherwise be obtained by breaking up the wafer) may be used in embodiments described herein. DNA probe array wafers generally comprise glass wafers on which high density arrays of DNA probes (short segments of DNA) have been placed.

Each of these wafers can hold, for example, approximately 60 million DNA probes that are used to recognize longer sample DNA sequences (e.g., from individuals or populations, e.g., that comprise methylation sites of interest). The recognition of sample DNA by the set of DNA probes on the glass wafer takes place through DNA hybridization. When a DNA sample hybridizes with an array of DNA probes, the sample binds to those probes that are complementary to the sample DNA sequence. By evaluating to which probes the sample DNA for an individual hybridizes more strongly, it is possible to determine whether a known sequence of nucleic acid is present or not in the sample, thereby determining whether a uracil, thymine, or cytosine is present at a polynucleotide site corresponding to a genomic methylation site. One can also use this approach to control the hybridization conditions to permit single nucleotide discrimination, e.g., for the identification of methylation at a site of interest. Arrays provide one convenient embodiment for detecting multiple methylation sites simultaneously (or in series). Of course, any detection technology (PCR, LCR, and/or sequencing etc.) can similarly be used, e.g., with multiplex amplification/detection/sequencing reactions, or simply by running several separate reactions, e.g., simultaneously or in series.

In embodiments, the use of DNA probe arrays to obtain methylation information involves the following general steps: design and manufacture of DNA probe arrays, preparation of the sample, bisulfite treatment, hybridization of sample DNA to the array, detection of hybridization events and data analysis to determine sequence. In embodiments, an array is used to capture polynucleotides containing a

methylation site of interest, and the captured polynucleotides are subsequently amplified and/or sequenced. Preferred wafers are manufactured using a process adapted from semiconductor manufacturing to achieve cost effectiveness and high quality, and are available, e.g., from Affymetrix, Inc. of Santa Clara, Calif.

For example, probe arrays can be manufactured by light-directed chemical synthesis processes, which combine solid-phase chemical synthesis with photolithographic fabrication techniques as employed in the semiconductor industry. Using a series of photolithographic masks to define chip exposure sites, followed by specific chemical synthesis steps, the process constructs high-density arrays of oligonucleotides, with each probe in a predefined position in the array. Multiple probe arrays can be synthesized simultaneously on a large glass wafer. This parallel process enhances reproducibility and helps achieve economies of scale.

In embodiments, DNA probe arrays can be used to obtain data regarding presence of sequences (e.g., corresponding to methylated or unmethylated DNA) of interest. The DNA samples may be tagged with biotin and/or a fluorescent reporter group by standard biochemical methods. The labeled samples are incubated with an array, and segments of the samples bind, or hybridize, with complementary sequences on the array. The array can be washed and/or stained to produce a hybridization pattern. The array is then scanned and the patterns of hybridization are detected by emission of light from the fluorescent reporter groups. Because the identity and position of each probe on the array is known, the nature of the DNA sequences in the sample applied to the array can be determined.

In embodiments, the nucleic acid sample to be analyzed is isolated, bisulfite-treated, amplified and, optionally, labeled with biotin and/or a fluorescent reporter group. The labeled nucleic acid sample may then be incubated with the array using a fluidics station and hybridization oven. The array can be washed and/or stained or counter-stained, as appropriate to the detection method. After hybridization, washing and staining, the array is inserted into a scanner, where patterns of hybridization are detected. The hybridization data are collected as light emitted from the fluorescent reporter groups already incorporated into the labeled nucleic acid, which is now bound to the probe array. Probes that most clearly match the labeled nucleic acid produce stronger signals than those that have mismatches. Since the sequence and position of each probe on the array are known, by complementarity, the identity of the nucleic acid sample applied to the probe array can be identified. In embodiments, hybridization techniques and conditions that allow only fully complementary nucleotide sequences to hybridize with probes in an array are used.

Prior to amplification and/or detection of a nucleic acid comprising a sequence of interest, the nucleic acid is optionally purified from the samples by any available method, e.g., those taught in Berger and Kimmel, *Guide to Molecular Cloning Techniques, Methods in Enzymology* volume 152 Academic Press, Inc., San Diego, Calif. (Berger); Sambrook et al., *Molecular Cloning—A Laboratory Manual* (3rd Ed.), Vol. 1-3, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 2001 ("Sambrook"); and/or Current Protocols in Molecular Biology, F. M. Ausubel et al., eds., *Current Protocols*, a joint venture between Greene Publishing Associates, Inc. and John Wiley & Sons, Inc., (supplemented through 2002) ("Ausubel"). A plethora of kits are also commercially available for the purification of nucleic acids from cells or other samples (see, e.g., EasyPrep™, Flex-iPrep™, both from Pharmacia Biotech; StrataClean™, from

Stratagene; and, QIAprep™ from Qiagen). Alternately, samples can simply be directly subjected to amplification or detection, e.g., following aliquotting and/or dilution.

Thyroid Cancer Diagnostic System and Processes

FIG. 4 depicts a block diagram illustrating an exemplary thyroid cancer diagnostic system 600. Referring to FIG. 4, the thyroid cancer diagnostic system 600 can include an input module 610, an isolation module 612, a conversion module 614, a detection module 616, a diagnosis module 618, a treatment module 620, and a user interface (UI) module 622. The thyroid cancer diagnostic system 600 can be configured to provide a diagnosis indicative of a presence of thyroid cancer and/or a risk of developing thyroid cancer. Moreover, the thyroid cancer diagnostic system 600 can be further configured to generate a treatment plan for a subject based on the diagnosis. For instance, when the diagnosis indicates a presence and/or risk of thyroid cancer in a subject, the thyroid cancer diagnostic system 600 can recommend one or more treatments including, for example, thyroid surgery, radiation therapy, radioactive iodine therapy, chemotherapy, thyroid hormone therapy, and administration of an active agent.

One or more modules of the thyroid cancer diagnostic system 600 can be realized in digital electronic circuitry, integrated circuitry, specially designed application specific integrated circuits (ASICs), field programmable gate arrays (FPGAs) computer hardware, firmware, software, and/or combinations thereof. The thyroid cancer diagnostic system 600 can further be communicatively coupled with one or more devices including, for example, a device 630. The thyroid cancer diagnostic system 600 can communicate with the device 620 via a wired and/or wireless network 640 (e.g., a wide area network (WAN), a local area network (LAN), and/or the Internet). As shown in FIG. 4, the thyroid cancer diagnostic system 600 can be further coupled with a data store 650.

The input module 610 can be adapted to receive and/or collect a sample of a thyroid nodule obtained from a subject. The isolation module 612 can be configured to isolate DNA from the thyroid nodule sample received by the input module 610 thereby forming isolated thyroid nodule DNA. The conversion module 614 can be configured to treat the isolated thyroid nodule DNA including by contacting the isolated thyroid nodule DNA with one or more bisulfite reagents including, for example, a bisulfite salt. Exposing the isolated thyroid nodule DNA to one or more bisulfite reagents can convert cytosine to uracil while 5-mC is left unmodified. Thus, the 5-mC present in the isolated thyroid nodule DNA will remain in the reacted thyroid nodule DNA. Meanwhile, any cytosine in the isolated thyroid nodule DNA will be replaced by uracil in the reacted thyroid nodule DNA. In embodiments, the treatment of the isolated thyroid nodule DNA can be performed by applying one or more kits (e.g., the Bisulflash DNA Modification Kit (Epigentek) or Imprint DNA Modification Kit (Sigma)).

In embodiments, the conversion module 614 can be further adapted to ensure optimal bisulfite conversion (e.g., with desired DNA fragment size for post-bisulfite ligation) by controlling one or more of a concentration of the bisulfite reagents, temperature, and reaction time period. It should be appreciated that the conversion module 614 can be adapted to use a different and/or additional type of reagent without departing from the scope of the present subject matter. For example, the conversion module 614 can treat the isolated thyroid nodule DNA with potassium chloride, which may reduce the thermophilic DNA degradation associated with the conversion of cytosine to uracil. Moreover, the conver-

199

sion module **614** can be configured to perform additional processing of the reacted thyroid nodule DNA including, for example, desulphonation (e.g., with an alkalized solution), cleansing (e.g., by elution), and amplification (e.g., using the PCR method).

The detection module **616** can be configured to detect a methylation and/or unmethylation of the thyroid nodule DNA. For instance, the detection module **616** can detect methylation by detecting a presence of uracil in the reacted thyroid nodule DNA generated by the conversion module **614**. Alternately and/or additionally, the detection module **616** can detect unmethylation by detecting an absence of uracil in the reacted thyroid nodule DNA. In embodiments, the detection module **616** can be configured to detect the presence and/or absence of uracil at specific methylation sites. That is, the detection module **616** can be configured to detect the presence and/or absence of uracil at specific chromosomal positions of certain chromosomes. For example, the thyroid cancer diagnostic system **600** can store a plurality of specific methylation sites (e.g., Table 1) in the data store **650**. As such, to detect methylation, the detection module **616** can be configured to obtain, from the data store **650**, one or more specific methylation sites at which to test for the presence and/or absence of uracil. Moreover, in embodiments, the detection module **616** can be configured to determine a level of methylation and/or unmethylation at the specific methylation sites. The level of methylation at a particular site can correspond to a proportion of the reacted thyroid nodule DNA that has a cytosine rather than a uracil at that site. By contrast, the level of unmethylation at a particular site can correspond to a proportion of reacted thyroid nodule DNA that has a uracil rather than a cytosine at that site.

In embodiments, the conversion module **614** may amplify the reacted thyroid nodule DNA such as by using a PCR method. The detection of methylation and/or unmethylation in amplified reacted thyroid nodule DNA may require detection of a presence and/or absence of thymidine at a site of interest in amplicons amplified from the reacted thyroid nodule DNA. That is, instead of detecting the presence and/or absence of uracil, the detection module **616** can be configured to detect methylation and/or unmethylation of amplified reacted thyroid nodule DNA by detecting a presence and/or absence of thymidine at specific methylation sites (e.g., as set forth in Table 1).

The diagnosis module **618** can be configured to generate a diagnosis for the subject based on whether the detection module **616** detects methylation and/or unmethylation at the plurality of specific methylation sites (e.g., Table 1). Alternately or additionally, the diagnosis module **618** can be configured to generate a diagnosis for the subject based on a level of methylation and/or unmethylation detected by the detection module **616** at the plurality of specific methylation sites. For instance, diagnosis module **618** can determine that the thyroid nodule is malignant (e.g., cancerous) when the unmethylation level (e.g., proportion of uracil) at different methylation sites exceeds the corresponding thresholds (e.g., as set forth in Table 2). In embodiments, the diagnosis module **618** can further generate a diagnosis for the subject based on one or more of the subject's PTC methylation alteration score, a BTN methylation alteration score, and/or a Composite Cancer Risk Score.

In embodiments, the diagnosis module **618** can be configured to determine a PTC methylation alteration score for the subject. In embodiments, the PTC methylation alteration score can correspond to a number of specific methylation sites (e.g., as set forth in Table 1) that have a uracil level (or

200

corresponding thymidine level if amplicons are being analyzed) equal to or greater than the corresponding thresholds (e.g., as set forth in Table 2). Alternately or additionally, the diagnosis module **618** can be configured to determine a BTN methylation alteration score for the subject. The BTN methylation alteration score can correspond to a number of specific methylation sites (e.g., as set forth in Table 1) that have a uracil level (or corresponding thymidine level if amplicons are being analyzed) equal to or greater than the various corresponding threshold level (e.g., as set forth in Table 3 and/or Table 4).

In embodiments, the diagnosis module **618** can further be configured to compute a Composite Cancer Risk Score for the subject. The diagnosis module **618** can compute the Composite Cancer Risk Score based on the PTC methylation alteration score and the BTN methylation alteration score for the subject. For example, the Composite Cancer Risk Score for the subject can be computed based on equation (1):

$$\frac{[\text{the PTC methylation alteration score for the subject}]}{[\text{BTN methylation alteration score for the subject}]} \quad (1)$$

Alternately or additionally, the Composite Cancer Risk Score for the subject can be computed based on equation (2):

$$\frac{[(\text{the PTC methylation alteration score for the subject}) + 1]}{[(\text{BTN methylation alteration score for the subject}) + 1]} \quad (2)$$

The treatment module **620** can be configured to formulate a treatment plan for the subject based on the diagnosis generated by the diagnosis module **618**. For instance, when the diagnosis generated by the diagnosis module **618** indicates a presence and/or risk of a malignant (e.g., cancerous) thyroid nodule, the treatment module **620** can prescribe one or more treatments including, for example, thyroid surgery, radiation therapy, radioactive iodine therapy, chemotherapy, thyroid hormone therapy, and administration of an active agent. In embodiments, the treatment module **620** can be configured to provide the treatment plan to the device **630** via the network **640**. Alternately or additionally, the treatment module **620** can store the treatment plan in the data store **650**.

The UI module **622** can be configured to generate a UI through which a user (e.g., a physician) can interface with the thyroid cancer diagnostic system **600**. For example, the UI module **622** can provide one or more graphic user interfaces (GUIs) configured to display the diagnosis and/or treatment plan for the subject.

FIG. 5 depicts a flowchart illustrating an exemplary process **700** for diagnosing thyroid cancer. Referring to FIGS. 4-5, the process **700** can be performed by the thyroid cancer diagnostic system **600**.

The thyroid cancer diagnostic system **600** (e.g., the input module **610**) can receive a sample of a thyroid nodule from a subject (**702**). The thyroid cancer diagnostic system **600** (e.g., the isolation module **612**) can isolate thyroid nodule DNA from the thyroid nodule sample (**704**). The thyroid cancer diagnostic system **600** (e.g., the conversion module **614**) can treat the isolated thyroid nodule DNA with a bisulfite salt to generate reacted thyroid nodule DNA (**706**). Treating the isolated thyroid nodule DNA with the bisulfite salt can form a reacted thyroid nodule DNA by converting the cytosine present in the isolated thyroid nodule DNA to uracil. In embodiments, the thyroid cancer diagnostic system

201

600 can further process the reacted thyroid nodule DNA by desulphonating, cleansing, and/or amplifying the reacted thyroid nodule DNA.

The thyroid cancer diagnostic system **600** (e.g., the detection module **616**) can detect methylation and/or unmethylation of the isolated thyroid nodule DNA by at least detecting a presence and/or absence of uracil in the reacted thyroid nodule DNA (**708**). In embodiments, the thyroid cancer diagnostic system **600** can be configured to detect a presence and/or absence of uracil at specific methylation sites (e.g., as set forth in Table 1). Moreover, the thyroid cancer diagnostic system **600** can be configured to detect a level of methylation and/or unmethylation at the methylation sites.

The thyroid cancer diagnostic system **600** (e.g., the diagnostics module **618**) can generate a diagnosis for the subject based on the methylation and/or unmethylation of the isolated thyroid nodule DNA (**710**). For example, the thyroid cancer diagnostic system **600** can generate a diagnosis based on a level of methylation and/or unmethylation at a plurality of specific methylation sites. Each methylation site may be associated with a certain threshold unmethylation level (e.g., as set forth in Table 2). As such, the thyroid cancer diagnostic system **600** can determine that the thyroid nodule from the subject is malignant (e.g., cancerous) if the level of unmethylation at the plurality of methylation sites exceeds the corresponding thresholds.

The thyroid cancer diagnostic system **600** (e.g., the treatment module **620**) can formulate, based on the diagnosis, a treatment plan for the subject (**712**). For example, when the diagnosis indicates that a presence and/or risk of malignant thyroid nodules in the subject, the thyroid cancer diagnostic system **600** can prescribe thyroid surgery, radiation therapy, radioactive iodine therapy, chemotherapy, thyroid hormone therapy, and/or administration of an active agent. The thyroid cancer diagnostic system **600** (e.g., the UI module **622**) can provide, via a UI (e.g., GUI at the device **630**), the diagnosis and/or the treatment plan for the subject (**714**).

FIG. 6 depicts a flowchart illustrating an exemplary process **800** for diagnosing thyroid cancer. Referring to FIGS. 4 and 6, the process **700** can be performed by the thyroid cancer diagnostic system **600**.

The thyroid cancer diagnostic system **600** (e.g., the input module **610**) can receive a sample of a thyroid nodule from a subject (**802**). The thyroid cancer diagnostic system **600** (e.g., the isolation module **612**) can isolate thyroid nodule DNA from the thyroid nodule sample (**804**). The thyroid cancer diagnostic system **600** (e.g., the conversion module **614**) can treat the isolated thyroid nodule DNA with a bisulfite salt to generate reacted thyroid nodule DNA (**806**).

As shown in FIG. 6, the thyroid cancer diagnostic system **600** (e.g., the conversion module **614**) can amplify the reacted thyroid nodule DNA (**808**). For instance, the thyroid cancer diagnostic system **600** can amplify the reacted thyroid nodule DNA subsequent to treating the isolated thyroid nodule NA with the bisulfite salt to generate the reacted thyroid nodule DNA. The thyroid cancer diagnostic system **600** can detect methylation and/or unmethylation of the isolated thyroid nodule DNA by detecting a presence and/or absence of thymidine in the amplified reacted thyroid nodule DNA (**810**).

The thyroid cancer diagnostic system **600** (e.g., the diagnostics module **618**) can generate a diagnosis for the subject based on the methylation and/or unmethylation of the isolated thyroid nodule DNA (**812**). Moreover, the thyroid cancer diagnostic system **600** (e.g., the treatment module **620**) can formulate, based on the diagnosis, a treatment plan for the subject (**814**). The thyroid cancer diagnostic system

202

600 (e.g., the UI module **622**) can provide, via a UI, the diagnosis and/or treatment plan for the subject.

It should be appreciated that the process **700** and/or **800** can include different and/or additional operations without departing from the scope of the present subject matter. Moreover, one or more operations of the process **700** and/or **800** can be omitted and/or repeated without departing from the scope of the present subject matter.

Implementations of the present subject matter can include, but are not limited to, methods consistent with the descriptions provided above as well as articles that comprise a tangibly embodied machine-readable medium operable to cause one or more machines (e.g., computers, etc.) to result in operations implementing one or more of the described features. Similarly, computer systems are also described that can include one or more processors and one or more memories coupled to the one or more processors. A memory, which can include a computer-readable storage medium, can include, encode, store, or the like one or more programs that cause one or more processors to perform one or more of the operations described herein. Computer implemented methods consistent with one or more implementations of the current subject matter can be implemented by one or more data processors residing in a single computing system or multiple computing systems. Such multiple computing systems can be connected and can exchange data and/or commands or other instructions or the like via one or more connections, including but not limited to a connection over a network (e.g. the Internet, a wireless wide area network, a local area network, a wide area network, a wired network, or the like), via a direct connection between one or more of the multiple computing systems, etc.

One or more aspects or features of the subject matter described herein can be realized in digital electronic circuitry, integrated circuitry, specially designed ASICs, FPGAs, computer hardware, firmware, software, and/or combinations thereof. These various aspects or features can include implementation in one or more computer programs that are executable and/or interpretable on a programmable system including at least one programmable processor, which can be special or general purpose, coupled to receive data and instructions from, and to transmit data and instructions to, a storage system, at least one input device, and at least one output device. The programmable system or computing system can include clients and servers. A client and server are generally remote from each other and typically interact through a communication network. The relationship of client and server arises by virtue of computer programs running on the respective computers and having a client-server relationship to each other.

These computer programs, which can also be referred to as programs, software, software applications, applications, components, or code, include machine instructions for a programmable processor, and can be implemented in a high-level procedural language, an object-oriented programming language, a functional programming language, a logical programming language, and/or in assembly/machine language. As used herein, the term "machine-readable medium" refers to any computer program product, apparatus and/or device, such as for example magnetic discs, optical disks, memory, and Programmable Logic Devices (PLDs), used to provide machine instructions and/or data to a programmable processor, including a machine-readable medium that receives machine instructions as a machine-readable signal. The term "machine-readable signal" refers to any signal used to provide machine instructions and/or data to a programmable processor. The machine-readable

203

medium can store such machine instructions non-transitorily, such as for example as would a non-transient solid-state memory or a magnetic hard drive or any equivalent storage medium. The machine-readable medium can alternatively or additionally store such machine instructions in a transient manner, such as for example as would a processor cache or other random access memory associated with one or more physical processor cores.

To provide for interaction with a user, one or more aspects or features of the subject matter described herein can be implemented on a computer having a display device, such as for example a cathode ray tube (CRT) or a liquid crystal display (LCD) or a light emitting diode (LED) monitor for displaying information to the user and a keyboard and a pointing device, such as for example a mouse or a trackball, by which the user may provide input to the computer. Other kinds of devices can be used to provide for interaction with a user as well. For example, feedback provided to the user can be any form of sensory feedback, such as for example visual feedback, auditory feedback, or tactile feedback; and input from the user can be received in any form, including, but not limited to, acoustic, speech, or tactile input. Other possible input devices include, but are not limited to, touch screens or other touch-sensitive devices such as single or multi-point resistive or capacitive trackpads, voice recognition hardware and software, optical scanners, optical pointers, digital MRI image capture devices and associated interpretation software, and the like.

Examples are provided below to facilitate a more complete understanding of the invention. The following examples illustrate the exemplary modes of making and practicing the invention. However, the scope of the invention is not limited to specific embodiments disclosed in these Examples, which are for purposes of illustration only, since alternative methods can be utilized to obtain similar results.

EMBODIMENTS

Embodiments include embodiments P1 to P41 following.

Embodiment P1. A method of detecting methylation or unmethylation of a thyroid nodule DNA of a subject, the method comprising: (i) isolating DNA from a thyroid nodule of said subject thereby forming isolated thyroid nodule DNA, (ii) contacting said isolated thyroid nodule DNA with sodium bisulfite thereby forming a reacted thyroid nodule DNA, (iii) detecting the presence or absence of uracil in said reacted thyroid nodule DNA at a methylation site set forth in Table 1, thereby detecting methylation or unmethylation of said thyroid nodule DNA of said subject.

Embodiment P2. The method of embodiment P1, further comprising determining alteration in methylation at a plurality of methylation sites set forth in Table 1.

Embodiment P3. The method of embodiment P2, said alteration comprises increase or loss of uracil level at said plurality of methylation sites.

Embodiment P4. The method of embodiment P3, wherein said uracil level is above a threshold as set forth in Table 2.

Embodiment P5. The method of embodiment P3, wherein said uracil level is above a threshold as set forth in Table 3.

Embodiment P6. The method of embodiment P3, wherein said uracil level is below a threshold as set forth in Table 4.

Embodiment P7. The method of embodiment P3, wherein said subject is a candidate thyroid cancer patient.

Embodiment P8. The method of embodiment P4, wherein said above threshold identifies said thyroid nodule as a cancerous thyroid nodule.

204

Embodiment P9. The method of embodiment P5, wherein said above threshold identifies said thyroid nodule as a benign thyroid nodule.

Embodiment P10. The method of embodiment P6, wherein said below threshold identifies said thyroid nodule as a benign thyroid nodule.

Embodiment P11. The method of one of the above embodiments, wherein said thyroid nodule is a specimen obtained by biopsy or by surgical resection of said subject.

Embodiment P12. The method of embodiment P11, wherein said subject has undergone thyroid surgery, radiation therapy, radioactive iodine therapy, chemotherapy, thyroid hormone therapy, and administration of an active agent.

Embodiment P13. The method of embodiment P12, wherein said active agent is chosen from Cabozantinib-S-Malate, Caprelsa (Vandetanib), Cometriq (Cabozantinib-S-Malate), Doxorubicin Hydrochloride, Lenvatinib Mesylate, Lenvima (Lenvatinib Mesylate), Nexavar (Sorafenib Tosylate), Sorafenib Tosylate, and Vandetanib.

Embodiment P14. A method of determining a thyroid cancer or risk of developing thyroid cancer in a subject in need thereof, said method comprising: (i) isolating DNA from a thyroid nodule of said subject thereby forming isolated thyroid nodule DNA; (ii) contacting said isolated thyroid nodule DNA with sodium bisulfite thereby forming a reacted thyroid nodule DNA; and (iii) detecting the presence or absence of uracil in said reacted thyroid nodule DNA at a methylation site set forth in Table 1; thereby determining said thyroid cancer in said subject.

Embodiment P15. The method of embodiment P14, further comprising selecting a subject that has or is at risk for developing thyroid cancer.

Embodiment P16. The method of embodiment P14, further comprising determining alteration in methylation at a plurality of methylation sites set forth in Table 1.

Embodiment P17. The method of embodiment P16, said alteration comprises increase or loss of uracil level at said plurality of methylation sites.

Embodiment P18. The method of embodiment P17, wherein said uracil level is above a threshold as set forth in Table 2.

Embodiment P19. The method of embodiment P17, wherein said uracil level is above a threshold as set forth in Table 3.

Embodiment P20. The method of embodiment P17, wherein said uracil level is below a threshold as set forth in Table 4.

Embodiment P21. The method of embodiment P17, wherein said subject is a candidate thyroid cancer patient.

Embodiment P22. The method of embodiment P18, wherein said above threshold identifies said thyroid nodule as a cancerous thyroid nodule.

Embodiment P23. The method of embodiment P19, wherein said above threshold identifies said thyroid nodule as a benign thyroid nodule.

Embodiment P24. The method of embodiment P20, wherein said below threshold identifies said thyroid nodule as a benign thyroid nodule.

Embodiment P25. The method of embodiments P14-P24, wherein said thyroid nodule is a specimen obtained by biopsy or by surgical resection of said subject.

Embodiment P26. The method of embodiment P25, wherein said subject has undergone thyroid surgery, radiation therapy, radioactive iodine therapy, chemotherapy, thyroid hormone therapy, and administration of an active agent, before said determination.

205

Embodiment P27. The method of embodiment P26, wherein said active agent is chosen from Cabozantinib-S-Malate, Caprelsa (Vandetanib), Cometriq (Cabozantinib-S-Malate), Doxorubicin Hydrochloride, Lenvatinib Mesylate, Lenvima (Lenvatinib Mesylate), Nexavar (Sorafenib Tosylate), Sorafenib Tosylate, and Vandetanib.

Embodiment P28. A method of treating thyroid cancer in a subject determined by the method as set forth in embodiment P22, comprising administering to said subject an active agent for treating thyroid cancer.

Embodiment P29. The method of embodiment P28, wherein said subject has undergone surgery, radiation therapy, radioactive iodine therapy, chemotherapy, or thyroid hormone therapy, before said detection of embodiment 14 at (iii).

Embodiment P30. The method of embodiment P29, wherein said active agent is chosen from Cabozantinib-S-Malate, Caprelsa (Vandetanib), Cometriq (Cabozantinib-S-Malate), Doxorubicin Hydrochloride, Lenvatinib Mesylate, Lenvima (Lenvatinib Mesylate), Nexavar (Sorafenib Tosylate), Sorafenib Tosylate, and Vandetanib.

Embodiment P31. The method of one of above embodiments, wherein said subject has or is at risk of papillary thyroid cancer, follicular thyroid cancer, medullary thyroid cancer, or anaplastic thyroid cancer.

Embodiment P32. A deoxyribonucleic acid 5 to 100 nucleotides in length comprising a uracil-containing sequence identical to at least a 5 contiguous nucleotide sequence within a sequence chosen from SEQ ID NO:1 to SEQ ID NO:550.

Embodiment P33. The deoxyribonucleic acid of embodiment P32 identical to 5-10, 10-20, 20-30, 30-40, 40-50, 50-60, 60-70, 70-80, 80-90, 90-100, 100-110, 110-120, 120-130, 130-140, 140-150, 150-160, 160-170, 170-180, 180-190, or 190-200 of contiguous nucleotide sequence of said sequence chosen from SEQ ID NO: 1 to SEQ ID NO:550.

Embodiment P34. The deoxyribonucleic acid of embodiment P32 or P33, wherein said sequence comprises a methylation site set forth in Table 2.

Embodiment P35. The deoxyribonucleic acid of embodiment P34, wherein a plurality of methylation sites set forth in Table 2 are methylated or unmethylated.

Embodiment P36. A deoxyribonucleic acid chosen from SEQ ID NO:551 to SEQ ID NO: 782, wherein said nucleic acid is hybridized to a complementary DNA sequence comprising uridine or cytosine.

Embodiment P37. The deoxyribonucleic acid of embodiment P36, further comprising an enzyme in a complex with said hybridized complementary DNA sequence.

Embodiment P38. The deoxyribonucleic acid of embodiment P37, wherein said enzyme is Taq polymerase.

Embodiment P39. A kit comprising 322 nucleic acids each independently comprising SEQ ID NO:551 to SEQ ID NO:782, wherein said nucleic acids do not simultaneously comprise the same SEQ ID NO:551 to SEQ ID NO:782.

Embodiment P40. The kit according to embodiment P39, further comprising: enzymes, reagents for deamination of cytosine, buffers, vials, plasmid vectors, control DNA, devices for collecting thyroid tissue samples, reagents for isolating DNA, reagents for labeling DNA, or any combinations thereof.

Embodiment P41. The kit according to embodiment P40, wherein the enzymes are selected from the group consisting of: thermostable DNA polymerase enzymes, restriction enzymes, and combination thereof.

206

Further embodiments include embodiments 1-58 following.

Embodiment 1. A method of detecting methylation or unmethylation of a thyroid nodule DNA molecule of a subject, the method comprising: (i) isolating a thyroid nodule DNA molecule from a thyroid nodule of said subject thereby forming an isolated thyroid nodule DNA molecule, (ii) contacting said isolated thyroid nodule DNA molecule with a bisulfite salt thereby forming a reacted thyroid nodule DNA molecule, (iii) detecting the presence or absence of uracil in said reacted thyroid nodule DNA molecule at a methylation site set forth in Table 1, thereby detecting methylation or unmethylation of said thyroid nodule DNA molecule of said subject.

Embodiment 2. The method of embodiment 1, further comprising detecting the presence or absence of uracil in said reacted thyroid nodule DNA molecule at a plurality of methylation sites set forth in Table 1, wherein said methylation site forms a part of said plurality of methylation sites.

Embodiment 3. The method of embodiment 1, the method further comprising: (i) isolating a plurality of thyroid nodule DNA molecules from said thyroid nodule of said subject thereby forming a plurality of isolated thyroid nodule DNA molecules, wherein said isolated thyroid nodule DNA molecule forms part of said plurality of isolated thyroid nodule DNA molecules, (ii) contacting said plurality of isolated thyroid nodule DNA molecules with said bisulfite salt thereby forming a plurality of reacted thyroid nodule DNA molecules, wherein said reacted thyroid nodule DNA molecule forms part of said plurality of reacted thyroid nodule DNA molecules, (iii) detecting the level of reacted thyroid nodule DNA molecules in said plurality of reacted thyroid nodule DNA molecules having a uracil at a methylation site set forth in Table 1, thereby detecting the level of methylation or unmethylation in said plurality of thyroid nodule DNA molecules of said subject.

Embodiment 4. The method of embodiment 3, further comprising determining the level of uracil in said reacted thyroid nodule DNA molecule at a plurality methylation sites set forth in Table 1, wherein said methylation site forms a part of said plurality of methylation sites.

Embodiment 5. The method of embodiment 4, wherein said uracil level is above a threshold as set forth in Table 2.

Embodiment 6. The method of embodiment 4, wherein said uracil level is above a threshold as set forth in Table 3.

Embodiment 7. The method of embodiment 4, wherein said uracil level is below a threshold as set forth in Table 4.

Embodiment 8. The method of one of the above embodiments, wherein said subject is suspected of having thyroid cancer.

Embodiment 9. The method of one of the above embodiments, wherein said thyroid nodule is a specimen obtained by biopsy or by surgical resection of said subject.

Embodiment 10. The method of one of the above embodiments, wherein said subject has undergone thyroid surgery, radiation therapy, radioactive iodine therapy, chemotherapy, thyroid hormone therapy, and/or administration of an active agent.

Embodiment 11. The method of embodiment 10, wherein said active agent is chosen from Cabozantinib-S-Malate, Caprelsa (Vandetanib), Cometriq (Cabozantinib-S-Malate), Doxorubicin Hydrochloride, Lenvatinib Mesylate, Lenvima (Lenvatinib Mesylate), Nexavar (Sorafenib Tosylate), Sorafenib Tosylate, and/or Vandetanib.

Embodiment 12. A method of detecting a thyroid cancer or risk of developing thyroid cancer in a subject in need thereof, said method comprising:

207

- (i) isolating a thyroid nodule DNA molecule from a thyroid nodule of said subject thereby forming an isolated thyroid nodule DNA molecule;
- (ii) contacting said isolated thyroid nodule DNA molecule with a bisulfite salt thereby forming a reacted thyroid nodule DNA molecule; and
- (iii) detecting the presence or absence of uracil in said reacted thyroid nodule DNA molecule at a methylation site set forth in Table 1; thereby detecting said thyroid cancer in said subject.

Embodiment 13. The method of embodiment 12, wherein said subject (a) is a woman; (b) is about 20 to about 55 years old; (c) has a mutated Ret Proto-Oncogene; (d) has a grandparent, parent, or sibling who has been diagnosed with thyroid cancer; (e) self-identifies as being Caucasian or Asian; and/or (f) has or has had breast cancer.

Embodiment 14. The method of embodiment 12, further comprising detecting the presence or absence of uracil in said reacted thyroid nodule DNA molecule at a plurality of methylation sites set forth in Table 1, wherein said methylation site forms a part of said plurality of methylation sites.

Embodiment 15. The method of embodiment 12, the method further comprising: (i) isolating a plurality of thyroid nodule DNA molecules from said thyroid nodule of said subject thereby forming a plurality of isolated thyroid nodule DNA molecules, wherein said isolated thyroid nodule DNA molecule forms part of said plurality of isolated thyroid nodule DNA molecules, (ii) contacting said plurality of isolated thyroid nodule DNA molecules with said bisulfite salt thereby forming a plurality of reacted thyroid nodule DNA molecules, wherein said reacted thyroid nodule DNA molecule forms part of said plurality of reacted thyroid nodule DNA molecules, (iii) detecting the level of reacted thyroid nodule DNA molecules in said plurality of reacted thyroid nodule DNA molecules having a uracil at a methylation site set forth in Table 1; thereby detecting said thyroid cancer in said subject.

Embodiment 16. The method of embodiment 15, further comprising determining the level of uracil in said reacted thyroid nodule DNA molecule at a plurality methylation sites set forth in Table 1, wherein said methylation site forms a part of said plurality of methylation sites.

Embodiment 17. The method of embodiment 16, wherein said uracil level is above a threshold as set forth in Table 2.

Embodiment 18. The method of embodiment 16, wherein said uracil level is above a threshold as set forth in Table 3.

Embodiment 19. The method of embodiment 16, wherein said uracil level is below a threshold as set forth in Table 4.

Embodiment 20. The method of one of the above embodiments, wherein said subject is suspected of having thyroid cancer.

Embodiment 21. The method of one of the above embodiments, wherein said thyroid nodule is a specimen obtained by biopsy or by surgical resection of said subject.

Embodiment 22. The method of one of the above embodiments, wherein said subject has undergone thyroid surgery, radiation therapy, radioactive iodine therapy, chemotherapy, thyroid hormone therapy, and administration of an active agent, before said determination.

Embodiment 23. The method of embodiment 22, wherein said active agent is chosen from Cabozantinib-S-Malate, Caprelsa (Vandetanib), Cometriq (Cabozantinib-S-Malate), Doxorubicin Hydrochloride, Lenvatinib Mesylate, Lenvima (Lenvatinib Mesylate), Nexavar (Sorafenib Tosylate), Sorafenib Tosylate, and.

Embodiment 24. A method of treating thyroid cancer in a subject determined by the method as set forth in any of

208

embodiments 12 to 23, comprising administering to said subject an active agent for treating thyroid cancer.

Embodiment 25. The method of embodiment 24, wherein said subject has undergone surgery, radiation therapy, radioactive iodine therapy, chemotherapy, or thyroid hormone therapy, before said detection of claim 12 at (iii).

Embodiment 26. The method of embodiment 25, wherein said active agent is chosen from Cabozantinib-S-Malate, Caprelsa (Vandetanib), Cometriq (Cabozantinib-S-Malate), Doxorubicin Hydrochloride, Lenvatinib Mesylate, Lenvima (Lenvatinib Mesylate), Nexavar (Sorafenib Tosylate), Sorafenib Tosylate, and Vandetanib.

Embodiment 27. The method of one of the above embodiments, wherein said subject has or is at risk of papillary thyroid cancer, follicular thyroid cancer, medullary thyroid cancer, or anaplastic thyroid cancer.

Embodiment 28. The method of one of the above embodiments, wherein said bisulfite salt is sodium bisulfite.

Embodiment 29. The method of one of the above embodiments, further comprising determining a papillary thyroid carcinoma (PTC) methylation alteration score for said subject, wherein the PTC methylation alteration score is equal to: the number of methylation sites in Table I having a uracil level equal to or greater than the corresponding threshold level set forth in Table 2.

Embodiment 30. The method of one of the above embodiments, further comprising determining a benign thyroid nodule (BTN) methylation alteration score for said subject, wherein the BTN methylation alteration score is equal to:

- (a) the number of methylation sites in Table 1 having a uracil level equal to or greater than the corresponding threshold level set forth in Table 3;
- (b) the number of methylation sites in Table 1 having a uracil level equal to or less than the corresponding threshold level set forth in Table 4; or
- (c) the number of methylation sites in Table 1 having a uracil level equal to or greater than the corresponding threshold level set forth in Table 3 plus the number of methylation sites in Table 1 having a uracil level equal to or less than the corresponding threshold level set forth in Table 4.

Embodiment 31. The method of embodiment 29, further comprising calculating a Composite Cancer Risk Score for said subject.

Embodiment 32. The method of embodiment 31, wherein said Composite Cancer Risk Score for said subject equals:

$$\frac{[\text{the PTC methylation alteration score for said subject}+1]}{[\text{the BTN methylation alteration score for said subject}+1]}$$

Embodiment 33. The method of embodiment 31, wherein said Composite Cancer Risk Score for said subject equals:

$$\frac{[(\text{the PTC methylation alteration score for said subject}+1)+(\text{the BTN methylation alteration score for said subject}+1)]}{2}$$

Embodiment 34. The method of one of embodiments 29 to 33, wherein said subject is identified as being at risk of developing thyroid cancer or diagnosed as having thyroid cancer if (a) the PTC methylation alteration score for said subject is at least 5, 6, 7, 8, 9, or 10; (b) the BTN methylation alteration score for said subject is at least 5, 6, 7, 8, 9, or 10; and/or (c) the Composite Cancer Risk Score for said subject is at least about 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, or 3.0.

Embodiment 35. The method of one of embodiments 29 to 33, wherein said subject is treated for thyroid cancer or directed to receive additional screening for thyroid cancer if

209

(a) the PTC methylation alteration score for said subject is at least 5, 6, 7, 8, 9, or 10; (b) the BTN methylation alteration score for said subject is at least 5, 6, 7, 8, 9, or 10; and/or (c) the Composite Cancer Risk Score for said subject is at least about 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, or 3.0.

Embodiment 36. A deoxyribonucleic acid at least 5 to 100 nucleotides in length comprising a uracil-containing sequence that is identical to a sequence of at least a 5 contiguous nucleotides within a sequence chosen from SEQ ID NO:1 to SEQ ID NO:550.

Embodiment 37. The deoxyribonucleic acid of embodiment 36, comprising a uracil-containing sequence that is identical to a sequence of at least 5-10, 10-20, 20-30, 30-40, 40-50, 50-60, 60-70, 70-80, 80-90, 90-100, 100-110, 110-120, 120-130, 130-140, 140-150, 150-160, 160-170, 170-180, 180-190, or 190-200 contiguous nucleotides within said sequence chosen from SEQ ID NO:1 to SEQ ID NO:550.

Embodiment 38. The deoxyribonucleic acid of embodiment 36 or 37, wherein said sequence comprises a methylation site set forth in Table 1.

Embodiment 39. The deoxyribonucleic acid of one of embodiments 36 to 38, wherein a plurality of methylation sites set forth in Table 1 contain a uracil or a cytosine.

Embodiment 40. A deoxyribonucleic acid chosen from SEQ ID NO:551 to SEQ ID NO: 782, wherein said nucleic acid is hybridized to a complementary DNA sequence comprising uridine or cytosine.

Embodiment 41. The deoxyribonucleic acid of embodiment 40, further comprising an enzyme in a complex with said hybridized complementary DNA sequence.

Embodiment 42. The deoxyribonucleic acid of embodiment 41, wherein said enzyme is Taq polymerase.

Embodiment 43. A kit comprising a plurality of nucleic acids each independently comprising SEQ ID NO:551 to SEQ ID NO:782, wherein each nucleic acid of said plurality is unique.

Embodiment 44. The kit according to embodiment 43, further comprising: an enzyme, a reagent for deamination of cytosine, a buffer, a vial, a plasmid vector, a control DNA, a device for collecting a thyroid tissue sample, a reagent for isolating DNA, a reagent for labeling DNA, or any combination thereof.

Embodiment 45. The kit according to embodiment 44, wherein the enzyme comprises a thermostable DNA polymerase enzyme and/or a restriction enzyme.

Embodiment 46. A system for detecting methylation or unmethylation of a thyroid nodule deoxyribonucleic acid (DNA) of a subject, the system comprising:

at least one processor; and

at least one memory including program code which when executed by the at least one memory provides operations comprising:

isolating a thyroid nodule DNA molecule from a thyroid nodule of said subject thereby forming an isolated thyroid nodule DNA molecule;

contacting said isolated thyroid nodule DNA molecule with a bisulfite salt thereby forming a reacted thyroid nodule DNA molecule;

detecting the presence or absence of uracil in said reacted thyroid nodule DNA molecule at a methylation site set forth in Table 1, thereby detecting methylation or unmethylation of said thyroid nodule DNA molecule of said subject;

210

generating a diagnosis for said subject based at least in part on the presence or absence of uracil in said reacted thyroid nodule DNA molecule at the methylation site set forth in Table 1; and

providing, via a user interface, the diagnosis for said subject.

Embodiment 47. The system of embodiment 46, wherein the system is further configured to detect the presence or absence of uracil in said reacted thyroid nodule DNA molecule at a plurality of methylation sites set forth in Table 1, wherein said methylation site forms a part of said plurality of methylation sites.

Embodiment 48. The system of embodiment 46, wherein the system is further configured to: (i) isolate a plurality of thyroid nodule DNA molecules from said thyroid nodule of said subject thereby forming a plurality of isolated thyroid nodule DNA molecules, wherein said isolated thyroid nodule DNA molecule forms part of said plurality of isolated thyroid nodule DNA molecules, (ii) contact said plurality of isolated thyroid nodule DNA molecules with said bisulfite salt thereby forming a plurality of reacted thyroid nodule DNA molecules, wherein said reacted thyroid nodule DNA molecule forms part of said plurality of reacted thyroid nodule DNA molecules, (iii) detect the level of reacted thyroid nodule DNA molecules in said plurality of reacted thyroid nodule DNA molecules having a uracil at a methylation site set forth in Table 1, thereby detecting the level of methylation or unmethylation in said plurality of thyroid nodule DNA molecules of said subject.

Embodiment 49. The system of embodiment 48, wherein the system is further configured to detect the level of uracil in said reacted thyroid nodule DNA molecule at a plurality of methylation sites set forth in Table 1, wherein said methylation site forms a part of said plurality of methylation sites.

Embodiment 50. The system of embodiment 49, wherein said uracil level is above a threshold as set forth in Table 2.

Embodiment 51. The system of embodiment 49, wherein said uracil level is above a threshold as set forth in Table 3.

Embodiment 52. The system of embodiment 49, wherein said uracil level is below a threshold as set forth in Table 4.

Embodiment 53. The system of embodiment 49, wherein said subject is a candidate thyroid cancer patient.

Embodiment 54. The system of one of embodiments 46 to 53, wherein said thyroid nodule is a specimen obtained by biopsy or by surgical resection of said subject.

Embodiment 55. The system of one of embodiments 46 to 54, wherein said subject has undergone thyroid surgery, radiation therapy, radioactive iodine therapy, chemotherapy, thyroid hormone therapy, and/or administration of an active agent.

Embodiment 56. The system of embodiment 55, wherein said active agent is chosen from Cabozantinib-S-Malate, Caprelsa (Vandetanib), Cometriq (Cabozantinib-S-Malate), Doxorubicin Hydrochloride, Lenvatinib Mesylate, Lenvima (Lenvatinib Mesylate), Nexavar (Sorafenib Tosylate), Sorafenib Tosylate, and Vandetanib.

Embodiment 57. The system of one of embodiments 46 to 56, wherein the system is further configured to:

formulate, based at least in part on the diagnosis, a treatment plan for said subject; and

provide, via the user interface, the treatment plan.

Embodiment 58. The system of embodiment 57, wherein the treatment plan includes one or more of thyroid surgery, radiation therapy, radioactive iodine therapy, chemotherapy, thyroid hormone therapy, and administration of an active agent.

211
EXAMPLES

Example 1

Human frozen specimens were blindly evaluated by a pathologist. In the study, 28 benign nodules and 40 thyroid cancer specimens were analyzed.

DNA Methylation Profiling

Genomic DNA was isolated by using a standard phenol/chloroform extraction approach followed by ethanol precipitation. Further, genomic DNA underwent Reduced Representation Bisulfite Sequencing (RRBS) procedure. RRBS DNA amplicons were paired-end sequenced by using Hiseq 2500 (Illumina). For each sample, at least 15 million aligned reads were obtained. BTN and PTC specific signatures were determined based on cytosines which are characterized by at least 5 sequencing reads in each sample.

Identification of BTN Specific and PTC Specific DNA Methylation Changes

DNA methylation patterns were analyzed in 114 thyroid specimens including 28 benign nodules, 40 thyroid cancer, and 46 adjacent normal thyroid tissues, to identify the presence of thyroid cancer specific and benign nodule specific signatures. After genome alignment, a search was performed for DNA regions which have BTN or PTC specific alterations. For identification of a DNA region with a BTN specific loss of DNA methylation, DNA regions were identified which had a DNA methylation level in at least 6 out of 28 that was at least 2-fold less than the level of methylation in the same DNA region any analyzed PTC specimen; where the lowest value of DNA methylation at this DNA region among all PTC specimens is 20% or higher (FIG. 1A). For identification of DNA regions with BTN specific DNA methylation accumulation, the following criteria were used: a level of DNA methylation in an individual BTN that is at least 2-fold higher than the level of DNA methylation in the same DNA region in any analyzed PTC; where the value of DNA methylation of analyzed BTN specimen is at least 20% or more greater (FIG. 1B). The BTN signature includes DNA regions which were affected by DNA methylation loss in at least 6 out of 28 analyzed BTN samples and regions which were affected by DNA methylation accumulation in at least 6 out of 28 analyzed BTN samples.

Further, regions were determined which undergo PTC specific DNA methylation alterations. The criteria for the identification of DNA regions with a PTC specific loss of DNA methylation, was: a level of DNA methylation in 6 out of 46 PTC that is 2-fold less than in any analyzed adenoma and any normal matching tissue, where the lowest value of DNA methylation in the region among all non-malignant specimens is 20% or higher. The criteria for the identification of DNA regions with PTC specific DNA methylation accumulation was a level of DNA methylation in an individual PTC that is at least 2-fold higher than the level of methylation in any analyzed adenoma and normal matching tissue, where the value of DNA methylation in analyzed PTC sample should be 20% or higher. There were no DNA regions that were affected by DNA methylation accumulation in at least 6 PTC out of 46 analyzed PTC. Therefore, the PTC specific DNA methylation signatures contain only DNA regions which are affected by DNA methylation loss in at least 6 out of 46 analyzed PTC.

The total number of identified DNA regions which fall in PTC specific or BTN specific signature is 258, which comprises DNA methylation information for 364 cytosines

212

(FIG. 2A). There are 230 cytosines which characterize the PTC signature and 134 cytosines characterizing the BTN signature.

Evaluation of the cancer specific and benign specific changes revealed that 10 out of 40 thyroid cancer specimens are characterized by few (less than 5) or no cancer specific changes, and 4 out of 28 benign nodules indicated very few (less than 5) benign specific changes (FIG. 2A). Since the approach described herein is based on the identification of the tissue specific alterations, these specimens were determined to be “epigenetically indeterminate.”

For specimens with a determinate epigenetic state, clustering analysis revealed a strict separation of thyroid cancer from benign nodules based on DNA methylation levels of cytosines associated with benign and cancer scores (FIG. 2B). Thus, the use of benign and cancer scores can provide a unique thyroid nodule diagnostic tool.

Development of Diagnostic Panel Based on BTN/PTC Signature Scores.

The data disclosed herein demonstrates that analysis of DNA methylation of one or more of 258 DNA regions can provide substantial information regarding a presence of malignancy in thyroid samples. Therefore, DNA methylation analysis within BTN and PTC signature can be used as a PTC diagnostic tool. According to the data, PTC diagnosis can be made by using both BTN and PTC signatures. Each signature can be a score based on the number of specific alterations within the signature for each individual sample. For example, the number of BTN specific alterations within BTN signature DNA regions reflects a BTN signature score. At the same time, the number of PTC specific alterations for DNA regions within PTC signature group indicates PTC signature score.

In order to validate the approach disclosed herein and estimate an accuracy of the proposed signatures, a statistical analysis was performed based on the leave-one-out-cross-validation technique. Specifically, cancer and benign scores were determined for each individual nodule by using benign and cancer signatures which were developed based on DNA methylation patterns of the rest of samples excluding the testing sample. In order to predict benign and cancer scores for 68 nodules, 68 benign and cancer unique predictive signatures were developed.

After cross-validation, DNA methylation signatures (score ≥ 5) were observed in 80% (32 out of 40) of thyroid cancers and 82% (23 out of 28) of benign nodules (FIG. 3A). These specimens with a determinate epigenetic state were used for the further analysis.

According to the cross-validation observations, both, benign and malignant diagnostic scores provided accurate results for thyroid nodule diagnostics (FIG. 3A). However, a combining of benign and malignant scores into a cancer risk score is associated with even higher diagnostic performance. The cancer risk score was calculated using the following equation: Cancer Risk Score = (cancer score + 1) / (benign score + 1)

According to the data herein, specimens with cancer risk score above 2.6 represent thyroid cancer and specimens with cancer score below 2.6 are benign nodules. Based on these criteria, all 23 nodules were correctly diagnosed as benign and 30 out of 32 thyroid malignancies were diagnosed as a cancer (FIG. 3B). Therefore, the test had a specificity of 100% and a sensitivity of 94%, with a 100% positive predictive value (PPV) and a 92% negative predictive value (NPV). These data suggest that DNA methylation analysis of

213

258 DNA regions in thyroid specimens can serve as a potential diagnostic tool for the determination of malignancy.

An algorithm for performing a thyroid nodule diagnostic evaluation is shown in FIG. 3C. Specimens with benign and malignant signatures are associated with indeterminate epigenetic state and were excluded from the study. Specimens with a cancer risk score above 2.6 are considered to be malignant, and thyroid nodules with a cancer risk score below 2.6 are considered to be benign.

214

This scoring approach clearly differentiates benign from malignant specimens. These data suggest that DNA methylation analysis of 258 DNA regions in thyroid specimens, including potentially FNA specimens, can serve as a diagnostic tool for the determination of malignancy.

The data indicates that malignancy of thyroid specimens can be determined by DNA methylation pattern analysis of one or more of 258 different DNA regions.

SEQUENCE LISTING

The patent contains a lengthy sequence listing. A copy of the sequence listing is available in electronic form from the USPTO web site (<https://seqdata.uspto.gov/?pageRequest=docDetail&DocID=US12391993B2>). An electronic copy of the sequence listing will also be available from the USPTO upon request and payment of the fee set forth in 37 CFR 1.19(b)(3).

What is claimed is:

1. A method of treating papillary thyroid cancer in a subject in need thereof, the method comprising:
 - (i) measuring decreased DNA methylation levels, relative to a control, at papillary thyroid carcinoma DNA methylation sites in an isolated DNA obtained from a thyroid nodule from the subject, wherein the papillary thyroid carcinoma DNA methylation sites, with respect to reference human genome assembly hg19, comprise:
 - (a) chromosome 10, position 112259015,
 - (b) chromosome 12, position 56115043, and
 - (c) chromosome 15, position 85402496; and
 - (ii) administering cabozantinib-S-malate, doxorubicin hydrochloride, lenvatinib mesylate, sorafenib tosylate, vandetanib, or a combination of two or more thereof to the subject having the decreased DNA methylation levels at the papillary thyroid carcinoma DNA methylation sites in step (i) to treat the papillary thyroid cancer.
2. The method of claim 1, further comprising measuring a decreased DNA methylation level, relative to a control, at a benign thyroid nodule DNA methylation site in an isolated DNA obtained from a thyroid nodule from the subject, wherein the benign thyroid nodule DNA methylation site, with respect to reference human genome assembly hg19, is chromosome 2, position 8793724.
3. The method of claim 1, further comprising measuring a decreased DNA methylation level, relative to a control, at a benign thyroid nodule DNA methylation site in an isolated DNA obtained from a thyroid nodule from the subject, wherein the benign thyroid nodule DNA methylation site, with respect to reference human genome assembly hg19, is chromosome 12, position 45610695.
4. The method of claim 1, wherein the papillary thyroid carcinoma DNA methylation sites are unmethylated.
5. The method of claim 1, wherein the control is a subject that does not have papillary thyroid cancer.
6. The method of claim 1, wherein the papillary thyroid carcinoma DNA methylation sites, with respect to human genome assembly hg19, consist of: (a) chromosome 10, position 112259015, (b) chromosome 12, position 56115043, and (c) chromosome 15, position 85402496.
7. The method of claim 1, wherein the isolated DNA is obtained from the thyroid nodule in the subject by a biopsy or a surgical resection.
8. The method of claim 1, wherein the subject: (a) is a woman; (b) is about 20 years old to about 55 years old; (c) has a mutated Ret proto-oncogene; (d) has a grandparent, parent, or sibling who has been diagnosed with thyroid cancer; (e) self-identifies as Caucasian or Asian; (f) has or has had breast cancer, or (g) any combination of two or more of (a)-(f).
9. A method of measuring DNA methylation levels at papillary thyroid carcinoma DNA methylation sites in a human subject with thyroid carcinoma, the method comprising measuring decreased DNA methylation levels, relative to a control, at papillary thyroid carcinoma DNA methylation sites in an isolated DNA obtained from a thyroid nodule from the human subject, wherein the papillary thyroid carcinoma DNA methylation sites, with respect to reference human genome assembly hg19, comprise: (a) chromosome 10, position 112259015, (b) chromosome 12, position 56115043, and (c) chromosome 15, position 85402496 and measuring methylation levels comprises amplifying DNA by contacting the DNA with a primer complementary to a sequence at or within 1000 nucleotides of the chromosomal positions to produce amplicons thereof to measure methylation levels.
10. The method of claim 9, wherein the papillary thyroid carcinoma DNA methylation sites are unmethylated.
11. The method of claim 9, wherein the control is a subject that does not have papillary thyroid cancer.
12. The method of claim 9, further comprising measuring a decreased DNA methylation level, relative to a control, at a benign thyroid nodule DNA methylation site in an isolated DNA obtained from a thyroid nodule from the subject, wherein the benign thyroid nodule DNA methylation site, with respect to reference human genome assembly hg19, is chromosome 2, position 8793724.
13. The method of claim 9, further comprising measuring a decreased DNA methylation level, relative to a control, at a benign thyroid nodule DNA methylation site in an isolated DNA obtained from a thyroid nodule from the subject, wherein the benign thyroid nodule DNA methylation site,

215

with respect to reference human genome assembly hg19, is chromosome 12, position 45610695.

14. The method of claim **9**, wherein the isolated DNA is obtained from the thyroid nodule in the subject by a biopsy or a surgical resection.

15. The method of claim **9**, wherein the papillary thyroid carcinoma DNA methylation sites are unmethylated.

16. A method of measuring DNA methylation levels at papillary thyroid carcinoma methylation sites in an isolated DNA obtained from a thyroid nodule in a human subject, the method comprising: (i) contacting the isolated DNA with a bisulfite salt, thereby forming a reacted thyroid nodule DNA, and (ii) measuring decreased DNA methylation levels, relative to a control, at papillary thyroid carcinoma DNA methylation sites by detecting the presence of uracil in the reacted thyroid nodule DNA; wherein the papillary thyroid carcinoma DNA methylation sites, with respect to reference human genome assembly hg19, comprise: (a) chromosome 10, position 112259015, (b) chromosome 12, position

216

56115043, and (c) chromosome 15, position 85402496 and measuring methylation levels comprises amplifying DNA by contacting the DNA with a primer complementary to a sequence at or within 1000 nucleotides of the chromosomal positions to produce amplicons thereof to measure methylation levels.

17. The method of claim **16**, wherein the bisulfite salt is sodium bisulfite or ammonium bisulfite.

18. The method of claim **16**, wherein the bisulfite salt is sodium bisulfite, potassium bisulfite, ammonium bisulfite, magnesium bisulfite, sodium metabisulfite, potassium metabisulfite, ammonium metabisulfite and magnesium metabisulfite.

19. The method of claim **16**, wherein the control is a subject that does not have papillary thyroid cancer.

20. The method of claim **16**, wherein the isolated DNA is obtained from the thyroid nodule in the subject by a biopsy or by a surgical resection.

* * * * *